0001070081-24-00002310-Q PTC THERAPEUTICS, INC. 20241107202411071635521635521635521

310001070081ptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001070081us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2024-09-300001070081us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2024-09-300001070081us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2023-12-310001070081us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2023-12-310001070081us-gaap:CorporateDebtSecuritiesMember2023-12-310001070081us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001070081us-gaap:CorporateDebtSecuritiesMember2024-09-300001070081us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2024-09-300001070081us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001070081us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2023-12-310001070081us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001070081ptct:RestrictedStockAndRestrictedStockUnitsMember2024-01-012024-09-300001070081us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001070081ptct:RestrictedStockAndRestrictedStockUnitsMember2023-01-012023-09-300001070081us-gaap:FiniteLivedIntangibleAssetsMember2024-07-012024-09-300001070081us-gaap:FiniteLivedIntangibleAssetsMemberptct:UpstazaMember2024-01-012024-09-300001070081us-gaap:FiniteLivedIntangibleAssetsMemberptct:EmflazaMember2024-01-012024-09-300001070081us-gaap:FiniteLivedIntangibleAssetsMember2023-07-012023-09-300001070081us-gaap:FiniteLivedIntangibleAssetsMember2023-01-012023-09-300001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member2024-07-012024-09-300001070081us-gaap:LineOfCreditMember2023-07-012023-09-300001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member2023-07-012023-09-300001070081us-gaap:LineOfCreditMember2023-01-012023-09-300001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member2023-01-012023-09-300001070081us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300001070081us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001070081us-gaap:EmployeeStockMember2024-07-012024-09-300001070081us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300001070081us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001070081us-gaap:EmployeeStockMember2024-01-012024-09-300001070081ptct:RestrictedStockUnitsPerformanceBasedPsusMember2024-01-012024-09-300001070081us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001070081us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001070081us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001070081us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001070081us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001070081us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001070081us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001070081ptct:AkceaMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberptct:WaylivraMember2024-09-300001070081ptct:AkceaMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberptct:TegsediMember2024-09-300001070081srt:MinimumMemberptct:HopewellCampusMember2019-01-012019-12-310001070081us-gaap:LineOfCreditMember2024-01-012024-09-300001070081us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001070081us-gaap:CommonStockMember2023-01-012023-09-300001070081us-gaap:StockOptionMemberptct:InducementStockIncentivePlan2020Member2024-09-300001070081us-gaap:StockOptionMemberptct:InducementStockIncentivePlan2020Member2024-01-012024-09-300001070081srt:MaximumMemberus-gaap:StockOptionMemberptct:InducementStockIncentivePlan2020Member2024-09-300001070081srt:MinimumMemberus-gaap:StockOptionMemberptct:InducementStockIncentivePlan2020Member2024-09-300001070081ptct:RestrictedStockUnitsPerformanceBasedPsusMember2023-12-012023-12-310001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member2024-01-012024-09-300001070081srt:MaximumMemberptct:AtMarketOfferingSalesAgreementMember2019-08-310001070081srt:MaximumMemberptct:AtMarketOfferingSalesAgreementMember2024-01-012024-09-300001070081ptct:RoyaltyPharmaMemberptct:AndRRoyaltyPurchaseAgreementMember2024-06-300001070081srt:MinimumMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:SalesMilestonesMemberus-gaap:ValuationTechniqueOptionPricingModelMember2024-09-300001070081srt:MinimumMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberptct:DevelopmentandRegulatoryMilestoneMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-09-300001070081srt:MaximumMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:SalesMilestonesMemberus-gaap:ValuationTechniqueOptionPricingModelMember2024-09-300001070081srt:MaximumMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberptct:DevelopmentandRegulatoryMilestoneMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-09-300001070081srt:MinimumMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:SalesMilestonesMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-12-310001070081srt:MinimumMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberptct:DevelopmentandRegulatoryMilestoneMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-12-310001070081srt:MaximumMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:SalesMilestonesMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-12-310001070081srt:MaximumMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberptct:DevelopmentandRegulatoryMilestoneMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-12-310001070081srt:WeightedAverageMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:UpstazaMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueOptionPricingModelMember2024-09-300001070081srt:WeightedAverageMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:UpstazaMemberptct:ProbabilityofSuccessMemberus-gaap:ValuationTechniqueOptionPricingModelMember2024-09-300001070081srt:WeightedAverageMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberptct:UpstazaMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-09-300001070081srt:WeightedAverageMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberptct:UpstazaMemberptct:ProbabilityofSuccessMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-09-300001070081srt:MinimumMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:ProbabilityofSuccessMemberus-gaap:ValuationTechniqueOptionPricingModelMember2024-09-300001070081srt:MinimumMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-09-300001070081srt:MaximumMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:ProbabilityofSuccessMemberus-gaap:ValuationTechniqueOptionPricingModelMember2024-09-300001070081srt:MaximumMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-09-300001070081ptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueOptionPricingModelMember2024-09-300001070081ptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberptct:ProbabilityofSuccessMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-09-300001070081srt:MinimumMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:ProbabilityofSuccessMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-12-310001070081srt:MinimumMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-12-310001070081srt:MinimumMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberptct:ProbabilityofSuccessMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-12-310001070081srt:MaximumMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:ProbabilityofSuccessMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-12-310001070081srt:MaximumMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-12-310001070081srt:MaximumMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberptct:ProbabilityofSuccessMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-12-310001070081srt:MaximumMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:SalesMilestonesMemberus-gaap:CollaborativeArrangementMember2024-09-300001070081ptct:ResearchAndDevelopmentEventMilestonesMemberus-gaap:CollaborativeArrangementMember2024-09-300001070081ptct:SalesMilestonesMembersrt:MaximumMemberus-gaap:CollaborativeArrangementMember2011-11-300001070081ptct:ResearchAndDevelopmentEventMilestonesMembersrt:MaximumMemberus-gaap:CollaborativeArrangementMember2011-11-300001070081us-gaap:ConvertibleDebtSecuritiesMember2024-07-012024-09-300001070081us-gaap:ConvertibleDebtSecuritiesMember2024-01-012024-09-300001070081ptct:SmaFoundationMembersrt:MaximumMemberus-gaap:CollaborativeArrangementMember2023-01-012023-12-310001070081ptct:WarrenPremisesMember2022-06-012022-06-300001070081ptct:HopewellCampusMember2019-01-012019-12-310001070081ptct:AndRRoyaltyPurchaseAgreementMember2024-01-012024-09-300001070081ptct:AkceaMemberptct:WaylivraMember2024-01-012024-09-300001070081ptct:AkceaMemberptct:TegsediMember2024-01-012024-09-300001070081ptct:AgilisMemberptct:LiabilityRegulatoryMilestoneMember2024-07-012024-09-300001070081ptct:AgilisMemberptct:LiabilityRegulatoryMilestoneMember2024-05-012024-05-310001070081ptct:FormerCensaSecurityholdersMemberptct:LiabilityRegulatoryMilestoneMember2024-01-012024-09-300001070081ptct:AgilisMemberptct:LiabilityRegulatoryMilestoneMember2024-01-012024-09-300001070081ptct:AgilisMember2022-01-012022-12-310001070081ptct:WellcomeTrustLimitedMemberptct:LiabilityDevelopmentMilestoneMember2016-04-012016-06-300001070081srt:MaximumMemberptct:AndRRoyaltyPurchaseAgreementMember2024-06-012024-06-300001070081us-gaap:CollaborativeArrangementMember2024-01-012024-09-300001070081us-gaap:MutualFundMember2024-01-012024-09-300001070081ptct:HopewellCampusMember2024-06-170001070081ptct:HopewellCampusMember2024-06-160001070081us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300001070081us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001070081us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001070081us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300001070081us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2024-07-012024-09-300001070081us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2024-01-012024-09-300001070081us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2023-07-012023-09-300001070081us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2023-01-012023-09-300001070081ptct:FormerCensaSecurityholdersMemberptct:LiabilityRegulatoryMilestoneMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-09-300001070081ptct:FormerCensaSecurityholdersMemberptct:LiabilityRegulatoryMilestoneMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-07-310001070081ptct:FormerCensaSecurityholdersMemberptct:LiabilityRegulatoryMilestoneMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-05-310001070081us-gaap:AccountsPayableAndAccruedLiabilitiesMemberptct:LiabilityRegulatoryMilestoneMember2024-09-300001070081us-gaap:EquitySecuritiesMember2024-07-012024-09-300001070081us-gaap:EquitySecuritiesMember2024-01-012024-09-300001070081us-gaap:EquitySecuritiesMember2023-07-012023-09-300001070081us-gaap:EquitySecuritiesMember2023-01-012023-09-300001070081ptct:AndRRoyaltyPurchaseAgreementAmendmentTrancheTwoMember2024-06-300001070081ptct:AndRRoyaltyPurchaseAgreementAmendmentTrancheThreeMember2024-06-300001070081ptct:AndRRoyaltyPurchaseAgreementAmendmentTrancheOneMember2024-06-300001070081ptct:WarrenPremisesMember2022-06-012022-06-010001070081ptct:WarrenPremisesMember2022-06-010001070081ptct:HopewellCampusMember2024-06-172024-06-170001070081us-gaap:FiniteLivedIntangibleAssetsMemberptct:WaylivraMember2024-01-012024-09-300001070081us-gaap:FiniteLivedIntangibleAssetsMemberptct:TegsediMember2024-01-012024-09-300001070081us-gaap:FiniteLivedIntangibleAssetsMember2024-01-012024-09-300001070081ptct:AgilisMember2024-06-300001070812023-09-300001070812022-12-310001070081us-gaap:EmployeeStockMember2021-06-012021-06-300001070081srt:MaximumMemberptct:BioElectronMember2024-09-300001070081ptct:WellcomeTrustLimitedMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2022-12-310001070081ptct:AgilisMember2024-01-012024-09-300001070081ptct:FormerCensaSecurityholdersMember2023-01-012023-03-310001070081us-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMember2022-10-270001070081us-gaap:LineOfCreditMemberus-gaap:BaseRateMember2022-10-270001070081ptct:LineOfCreditCommittedLoanFacilityMember2022-10-272022-10-270001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Memberus-gaap:ConvertibleDebtMember2019-09-300001070812023-07-012023-09-300001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Memberus-gaap:ConvertibleDebtMember2019-09-012019-09-300001070081us-gaap:ConvertibleDebtSecuritiesMember2024-09-300001070081us-gaap:ConvertibleDebtSecuritiesMember2024-06-300001070081us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001070081us-gaap:ConvertibleDebtSecuritiesMember2023-12-310001070081us-gaap:ConvertibleDebtSecuritiesMember2023-09-300001070081us-gaap:ConvertibleDebtSecuritiesMember2023-06-300001070081us-gaap:ConvertibleDebtSecuritiesMember2022-12-310001070081srt:MinimumMemberptct:AgilisMember2024-09-300001070081srt:MaximumMemberptct:AgilisMember2024-01-012024-09-300001070081srt:MaximumMemberptct:AgilisMember2024-09-300001070081ptct:AgilisMemberptct:RightsExchangeAgreementMember2020-04-292020-04-290001070081us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001070081us-gaap:FairValueMeasurementsRecurringMember2024-09-300001070081ptct:ClearpointEquityInvestmentMember2024-09-300001070081ptct:ClearpointEquityInvestmentMember2024-06-300001070081us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001070081us-gaap:FairValueMeasurementsRecurringMember2023-12-310001070081ptct:ClearpointEquityInvestmentMember2023-12-310001070081ptct:ClearpointEquityInvestmentMember2023-09-300001070081ptct:ClearpointEquityInvestmentMember2023-06-300001070081ptct:ClearpointEquityInvestmentMember2022-12-310001070081ptct:ClearpointEquityInvestmentMember2024-07-012024-09-300001070081ptct:ClearpointEquityInvestmentMember2024-01-012024-09-300001070081ptct:ClearpointEquityInvestmentMember2023-07-012023-09-300001070081ptct:ClearpointEquityInvestmentMember2023-01-012023-09-300001070812023-01-012023-09-300001070081srt:ScenarioForecastMember2024-01-012024-12-310001070081us-gaap:ConvertibleDebtSecuritiesMember2020-01-310001070081ptct:AndRRoyaltyPurchaseAgreementMember2024-06-300001070081ptct:CensaMembersrt:MaximumMember2020-05-050001070081ptct:CensaMember2020-05-050001070081ptct:RoyaltyPharmaMemberptct:AndRRoyaltyPurchaseAgreementMember2024-01-012024-09-300001070081ptct:AndRRoyaltyPurchaseAgreementAmendmentTrancheTwoMember2024-06-012024-06-300001070081ptct:AndRRoyaltyPurchaseAgreementAmendmentTrancheThreeMember2024-06-012024-06-

300001070081ptct:AndRRoyaltyPurchaseAgreementAmendmentTrancheOneMember2024-06-012024-06-300001070081ptct:AndRRoyaltyPurchaseAgreementMember2024-06-012024-06-300001070081ptct:AllanJacobsonMemberptct:CommonStockTradingArrangementMember2024-09-300001070700812024-09-3000010700812023-12-310001070081ptct:ChristineUtterMemberptct:CommonStockTradingArrangementMember2024-09-300001070081ptct:AllanJacobsonMemberptct:CommonStockTradingArrangementMember2024-09-300001070081ptct:ChristineUtterMemberptct:CommonStockTradingArrangementMember2024-07-012024-09-300001070081ptct:AllanJacobsonMemberptct:CommonStockTradingArrangementMember2024-07-012024-09-3000010700812024-07-012024-09-3000010700812024-11-0500010700812024-01-012024-09-30ptct:productptct:periodptct:trancheutr:sqftptct:Dptct:segmentxbrli:sharesiso4217:USDxbrli:pureiso4217:USDxbrli:sharesptct:buildingptct:countryptct:Distributorptct:componentptct:fundTable of Contentsâ€‹UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORMÂ 10-Q(Mark One)â˜´Â Â Â Â QUARTERLY REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended SeptemberÂ 30,Â 2024orâ˜Â Â Â Â Â Â Â Â TRANSITION REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromÂ Â Â Â Â Â Â Â Â Â Â toCommission file number: 001-35969PTC Therapeutics,Â Inc.(Exact name of registrant as specified in its charter)â€‹â€‹â€‹â€‹DelawareÂ Â Â Â 04-3416587(State or other jurisdiction of incorporation or organization)â€‹(I.R.S. Employer Identification No.)â€‹â€‹â€‹â€‹500 Warren Corporate Center DriveÂ Â Â Â â€‹Warren, NJâ€‹07059(Address of principal executive offices)â€‹(Zip Code)â€‹(908) 222-7000(Registrantâ€™s telephone number, including area code)Securities registered pursuant to SectionÂ 12(b)Â of the Act:â€‹â€‹â€‹â€‹â€‹â€‹Title of each classÂ Â Â Â Trading Symbol(s)Â Â Â Â Name of each exchange on which registeredCommon Stock, $0.001 par value per shareâ€‹PTCTâ€‹Nasdaq Global Select Marketâ€‹Indicate by check mark whether the registrant (1)Â has filed all reports required to be filed by SectionÂ 13 or 15(d)Â of the Securities Exchange Act of 1934 during the preceding 12Â months (or for such shorter period that the registrant was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90Â days. YesÂ Ã¾Â NoÂ â˜Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to RuleÂ 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12Â months (or for such shorter period that the registrant was required to submit such files). YesÂ Ã¾Â NoÂ â˜Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and "emerging growth company" in RuleÂ 12b-2 of the Exchange Act.â€‹â€‹â€‹â€‹â€‹Large accelerated filerÃ¾Accelerated filerâ˜â€‹â€‹â€‹Non-accelerated filerâ˜Smaller reporting companyâ˜â€‹â€‹â€‹â€‹â€‹Emerging growth companyâ˜Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to SectionÂ 13(a)Â of the Exchange Act. â˜Â Indicate by check mark whether the registrant is a shell company (as defined in RuleÂ 12b-2 of the Exchange Act). YesÂ â˜Â NoÂ Ã¾â€‹As of November 5, 2024, there were 77,125,143 shares of Common Stock, $0.001 par value per share, outstanding.â€‹â€‹â€‹ Table of ContentsTABLE OF CONTENTSPTC Therapeutics,Â Inc.â€‹â€‹â€‹PageÂ No.PART Iâ€”FINANCIAL INFORMATIONâ€‹Â Â Â Â Â Â Â Â Â Â

(3,580,987)â€‹$
(1,054,352)â€‹â€‹â€‹

FA in the United States in December 2024. The Company initiated a Phase 2 registration directed trial of utreloxastat for amyotrophic lateral sclerosis, or ALS, in the first quarter of 2022. The Company expects topline results from this trial in the fourth quarter of 2024.â€‹In addition, the Company has a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas for rare diseases.As of SeptemberÂ 30,Â 2024, the Company had an accumulated deficit of approximately $3,581.0 million. The Company has financed its operations to date primarily through the private offerings of convertible senior notes (see Note 9), public and â€œat the market offeringsâ€ of common stock, proceeds from royalty purchase agreements (see Note 2), net proceeds from the Companyâ€™s borrowings under its credit agreement with Blackstone (see Note 9), private placements of its convertible preferred stock and common stock, collaborations, bank and institutional lender debt, other convertible debt, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Companyâ€™s product candidates. The Company has also relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States since 2014, Emflaza for the treatment of DMD in the United States since 2017, and Upstaza for the treatment of AADC deficiency in the EEA since 2022. The Company has also relied on revenue associated with milestone and royalty payments from Roche pursuant to the License and Collaboration Agreement (the â€œSMA License Agreementâ€) dated as of November 23, 2011, by and among the Company, Roche and, for the limited purposes set forth therein, the SMA Foundation, under its SMA program. The Company expects that cash flows from the sales of its products, milestone and royalty payments from Roche, together with the Companyâ€™s cash, cash equivalents and marketable securities, will be sufficient to fund its operations for at least the next twelve months. Â â€‹â€‹2.Â Â Â Â Â Â Â Â Summary of significant accounting policiesThe Companyâ€™s complete listing of significant accounting policies is set forth in NoteÂ 2 of the notes to the Companyâ€™s audited financial statements as of DecemberÂ 31,Â 2023 included in the Companyâ€™s Annual Report on FormÂ 10-K filed with the Securities and Exchange Commission (the "SEC") on February 29, 2024 (the "2023 FormÂ 10-K"). Selected significant accounting policies are discussed in further detail below.11 Table of ContentsBasis of presentationThe accompanying financial information as of SeptemberÂ 30,Â 2024 and for the three and nine months ended SeptemberÂ 30,Â 2024 and 2023 has been prepared by the Company, without audit, pursuant to the rulesÂ and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to such rulesÂ and regulations. These interim financial statements should be read in conjunction with the Companyâ€™s audited financial statements as of DecemberÂ 31,Â 2023 and notes thereto included in the 2023 FormÂ 10-K.In the opinion of management, the unaudited financial information as of SeptemberÂ 30,Â 2024 and for the three and nine months ended SeptemberÂ 30,Â 2024 and 2023 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations, stockholdersâ€™ deficit, and cash flows. The results of operations for the three and nine months ended SeptemberÂ 30,Â 2024 are not necessarily indicative of the results to be expected for theÂ year ended DecemberÂ 31,Â 2024 or for any other interim period or for any other futureÂ year.Use of estimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, royalty revenue, certain accruals related to the Companyâ€™s research and development expenses, valuation procedures for liability for sale of future royalties, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.Restricted cashRestricted cash included in deposits and other assets on the consolidated balance sheet contains an unconditional, irrevocable and transferable letter of credit that was entered into during the twelve-month period ended DecemberÂ 31, 2019 in connection with obligations under a facility lease for the Companyâ€™s facility in Hopewell Township, New Jersey. The amount of the letter of credit was $7.5 million and was to be maintained for a term of not less than five years and had the potential to be reduced to $3.8 million if after five years the Company was not in default of its lease. In June 2024, in connection with an amendment and restatement of the lease, the letter of credit was reduced to $5.0 million, and has the potential to be reduced to $3.0 million if after July 1, 2025, the Company is not in default of its lease. Refer to Note 3 for further details. Restricted cash also contains an unconditional, irrevocable and transferable letter of credit that was entered into during June 2022 in connection with obligations for the Companyâ€™s new facility lease in Warren, New Jersey. The amount of the letter of credit is $8.1 million and has the potential to be reduced to $4.1 million if after five years the Company is not in default of its lease. Both amounts are classified within deposits and other assets on the consolidated balance sheet that sum to the total of the same amounts shown in the statement of cash flows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â End ofÂ Â Â Â Â â€‹Beginning ofâ€‹Â period-Â period-â€‹Â SeptemberÂ 30,Â Â DecemberÂ 31,Â â€‹Â 2024â€‹2023Cash and cash equivalentsâ€‹$ 526,001â€‹$ 594,001Restricted cash included in deposits and other assets â€‹Â 13,789â€‹Â 16,283Total Cash, cash equivalents and restricted cash per statement of cash flowsâ€‹$ 539,790â€‹$ 610,284â€‹12 Table of ContentsMarketable securitiesThe Companyâ€™s marketable securities consists of both debt securities and equity investments. The Company considers its investments in debt securities with original maturities of greater than 90Â days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within accumulated other comprehensive income. The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the securityâ€™s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. For the three and nine months ended SeptemberÂ 30,Â 2024 and 2023, no allowance was recorded for credit losses.Marketable securities that are equity investments are measured at fair value, as it is readily available, and as such are classified as Level 1 assets. Unrealized holding gains and losses for these equity investments are components of other expense, net within the consolidated statement of operations.Inventory and cost of product salesInventoryInventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Products which may be used in clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes. Inventory used for marketing efforts are charged to selling, general and administrative expense. Amounts related to clinical development programs and marketing efforts are immaterial.The following table summarizes the components of the Companyâ€™s inventory for the periods indicated:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SeptemberÂ 30,Â 2024Â Â Â Â DecemberÂ 31,Â 2023Raw materialsâ€‹$ 2,738â€‹$ 952Work in progressâ€‹Â 24,440â€‹Â 17,991Finished goodsâ€‹Â 8,493â€‹Â 11,634Total inventoryâ€‹$ 35,671â€‹$ 30,577â€‹The Company periodically reviews its inventories for excess amounts or obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value. For the three months ended SeptemberÂ 30,Â 2024 and 2023, the inventory write-downs were immaterial. For the nine months ended SeptemberÂ 30,Â 2024, the Company recorded inventory write-downs of $2.5 million, primarily related to adjustments to inventory reserves and product approaching expiration. For the nine months ended SeptemberÂ 30,Â 2023, the Company recorded inventory write-downs of $0.4 million, primarily related to product approaching expiration. Additionally, though the Companyâ€™s product is subject to strict quality control and monitoring which it performs throughout the manufacturing processes, certain batches or units of product may not meet quality specifications resulting in a charge to cost of product sales. For the three and nine months ended SeptemberÂ 30,Â 2024 and 2023, these amounts were immaterial.13 Table of ContentsCost of product salesCost of product sales consists of the cost of inventory sold, manufacturing and supply chain costs, storage costs, amortization of the acquired intangible asset, royalty payments associated with net product sales, and royalty payments to collaborative partners associated with royalty revenues and collaboration revenue related to milestones. Production costs are expensed as cost of product sales when the related products are sold or royalty revenues and collaboration revenue milestones are earned.Revenue recognitionNet product revenueThe Companyâ€™s net product revenue primarily consists of sales of Translarna in territories outside of the U.S. for the treatment of nmDMD and sales of Emflaza in the U.S. for the treatment of DMD. The Company recognizes revenue when its performance obligations with its customers have been satisfied. The Companyâ€™s performance obligations are to provide products based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies. The performance obligations are satisfied at a point in time when the Companyâ€™s customer obtains control of the product, which is typically upon delivery. The Company invoices its customers after the products have been delivered and invoice payments are generally due within 30 to 90Â days of the invoice date. The Company determines the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods the Company has yet to provide. As the Company has identified only one distinct performance obligation, the transaction price is allocated entirely to product sales. In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers product to when the customers pay for the product is typically less than oneÂ year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the sameÂ month.The Company records product sales net of any variable consideration, which includes discounts, allowances, rebates related to Medicaid and other government pricing programs, and distribution fees. The Company uses the expected value or most likely amount method when estimating its variable consideration, unless discount or rebate terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained. For the threeÂ months ended SeptemberÂ 30,Â 2024 and 2023, net product sales outside of the United States were $83.5 million and $76.6 million, respectively, consisting of sales of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $72.3Â million and $69.0Â million of the net product sales outside of the United States for the three months ended SeptemberÂ 30,Â 2024 and 2023, respectively. For the three months ended SeptemberÂ 30,Â 2024 and 2023, net product sales in the United States were $51.9 million and $67.4 million, respectively, consisting solely of sales of Emflaza.Â During the three months ended SeptemberÂ 30,Â 2024, two countries, the United States and Brazil, accounted for at least 10% of the Companyâ€™s net product sales, representing $51.9 million and $29.2 million of net product sales, respectively. During the three months ended SeptemberÂ 30,Â 2023, one country, the United States, accounted for at least 10% of the Companyâ€™s net product sales, representing $67.4 million of net product sales. For the nine months ended SeptemberÂ 30,Â 2024 and 2023, net product sales outside of the United States were $289.5 million and $318.5 million, respectively, consisting of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $246.2 million and $280.6 million of the net product sales outside of the United States for the nine months ended SeptemberÂ 30,Â 2024 and 2023, respectively. For the nine months ended SeptemberÂ 30,Â 2024 and 2023, net product sales in the United States were $156.7 million and $187.7 million, respectively, consisting solely of Emflaza. During the nine months ended SeptemberÂ 30,Â 2024, three countries, the United States, Brazil, and Russia, accounted for at least 10% of the Companyâ€™s net product sales, representing $156.7 million, $68.3 million, and $55.7 million of net product sales, respectively. During the nine months ended SeptemberÂ 30,Â 2023, three countries, the United States, Russia, and Brazil, accounted for at least 10% of the Companyâ€™s net product sales, representing $187.7 million, $69.0 million, and $52.5 million of net product sales, respectively.14 Table of ContentsIn relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. The Company considers any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise. Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense.Collaboration and royalty revenueThe terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.At the inception of a collaboration arrangement, the Company needs to first evaluate if the arrangement meets the criteria in Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Codification (â€œASCâ€) Topic 808 â€œCollaborative Arrangementsâ€ to then determine if ASC Topic 606 is applicable by considering whether the collaborator meets the definition of a customer. If the criteria are met, the Company assesses the promises in the arrangement to identify distinct performance obligations.For licenses of intellectual property, the Company assesses, at contract inception, whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license will be bundled with other promises in the arrangement into one distinct performance obligation. The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.For milestone payments, the Company assesses, at contract inception, whether the development or sales-based milestones are considered probable of being achieved. If it is probable that a significant revenue reversal will occur, the Company will not record revenue until the uncertainty has been resolved. Milestone payments that are contingent upon regulatory approval are not considered probable of being achieved until the applicable regulatory approvals or other external conditions are obtained as such conditions are not within the Companyâ€™s control. If it is probable that a significant revenue reversal will not occur, the Company will estimate the milestone payments using the most likely amount method. The Company will re-assess the development and sales-based milestones each reporting period to determine the probability of achievement. The Company recognizes royalties from product sales at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied. If it is probable that a significant revenue reversal will not occur, the Company will estimate the royalty payments using the most likely amount method.The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.For the three and nine months ended September 30, 2024, the Company did not recognize collaboration revenue related to the SMA License Agreement with Roche. For the three and nine months ended SeptemberÂ 30,Â 2023, the amounts recognized for the collaboration revenue related to the SMA License Agreement with Roche were immaterial.â€‹For the three and nine months ended SeptemberÂ 30,Â 2024, the Company recognized $61.4 million and $145.7 million of royalty revenue, respectively, related to Evrysdi. For the three and nine months ended SeptemberÂ 30,Â 2023, the Company recognized $50.2 million and $117.9 million of royalty revenue, respectively, related to Evrysdi.â€‹Manufacturing Revenueâ€‹15 Table of ContentsThe Company has manufacturing services related to the production of plasmid deoxyribonucleic acid (â€œDNAâ€) and adeno-associated virus (â€œAAVâ€) vectors for gene therapy applications for external customers. Performance obligations vary but may include manufacturing plasmid DNA and/or AAV vectors, material testing, stability studies, and other services related to material development. The transaction prices for these arrangements are fixed and include amounts stated in the contracts for each promised service. Typically, the performance obligations within a manufacturing contract are highly interdependent, in which case, the Company will combine them into a single performance obligation. The Company has determined that the assets created have no alternative use to the Company, and the Company has an enforceable right to payment for the performance completed to date, therefore revenue related to these services are recognized over time and is measured using an output method based on performance of manufacturing milestones completed to date.â€‹Manufacturing service contracts may also include

performance obligations related to project management services or obtaining materials from third parties. The Company has determined that these are separate performance obligations for which revenue is recognized at the point in time the services are performed. For performance obligations related to obtaining third party materials, the Company has determined that it is the principal as the Company has control of the materials and has discretion in setting the price. Therefore, the Company recognizes revenue on a gross basis related to obtaining third party materials.â€‹Certain arrangements require a portion of the contract consideration to be received in advance at the commencement of the contract, and such advance payment is initially recorded as a contract liability. A contract asset may be recognized in the event the Companyâ€™s satisfaction of performance obligations outpaces customer billings. â€‹For the three months ended September 30, 2024, the Company did not recognize any revenue related to plasmid DNA and AAV vector production for external customers. For the nine months ended September 30, 2024, the Company recognized $1.7 million of manufacturing revenue related to plasmid DNA and AAV vector production for external customers. For the three and nine months ended SeptemberÂ 30,Â 2023 the Company recognized $2.4 million and $6.7 million of manufacturing revenue, respectively, related to plasmid DNA and AAV vector production for external customers. As of SeptemberÂ 30,Â 2024, the Company has no contract assets and no remaining performance obligations related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. For the period ended December 31, 2023, the Company had contract assets of $0.2 million and remaining performance obligations of $0.8 million related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers.â€‹In June 2024, the Company sold its gene therapy manufacturing business in Hopewell Township, New Jersey. Accordingly, the Company does not expect to have manufacturing revenue going forward.Allowance for doubtful accountsThe Company maintains an allowance for estimated losses resulting from the inability of its customers to make required payments. The Company estimates uncollectible amounts based upon current customer receivable balances, the age of customer receivable balances, the customerâ€™s financial condition and current economic trends. The Company also assesses whether an allowance for expected credit losses may be required which includes a review of the Companyâ€™s receivables portfolio, which are pooled on a customer basis or country basis.Â In making its assessment of whether an allowance for credit losses is required, the Company considers its historical experience with customers, current balances, levels of delinquency, regulatory and legal environments, and other relevant current and future forecasted economic conditions. For the three and nine months ended SeptemberÂ 30,Â 2024 and 2023, no allowance was recorded for credit losses. The allowance for doubtful accounts was $1.3 million as of SeptemberÂ 30,Â 2024 and $1.2 million as of DecemberÂ 31,Â 2023. For the three and nine months ended SeptemberÂ 30,Â 2024, bad debt expense was $0.7 million and $0.5 million, respectively. For the three and nine months ended SeptemberÂ 30,Â 2023, bad debt expense was $0.4 million and $0.7 million, respectively.Liability for sale of future royalties In June 2024, the Company, Royalty Pharma Investments 2019 ICAV (â€œRoyalty Pharmaâ€) and Royalty Pharma plc, entered into an amendment to the Amended and Restated Royalty Purchase Agreement, dated as of October 18, 2023 (as amended, the â€œA&R Royalty Purchase Agreementâ€). The A&R Royalty Purchase Agreement amended and restated in its entirety the original Royalty Purchase Agreement, dated as of July 17, 2020 (the â€œOriginal Royalty Purchase Agreementâ€). Â 16 Table of ContentsPursuant to the A&R Royalty Purchase Agreement, the Company has sold to Royalty Pharma a portion of the Companyâ€™s right to receive sales-based royalty payments (the â€œRoyaltyâ€) on worldwide net sales of Evrysdi and any other product developed pursuant to the License and Collaboration Agreement (the â€œLicense Agreementâ€), dated as of November 23, 2011, by and among the Company, Roche and, for the limited purposes set forth therein, the SMA Foundation under the SMA program. â€‹Pursuant to the guidance in ASC 470-10-25-2, the Company determined that cash consideration obtained pursuant to the A&R Royalty Purchase Agreement should be classified as debt and recorded it as â€œliability for sale of future royalties-currentâ€ and â€œliability for sale of future royalties-noncurrentâ€ on the Companyâ€™s consolidated balance sheet based on the timing of the expected payments to be made to Royalty Pharma at the time of the transaction. Under the A&R Royalty Purchase Agreement, the Company exercised a put option in June 2024, resulting in the Company receiving $241.8 million in cash consideration. In connection with the put option exercise, the change in rights and obligations resulted in a change in the terms of the liability for sale of future royalties, which was evaluated by the Company in accordance with ASC 470-50, Debt â€”Modifications and Extinguishments. The Company determined that the present value of the cash flows after the put option exercise was not substantially different and was therefore determined to be a modification. The $241.8 million in cash consideration obtained was added to the liability for sale of future royalties and the annual effective interest rate under the A&R Royalty Purchase Agreement was determined to be 9.9%. The liability is amortized using the effective interest method over the life of the arrangement, in accordance with the respective guidance, utilizing the prospective method to account for subsequent changes in the estimated future payments to be made to Royalty Pharma and the Company updates the effective interest rate on a quarterly basis. Refer to Note 9 for further details.â€‹To date, the Company has sold to Royalty Pharma a total of 90.49% of the Royalty, which will be reduced to 83.33% (the â€œAssigned Royalty Rightsâ€) after Royalty Pharma receives $1.3Â billion in aggregate payments (the â€œAssigned Royalty Capâ€) from the Royalty assigned at the closing of the Original Purchase Agreement. Â In exchange for the Assigned Royalty Rights, Royalty Pharma has paid to the Company upfront cash consideration totaling $1.9 billion, less Royalty payments received by the Company with respect to the Assigned Royalty Rights. The Company currently retains 9.51% of the Royalty, which increases to 16.67% after the Assigned Royalty Cap has been met. Â The Company has the option under the A&R Royalty Purchase Agreement to sell its retained portions of the Royalty to Royalty Pharma in up to three tranches for the following payments: Â (1) $100.0 million in exchange for 3.81% of the Royalty, which increases to 6.67% after the Assigned Royalty Cap has been met, (2) $100.0 million in exchange for 3.81% of the Royalty, which increases to 6.67% after the Assigned Royalty Cap has been met, and (3) $50.0 million in exchange for 1.90% of the Royalty, which increases to 3.33% after the Assigned Royalty Cap has been met, in each case less Royalty payments received by the Company with respect to the Assigned Royalty Rights. Â The A&R Royalty Purchase Agreement will terminate 60 days following the date on which Roche is no longer obligated to make any payments of the Royalty pursuant to the License Agreement.â€‹Indefinite-lived intangible assetsIndefinite-lived intangible assets consist of in process research and development ("IPR&D"). IPR&D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise, they are expensed. The fair values of IPR&D projects and license agreement assets acquired in business combinations are capitalized. Several methods may be used to determine the estimated fair value of the IPR&D and license agreement assets acquired in a business combination. The Company utilizes the "income method" and uses estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible assetâ€™s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible 17 Table of Contentsassets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Companyâ€™s outlook and market performance of the Companyâ€™s industry and recent and forecasted financial performance. GoodwillGoodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Companyâ€™s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. The Company reassesses its reporting units as part of its annual segment review. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. Income TaxesOn December 15, 2022, the EU Member States formally adopted the EUâ€™s Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (â€œOECDâ€) Pillar Two Framework that was supported by over 130 countries worldwide. The EU effective dates are January 1, 2024, and January 1, 2025, for different aspects of the directive. A significant number of other countries are also implementing similar legislation. As a result, the tax laws in the U.S. and other countries in which PTC and its affiliates do business could change on a prospective or retroactive basis and any such changes could materially adversely affect the Companyâ€™s business. The Company is continuing to evaluate the potential impact on future periods of the Pillar Two Framework, pending legislative adoption by additional individual countries, including those within the European Union.On DecemberÂ 22, 2017, the U.S. government enacted the 2017 Tax Cuts and Jobs Act (â€œTCJAâ€), which significantly revised U.S. tax law by, among other provisions, lowering the U.S. federal statutory corporate income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Global Intangible Low-Taxed Income (â€œGILTIâ€) provisions of the TCJA require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiaryâ€™s tangible assets. The Company has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements for the period ended SeptemberÂ 30,Â 2024.Since 2022, TCJA amendments to IRC Section 174 no longer permit an immediate deduction for research and development expenditures in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over either a five- or 15-year period, depending on the location of the activities performed. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year five for activities conducted in the United States or year 15 in the case of development conducted on foreign soil. This tax law change is anticipated to result in an increased current taxable income of the Company by $121.0 million for the year ending December 31, 2024.Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured at rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. A valuation allowance is recorded when it is not more likely than not that all or a portion of the net deferred tax assets will be realized.On August 23, 2018, the Company completed its acquisition of Agilis Biotherapeutics, Inc. (â€œAgilisâ€), pursuant to an Agreement and Plan of Merger, dated as of July 19, 2018 (the â€œAgilis Merger Agreementâ€), by and among the Company, Agility Merger Sub, Inc., a Delaware corporation and the Companyâ€™s wholly owned, indirect subsidiary, Agilis and, solely 18 Table of Contentsin its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC, (the â€œAgilis Mergerâ€). The Company recorded a deferred tax liability in conjunction with the Agilis Merger of $122.0 million in 2018, related to the tax basis difference in the IPRD indefinite-lived intangibles acquired. The Companyâ€™s policy is to record a deferred tax liability related to acquired IPR&D which may eventually be realized either upon amortization of the asset when the research is completed, and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful. In July 2022, the Company received EMEA approval for a portion of the IPR&D assets, and thus, began the amortization of the intangible. In May 2023, the Company announced the discontinuation of its preclinical and early research programs in gene therapy as part of a strategic portfolio prioritization. In conjunction with the announcement, the Company recorded an impairment to its indefinite-lived intangible for IP research and development relating to the Friedreich ataxia and Angelman syndrome gene therapy assets. As a result of the impairment, the Company recorded a deferred tax benefit of $46.9 million during the 2023 tax year.LeasesThe Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company accounts for as a single lease component for all leases. Operating and finance leases are classified as right of use ("ROU") assets, short term lease liabilities, and long term lease liabilities. Operating and finance lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. ROU assets are amortized and lease liabilities accrete to yield straight-line expense over the term of the lease. Lease payments included in the measurement of the lease liability are comprised of fixed payments.Variable lease payments associated with the Companyâ€™s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Companyâ€™s consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases.Leases with an initial term of 12Â months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.A lessee is required to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Companyâ€™s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company gives consideration to its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates.The lease term for all of the Companyâ€™s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Leasehold improvements are capitalized and depreciated over the lesser of useful life or lease term. Refer to NoteÂ 3 for further details. Â Tangible asset impairment and losses (gains) on transactions, net Tangible asset impairment and losses (gains) on transactions, net includes impairments identified on fixed assets, losses and gains on sales of fixed assets, and gains on lease terminations. For the three months ended September 30, 2024, these amounts consisted of a $1.3 million loss for fixed asset impairments related to the South Plainfield, New Jersey office closure, as well as a $0.5 million loss on sales of fixed assets. 19 Table of ContentsFor the nine months ended September 30, 2024, these amounts consisted of a $4.4 million loss primarily related to the sale of certain assets for gene therapy manufacturing, and a $1.5 million loss primarily related to fixed asset impairments related to the South Plainfield, New Jersey office closure. These amounts were partially offset by a gain of $2.2 million on lease terminations (Note 3) and a $0.1 million gain on sales of fixed assets.Recently issued accounting standardsIn November 2023, the FASB issuedÂ ASU 2023-07,Â Segment Reporting (Topic 280) â€” Improvements to Reportable Segment Disclosures. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements, unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently planning to adopt this guidance when effective. The Company is assessing the impact of the adoption on the Companyâ€™s consolidated financial statements and accompanying footnotes.â€‹In December 2023, the FASB issuedÂ ASU 2023-09,Â Improvements to Income Tax Disclosures. ASU 2023-09 enhances the transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The guidance is effective for public business entities for annual periods beginning after December 15, 2024. For entities other than public business entities, the amendments are effective for annual periods beginning after December 15, 2025. Early adoption is permitted. The Company is currently planning to adopt this guidance when effective. The Company is assessing the impact of the adoption on the Companyâ€™s consolidated financial statements and accompanying footnotes.Â â€‹3.Â Â Â Â Â Â Â Â Â LeasesEffective April 2024, the Company began utilizing the Warren Premises, as described below, as its principal office space. The Company also leases laboratory space in Bridgewater, New Jersey and other locations throughout the United States and office space in various countries for international employees primarily through workspace providers. The Companyâ€™s lease for office space in South Plainfield, New Jersey expired in August 2024.The Company has a lease agreement (the â€œWarren Leaseâ€) with Warren CC Acquisitions, LLC (the â€œWarren Landlordâ€) relating to the lease of two entire buildings comprised of approximately 360,000 square feet of shell condition, modifiable space (the â€œWarren

Premisesâ€) at a facility located in Warren, New Jersey. The rental term of the Warren Lease commenced on June 1, 2022, with an initial term of seventeen years (the â€œWarren Initial Termâ€), followed by three consecutive five-year renewal periods at the Companyâ€™s option. The aggregate base rent for the Warren Initial Term is approximately $163.0 million; provided, however, that if the Company is not subject to an Event of Default (as defined in the Warren Lease), the Company is entitled to a base rent abatement over the first three years of the Warren Initial Term of approximately $18.6 million, reducing the Companyâ€™s total base rent obligation to $144.4 million. The Company is entitled to an allowance of approximately $36.2 million to be provided by the Warren Landlord to be used towards such improvements. The Landlord is providing the allowance to cover those assets that are real property improvements, such as structural components, roofs, flooring, etc., whose useful lives are typically longer in nature. The Company evaluated the leasehold improvements under ASC 842 and determined that the Company will be the owner of the improvements, and therefore the $36.2 million allowance and $5.0 million due from the Landlord were treated as lease incentives at the commencement of the lease and included in the calculation of the lease ROU asset and lease ROU liability, effectively reducing both at the commencement date of the lease. As a result, the Company recorded an operating lease ROU asset of $28.9 million and an operating lease ROU liability of $28.9 million as of the commencement date of the lease.The Company also leases office and laboratory space at a facility located in Hopewell Township, New Jersey pursuant to a Lease Agreement (the â€œHopewell Leaseâ€) with Hopewell Campus Owner LLC. In connection with the disposition of 20 Table of Contentscertain assets related to gene therapy manufacturing, on June 17, 2024, the Company and Hopewell Campus Owner LLC entered into an amendment and restatement of the Hopewell Lease (the â€œHopewell Lease Amendmentâ€). At its inception, the Hopewell Lease was determined to have four separate lease components. The Hopewell Lease Amendment terminated three of the four lease components, reducing the leased space from 220,500 square feet to 93,461 square feet and significantly reducing the corresponding rent subject to the lease. The Company did not pay any termination fees in connection with the Hopewell Lease Amendment. As a result of the three terminated lease components, the related ROU asset was written off, the lease liability was derecognized, and the Company recognized a gain of $2.2 million during the nine months ended September 30, 2024. The gain is included within tangible asset impairment and losses (gains) on transactions, net on the Companyâ€™s consolidated statements of operations. The Hopewell Lease Amendment did not fully or partially terminate the remaining lease component, which was therefore remeasured using an incremental borrowing rate at the date of modification of 7.5%, which resulted in an increase of the ROU asset and operating lease liability of $1.6 million, respectively. In connection with the Hopewell Lease Amendment, $2.5 million of the letter of credit was returned to the Company.The Company also has a finance lease related to its commercial manufacturing agreement with MassBiologics of the University of Massachusetts Medical School (â€œMassBioâ€). As of SeptemberÂ 30,Â 2024, the balance of the finance lease liabilities-current and finance lease liabilities-noncurrent are $2.6 million and $15.6 million, respectively, and are directly related to the Companyâ€™s MassBio agreement. As of December 31, 2023, the balance of the finance lease liabilities-current and finance lease liabilities-noncurrent were $3.0 million and $17.2 million, respectively. Additionally, the Company recorded finance lease costs of $0.4 million and $1.0 million related to interest on the lease liability during the three and nine months ended SeptemberÂ 30,Â 2024, respectively. The Company recorded finance lease costs of $0.4 million and $1.1 million related to interest on the lease liability during the three and nine months ended SeptemberÂ 30,Â 2023, respectively.The Company also leases certain vehicles, lab equipment, and office equipment under operating leases. The Companyâ€™s leases have remaining operating lease terms ranging from 0.1Â years to 14.7Â years and certain of the leases include renewal options to extend the lease for up to 15 years. For the three and nine months ended SeptemberÂ 30,Â 2024, rent expense was $5.9 million and $19.5 million, respectively. For the three and nine months ended SeptemberÂ 30,Â 2023, rent expense was $7.1 million and $21.5 million, respectively.The components of operating lease expense were as follows:â€‹â€‹â€‹

or equal toÂ 12Â monthsâ€‹Totalâ€‹Â Â Â UnrealizedÂ lossesÂ Â Â FairÂ ValueÂ Â Â UnrealizedÂ lossesÂ Â Â FairÂ ValueÂ Â Â UnrealizedÂ lossesÂ Â Â FairÂ ValueCorporate debt securitiesâ€‹$ (8)â€‹â€‹ 14,984â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ (8)â€‹$ 14,984Totalâ€‹$ (8)â€‹$ 14,984â€‹$ â€”â€‹$ â€”â€‹$ (8)â€‹$ 14,984â€‹25 Table of ContentsThe unrealized losses and fair values of available for sale debt securities that have been in an unrealized loss position for a period of less than and greater than or equal to 12Â months as ofÂ DecemberÂ 31, 2023 are as follows:â€‹â€‹â€‹

sale of future royaltiesThe following table shows the activity within the â€œliability for sale of future royalties- currentâ€ and â€œliability for sale of future royalties- noncurrentâ€ accounts for the nine months ended SeptemberÂ 30,Â 2024:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Nine Months Ended SeptemberÂ 30,Â â€‹Liability for sale of future royalties- (current and noncurrent)â€‹2024â€‹Beginning balance as of December 31, 2023â€‹$ 1,814,097â€‹Less: Non-cash royalty revenue payable to Royalty Pharmaâ€‹â€‹ (128,877)â€‹Plus: Non-cash interest expense recognizedâ€‹â€‹ 155,039â€‹Plus: Cash received from Royalty Pharmaâ€‹â€‹ 241,792â€‹Ending balanceâ€‹$ 2,082,051â€‹Effective interest rate as of September 30, 2024â€‹Â 9.9%â€‹â€‹Non-cash interest expense is recorded in the statement of operations within â€œInterest expense, netâ€. Â â€‹Senior Secured Term Loanâ€‹On October 27, 2022 (the â€œClosing Dateâ€), the Company entered into a credit agreement (the â€œBlackstone Credit Agreementâ€) for fundings of up to $950.0 million consisting of a committed loan facility of $450.0 million and further contemplating the potential for up to $500.0 million of additional financing, to the extent that the Company requested such additional financing and subject to the Lendersâ€™ agreement to provide such additional financing and to mutual agreement on terms, among the Company, certain subsidiaries of the Company (together with the Company, the â€œLoan Partiesâ€) and funds and other affiliated entities advised or managed by Blackstone Life Sciences and Blackstone Credit (collectively, â€œBlackstoneâ€, and such lenders, together with their permitted assignees, the â€œLendersâ€ and each a â€œLenderâ€) and Wilmington Trust, National Association, as the administrative agent for the Lenders. Â â€‹The Blackstone Credit Agreement provided for a senior secured term loan facility funded on the Closing Date in the aggregate principal amount of $300.0 million (the â€œInitial Loansâ€) and a committed delayed draw term loan facility of up to $150.0 million (the â€œDelayed Draw Loansâ€ and, together with the Initial Loans, the â€œLoansâ€) to be funded at the Companyâ€™s request within 18 months of the Closing Date subject to specified conditions. In addition, the Blackstone Credit Agreement contemplated the potential for further financings by Blackstone, by providing for incremental discretionary uncommitted further financings of up to $500.0 million. The Company capitalized approximately $11.6 million of debt issuance costs which are presented on the balance sheet as a direct deduction from the debt liability and are being amortized over the term of the senior secured term loan facility using the effective interest rate method.â€‹The Loans were to mature on the date that is seven years from the Closing Date. Borrowings under the Blackstone Credit Agreement bore interest at a variable rate equal to, at the Companyâ€™s option, either an adjusted Term SOFR rate plus seven and a quarter percent (7.25%) or the Base Rate plus six and a quarter percent (6.25%), subject to a floor of one percent (1%) and two percent (2%) with respect to Term SOFR rate and Base Rate (each as defined in the Blackstone Credit Agreement), respectively. Payment of the Loans were subject to certain premiums specified in the Blackstone Credit Agreement, in each case, from the date of the applicable Loan funded.â€‹On October 19, 2023, the Company terminated the Blackstone Credit Agreement. In connection with the termination of the Credit Agreement, the Company repaid outstanding principal of $300.0 million, accrued interest of $2.1 million, an additional $82.0 million in prepayment premiums, exit fees, and creditor expenses, and $0.2 million in legal fees. The Company recorded a loss on the extinguishment of debt of $92.7 million which was included on the statement of operations for the period ended December 31, 2023. The loss on extinguishment of debt consisted of $82.0 million in prepayment premiums, exit fees, and creditor expenses and debt issuance costs of $10.7 million. All liens and security interests securing the loans made pursuant to the Blackstone Credit Agreement were released upon termination.â€‹32 Table of ContentsThe Blackstone Credit Agreement consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SeptemberÂ 30,Â 2024â€‹DecemberÂ 31,Â 2023Principalâ€‹$ â€”â€‹$ 300,000Less: Debt issuance costsâ€‹Â â€”â€‹â€‹ â€”Repayment of senior secured term loanâ€‹â€‹ â€”â€‹â€‹ (300,000)Net carrying amountâ€‹$ â€”â€‹$ â€”â€‹â€‹The following table sets forth total interest expense recognized related to the Blackstone Credit Agreement:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹Nine Months Ended â€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹2024â€‹2023â€‹Contractual interest expense$ â€”â€‹$ 9,554â€‹$ â€”â€‹â€‹$ 28,087â€‹Amortization of debt issuance costsÂ â€”â€‹Â 280â€‹â€‹ â€”â€‹â€‹ 702â€‹Total$ â€”â€‹$ 9,834â€‹$ â€”â€‹$ 28,789â€‹Effective interest rateâ€‹ â€”%â€‹ 13.1%â€‹ â€”%â€‹ 13.1%â€‹â€‹2026 Convertible NotesInÂ SeptemberÂ 2019, the Company issued, at par value,Â $287.5 millionÂ aggregate principal amount ofÂ 1.50%Â convertible senior notes due 2026, which included an option to purchase up to an additional $37.5 million in aggregate principal amount of the 2026 Convertible Notes, which was exercised in full by the initial purchasers. The 2026 Convertible NotesÂ bear cash interest at a rate ofÂ 1.50%Â perÂ year, payable semi-annually onÂ MarchÂ 15Â andÂ SeptemberÂ 15Â of eachÂ year, beginning onÂ MarchÂ 15, 2020. The 2026 Convertible NotesÂ will mature onÂ SeptemberÂ 15, 2026, unless earlier repurchased or converted. The net proceeds to the Company from the offering wereÂ $279.3 million after deducting the initial purchasersâ€™ discounts and commissions and the offering expenses payable by the Company.The 2026 Convertible NotesÂ are governed by an indenture (the "2026 Convertible NotesÂ Indenture") with U.S Bank National Association as trustee (the "2026 Convertible NotesÂ Trustee").Holders of the 2026 Convertible Notes may convert their 2026 Convertible NotesÂ at their option at any time prior to the close of business on the business day immediately precedingÂ MarchÂ 15, 2026Â only under the following circumstances:â—during any calendar quarter commencing on or afterÂ DecemberÂ 31, 2019Â (and only during such calendar quarter), if the last reported sale price of the Companyâ€™s common stock for at leastÂ 20Â tradingÂ days (whether or not consecutive) during a period ofÂ 30Â consecutive tradingÂ days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal toÂ 130%Â of the conversion price on each applicable trading day;â—during theÂ fiveÂ business day period after anyÂ fiveÂ consecutive trading day period (the â€œmeasurement periodâ€) in which the trading price (as defined in the 2026 Convertible NotesÂ Indenture) per $1,000 principal amount of 2026 Convertible NotesÂ for each trading day of the measurement period was less thanÂ 98%Â of the product of the last reported sale price of the Companyâ€™s common stock and the conversion rate on each such trading day;â—during any period after the Company has issued notice of redemption until the close of business on the scheduled trading day immediately preceding the relevant redemption date; orâ—upon the occurrence of specified corporate events.33 Table of ContentsOn or after MarchÂ 15, 2026, until the close of business on the business day immediately preceding the maturity date, holders may convert their 2026 Convertible NotesÂ at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Companyâ€™s common stock or any combination thereof at the Companyâ€™s election.The conversion rate for the 2026 Convertible NotesÂ was initially, and remains, 19.0404 shares of the Companyâ€™s common stock per $1,000 principal amount of the 2026 Convertible Notes, which is equivalent to an initial conversion price of approximatelyÂ $52.52 per share of the Companyâ€™s common stock. The conversion rate may be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.The Company was not permitted to redeem the 2026 Convertible NotesÂ prior to SeptemberÂ 20, 2023. The Company may redeem for cash all or any portion of the 2026 Convertible Notes, at its option, if the last reported sale price of its common stock has been at least 130% of the conversion price then in effect on the last trading day of, and for at least 19 other tradingÂ days (whether or not consecutive) during, any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100% of the principal amount of the 2026 Convertible NotesÂ to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2026 Convertible Notes, which means that the Company is not required to redeem or retire the 2026 Convertible NotesÂ periodically.If the Company undergoes a â€œfundamental changeâ€ (as defined in the 2026 Convertible NotesÂ Indenture), subject to certain conditions, holders of the 2026 Convertible NotesÂ may require the Company to repurchase for cash all or part of their 2026 Convertible NotesÂ at a repurchase price equal to 100% of the principal amount of the 2026 Convertible NotesÂ to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.The 2026 Convertible NotesÂ represent senior unsecured obligations and will rank senior in right of payment to the Companyâ€™s future indebtedness that is expressly subordinated in right of payment to the notes, equal in right of payment to the Companyâ€™s existing and future unsecured indebtedness that is not so subordinated, effectively junior in right of payment to any of the Companyâ€™s secured indebtedness to the extent of the value of the assets securing such indebtedness, and structurally subordinated to all existing and future indebtedness and other liabilities (including trade payables) incurred by the Companyâ€™s subsidiaries. The 2026 Convertible NotesÂ Indenture contains customary events of default with respect to the 2026 Convertible Notes, including that upon certain events of default (including the Companyâ€™s failure to make any payment of principal or interest on the 2026 Convertible NotesÂ when due and payable) occurring and continuing, the 2026 Convertible NotesÂ Trustee by notice to the Company, or the holders of at least 25% in principal amount of the outstanding 2026 Convertible NotesÂ by notice to the Company and the Convertible NotesÂ Trustee, may, and the 2026 Convertible NotesÂ Trustee at the request of such holders (subject to the provisions of the 2026 Convertible NotesÂ Indenture) shall, declare 100% of the principal of and accrued and unpaid interest, if any, on all the 2026 Convertible NotesÂ to be due and payable. In case of certain events of bankruptcy, insolvency or reorganization, involving the Company or a significant subsidiary, 100% of the principal of and accrued and unpaid interest on the 2026 Convertible NotesÂ will automatically become due and payable. Upon such a declaration of acceleration, such principal and accrued and unpaid interest, if any, will be due and payable immediately.The 2026 Convertible NotesÂ consist of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

Agreement, BioElectron may become entitled to receive contingent milestone payments of up to $200.0 million (in cash or in shares of the Companyâ€™s common stock, as determined by the Company) from the Company based on the achievement of certain regulatory and net sales milestones. 36 Table of ContentsSubject to the terms and conditions of the BioElectron Asset Purchase Agreement, BioElectron may also become entitled to receive contingent payments based on aÂ percentage of net sales of certain products.Subject to the terms and conditions of the Agreement and Plan of Merger, dated as of May 5, 2020 (the â€œCensa Merger Agreementâ€) by and among the Company, Hydro Merger Sub, Inc., the Companyâ€™s wholly owned, indirect subsidiary, and, solely in its capacity as the representative, agent and attorney-in-fact of the securityholders of Censa, Shareholder Representative Services LLC (such merger pursuant thereto, the â€œCensa Mergerâ€), former Censa securityholders may become entitled to receive contingent payments from the Company based on (i)Â the achievement of certain development and regulatory milestones up to an aggregate maximum amount of $217.5Â million for sepiapterinâ€™s two most advanced programs and receipt of a priority review voucher from the FDA as set forth in the Censa Merger Agreement, (ii)Â $109.0Â million in development and regulatory milestones for each additional indication of sepiapterin, (iii)Â the achievement of certain net sales milestones up to an aggregate maximum amount of $160.0Â million, (iv)Â aÂ percentage of annual net sales during specified terms, ranging from single to low double digits of the applicable net sales threshold amount, and (v)Â any sublicense fees paid to the Company in consideration of any sublicense of Censaâ€™s intellectual property to commercialize sepiapterin, on a country-by-country basis, which contingent payment shall equal to a mid-double digitÂ percentage of any such sublicense fees. In February 2023, the Company completed enrollment of its Phase 3 placebo-controlled clinical trial for sepiapterin for PKU. Â In connection with this event and pursuant to the Censa Merger Agreement, the Company paid a $30.0 million development milestone to the former Censa securityholders during the three months ended March 31, 2023. The Company elected to pay this milestone in the form of shares of its common stock, less certain cash payments in accordance with the Censa Merger Agreement. Pursuant to such election, the Company issued 657,462 shares of its common stock and paid $0.4 million to the former Censa securityholders. In May 2024, the Company announced the validation and acceptance for review of an MMA for sepiapterin by the EMA for the treatment of PKU. Pursuant to the Censa Merger Agreement, the acceptance triggered a $15.0 million regulatory milestone to the former Censa securityholders, which was recorded in research and development expense for the nine months ended September 30, 2024. As of September 30, 2024, the $15.0 million regulatory milestone was paid.In July 2024, the Company announced the submission of an NDA to the FDA for sepiapterin for the treatment of pediatric and adult patients with PKU, including the full spectrum of ages and disease subtypes. Pursuant to the Censa Merger Agreement, the decision to submit the NDA triggered a $25.0Â million regulatory milestone to the former Censa securityholders. In September 2024, the Company announced the FDA acceptance for filing of the NDA. Pursuant to the Censa Merger Agreement, the acceptance triggered a $25.0Â million regulatory milestone to the former Censa securityholders. Together, the $50.0Â million of regulatory milestones were recorded in research and development expense for the three and nine months ended September 30, 2024 and are recorded in accounts payable and accrued expenses on the consolidated balance sheet as of September 30, 2024.The Company also has the Tegsedi-Waylivra Agreement for the commercialization of Tegsedi and Waylivra, and products containing those compounds in countries in Latin America and the Caribbean. Akcea is entitled to receive royalty payments subject to certain terms set forth in the Tegsedi-Waylivra Agreement.The Company has employment agreements with certain employees which require the funding of a specific level of payments, if certain events, such as a change in control or termination without cause, occur. Additionally, the Company has royalty payments associated with Translarna, Emflaza, and Upstaza net product revenue, payable quarterly or annually in accordance with the terms of the related agreements.From time to time in the ordinary course of its business, the Company is subject to claims, legal proceedings and disputes. The Company is not currently aware of any material legal proceedings against it.37 Table of Contents11.Â Â Â Â Â Â Â Â Revenue recognitionNet product salesThe Company views its operations and manages its business in one operating segment.During the threeÂ months endedÂ SeptemberÂ 30,Â 2024 and 2023, net product sales outside of the United States were $83.5 million and $76.6 million, respectively, consisting of sales of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $72.3 million and $69.0 million of the net product sales outside of the United States for the three months ended SeptemberÂ 30,Â 2024 and 2023, respectively. During the three months ended SeptemberÂ 30,Â 2024 and 2023, net product sales in the United States were $51.9 million and $67.4 million, respectively, consisting solely of sales of Emflaza. During the three months ended SeptemberÂ 30,Â 2024, two countries, the United States and Brazil, accounted for at least 10% of the Companyâ€™s net product sales, representing $51.9 million and $29.2 million of the net product sales, respectively. During the three months ended SeptemberÂ 30,Â 2023, one country, the United States, accounted for at least 10% of the Companyâ€™s net product sales, representing $67.4 million of the net product sales. For the three months ended SeptemberÂ 30,Â 2024 and 2023, the Company had two and three distributors, respectively, that accounted for over 10% of the Companyâ€™s net product sales.For the nine months ended SeptemberÂ 30,Â 2024 and 2023, net product sales outside of the United States were $289.5 million and $318.5 million, respectively, consisting of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $246.2 million and $280.6 million of the net product sales outside of the United States for the nine months ended SeptemberÂ 30,Â 2024 and 2023, respectively. For the nine months ended SeptemberÂ 30,Â 2024 and 2023, net product sales in the United States were $156.7 million and $187.7 million, respectively, consisting solely of Emflaza. During the nine months ended SeptemberÂ 30,Â 2024, three countries, the United States, Brazil, and Russia, accounted for at least 10% of the Companyâ€™s net product sales, representing $156.7 million, $68.3 million, and $55.7 million of net product sales, respectively. During the nine months ended SeptemberÂ 30,Â 2023, three countries, the United States, Russia, and Brazil, accounted for at least 10% of the Companyâ€™s net product sales, representing $187.7 million, $69.0 million, and $52.5 million of net product sales, respectively. For the nine months ended SeptemberÂ 30,Â 2024 and 2023, the Company had two and two distributors, respectively, that each accounted for over 10% of the Companyâ€™s net product sales.As of SeptemberÂ 30,Â 2024 and December 31, 2023, the Company does not have a contract liabilities balance related to net product sales, and has not made significant changes to the judgments made in applying ASC Topic 606.Collaboration and Royalty revenueIn NovemberÂ 2011, the Company and the SMA Foundation entered into a licensing and collaboration agreement with Roche. Under the terms of the SMA License Agreement, Roche acquired an exclusive worldwide license to the Companyâ€™s SMA program.Under the agreement, the Company is eligible to receive additional payments from Roche if specified events are achieved with respect to each licensed product, including up to $135.0 million in research and development event milestones, up to $325.0 million in sales milestones upon achievement of specified sales events, and up to double digit royalties on worldwide annual net sales of a commercial product. The SMA program currently has one approved product, Evrysdi, which was approved in August 2020 by the FDA for the treatment of SMA in adults and children two months and older. As of SeptemberÂ 30,Â 2024, the Company does not have any remaining research and development event milestones that can be received. The remaining potential sales milestones that can be received is $150.0 million. For the three and nine months ended SeptemberÂ 30,Â 2024, the Company did not recognize collaboration revenue related to the SMA License Agreement with Roche. For the three and nine months ended September 30, 2023, the amounts recognized for the collaboration revenue related to the SMA License Agreement with Roche were immaterial.â€‹38 Table of ContentsIn addition to research and development and sales milestones, the Company is eligible to receive up to double-digit royalties on worldwide annual net sales of a commercial product under the SMA License Agreement. For the three and nine months ended SeptemberÂ 30,Â 2024, the Company has recognized $61.4 million and $145.7 million of royalty revenue, respectively, related to Evrysdi. For the three and nine months ended SeptemberÂ 30,Â 2023, the Company has recognized $50.2 million and $117.9 million of royalty revenue related to Evrysdi, respectively.Manufacturing Revenueâ€‹For the three months ended September 30, 2024, the Company did not recognize any revenue related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. For the nine months ended September 30, 2024, the Company recognized $1.7 million of manufacturing revenue related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. For the three and nine months ended SeptemberÂ 30,Â 2023, the Company recognized $2.4 million and $6.7 million of manufacturing revenue, respectively, related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. The Company has not made significant changes to the judgments made in applying ASC Topic 606 for the three and nine months ended SeptemberÂ 30,Â 2024 and 2023.As of SeptemberÂ 30,Â 2024, the Company does not have a contract liabilities balance related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. As of December 31, 2023, the Company had a contract liabilities balance of $0.8 million related to the production of plasmid DNA and AAV vectors for external customers, which is recorded within deferred revenue on the consolidated balance sheet. For the nine months ended SeptemberÂ 30,Â 2024, the Company recognized $0.8 million related to the amounts included in the contract liability balance at the beginning of the period. As of SeptemberÂ 30,Â 2024, the Company has no contract assets related to plasmid DNA and AAV production for external customers. As of December 31, 2023, the Company had contract assets of $0.2 million related to plasmid DNA and AAV production for external customers, which is recorded within prepaid expenses and other current assets on the consolidated balance sheet.In June 2024, the Company sold its gene therapy manufacturing business in Hopewell Township, New Jersey. Accordingly, the Company does not expect to have manufacturing revenue going forward.Remaining performance obligationsThere are no remaining performance obligations as of SeptemberÂ 30,Â 2024. The Companyâ€™s remaining performance obligations of $0.8 million as of December 31, 2023 were fully recognized during the nine months ended SeptemberÂ 30,Â 2024. â€‹12.Â Â Â Â Â Â Â Â Intangible assets and goodwillDefinite-lived intangiblesDefinite-lived intangible assets consisted of the following at SeptemberÂ 30,Â 2024 and December 31, 2023:â€‹â€‹â€‹

quarter ended SeptemberÂ 30,Â 2024, we recognized $51.9 million in net sales of Emflaza.Our marketing authorization for Translarna in the EEA is subject to annual review and renewal by the European Commission, or EC, following reassessment by the European Medicines Agency, or EMA, of the benefit-risk balance of the authorization, which we refer to as the annual EMA reassessment. In September 2022, we submitted a Type II variation to the EMA to support conversion of the conditional marketing authorization for Translarna to a standard marketing authorization, which included a report on the placebo-controlled trial of Study 041 and data from the open-label extension as further described below. Study 041 was an 18-month, placebo-controlled trial, followed by an 18-month open-label extension of Translarna in the treatment of ambulatory patients with nmDMD aged five years or older. In February 2023, we also submitted an annual marketing authorization renewal request to the EMA. In September 2023, the Committee for Medicinal Products for Human Use, or CHMP, gave a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna for the treatment of nmDMD and a negative opinion on the 42 Table of Contentsrenewal of the existing conditional marketing authorization of Translarna for the treatment of nmDMD. In January 2024, the CHMP issued a negative opinion for the renewal of the conditional marketing authorization following a re-examination procedure. In May 2024, the EC decided not to adopt the CHMPâ€™s negative opinion for the renewal of the conditional marketing authorization of Translarna and returned such opinion to the CHMP for re-evaluation. In June 2024, following the ECâ€™s request for re-review, the CHMP issued a negative opinion on the renewal of the conditional marketing authorization of Translarna for the treatment of nmDMD. On October 18, 2024, the CHMP maintained its negative opinion for the renewal of the conditional marketing authorization following the requested reexamination procedure. In accordance with EMA regulations, the opinion will be reviewed by the EC which is expected to decide on opinion adoption approximately 67 days from the date of issuance. If the EC adopts the negative opinion, Translarna would no longer have marketing authorization in the member states of the EEA. The marketing authorization for Translarna remains in effect, pending the ECâ€™s potential adoption of the negative opinion. Based on the timeline of these procedures, we expect the marketing authorization for Translarna to remain in effect approximately through the end of 2024. We are exploring other potential mechanisms by which we may provide Translarna to nmDMD patients in the EEA if the negative opinion is adopted by the EC.Each country, including each member state of the EEA, has its own pricing and reimbursement regulations. In order to commence commercial sale of product pursuant to our Translarna marketing authorization in any particular country in the EEA, we must finalize pricing and reimbursement negotiations with the applicable government body in such country. As a result, our commercial launch will continue to be on a country-by-country basis. We also have made, and expect to continue to make, product available under early access programs, or EAP programs, or similar styled programs both in countries in the EEA and other territories. Our ability to negotiate, secure and maintain reimbursement for product under commercial and EAP programs can be subject to challenge in any particular country and can also be affected by political, economic and regulatory developments in such country.There is substantial risk that if the EC adopts the CHMPâ€™s negative opinion, or we are otherwise unable to renew our EEA marketing authorization during any annual renewal cycle,Â or we are unable to identify other potential mechanisms by which we may provide Translarna to nmDMD patients in the EEA should the EC adopt the CHMPâ€™s negative opinion or our product label is materially restricted, we would lose all, or a significant portion of, our ability to generate revenue from sales of Translarna in the EEA and other territories.Translarna is an investigational new drug in the United States. During the first quarter of 2017, we filed a New Drug Application, or NDA, for Translarna for the treatment of nmDMD over protest with the United States Food and Drug Administration, or FDA. In October 2017, the Office of Drug Evaluation I of the FDA issued a Complete Response Letter for the NDA, stating that it was unable to approve the application in its current form. In response, we filed a formal dispute resolution request with the Office of New Drugs of the FDA. In February 2018, the Office of New Drugs of the FDA denied our appeal of the Complete Response Letter. In its response, the Office of New Drugs recommended a possible path forward for the ataluren NDA submission based on the accelerated approval pathway. This would involve a re-submission of an NDA containing the current data on effectiveness of ataluren with new data to be generated on dystrophin production in nmDMD patientsâ€™ muscles. We followed the FDAâ€™s recommendation and collected, using newer technologies via procedures and methods that we designed, such dystrophin data in a new study, Study 045, and announced the results of Study 045 in February 2021. Study 045 did not meet its pre-specified primary endpoint. In June 2022, we announced top-line results from the placebo-controlled trial of Study 041. Following this announcement, we submitted a meeting request to the FDA to gain clarity on the regulatory pathway for a potential re-submission of an NDA for Translarna. The FDA provided initial written feedback that Study 041 does not provide substantial evidence of effectiveness to support NDA re-submission. We held a Type C meeting with the FDA in the fourth quarter of 2023 to discuss the totality of Translarna data. Based on feedback from the FDA, we re-submitted the NDA in July 2024, based on the results from Study 041 and from our international drug registry study for nmDMD patients receiving Translarna. In October 2024, the FDA accepted for review the resubmission of the NDA for Translarna for the treatment of nmDMD. As this was an NDA resubmission following a complete response letter to the NDA which was filed over protest in 2016, the FDA is not obligated to follow the review timelines under Prescription Drug User Free Act guidelines and an action date has not been provided.We have previously relied on Emflazaâ€™s seven-year marketing exclusivity period in the United States for its approved indications under the provisions of the Orphan Drug ActÂ of 1983, or theÂ Orphan Drug Act, when commercializing Emflaza. 43 Table of ContentsEmflazaâ€™s seven-year period of orphan drug exclusivity related to the treatment of DMD in patients five years and older expired in February 2024. We expect the expiration of this orphan drug exclusivity to have a significant negative impact on Emflaza net product revenue. Emflazaâ€™s orphan drug exclusivity related to the treatment of DMD in patients two years of age to less than five expires in June 2026.Upstazaâ„¢ (eladocagene exuparvovec)Our product Upstaza is a gene therapy used for the treatment of Aromatic L-Amino Decarboxylase, or AADC, deficiency, a rare central nervous system, or CNS, disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene. In July 2022, the EC approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the EEA. In November 2022, the Medicines and Healthcare Products Regulatory Agency approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the United Kingdom. In March 2024, we submitted a biologics license application, or BLA, to the FDA for eladocagene exuparvovec for the treatment of AADC deficiency in the United States. In May 2024, the FDA accepted for filing the BLA for eladocagene exuparvovec for the treatment of AADC deficiency and granted priority review with a target regulatory action date of November 13, 2024.TegsediÂ® (inotersen) and Waylivraâ„¢ (volanesorsen)We hold the rights for the commercialization of Tegsedi and Waylivra for the treatment of rare diseases in countries in Latin America and the Caribbean pursuant to a Collaboration and License Agreement, or the Tegsedi-Waylivra Agreement, dated August 1, 2018, by and between us and Akcea Therapeutics, Inc., or Akcea, a subsidiary of Ionis Pharmaceuticals, Inc. Tegsedi has received marketing authorization in the United States, European Union, or EU, and Brazil for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis, or hATTR amyloidosis. In August 2021, ANVISA, the Brazilian health regulatory authority, approved Waylivra as the first treatment for familial chylomicronemia syndrome, or FCS, in Brazil. In December 2022, ANVISA approved Waylivra for the treatment of familial partial lipodystrophy, or FPL. Waylivra has also received marketing authorization in the EU for the treatment of FCS.EvrysdiÂ® (risdiplam)We also have a spinal muscular atrophy, or SMA, collaboration with F. Hoffman La Roche Ltd. and Hoffman La Roche inc., which we refer to collectively as Roche, and the Spinal Muscular Atrophy Foundation, or SMA Foundation.Â The SMA program has one approved product, Evrysdi (risdiplam), which was approved by the FDA in August 2020 for the treatment of SMA in adults and children two months and older and by the EC in March 2021 for the treatment of 5q SMA in patients two months and older with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. Evrysdi also received marketing authorization for the treatment of SMA in over 100 countries. In May 2022, the FDA approved a label expansion for Evrysdi to include infants under two months old with SMA. In August 2023, the EC approved an extension of the Evrysdi marketing authorization to include infants under two months old in the EU.Diversified Development PipelineSepiapterinOne of our most advanced clinical stage molecules is sepiapterin. Sepiapterin is a precursor to intracellular tetrahydrobiopterin, which is a critical enzymatic cofactor involved in metabolism and synthesis of numerous metabolic products. In May 2023, we announced that the primary endpoint was achieved in our registration-directed Phase 3 trial for sepiapterin for phenylketonuria, or PKU. The primary endpoint of the study was the achievement of statistically-significant reduction in blood Phe level. The primary analysis population included those patients who have a greater than 30% reduction in blood Phe levels during the Part 1 run-in phase of the trial. Sepiapterin demonstrated Phe level reduction of approximately 63% in the overall primary analysis population and Phe level reduction of approximately 69% in the subset for classical PKU patients. Additionally, sepiapterin was well tolerated with no serious adverse events. Following the placebo-controlled study, patients were eligible to enroll in a long-term open-label study, which is still ongoing and will evaluate long-term safety, durability and Phe tolerance. In March 2024, we submitted a marketing authorization 44 Table of Contentsapplication, or MAA, to the EMA for sepiapterin for the treatment of PKU in the EEA, which was validated and accepted for review by the EMA in May 2024. In the third quarter of 2023, we participated in a pre-NDA meeting with the FDA. At that meeting, the FDA stated that the sepiapterin clinical safety and efficacy data supported NDA submission for the treatment of pediatric and adult PKU patients. However, the FDA requested that we complete a 26-week nonclinical mouse study to assess sepiapterin carcinogenicity potential prior to NDA submission. This nonclinical study was not initially required when we acquired sepiapterin, as the NDA submission was planned under the Section 505(b)(2) pathway. Given that sepiapterin is a novel therapy with distinct pharmacology, biodistribution, mechanism of action and differentiated efficacy, we subsequently decided to make the NDA submission under the Section 505(b)(1) pathway, which requires the 26-week study, which is considered a required NDA component needed to inform labeling and is typically completed prior to submission. In July 2024, following completion of the in-life portion of the study, we submitted an NDA to the FDA for sepiapterin for the treatment of pediatric and adult patients with PKU, including the full spectrum of ages and disease subtypes, in the United States. In September 2024, the FDA accepted for filing the NDA, with a target regulatory action date of July 29, 2025. We also made a regulatory submission for sepiapterin for the treatment of PKU in Brazil in the third quarter of 2024, and expect to do the same in Japan in the fourth quarter of 2024.Splicing PlatformIn addition to our SMA program, our splicing platform also includes PTC518, which is being developed for the treatment of Huntingtonâ€™s disease, or HD. We announced the results from our Phase 1 study of PTC518 in healthy volunteers in September 2021 demonstrating dose-dependent lowering of huntingtin messenger ribonucleic acid and protein levels, that PTC518 efficiently crosses blood brain barrier at significant levels and that PTC518 was well tolerated. Â We initiated a Phase 2 study of PTC518 for the treatment of HD in the first quarter of 2022, which consists of an initial 12-week placebo-controlled phase focused on safety, pharmacology and pharmacodynamic effects followed by a nine-month placebo-controlled phase focused on PTC518 biomarker effect. In June 2023, we announced interim data from the 12-week placebo-controlled phase. The study demonstrated dose-dependent lowering of Huntingtin, or HTT, protein levels in peripheral blood cells, reaching an approximate mean 30% reduction in mutant HTT levels at the 10mg dose level. In addition, PTC518 exposure in the cerebrospinal fluid was consistent with or higher than plasma unbound drug levels. Furthermore, PTC518 was well tolerated with no treatment-related serious adverse events. In June 2024, we announced additional interim results from the Phase 2 study of PTC518. At month 12, PTC518 treatment demonstrated durable dose-dependent lowering of mutant HTT, or mHTT, protein in the blood and dose-dependent lowering of mHTT protein in the cerebrospinal fluid in the interim cohort of stage 2 patients. In addition, favorable trends were demonstrated on several relevant HD clinical assessments. Furthermore, following 12 months of treatment, PTC518 continued to be well tolerated. Based on its review of the interim Phase 2 study data, the FDA lifted the partial clinical hold on the program. In September 2024, the FDA granted Fast Track designation to the PTC518 program for the treatment of HD.Ferroptosis and Inflammation PlatformOur ferroptosis and inflammation platform consists of small molecule compounds that target oxidoreductase enzymes that regulate oxidative stress and inflammatory pathways central to the pathology of a number of CNS diseases. The two most advanced molecules in our ferroptosis and inflammation platform are vatiquinone and utreloxastat. Â We announced topline results from a registration-directed Phase 3 trial of vatiquinone in children and young adults with Friedreich ataxia, or FA, called MOVE-FA, in May 2023. While the study did not meet its primary endpoint of statistically significant change in modified Friedreich Ataxia Rating Scale, or mFARS, score at 72 weeks in the primary analysis population, vatiquinone treatment did demonstrate significant benefit on key disease subscales and secondary endpoints. In addition, in the population of subjects that completed the study protocol, significance was reached in the mFARS endpoint and several secondary endpoints, including the upright stability subscale. Furthermore, vatiquinone was well tolerated. In the first quarter of 2024, we met with the FDA, who expressed willingness to review an NDA for vatiquinone for the treatment of Friedreich ataxia based on the MOVE-FA trial as well as data from the ongoing open label extension study following the MOVE-FA trial. In October 2024, we announced that the pre-specified endpoint for two different FA long-term extension studies was met, with statistically significant evidence of durable treatment benefit on disease progression. We plan to submit an NDA for vatiquinone for the treatment of FA in the United States in December 2024. In the third quarter of 2021, we completed a Phase 1 trial in healthy volunteers to evaluate the safety and pharmacology of utreloxastat. Utreloxastat was found to be well-tolerated with no reported serious adverse events while demonstrating predictable 45 Table of Contentspharmacology.Â We initiated a Phase 2 registration directed trial of utreloxastat for amyotrophic lateral sclerosis, or ALS, in the first quarter of 2022. We expect topline results from this trial in the fourth quarter of 2024.Multi-Platform DiscoveryIn addition, we have a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas, including rare diseases.FundingThe success of our products and any other product candidates we may develop, depends largely on obtaining and maintaining reimbursement from governments and third-party insurers. Our revenues are primarily generated from sales of Translarna for the treatment of nmDMD in countries where we were able to obtain acceptable commercial pricing and reimbursement terms and in select countries where we are permitted to distribute Translarna under our EAP programs or through similar styled programs, and from sales of Emflaza for the treatment of DMD in the United States. We also generate revenue from sales of Upstaza for the treatment of AADC deficiency in the EEA and have recognized revenue associated with milestone and royalty payments from Roche pursuant to a License and Collaboration Agreement, or the SMA License Agreement, by and among us, Roche and, for the limited purposes set forth therein, the SMA Foundation, under our SMA program.To date, we have financed our operations primarily through the private offerings of convertible senior notes, public and â€œat the marketâ€ offerings of common stock, proceeds from royalty purchase agreements, net proceeds from our borrowings under our credit agreement with Blackstone, private placements of our convertible preferred stock and common stock, collaborations, bank and institutional lender debt, other convertible debt, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by our product candidates.. We have relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States since 2014, Emflaza for the treatment of DMD in the United States since 2017 and Upstaza for the treatment of AADC deficiency in the EEA since 2022. We have also relied on revenue associated with milestone and royalty payments from Roche pursuant to the SMA License Agreement, under our SMA program.In June 2024, we entered into an amendment with Royalty Pharma Investments 2019 ICAV, or Royalty Pharma, and Royalty Pharma plc, to the Amended and Restated Royalty Purchase Agreement, dated October 18, 2023, or the A&R Royalty Purchase Agreement, which amends and restates in its entirety the Royalty Purchase Agreement, dated as of July 17, 2020, or the Original Royalty Purchase Agreement. Pursuant to the A&R Royalty Purchase Agreement, we have sold to Royalty Pharma a portion of our right to receive sales-based royalty payments, or the Royalty, on worldwide net sales of Evrysdi and any other product developed pursuant to the SMA License Agreement under the SMA program. Â To date, Royalty Pharma has paid to us cash consideration of $1.9 billion (less Royalty payments received by us with respect to assigned Royalties, or the Assigned Royalty Rights) in exchange for 90.49% of the Royalty, which will be reduced to 83.33% after Royalty Pharma receives $1.3 billion in aggregate payments, or the Assigned Royalty Cap, from the Royalty assigned under the Original Royalty Purchase Agreement. Â We currently retain 9.51% of the Royalty, which increases to 16.67% after the Assigned Royalty Cap has been met. We have the option to sell our retained portions of the Royalty to Royalty Pharma in up to three tranches for the following payments: (1) $100.0 million in exchange for 3.81% of the Royalty, which increases to 6.67% after the Assigned Royalty Cap has been met, (2) $100.0 million in exchange for 3.81% of the Royalty, which increases to 6.67% after the Assigned Royalty Cap has been met, and (3) $50.0 million in exchange for 1.90% of the Royalty, which increases to 3.33% after the Assigned Royalty Cap has been met, in each case less Royalty payments received by us with respect to the Assigned Royalty Rights. See â€œItem 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€”Liquidity and capital resourcesâ€”Sources of Liquidityâ€ for additional information.The 2026 Convertible NotesÂ consist of $287.5 millionÂ aggregate principal amount ofÂ 1.50%Â convertible senior notes due 2026. The 2026 Convertible NotesÂ bear cash interest at a rate ofÂ 1.50%Â perÂ year, payable semi-annually on MarchÂ 15 and SeptemberÂ 15 of eachÂ year, beginning on MarchÂ 15, 2020. The 2026 Convertible NotesÂ will mature onÂ SeptemberÂ 15, 46 Table of Contents2026, unless earlier repurchased or converted. We received net proceeds ofÂ $279.3 million after deducting the initial purchasersâ€™ discounts and commissions and the offering expenses payable by us.In AugustÂ 2019, we entered into an At the Market Offering Sales Agreement, or the Sales Agreement, with Cantor Fitzgerald and RBC Capital Markets, LLC, or together, the Sales Agents,

pursuant to which, we may offer and sell shares of our common stock, having an aggregate offering price of up to $125.0 million from time to time through the Sales Agents by any method that is deemed to be an â€œat the market offeringâ€ as defined in RuleÂ 415(a)(4)Â promulgated under the Securities Act of 1933, as amended, or the Securities Act. During the three and nine months ended SeptemberÂ 30,Â 2024, we did not issue or sell any shares of common stock pursuant to the Sales Agreement. The remaining shares of our common stock available to be issued and sold, under the Sales Agreement, have an aggregate offering price of up to $93.0 million as of SeptemberÂ 30,Â 2024. As of SeptemberÂ 30,Â 2024, we had an accumulated deficit of $3,581.0 million. We had a net loss of $297.4 million and $470.8 million for the nine months ended SeptemberÂ 30,Â 2024 and 2023, respectively.We anticipate that we will continue to incur significant expenses in connection with our commercialization efforts in the United States, the EEA, Latin America and other territories, including expenses related to our commercial infrastructure and corresponding sales and marketing, legal and regulatory, and distribution and manufacturing undertakings as well as administrative and employee-based expenses. In addition to the foregoing, we expect to continue to incur significant costs in connection with ongoing, planned and potential future clinical trials and studies for sepiapterin and our splicing and ferroptosis and inflammation programs as well as studies in our products for maintaining authorizations, label extensions and additional indications. We continue to seek marketing authorization for Translarna for the treatment of nmDMD in territories that we do not currently have marketing authorization in. Additionally, the CHMP maintained its negative opinion for Translarna for the treatment of nmDMD following the request for re-examination procedure. In accordance with EMA regulations, the opinion will be reviewed by the EC which is expected to decide on opinion adoption approximately 67 days from the date of issuance. We are also exploring other potential mechanisms by which we may provide Translarna to nmDMD patients in the EEA if the negative opinion is adopted by the EC. In March 2024, we submitted a BLA to the FDA for our gene therapy for the treatment of AADC deficiency in the United States. In May 2024, the FDA accepted the filing for the BLA and granted priority review with a target regulatory action date of November 13, 2024. In March 2024, we submitted an MAA, to the EMA for sepiapterin for the treatment of PKU in the EEA. In July 2024, we submitted an NDA to the FDA for sepiapterin for the treatment of PKU in the United States. In September 2024, the FDA accepted for filing the NDA, with a target regulatory action date of July 29, 2025. These efforts may significantly impact the timing and extent of our commercialization and manufacturing expenses.â€‹We may seek to expand and diversify our product pipeline through opportunistically in-licensing or acquiring the rights to products, product candidates or technologies and we may incur expenses, including with respect to transaction costs, subsequent development costs or any upfront, milestone or other payments or other financial obligations associated with any such transaction, which would increase our future capital requirements.In July 2024, we announced the submission of an NDA to the FDA for sepiapterin for the treatment of PKU in the United States. Pursuant to the Agreement and Plan of Merger, dated May 5, 2020, or the Censa Merger Agreement, by and among us, Hydro Merger Sub, Inc., our wholly owned, indirect subsidiary, Censa Pharmaceuticals, Inc., or Censa, and, solely in its capacity as the representative, agent and attorney in fact of the securityholders of Censa, Shareholder Representative Services, LLC, the decision to submit the NDA triggered a $25.0Â million regulatory milestone to the former Censa securityholders. In September 2024, we announced the FDA acceptance for filing of the NDA. Pursuant to the Censa Merger Agreement, the acceptance triggered a $25.0Â million regulatory milestone to the former Censa securityholders. Together, the $50.0Â million of regulatory milestones were recorded in research and development expense for the three and nine months ended September 30, 2024 and are recorded in accounts payable and accrued expenses on the consolidated balance sheet as of September 30, 2024.Additionally, we expect to pay $4.5 million in regulatory milestone payments upon the approval of eladocagene exuparvovec for the treatment of AADC deficiency in the United States from the FDA pursuant to the Agreement and Plan of Merger, dated as of July 19, 2018, or the Agilis Merger Agreement, by and among us, Agility Merger Sub, Inc., a 47 Table of ContentsDelaware corporation and our wholly owned, indirect subsidiary, Agilis and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC. We also have certain significant contractual obligations and commercial commitments that require funding and we have disclosed these items under the heading â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations-Funding Obligationsâ€ in our 2023 Annual Report. There were no material changes to these obligations and commitments during the period ended SeptemberÂ 30,Â 2024. Furthermore, since we are a public company, we have incurred and expect to continue to incur additional costs associated with operating as such including significant legal, accounting, investor relations and other expenses.We have never been profitable and we will need to generate significant revenues to achieve and sustain profitability, and we may never do so. Accordingly, we may need to obtain substantial additional funding in connection with our continuing operations. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or our commercialization efforts.Financial operations overviewRevenuesNet product revenues. To date, our net product revenues have consisted primarily of sales of Translarna for the treatment of nmDMD in territories outside of the United States and sales of Emflaza for the treatment of DMD in the United States. We recognize revenue when performance obligations with customers have been satisfied. Our performance obligations are to provide products based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies. The performance obligations are satisfied at a point in time when our customer obtains control of the product, which is typically upon delivery. We invoice customers after the products have been delivered and invoice payments are generally due within 30 to 90Â days of invoice date. We determine the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods not yet provided. As we have identified only one distinct performance obligation, the transaction price is allocated entirely to the product sale. In determining the transaction price, a significant financing component does not exist since the timing from when we deliver product to when the customers pay for the product is typically less than oneÂ year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the sameÂ month.We record product sales net of any variable consideration, which includes discounts, allowances, rebates related to Medicaid and other government pricing programs, and distribution fees. We use the expected value or most likely amount method when estimating variable consideration, unless discount or rebate terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained.During the threeÂ months ended SeptemberÂ 30,Â 2024 and 2023, net product sales outside of the United States were $83.5 million and $76.6 million, respectively, consisting of sales of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $72.3 million and $69.0 million of the net product sales outside of the United States for the three months ended SeptemberÂ 30,Â 2024 and 2023, respectively. During the three months ended SeptemberÂ 30,Â 2024 and 2023, net product sales in the United States were $51.9 million and $67.4 million, respectively, consisting solely of sales of Emflaza. During the three months ended SeptemberÂ 30,Â 2024, two countries, the United States and Brazil, accounted for at least 10% of the Companyâ€™s net product sales, representing $51.9 million and $29.2 million of the net product sales, respectively. During the three months ended September 30, 2023, one country, the United States, accounted for at least 10% of the Companyâ€™s net product sales, representing $67.4 million of the net product sales, respectively. For the threeÂ months ended SeptemberÂ 30,Â 2024 and 2023, the Company had two and three distributors, respectively, accounted for over 10% of the Companyâ€™s net product sales.48 Table of ContentsDuring the nine months ended SeptemberÂ 30,Â 2024 and 2023, net product sales outside of the United States were $289.5 million and $318.5 million, respectively consisting of sales of Translarna, Tegsedi, Waylivra and Upstaza. Translarna net revenues made up $246.2 million and $280.6 million of the net product sales outside of the United States for the nine months ended SeptemberÂ 30,Â 2024 and 2023, respectively. Â For the nine months ended SeptemberÂ 30,Â 2024 and 2023, net product sales in the United States were $156.7 million and $187.7 million, respectively, consisting solely of sales of Emflaza. During the nine months ended SeptemberÂ 30,Â 2024, three countries, the United States, Brazil, and Russia, accounted for at least 10% of our net product sales, representing $156.7 million, $68.3 million, and $55.7 million of net product sales, respectively. During the nine months ended SeptemberÂ 30,Â 2023, three countries, the United States, Russia, and Brazil, accounted for at least 10% of our net product sales, representing $187.7 million, $69.0 million, and $52.5 million of net product sales, respectively. For the nine months ended SeptemberÂ 30,Â 2024 and 2023, we had a total of two and two distributors, respectively, that each accounted for over 10% of our net product sales.In relation to customer contracts, we incur costs to fulfill a contract but do not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. We consider any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise. Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense.Roche and the SMA Foundation Collaboration. In NovemberÂ 2011, we entered into the SMA License Agreement pursuant to which we are collaborating with Roche and the SMA Foundation to further develop and commercialize compounds identified under our SMA program with the SMA Foundation. The research component of this agreement terminated effective DecemberÂ 31, 2014. We are eligible to receive additional payments from Roche if specified events are achieved with respect to each licensed product, including up to $135.0 million in research and development event milestones, up to $325.0 million in sales milestones upon achievement of specified sales events, and up to double digit royalties on worldwide annual net sales of a commercial product. As of SeptemberÂ 30,Â 2024, we had recognized a total of $310.0 million in milestone payments and $487.5 million royalties on net sales pursuant to the SMA License Agreement. As of SeptemberÂ 30,Â 2024, there are no remaining research and development event milestones that we can receive. The remaining potential sales milestones as of SeptemberÂ 30,Â 2024 are $150.0 million upon achievement of certain sales events. For the three and nine months ended September 30, 2024, the Company did not recognize collaboration revenue related to the SMA License Agreement with Roche. For the three and nine months ended September 30, 2023, the amounts recognized for the collaboration revenue related to the SMA License Agreement with Roche were immaterial. For the three and nine months ended SeptemberÂ 30,Â 2024, we recognized $61.4 million and $145.7 million of royalty revenue, respectively, related to Evrysdi. For the three and nine months ended SeptemberÂ 30,Â 2023, we recognized $50.2 million and $117.9 million of royalty revenue, respectively, related to Evrysdi. Â In July 2020, we entered into the Original Royalty Purchase Agreement. Pursuant to the Original Royalty Purchase Agreement, we sold to Royalty Pharma 42.933%, or the Original Assigned Royalty Rights, of the Royalty for $650.0 million. At that time, we retained a 57.067% interest in the Royalty and all economic rights to receive the remaining potential regulatory and sales milestone payments under the SMA License Agreement.Pursuant to the A&R Royalty Purchase Agreement, Royalty Pharma has paid to us aggregate cash consideration of $1.9 billion (less Royalty payments received by us with respect to the Assigned Royalty Rights) in exchange for 90.49% of the Royalty, which will be reduced to 83.33% of the Royalty after Royalty Pharma receives $1.3 billion in aggregate payments from the Royalty assigned at the closing of the Original Purchase Agreement. Â We currently retain 9.51% of the Royalty, which increases to 16.67% after the Assigned Royalty Cap has been met, and all economic rights to receive the remaining potential regulatory and sales milestone payments under the SMA License Agreement.We have the option to sell our retained portions of the Royalty to Royalty Pharma in up to three tranches for the following payments: Â (1) $100.0 million in exchange for 3.81% of the Royalty, which increases to 6.67% after the Assigned Royalty Cap has been met, (2) $100.0 million in exchange for 3.81% of the Royalty, which increases to 6.67% after the Assigned Royalty Cap has been met, and (3) $50.0 million in exchange for 1.90% of the Royalty, which increases to 3.33% after the Assigned Royalty Cap has been met, in each case less Royalty payments received by us with respect to the Assigned 49 Table of ContentsRoyalty Rights. Â See â€œItem 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€”Liquidity and capital resourcesâ€”Sources of Liquidityâ€ for additional information.Research and development expenseResearch and development expenses consist of the costs associated with our research activities, as well as the costs associated with our drug discovery efforts, conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings. Our research and development expenses consist of:â—external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants;â—employee-related expenses, which include salaries and benefits, including share-based compensation, for the personnel involved in our drug discovery and development activities; andâ—facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities,Â IT, human resources and other support functions, depreciation of leasehold improvements and equipment, and laboratory and other supplies.We use our employee and infrastructure resources across multiple research projects, including our drug development programs. We track expenses related to our clinical programs and certain preclinical programs on a per project basis.We expect our research and development expenses to fluctuate in connection with our ongoing activities, particularly in connection with Study 041 and other studies for Translarna for the treatment of nmDMD, our activities under our splicing and ferroptosis and inflammation programs and performance of our post-marketing requirements imposed by regulatory agencies with respect to our products. The timing and amount of these expenses will depend upon the outcome of our ongoing clinical trials and the costs associated with our planned clinical trials. The timing and amount of these expenses will also depend on the costs associated with potential future clinical trials of our products or product candidates and the related expansion of our research and development organization, regulatory requirements, advancement of our preclinical programs, and product and product candidate manufacturing costs.The following tables provides research and development expense for our most advanced principal product development programs, for the three and nine months ended SeptemberÂ 30,Â 2024 and 2023. â€‹â€‹â€‹

of our lease for such facility.â€‹The successful development of our products and product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:â—the scope, rate of progress and expense of our clinical trials and other research and development activities;51 Table of Contentsâ—the potential benefits of our products and product candidates over other therapies;â—our ability to market, commercialize and achieve market acceptance for any of our products or product candidates that we are developing or may develop in the future, including our ability to negotiate pricing and reimbursement terms acceptable to us;â—clinical trial results;â—the terms and timing of regulatory approvals; andâ—the expense of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights.A change in the outcome of any of these variables with respect to the development of our products or product candidates could mean a significant change in the costs and timing associated with the development of those products or product candidates. For example, if the EMA or FDA or other regulatory authority were to require us to conduct clinical trials beyond those which we currently anticipate will be required for the completion of clinical development of any of our products or product candidates or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.Selling, general and administrative expenseSelling, general and administrative expenses consist primarily of salaries and other related costs for personnel, including share-based compensation expenses, in our executive, legal, business development, commercial, finance, accounting, information technology and human resource functions. Other selling, general and administrative expenses include facility-related costs not otherwise included in research and development expense; advertising and promotional expenses; costs associated with industry and trade shows; and professional fees for legal services, including patent-related expenses, accounting services and miscellaneous selling costs.We expect that selling, general and administrative expenses will increase in future periods in connection with our continued efforts to commercialize our products, including increased payroll, expanded infrastructure, commercial operations, increased consulting, legal, accounting and investor relations expenses.Interest expense, netInterest expense, net consists of interest expense from the liability for the sale of future royalties related to the Original Royalty Purchase Agreement, the A&R Royalty Purchase Agreement, the 2026 Convertible Notes outstanding, the Blackstone Credit Agreement that we repaid and terminated in October 2023, offset by interest income earned on investments.â€‹Critical accounting policies and significant judgments and estimatesOur managementâ€™s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. Actual results may differ from these estimates under different assumptions or conditions.During the three and nine months ended SeptemberÂ 30,Â 2024, there were no material changes to our critical accounting policies as reported in our 2023 Annual Report. 52 Table of ContentsResults of operationsThreeÂ months ended SeptemberÂ 30,Â 2024 compared to threeÂ months ended SeptemberÂ 30,Â 2023The following table summarizes revenues and selected expense and other income data for the threeÂ months ended SeptemberÂ 30,Â 2024 and 2023.â€‹â€‹â€‹

SeptemberÂ 30,Â 2023.Tangible asset impairment and losses (gains) on transactions, net. Tangible asset impairment and losses (gains) on transactions, net was $3.6 million for the nine months ended SeptemberÂ 30,Â 2024, an increase of $3.6 million, or 100%, from $0.0 million for the nine months ended SeptemberÂ 30,Â 2023. The increase was due to a $4.4 million loss primarily 56 Table of Contentsrelated to the sale of certain assets for gene therapy manufacturing, and a $1.5 million loss primarily related to fixed asset impairments in connection with the South Plainfield, New Jersey office closure in August 2024. These amounts were partially offset by a gain ofÂ $2.2 million on lease terminations and a $0.1 million gain on sales of fixed assets.Interest expense, net. Interest expense, net was $125.9 million for the nine months ended SeptemberÂ 30,Â 2024, an increase of $41.0 million, or 48%, from $84.9 million for the nine months ended SeptemberÂ 30,Â 2023. The increase in interest expense, net was primarily due to interest expense recorded from the liability for the sale of future royalties related to the A&R Royalty Purchase Agreement, offset by a decrease in interest expense due to the termination of our Blackstone Credit Agreement.Other expense, net. Other expense, net was $2.3 million for the nine months ended SeptemberÂ 30,Â 2024, a decrease of $6.5 million, or 74%, from other expense of $8.8 million for the nine months ended SeptemberÂ 30,Â 2023. The decrease in other expense primarily related to net realized and unrealized losses from foreign currency of $3.8 million for the nine months ended SeptemberÂ 30,Â 2024, offset by net unrealized and realized gains on our ClearPoint Neuro, Inc. convertible debt security and equity investments of $1.4 million. Â Other expense, net for the nine months ended September 30, 2023 was primarily related to realized and unrealized foreign exchange losses of $5.2 million and unrealized and realized losses, net, on our equity investments in ClearPoint Neuro, Inc. of $3.9 million and unrealized losses on our convertible debt security in ClearPoint Neuro, Inc. of $4.6 million. These expenses were offset by unrealized gains of $5.5 million on marketable securities â€“ equity investments for the nine months ended September 30, 2023. Income tax (expense) benefit. Income tax expense was $29.0 million for the nine months ended SeptemberÂ 30,Â 2024, a change of $97.2 million, or over 100%, compared to income tax benefit of $68.2 million for the nine months ended SeptemberÂ 30,Â 2023. The change in income tax expense (benefit) was attributable to the recognition of the revenue associated with the Royalty Pharma agreement of 2023. Additionally, we incur income tax expenses in various foreign jurisdictions, and our foreign tax liabilities are largely dependent upon the distribution of pre-tax earnings among these different jurisdictions.Liquidity and capital resources Sources of liquiditySince inception, we have incurred significant operating losses.As a growing commercial-stage biopharmaceutical company, we are engaging in significant commercialization efforts for our products while also devoting a substantial portion of our efforts on research and development related to our products, product candidates and other programs. To date, our product revenue has primarily consisted of sales of Translarna for the treatment of nmDMD in territories outside of the United States and from Emflaza for the treatment of DMD in the United States. Our ongoing ability to generate revenue from sales of Translarna for the treatment of nmDMD is dependent upon our ability to maintain our marketing authorizations in Brazil, Russia and in the EEA and secure market access through commercial programs following the conclusion of pricing and reimbursement terms at sustainable levels in the member states of the EEA or through EAP programs or similar styled programs in the EEA and other territories. In January 2024, the CHMP issued a negative opinion for the renewal of the conditional marketing authorization following a re-examination procedure. In May 2024, the EC decided not to adopt the CHMPâ€™s negative opinion for the renewal of the conditional marketing authorization of Translarna and returned such opinion to the CHMP for re-evaluation. In June 2024, following the ECâ€™s request for re-review, the CHMP issued a negative opinion on the renewal of the conditional marketing authorization of Translarna for the treatment of nmDMD. On October 18, 2024, the CHMP maintained its negative opinion for the renewal of the conditional marketing authorization following the requested reexamination procedure. In accordance with EMA regulations, the opinion will be reviewed by the EC which is expected to decide on opinion adoption approximately 67 days from the date of issuance. If the EC adopts the negative opinion, Translarna would no longer have marketing authorization in the member states of the EEA. The marketing authorization for Translarna remains in effect, pending the ECâ€™s potential adoption of the negative opinion. Based on the timeline of these procedures, we expect the marketing authorization for Translarna to remain in effect approximately through the end of 2024. We are exploring other potential mechanisms by which we may provide Translarna to nmDMD patients in the EEA if the negative opinion is adopted by the EC. Emflaza is approved in the United States for the treatment of DMD in patients two years and older. 57 Table of ContentsOur ability to generate product revenue from Emflaza will largely depend on the coverage and reimbursement levels set by governmental authorities, private health insurers and other third-party payors. Additionally, Emflazaâ€™s seven-year period of orphan drug exclusivity related to the treatment of DMD in patients five years and older expired in February 2024. We have previously relied on this exclusivity period to commercialize Emflaza in the United States. We expect the expiration of this orphan drug exclusivity to have a significant negative impact on Emflaza net product revenue. Emflazaâ€™s orphan drug exclusivity related to the treatment of DMD in patients two years of age to less than five expires in June 2026.â€‹We have historically financed our operations primarily through the issuance and sale of our common stock in public offerings, our â€œat the market offeringâ€ of our common stock, proceeds from the A&R Royalty Purchase Agreement, the private placements of our preferred stock, collaborations, bank and institutional lender debt, private offerings of convertible senior notes and convertible debt financings and grants and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease areas addressed by our product candidates. We expect to continue to incur significant expenses and operating losses for at least the next fiscal year. The net losses we incur may fluctuate significantly from quarter to quarter.In AugustÂ 2019, we entered into the Sales Agreement, pursuant to which, we may offer and sell shares of our common stock, having an aggregate offering price of up to $125.0 million from time to time through the Sales Agents by any method that is deemed to be an â€œat the market offeringâ€ as defined in RuleÂ 415(a)(4)Â promulgated under the Securities Act. See â€œItem 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€”Corporate Updatesâ€”Fundingâ€ for additional information.InÂ SeptemberÂ 2019, we closed a private offering ofÂ $287.5 millionÂ aggregate principal amount ofÂ 1.50%Â convertible senior notes due 2026 including the full exercise by the initial purchasers of an option to purchase an additional $37.5 million in aggregate principal amount of the 2026 Convertible Notes. The 2026 Convertible NotesÂ bear cash interest at a rate ofÂ 1.50%Â perÂ year, payable semi-annually onÂ MarchÂ 15Â andÂ SeptemberÂ 15Â of eachÂ year, beginning onÂ MarchÂ 15, 2020. The 2026 Convertible NotesÂ will mature onÂ SeptemberÂ 15, 2026, unless earlier repurchased or converted. We received net proceeds ofÂ $279.3 million after deducting the initial purchasersâ€™ discounts and commissions and the offering expenses payable by us.In October 2022, we entered into the Blackstone Credit Agreement for fundings of up to $950.0 million consisting of a committed loan facility funded on the Closing Date, in the aggregate principal amount of $300.0 million, and a delayed draw term loan facility of up to $150.0 million to be funded at our request within 18 months of the Closing Date subject to specified conditions, and further contemplating the potential for up to $500.0 million of additional financing, to the extent that we request such additional financing and subject to the Lendersâ€™ agreement to provide such additional financing and to mutual agreement on terms. In October 2023, we terminated the Blackstone Credit Agreement. All liens and security interests securing the loans made pursuant to the Blackstone Credit Agreement were released upon termination.We have received fundings from Royalty Pharma under the A&R Royalty Purchase Agreement in July 2020, October 2023 and June 2024 totaling $1.9 billion (less Royalty payments received by us with respect to the Assigned Royalty Rights). Â In exchange for these fundings, we sold Royalty Pharma 90.49% of the Royalty, which will be reduced to 83.33% after Royalty Pharma receives $1.3 billion in aggregate payments, or the Assigned Royalty Cap, from the Royalty assigned under the Original Royalty Purchase Agreement. Â We currently retain 9.51% of the Royalty, which increases to 16.67% after the Assigned Royalty Cap has been met. We have the option to sell our retained portions of the Royalty to Royalty Pharma in up to three tranches for the following payments: Â (1) $100.0 million in exchange for 3.81% of the Royalty, which increases to 6.67% after the Assigned Royalty Cap has been met, (2) $100.0 million in exchange for 3.81% of the Royalty, which increases to 6.67% after the Assigned Royalty Cap has been met, and (3) $50.0 million in exchange for 1.90% of the Royalty, which increases to 3.33% after the Assigned Royalty Cap has been met, in each case less Royalty payments received by us with respect to the Assigned Royalty Rights. Â The A&R Royalty Purchase Agreement includes specified negative and affirmative covenants with respect to our rights under the SMA License Agreement as well as other customary representations and warranties, covenants and other provisions. The A&R Royalty Purchase Agreement will terminate 60 days following the date on which Roche is no longer obligated to make any payments of the Royalty pursuant to the SMA License Agreement.58 Table of ContentsCash flowsAs of SeptemberÂ 30,Â 2024, we had cash, cash equivalents and marketable securities of $1.01 billion.The following table provides information regarding our cash flows and our capital expenditures for the periods indicated.â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Ended â€‹â€‹â€‹SeptemberÂ 30,Â â€‹(in thousands)Â Â Â Â 2024Â Â Â Â 2023â€‹Cash (used in) provided by:Â Â Â Â Â Â â€‹Operating activitiesâ€‹ (77,684)â€‹ (58,130)â€‹Investing activitiesâ€‹ (223,530)â€‹ (82,319)â€‹Financing activitiesâ€‹ 229,395â€‹ 25,915â€‹â€‹Net cash used in operating activities was $77.7 million for the nine months ended SeptemberÂ 30,Â 2024, and $58.1 million for the nine months ended SeptemberÂ 30,Â 2023. The net cash used in operating activities for the nine months ended September 30, 2024, was primarily related to spend supporting clinical development and commercial activities, partially offset by the cash received from the sales milestone of $100.0 million for the achievement of $1.5 billion in worldwide net sales from Evrysdi. The net cash used in operating activities for the nine months ended SeptemberÂ 30, 2023 primarily related to supporting clinical development and commercial activities.Net cash used in investing activities was $223.5 million for the nine months ended SeptemberÂ 30,Â 2024, and $82.3 million for the nine months ended SeptemberÂ 30,Â 2023. Cash used in investing activities for the nine months ended SeptemberÂ 30,Â 2024, was primarily related to the acquisition of product rights, purchases of marketable securities, and purchases of fixed assets, partially offset by net sales and redemption of marketable securities, proceeds from sales of fixed assets and proceeds from principal payment of the ClearPoint convertible debt security. Cash used in investing activities for the nine months ended September 30, 2023, was primarily related to the acquisition of product rights, purchases of marketable securities-equity investments, and purchases of fixed assets, partially offset by net sales and redemption of marketable securities.Net cash provided by financing activities was $229.4 million for the nine months ended SeptemberÂ 30,Â 2024, and $25.9 million for the nine months ended SeptemberÂ 30,Â 2023. Cash provided by financing activities for the nine months ended SeptemberÂ 30, 2024, was primarily attributable to proceeds from sales of future royalties, proceeds from our employee stock purchase plan, and proceeds from the exercise of options, partially offset by payments on our finance lease principal and payments on contingent consideration. Cash provided by financing activities for the nine months ended SeptemberÂ 30,Â 2023 was primarily attributable to cash received from the exercise of options, and proceeds from our employee stock purchase plan, partially offset by payments on our finance lease principal and debt issuance costs related to the senior secured term loan.Funding requirementsWe anticipate that we will continue to incur significant expenses in connection with our commercialization efforts in the United States, the EEA, Latin America and other territories, including expenses related to our commercial infrastructure and corresponding sales and marketing, legal and regulatory, and distribution and manufacturing undertakings as well as administrative and employee-based expenses. In addition to the foregoing, we expect to continue to incur significant costs in connection with ongoing, planned and potential future clinical trials and studies for sepiapterin and our splicing and ferroptosis and inflammation programs as well as studies in our products for maintaining authorizations, label extensions and additional indications. We continue to seek marketing authorization for Translarna for the treatment of nmDMD in territories that we do not currently have marketing authorization in. Additionally, the CHMP maintained its negative opinion for Translarna for the treatment of nmDMD following the request for re-examination procedure. In accordance with EMA regulations, the opinion will be reviewed by the EC, which is expected to decide on opinion adoption approximately 67 days from the date of issuance. We are exploring other potential mechanisms by which we may provide Translarna to nmDMD patients in the EEA if the negative opinion is adopted by the EC. In March 2024, we submitted a BLA to the FDA for our gene therapy for the treatment of AADC deficiency in the United States. In May 2024, the FDA 59 Table of Contentsaccepted the filing of the BLA and granted priority review with a target regulatory action date of November 13, 2024. Also in March 2024, we submitted an MAA to the EMA for sepiapterin for the treatment of PKU, which was validated and accepted for review by the EMA in May 2024. In July 2024, we submitted an NDA to the FDA for sepiapterin for the treatment of PKU. In September 2024, the FDA accepted for filing the NDA, with a target regulatory action date of July 29, 2025. These efforts may significantly impact the timing and extent of our commercialization and manufacturing expenses.In addition, our expenses will increase if and as we:â—seek to satisfy contractual and regulatory obligations that we assumed through our acquisitions and collaborations;â—execute our commercialization strategy for our products, including initial commercialization launches of our products, label extensions or entering new markets;â—are required to complete any additional clinical trials, non-clinical studies or Chemistry, Manufacturing and Controls, or CMC, assessments or analyses in order to advance Translarna for the treatment of nmDMD in the United States or elsewhere;â—are required to take other steps to maintain our current marketing authorization in the EEA, Brazil and Russia for Translarna for the treatment of nmDMD or to obtain further marketing authorizations for Translarna for the treatment of nmDMD or other indications;â—initiate or continue the research and development of sepiapterin and our splicing and ferroptosis and inflammation programs as well as studies in our products for maintaining authorizations, label extensions and additional indications;â—seek to discover and develop additional product candidates;â—seek to expand and diversify our product pipeline through strategic transactions;â—maintain, expand and protect our intellectual property portfolio; andâ—add operational, financial and management information systems and personnel, including personnel to support our product development and commercialization efforts.We believe that our cash flows from product sales, together with existing cash and cash equivalents, and marketable securities, will be sufficient to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.Our future capital requirements will depend on many factors, including:â—our ability to maintain our marketing authorization for Translarna for the treatment of nmDMD in the EEA following the CHMPâ€™s negative opinion on the conditional marketing authorization and the ECâ€™s potential adoption of the negative opinion or identify other potential mechanisms by which we may provide Translarna to nmDMD patients in the EEA;â—our ability to maintain the marketing authorization for Translarna and our other products in territories outside of the EEA;60 Table of Contentsâ—our ability to commercialize and market our products and product candidates that may receive marketing authorization;â—our ability to negotiate, secure and maintain adequate pricing, coverage and reimbursement terms, on a timely basis, with third-party payors for our products and products candidates;â—the amount of generic drug competition that we face for Emflaza following its loss of orphan drug exclusivity related to the treatment of DMD in patients five years and older;â—our ability to obtain marketing authorization for sepiapterin for the treatment of PKU in the United States and EEA;â—our ability to obtain marketing authorization for our gene therapy for the treatment of AADC deficiency in the United States;â—the costs, timing and outcome of our efforts to advance Translarna for the treatment of nmDMD in the United States, including, whether we will be required to perform additional clinical trials, non-clinical studies or CMC assessments or analyses at significant cost which, if successful, may support approval of Translarna for nmDMD in the United States;â—unexpected decreases in revenue or increase in expenses resulting from potential widespread outbreaks of contagious disease, such as COVID-19;â—our ability to successfully complete all post-marketing requirements imposed by regulatory agencies with respect to our products;â—the progress and results of activities for sepiapterin and our splicing and ferroptosis and inflammation programs as well as studies in our products for maintaining authorizations, label extensions and additional indications;â—the scope, costs and timing of our commercialization activities, including product sales, marketing, legal, regulatory, distribution and manufacturing, for any of our products and for any of our other product candidates that may receive marketing authorization or any additional territories in which we receive authorization to market Translarna;â—the costs, timing and outcome of regulatory review of sepiapterin and our splicing and ferroptosis and inflammation programs and Translarna and Upstaza in other territories;â—our ability to satisfy our obligations under the indenture governing the 2026 Convertible Notes;â—the timing and scope of any potential future growth in our employee base;â—the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our other product candidates, including those in our splicing and ferroptosis and inflammation programs;â—revenue received from commercial sales of our products or any of our product candidates;â—our ability to obtain additional and maintain existing reimbursed named patient and cohort EAP programs for Translarna for the treatment of nmDMD on adequate terms, or at all;â—the ability and willingness of patients and healthcare professionals to access Translarna through alternative means if pricing and reimbursement negotiations in the applicable territory do not have a positive outcome;61 Table of Contentsâ—our ability to satisfy our obligations under the terms of our lease agreements;â—the costs of preparing, filing and prosecuting patent applications, maintaining, and protecting our intellectual property rights and defending against intellectual property-related claims;â—the extent to which we acquire or invest in other businesses, products, product candidates, and technologies, including the success of any acquisition, in-licensing or other strategic transaction we may pursue, and the costs of subsequent development requirements and commercialization efforts, including with respect to our acquisitions of Emflaza, Agilis, our ferroptosis and inflammation platform and Censa and our licensing of Tegsedi and Waylivra; andâ—our ability to establish and maintain collaborations, including our collaborations with Roche and the SMA Foundation, and our ability to obtain research funding and achieve milestones under these agreements.With respect to our outstanding 2026 Convertible Notes, cash interest payments are payable on a semi-annual basis in arrears, which will require total funding of $4.3 million annually. In March

2024, we submitted a BLA to the FDA for our gene therapy for the treatment of AADC deficiency in the United States. Pursuant to the Censa Merger Agreement, the acceptance triggered a $15.0 million regulatory milestone to the former Censa securityholders, which was recorded in research and development expense for the nine months ended September 30, 2024. As of September 30, 2024, the $15.0 million milestone was paid. In July 2024, we announced the submission of an NDA to the FDA for sepiapterin for the treatment of pediatric and adult patients with PKU, including the full spectrum of ages and disease subtypes. Pursuant to the Censa Merger Agreement, the decision to submit the NDA triggered a $25.0 million regulatory milestone to the former Censa securityholders. In September 2024, we announced the FDA acceptance for filing of the NDA. Pursuant to the Censa Merger Agreement, the acceptance triggered a $25.0 million regulatory milestone to the former Censa securityholders. Together, the $50.0 million of regulatory milestones were recorded in research and development expense for the three and nine months ended September 30, 2024 and are recorded in accounts payable and accrued expenses on the consolidated balance sheet as of September 30, 2024.In March 2024, we submitted a BLA to the FDA for our gene therapy for the treatment of AADC deficiency in the United States. In May 2024, the FDA accepted the filing for the BLA and granted priority review with a target regulatory action date of November 13, 2024. Â As a result of the acceptance, we paid a $20.0 million milestone payment to former equity holders of Agilis, during the three and nine months ended September 30, 2024. As of September 30, 2024, the remaining potential regulatory milestones we expect to achieve is $11.1 million, and the remaining potential sales milestones we expect to achieve is $50.0 million, both of which relate solely to Upstaza.We also have certain significant contractual obligations and commercial commitments that require funding and we have disclosed these items under the heading â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations-Funding Obligationsâ€ in our 2023 Annual Report. There were no material changes to these obligations and commitments during the period ended SeptemberÂ 30,Â 2024. We have never been profitable and we will need to generate significant revenues to achieve and sustain profitability, and we may never do so. We may need to obtain substantial additional funding in connection with our continuing operations. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs primarily through a combination of equity offerings, debt financings, collaborations, strategic alliances, grants and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease areas addressed by our product and product candidates and marketing, distribution or licensing arrangements. Adequate additional financing may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our shareholders ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to 62 Table of Contentsrelinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.If we are unable to raise additional funds through equity, debt or other financings when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.â€‹ItemÂ 3. Quantitative and Qualitative Disclosures About Market Risk.During the period ended SeptemberÂ 30,Â 2024, there were no material changes in our market risk or how our market risk is managed, compared to those disclosed under the heading â€œQuantitative and Qualitative Disclosures about Market Riskâ€ in our 2023 Annual Report.â€‹ItemÂ 4. Controls and Procedures.Evaluation of Disclosure Controls and ProceduresOur management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of SeptemberÂ 30,Â 2024. The term â€œdisclosure controls and proceduresâ€, as defined in RulesÂ 13a-15(e)Â and 15d-15(e)Â under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commissionâ€™s rulesÂ and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the companyâ€™s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of SeptemberÂ 30,Â 2024, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.Changes in Internal Control over Financial ReportingNo change in our internal control over financial reporting occurred during the quarter ended SeptemberÂ 30,Â 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.â€‹PARTÂ IIâ€”OTHER INFORMATIONItemÂ 1. Legal Proceedings.From time to time in the ordinary course of our business, we are subject to claims, legal proceedings and disputes, including as a result of patients seeking to participate in our clinical trials or otherwise gain access to our product candidates. We are not currently aware of any material legal proceedings to which we are a party or of which any of our property is subject.â€‹ItemÂ 1A. Risk Factors.We have set forth in Item 1A to our Annual Report on Form 10-K for the year ended December 31, 2023, risk factors relating to our business, our industry, our structure and our common stock. Readers of this Quarterly Report on Form 10-Q are referred to such Item 1A for a more complete understanding of risks concerning us.â€‹63 Table of ContentsItem 5. Other Information.â€‹On November 5, 2024, William F. Bell, Jr., a member of the Companyâ€™s board of directors (the â€œBoardâ€), notified the Company of his resignation from the Board and the Compensation Committee thereof, effective as of November 7, 2024. Mr. Bell has informed the Company that his decision is based on his need to focus on other commitments and was not due to any disagreement with the Company.â€‹Director and Officer Trading ArrangementsA portion of the compensation of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) is in the form of equity awards and, from time to time, directors and officers engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or other Company securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, and for diversification or other personal reasons.Transactions in Company securities by directors and officers are required to be made in accordance with our insider trading policy, which requires that the transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in Company securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.The following table describes, for the quarterly period covered by this report, each trading arrangement for the sale or purchase of Company securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a â€œRule 10b5-1 trading arrangementâ€, or (2) a â€œnon-Rule 10b5-1 trading arrangementâ€ (as defined in Item 408(c) of Regulation S-K):â€‹Name(Title)Action Taken(DateÂ ofÂ Action)Type ofÂ TradingArrangementNatureÂ ofÂ TradingArrangement DurationÂ ofÂ TradingArrangementAggregateÂ Numberof Securities Allan Jacobson (Director)Adoption(AugustÂ 27, 2024)Rule 10b5-1 trading arrangementSaleUntil JanuaryÂ 2, 2025, or such earlier date upon which all transactions are completed.Up to 12,000 sharesChristine Utter(SVP, Chief Accounting Officer and Head of People Services)Adoption(AugustÂ 27, 2024)Rule 10b5-1 trading arrangementSaleUntil JanuaryÂ 2, 2025, or such earlier date upon which all transactions are completed.Up to 17,800 sharesâ€‹â€‹â€‹64 Table of ContentsItemÂ 6. Exhibits.â€‹â€‹â€‹ExhibitÂ NumberÂ DescriptionÂ ofÂ Exhibitâ€‹â€‹â€‹31.1*Â Certification of Principal Executive Officer pursuant to RuleÂ 13a-14(a)Â or RuleÂ 15d-14(a)Â of the Securities Exchange Act of 1934, as adopted pursuant to SectionÂ 302 of the Sarbanes-Oxley Act of 200231.2*Â Certification of Principal Financial Officer pursuant to RuleÂ 13a-14(a)Â or RuleÂ 15d-14(a)Â of the Securities Exchange Act of 1934, as adopted pursuant to SectionÂ 302 of the Sarbanes-Oxley Act of 200232.1*Â Certification of Principal Executive Officer pursuant to 18 U.S.C. SectionÂ 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 200232.2*Â Certification of Principal Financial Officer pursuant to 18 U.S.C. SectionÂ 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002101.INS*Â Inline XBRL Instance Document101.SCH*Â Inline XBRL Taxonomy Extension Schema Document101.CAL*Â Inline XBRL Taxonomy Extension Calculation Linkbase Document101.LAB*Â Inline XBRL Taxonomy Extension Label Linkbase Database101.PRE*Â Inline XBRL Taxonomy Extension Presentation Linkbase Document101.DEF*Â Inline XBRL Taxonomy Extension Definition Linkbase Document104â€‹The cover pageÂ from this Quarterly Report on FormÂ 10-Q, formatted in Inline XBRL*Â Â Â Â Â Submitted electronically herewith.In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed.â€‹â€‹â€‹65 Table of ContentsSIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.â€‹â€‹â€‹Â PTC THERAPEUTICS,Â INC.Â Â Â Â Â Â Date: November 7, 2024By:/s/ Pierre Gravierâ€‹â€‹â€‹Pierre Gravierâ€‹â€‹â€‹Chief Financial Officerâ€‹â€‹â€‹(Principal Financial Officer and Duly Authorized Signatory)â€‹â€‹â€‹â€‹â€‹â€‹â€‹66 EX-31.1 2 tmb-20240930xex31d1.htm EX-31.1 ExhibitÂ 31.1â€‹CERTIFICATIONSâ€‹I, Matthew B. Klein, certify that:â€‹1.Â Â Â Â Â Â Â Â Â Â Â I have reviewed this Quarterly Report on FormÂ 10-Q of PTC Therapeutics,Â Inc.;â€‹2.Â Â Â Â Â Â Â Â Â Â Â Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;â€‹3.Â Â Â Â Â Â Â Â Â Â Â Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;â€‹4.Â Â Â Â Â Â Â Â Â Â Â The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act RulesÂ 13a-15(e)Â and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act RulesÂ 13a-15(f)Â and 15d-15(f)) for the registrant and have:â€‹(a)Â Â Â Â Â Â Â Â Â Â Â Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;â€‹(b)Â Â Â Â Â Â Â Â Â Â Â Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;â€‹(c)Â Â Â Â Â Â Â Â Â Â Â Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andâ€‹(d)Â Â Â Â Â Â Â Â Â Â Â Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; andâ€‹5.Â Â Â Â Â Â Â Â Â Â Â The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):â€‹(a)Â Â Â Â Â Â Â Â Â Â Â All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andâ€‹(b)Â Â Â Â Â Â Â Â Â Â Â Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹Date: NovemberÂ 7, 2024By:/s/ MATTHEW B. KLEINÂ Â Matthew B. KleinÂ Â Chief Executive OfficerÂ Â (Principal Executive Officer)â€‹ EX-31.2 3 tmb-20240930xex31d2.htm EX-31.2 ExhibitÂ 31.2â€‹CERTIFICATIONSâ€‹I, Pierre Gravier, certify that:â€‹1.Â Â Â Â Â Â Â Â Â Â Â I have reviewed this Quarterly Report on FormÂ 10-Q of PTC Therapeutics,Â Inc.;â€‹2.Â Â Â Â Â Â Â Â Â Â Â Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;â€‹3.Â Â Â Â Â Â Â Â Â Â Â Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;â€‹4.Â Â Â Â Â Â Â Â Â Â Â The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act RulesÂ 13a-15(e)Â and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act RulesÂ 13a-15(f)Â and 15d-15(f)) for the registrant and have:â€‹(a)Â Â Â Â Â Â Â Â Â Â Â Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;â€‹(b)Â Â Â Â Â Â Â Â Â Â Â Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;â€‹(c)Â Â Â Â Â Â Â Â Â Â Â Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andâ€‹(d)Â Â Â Â Â Â Â Â Â Â Â Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; andâ€‹5.Â Â Â Â Â Â Â Â Â Â Â The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):â€‹(a)Â Â Â Â Â Â Â Â Â Â Â All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andâ€‹(b)Â Â Â Â Â Â Â Â Â Â Â Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹Date: November 7, 2024By:/s/ PIERRE GRAVIERÂ Â Pierre GravierÂ Â Chief Financial OfficerÂ Â (Principal Financial Officer)â€‹ EX-32.1 4 tmb-20240930xex32d1.htm EX-32.1 ExhibitÂ 32.1â€‹CERTIFICATION PURSUANT TO 18 U.S.C. SECTIONÂ 1350,AS ADOPTED PURSUANT TOSECTIONÂ 906 OF THE SARBANES-OXLEY ACT OF 2002â€‹In connection with the Quarterly Report on FormÂ 10-Q of PTC Therapeutics,Â Inc. (the â€œCompanyâ€) for the period ended SeptemberÂ 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), the undersigned, Matthew B. Klein, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. SectionÂ 1350, that to his knowledge:â€‹(1)Â Â Â Â Â Â Â Â Â Â Â the Report fully complies with the requirements of SectionÂ 13(a)Â or 15(d)Â of the Securities Exchange Act of 1934; andâ€‹(2)Â Â Â Â Â Â Â Â Â Â Â the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹Date: November 7, 2024By:/s/ MATTHEW B. KLEINÂ Â Matthew B. KleinÂ Â Chief Executive OfficerÂ Â (Principal Executive Officer)â€‹ EX-32.2 5 tmb-20240930xex32d2.htm EX-32.2 ExhibitÂ 32.2â€‹CERTIFICATION PURSUANT TO 18 U.S.C. SECTIONÂ 1350,AS ADOPTED PURSUANT TOSECTIONÂ 906 OF THE SARBANES-OXLEY ACT OF 2002â€‹In connection with the Quarterly Report on FormÂ 10-Q of PTC Therapeutics,Â Inc. (the â€œCompanyâ€) for the period ended SeptemberÂ 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), the undersigned, Pierre Gravier, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. SectionÂ 1350, that to his knowledge:â€‹(1)Â Â Â Â Â Â Â Â Â Â Â the Report fully complies with the requirements of SectionÂ 13(a)Â or 15(d)Â of the Securities Exchange Act of 1934; andâ€‹(2)Â Â Â Â Â Â Â Â Â Â Â the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹Date: November 7, 2024By:/s/ PIERRE GRAVIERâ€‹â€‹â€‹Pierre GravierÂ Â Chief Financial OfficerÂ Â (Principal Financial Officer)â€‹ EX-101.SCH 6 tmb-20240930.xsd EX-101.SCH 995200100 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 995200500 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 99940203 - Disclosure - Summary of significant accounting policies - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940302 -

Disclosure - Leases - Lease costs (Details) link:presentationLink link:calculationLink link:definitionLink 99940305 - Disclosure - Leases - Lease payments (Details) link:presentationLink link:calculationLink link:definitionLink 99940403 - Disclosure - Fair value of financial instruments and marketable securities - Marketable Securities, Unrealized Gains (Losses) (Details) link:presentationLink link:calculationLink link:definitionLink 99940404 - Disclosure - Fair value of financial instruments and marketable securities - Available-for-sale securities (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Accounts payable and accrued expenses - Components (Details) link:presentationLink link:calculationLink link:definitionLink 99940902 - Disclosure - Debt - Senior Secured Term Loan (Details) link:presentationLink link:calculationLink link:definitionLink 99940904 - Disclosure - Debt - Convertible Notes (Details) link:presentationLink link:calculationLink link:definitionLink 99941202 - Disclosure - Intangible assets and goodwill - Future Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - Consolidated Statements of Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 99930903 - Disclosure - Debt - (Tables) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - The Company (Details) link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - Summary of significant accounting policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940204 - Disclosure - Summary of significant accounting policies - Collaboration and Royalty Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 99940205 - Disclosure - Summary of significant accounting policies - Manufacturing Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 99940206 - Disclosure - Summary of significant accounting policies - Liability for Sale of Future Royalties (Details) link:presentationLink link:calculationLink link:definitionLink 99940207 - Disclosure - Summary of significant accounting policies - Tangible Asset Impairment and Losses (Gains) on Transactions, Net (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Fair value of financial instruments and marketable securities - Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 99940402 - Disclosure - Fair value of financial instruments and marketable securities - Hierarchy (Details) link:presentationLink link:calculationLink link:definitionLink 99940405 - Disclosure - Fair value of financial instruments and marketable securities - Marketable Securities, Balance Sheet Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 99940406 - Disclosure - Fair value of financial instruments and investments - Convertible senior notes (Details) link:presentationLink link:calculationLink link:definitionLink 99940407 - Disclosure - Fair value of financial instruments and investments - Summary of changes in the fair value of the Company's Level 3 valuation (Details) link:presentationLink link:calculationLink link:definitionLink 99940408 - Disclosure - Fair value of financial instruments and investments - Fair Value Liabilities Measured (Details) link:presentationLink link:calculationLink link:definitionLink 99940502 - Disclosure - Accounts payable and accrued expenses - Restructuring (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - Capitalization - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940702 - Disclosure - Net loss per share - Antidilutive (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Stock award plan - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940802 - Disclosure - Stock award plan - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 99940803 - Disclosure - Stock award plan - Assumptions Used (Details) link:presentationLink link:calculationLink link:definitionLink 99940804 - Disclosure - Stock award plan - Restricted Stock (Details) link:presentationLink link:calculationLink link:definitionLink 99940805 - Disclosure - Stock award plan - Share-based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - Debt - Liability for Sale of Future Royalties (Details) link:presentationLink link:calculationLink link:definitionLink 99940903 - Disclosure - Debt - 2026 Convertible Notes Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940905 - Disclosure - Debt - Convertible Notes Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - Revenue recognition - Net Product Sales (Details) link:presentationLink link:calculationLink link:definitionLink 99941102 - Disclosure - Revenue recognition - Collaboration and Royalty Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 99941103 - Disclosure - Revenue recognition - Manufacturing Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 99941104 - Disclosure - Revenue recognition - Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 99941201 - Disclosure - Intangible assets and goodwill - Definite-lived Intangibles (Details) link:presentationLink link:calculationLink link:definitionLink 99941203 - Disclosure - Intangible assets and goodwill - Indefinite-lived Intangibles (Details) link:presentationLink link:calculationLink link:definitionLink 99941204 - Disclosure - Intangible assets and goodwill - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - The Company link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Summary of significant accounting policies link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Fair value of financial instruments and marketable securities link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Accounts payable and accrued expenses link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Capitalization link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Net loss per share link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Stock award plan link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - Revenue recognition link:presentationLink link:calculationLink link:definitionLink 995211201 - Disclosure - Intangible assets and goodwill link:presentationLink link:calculationLink link:definitionLink 995211301 - Disclosure - Subsequent events link:presentationLink link:calculationLink link:definitionLink 99920202 - Disclosure - Summary of significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 99930203 - Disclosure - Summary of significant accounting policies (Tables) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - Leases - (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - Fair value of financial instruments and marketable securities - (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - Accounts payable and accrued expenses - (Tables) link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - Net loss per share - (Tables) link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - Stock award plan - (Tables) link:presentationLink link:calculationLink link:definitionLink 99931203 - Disclosure - Intangible assets and goodwill - (Tables) link:presentationLink link:calculationLink link:definitionLink 99940202 - Disclosure - Summary of significant accounting policies - Reconciliation of cash (Details) link:presentationLink link:calculationLink link:definitionLink 99940303 - Disclosure - Leases - Supplemental lease terms (Details) link:presentationLink link:calculationLink link:definitionLink 99940304 - Disclosure - Leases - Cash flow (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - Net loss per share - Numerator and Denominator (Details) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 tmb-20240930_cal.xml EX-101.CAL EX-101.DEF 8 tmb-20240930_def.xml EX-101.DEF EX-101.LAB 9 tmb-20240930_lab.xml EX-101.LAB Cover [Abstract] Document Type Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Securities Act File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Statement of Financial Position [Abstract] Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Marketable Securities, Current Marketable securities Receivables, Net, Current Trade and royalty receivables, net Inventory, Net Inventory, net Total inventory Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Fixed assets, net Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Goodwill Goodwill Operating Lease, Right-of-Use Asset Operating lease ROU assets Represents the carrying value of amounts transferred to third parties for security purposes and other noncurrent assets that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer. Deposits and Other Assets Noncurrent Deposits and other assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and stockholders' deficit Liabilities, Current [Abstract] Current liabilities: Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued expenses Accounts payable and accrued expenses Contract with Customer, Liability, Current Deferred revenue Operating Lease, Liability, Current Operating lease liabilities- current Finance Lease, Liability, Current Finance lease liabilities- current Amount of liabilities related to the sale of future royalties due within one year or the normal operating cycle, if longer. Liability, Sale of Future Royalties, Current Liability for sale of future royalties - current Liabilities, Current Total current liabilities Long-Term Debt, Excluding Current Maturities Long-term debt Business Combination, Contingent Consideration, Liability, Noncurrent Contingent consideration payable Deferred Income Tax Liabilities, Net Deferred tax liability Operating Lease, Liability, Noncurrent Operating lease liabilities- noncurrent Finance Lease, Liability, Noncurrent Finance lease liabilities- noncurrent Amount of liabilities related to the sale of future royalties due after one year or the normal operating cycle, if longer. Liability, Sale of Future Royalties, Noncurrent Liability for sale of future royalties- noncurrent Other Liabilities, Noncurrent Other long-term liabilities Liabilities Total liabilities Equity, Attributable to Parent [Abstract] Stockholders' deficit: Common Stock, Value, Issued Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 76,952,124 shares at September 30, 2024. Authorized 250,000,000 shares; issued and outstanding 75,708,889 shares at December 31, 2023 Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit) Accumulated deficit Equity, Attributable to Parent Balance at the end of the period Balance at the beginning of the period Total stockholders' deficit Liabilities and Equity Total liabilities and stockholders' deficit Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, authorized shares (in shares) Common stock, authorized shares (in shares) Common Stock, Shares, Issued Common stock, issued shares (in shares) Common Stock, Shares, Outstanding Common stock, outstanding shares (in shares) Income Statement [Abstract] Statement [Table] Statement [Table] Product and Service [Axis] Product and Service [Domain] Product [Member] Net product revenue Product Revenue generated under a collaboration agreement. Collaboration Revenue [Member] Collaboration revenue Royalty [Member] Royalty revenue Manufacturing product for third parties. Manufacturing [Member] Manufacturing revenue Statement [Line Items] Statement [Line Items] Revenues [Abstract] Revenues: Revenue from Contract with Customer, Excluding Assessed Tax Revenue Operating Expenses [Abstract] Operating expenses: Cost of Goods and Service, Excluding Amortization Of Intangible Assets Cost of Goods and Service, Excluding Amortization Of Intangible Assets Cost of product sales, excluding amortization of acquired intangible assets Amortization of Intangible Assets Amortization Amortization of acquired intangible assets Research and Development Expense Research and development Selling, General and Administrative Expense Selling, general and administrative Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset Change in the fair value of contingent consideration Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Impairment Intangible asset impairment Amount of net gain (loss) on disposition and impairment of tangible assets. Gain (Loss) On Disposition and Impairment Of Tangible Assets Tangible asset impairment and losses (gains) on transactions, net Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Interest Income (Expense), Nonoperating Interest expense, net Other Nonoperating Income (Expense) Other expense, net Gain (Loss) on Extinguishment of Debt Loss on extinguishment of debt Loss on extinguishment of debt Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income tax (expense) benefit Income Tax Expense (Benefit) Income tax (expense) benefit Net loss attributable to common stockholders Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted-average shares outstanding: Denominator Weighted Average Number of Shares Outstanding, Basic Basic Weighted Average Number of Shares Outstanding, Diluted Diluted Earnings Per Share [Abstract] Net loss per share-basic and diluted (in dollars per share) Earnings Per Share, Basic Basic Net loss per share - Basic Earnings Per Share, Diluted Diluted Net loss per share - Diluted Statement of Comprehensive Income [Abstract] Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive (loss) income: Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Unrealized gain on marketable securities, net of tax Unrealized gain on marketable securities, net of tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Foreign currency translation gain (loss), net of tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Statement of Stockholders' Equity [Abstract] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common stock Additional Paid-in Capital [Member] Additional paid-in capital AOCI Attributable to Parent [Member] Accumulated other comprehensive (loss) income Retained Earnings [Member] Accumulated deficit Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Shares, Issued Balance (in shares) Balance (in shares) Treasury Stock, Shares, Retired Retired shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Exercised (in shares) Exercise of options (in shares) Stock Issued During Period, Value, Stock Options Exercised Exercise of options Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Restricted stock vesting and issuance (in shares) Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Restricted stock vesting and issuance, net Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock in connection with an employee stock purchase plan (in shares) Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock in connection with an employee stock purchase plan Number of shares issued during the period as a result of a milestone payable. Stock Issued During Period, Shares, Milestone Payable Issuance of common stock in connection with a milestone payable (in shares) Shares issued for milestone payment Aggregate change in value for stock issued during the period as a result of milestone payable. Stock Issued During Period, Value, Milestone Payable Issuance of common stock in connection with a milestone payable APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Share-based compensation expense Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Comprehensive income (loss) Statement of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Operating Lease, Right-of-Use Asset, Periodic Reduction Non-cash operating lease expense Amount of royalty revenue included in net income relating to sale of future royalties that results in no cash inflow (outflow). Noncash Royalty Revenue, Sale of Future Royalties Non-cash royalty revenue related to sale of future royalties Amount of interest expense included in net income relating to the liability for sale of future royalties that results in no cash flow. Noncash Interest Expense, Liability Related to Sale of Future Royalties Non-cash interest expense on liability related to sale of future royalties Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Change in valuation of contingent consideration Tangible Asset Impairment Charges Tangible asset impairment Gain (Loss) on Disposition of Property Plant Equipment Loss on sale of fixed assets Gain (loss) on sale of fixed assets Gain (Loss) on Termination of Lease Gain on lease terminations Gain on lease terminations Gain on termination of lease components Amount of unrealized gain (loss) on ClearPoint equity investment measured at fair value with change in fair value recognized in net income (FV-NI). ClearPoint Equity Investment, FvNi Unrealized Gain (Loss) Unrealized (gain) loss on ClearPoint Equity Investments Unrealized Gain/(Loss) Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Unrealized loss on ClearPoint convertible debt security Unrealized Gain/(Loss) Equity Securities, FV-NI, Unrealized Gain (Loss) Unrealized gain on marketable securities - equity investments Unrealized Gain/(Loss) Amount of realized gain (loss) from sale of Clearpoint Equity Investment measured at fair value with change in fair value recognized in net income (FV-NI). Clearpoint Equity Investment, FV-NI, Realized Gain (Loss) Realized loss for the sale of ClearPoint Equity Investment Realized Gain/(Loss) Debt Securities, Available-for-Sale, Realized Gain (Loss) Realized loss on ClearPoint convertible debt security Realized Gain (Loss) Fair value of stock issued as payment of milestone. Issuance

of Stock for Milestone Payment Non-cash stock consideration, milestone payment Gain (Loss) on Disposition of Other Assets Disposal of asset Deferred Income Tax Expense (Benefit) Deferred tax benefit Deferred income taxes Accretion (Amortization) of Discounts and Premiums, Investments Amortization of discounts on investments, net Amortization of Debt Issuance Costs Amortization of debt issuance costs Share-Based Payment Arrangement, Noncash Expense Share-based compensation expense Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Unrealized foreign currency transaction losses, net Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Inventories Inventory, net Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Receivables Trade and royalty receivables, net Increase (Decrease) in Deposit Assets Deposits and other assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Increase (Decrease) in Other Operating Liabilities Other liabilities Increase (Decrease) in Contract with Customer, Liability Deferred revenue The increase (decrease) during the reporting period in the obligation liability recognized arising from contingent consideration in a business combination. Increase (Decrease) in Contingent Consideration Payments on contingent consideration Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash flows from investing activities Payments to Acquire Property, Plant, and Equipment Purchases of fixed assets Proceeds from Sale of Property, Plant, and Equipment Proceeds from sale of fixed assets Payments to Acquire Debt Securities, Available-for-Sale Purchases of marketable securities - available for sale Purchase of convertible note Payments to Acquire Marketable Securities Purchases of marketable securities - equity investments Investments Purchased Proceeds from Sale of Debt Securities, Available-for-Sale Sale and redemption of marketable securities- available for sale Proceeds from Sale and Maturity of Marketable Securities Redemptions/Sale Sale and redemption of marketable securities - equity investments The cash inflow associated with the aggregate amount received by the entity through sale or maturity of Clearpoint Equity Investment during the period. Proceeds From Sale And Maturity Of Clearpoint Equity Investment Redemptions/Sale Sale and redemption of ClearPoint Equity Investments The cash inflow associated with a principal payment received by the entity on Clearpoint convertible debt security during the period. Proceeds From Principal Payment of Clearpoint Convertible Debt Security Redemptions/Sale Proceeds from principal payment of Clearpoint convertible debt security Payments to Acquire Intangible Assets Acquisition of product rights and licenses Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities Proceeds from Stock Options Exercised Proceeds from exercise of options Proceeds from Stock Plans Proceeds from employee stock purchase plan Repayments of Secured Debt Repayment of senior secured term loan Payment for Debt Extinguishment or Debt Prepayment Cost Debt extinguishment costs related to senior secured term loan Prepayment premiums, expenses and other exit fees Cash received for sale of future royalties during the current period. Proceeds From Sale of Future Royalties Cash received from Royalty Pharma Proceeds from sales of future royalties Payments of Debt Issuance Costs Debt issuance costs related to secured term loan Payments on deferred and contingent consideration obligation. Payments On Deferred Consideration Obligation Payments on contingent consideration Payment of Finance Lease Principal Payment of Finance Lease Principal Payment of finance lease principal Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Effect of exchange rate changes on cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash and cash equivalents, and restricted cash end of period Cash and cash equivalents, and restricted cash beginning of period Total Cash, cash equivalents and restricted cash per statement of cash flows Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash information Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest Income Taxes Paid, Net Cash paid for income taxes Supplemental Cash Flow Elements [Abstract] Supplemental disclosure of non-cash investing and financing activity Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets obtained in exchange for operating lease obligations Noncash or Part Noncash Acquisition, Intangible Assets Acquired Acquisition of product rights and licenses The amount of fixed assets added through tenant improvement allowances that an Entity acquires in a noncash (or part noncash) acquisition. Noncash Or Part Noncash, Fixed Assets, Tenant Improvement Allowance Fixed asset additions through tenant improvement allowance The amount of recorded milestone payments payable. Milestone Payable Milestone payable Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature of Operations [Text Block] The Company Accounting Policies [Abstract] Basis of Presentation and Significant Accounting Policies [Text Block] Summary of significant accounting policies Leases The entire disclosure of information about leases. Lease Disclosure [Text Block] Leases Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair value of financial instruments and marketable securities Payables and Accruals [Abstract] Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accounts payable and accrued expenses Stockholders' Equity Note [Abstract] Equity [Text Block] Capital structure Earnings Per Share [Text Block] Net loss per share Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Text Block] Stock award plan Debt Disclosure [Abstract] Long-Term Debt [Text Block] Debt Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and contingencies Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Text Block] Revenue recognition Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Text Block] Intangible assets and goodwill Subsequent Events [Abstract] Subsequent Events [Text Block] Subsequent events Basis of Accounting, Policy [Policy Text Block] Basis of presentation Use of Estimates, Policy [Policy Text Block] Use of estimates Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Restricted Cash Marketable Securities, Policy [Policy Text Block] Marketable securities Disclosure of accounting policy for inventories and cost of revenue. Inventories And Cost Of Product Sales [Policy Text Block] Inventory and cost of product sales Revenue from Contract with Customer [Policy Text Block] Revenue recognition Credit Loss, Financial Instrument [Policy Text Block] Allowance for doubtful accounts Disclosure of accounting policy for liability resulting from the sale of future royalties. Liability for Sale of Future Royalties [Policy Text Block] Liability for sale of future royalties Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block] Indefinite-lived intangible assets Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Goodwill Income Tax, Policy [Policy Text Block] Income Taxes Lessee, Leases [Policy Text Block] Leases Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Tangible asset impairment and losses (gains) on transactions, net New Accounting Pronouncements, Policy [Policy Text Block] Recently issued accounting standards Restrictions on Cash and Cash Equivalents [Table Text Block] Reconciliation of cash Schedule of Inventory, Current [Table Text Block] Schedule of Inventory Lease, Cost [Table Text Block] Schedule of lease costs Tabular disclosure of supplemental cash flow information related to leases. Lease Supplemental Cash Flow Disclosure [Table Text Block] Schedule of supplemental cash flow information related to leases Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of future lease payments - Operating leases Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of future lease payments - Finance leases Marketable Securities [Table Text Block] Schedule of marketable securities Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of financial assets and liabilities that are required to be measured at fair value on a recurring basis Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Summary of marketable securities accounted for as available-for-sale debt securities Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Summary of unrealized losses and fair values of available-for-sale debt securities in a continuous unrealized loss position Debt Securities, Available-for-Sale [Table Text Block] Schedule of available-for-sale debt securities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Summary of changes in the fair value of the Company's Level 3 valuation for contingent consideration payable Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Fair value measurement inputs and valuation techniques Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of components of accounts payable and accrued expenses Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of computation of basic and diluted net loss available to common stockholders Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of historical dilutive common share equivalents outstanding Share-Based Payment Arrangement, Option, Activity [Table Text Block] Summary of stock option activity Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of assumptions used to estimate fair values of grants made on the date of grant Nonvested Restricted Stock Shares Activity [Table Text Block] Summary of information on the Company's restricted stock Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of share-based compensation expense recorded in the statement of operations Debt Instrument Redemption [Table] Debt Instrument Redemption [Table] Credit Facility [Axis] Credit Facility [Domain] Line of Credit [Member] Blackstone Credit Agreement Debt Instrument [Axis] Debt Instrument, Name [Domain] Convertible Senior Notes, 1.5%, Due September 15, 2026 [Member] 1.50% Convertible senior notes due 2026 1.50% Convertible senior notes due 2026 Debt Instrument, Redemption [Line Items] Debt Instrument, Redemption [Line Items] Tabular disclosure of activity related to the liability resulting from the sale of future royalties. Liability for Sale of Future Royalties [Table Text Block] Summary of liability for sale of future royalties Schedule of Line of Credit Facilities [Table Text Block] Schedule of credit agreement Convertible Debt [Table Text Block] Summary of convertible notes Tabular disclosure of interest expense recognized related to debt. Summary of Interest Expense Recognized Related to Debt [Table Text Block] Summary of interest expense recognized related to debt Tabular disclosure of interest expense recognized related to convertible debt. Schedule Of Interest Expense Recognized Related To Convertible Debt [Table Text Block] Summary of interest expense recognized related to the Convertible Notes Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of definite lived intangible assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of estimated future amortization of intangible assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Schedule of indefinite lived intangible assets Schedule of Long-Term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] Long-term debt Assigned royalty payments The number of products of the company. Number of Products Number of products Number of approved products Debt Instrument, Interest Rate, Stated Percentage Interest rate (as a percent) Accounting Standards Update and Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Information pertaining to the product Emflaza. Emflaza Emflaza Information pertaining to the product Translarna. Translarna Translarna Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Revenue from Contract with Customer Benchmark [Member] Net product revenue Concentration Risk Type [Axis] Concentration Risk Type [Domain] Geographic Concentration Risk [Member] Geographic concentration risk Customer Concentration Risk [Member] Customer concentration risk Geographical [Axis] Geographical [Domain] Non-US [Member] Non-US RUSSIAN FEDERATION Russia BRAZIL Brazil UNITED STATES United States Name of Property [Axis] Name of Property [Domain] Hopewell Campus Hopewell Campus Hopewell Campus Information pertaining to the leased premises in Warren, New Jersey. Warren Premises [Member] Warren Premises Fifth Anniversary [Member] Fifth Anniversary Fifth Anniversary Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Domain] Primary financial statement caption encompassing deposits and other noncurrent assets. Deposits and Other Noncurrent Assets [Member] Deposits and other assets Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Agilis [Member] Agilis Agilis Statistical Measurement [Axis] Statistical Measurement [Domain] Minimum [Member] Minimum Scenario [Axis] Scenario [Domain] Forecast [Member] Forecast New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Letters of Credit Outstanding, Amount Letters of credit Term for letter of credit Term for letter of credit Term for letter of credit (in years) Period after which Letter of Credit may be reduced if lease is not in default. Period After Which Letter of Credit May be Reduced if Lease Not in Default Period after which letter of credit may be reduced if lease is not in default Guaranty Liabilities Bank guarantee denominated in foreign currency Debt Securities, Available-for-Sale, Allowance for Credit Loss Allowance for credit loss Debt Securities, Available-for-Sale, Allowance for Credit Loss, Period Increase (Decrease) Increase in allowance for credit losses Accounts Receivable, Allowance for Credit Loss Allowance for doubtful accounts receivable Accounts Receivable, Credit Loss Expense (Reversal) Bad debt expense Number of countries exceeding the ten percent net product sales threshold. Number of Countries Exceeding Ten Percent Net Sales Threshold Number of countries exceeding 10% of net product sales Percentage of net product sales Percentage of net product sales threshold Current Federal, State and Local, Tax Expense (Benefit) [Abstract] Income taxes Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Federal income tax statutory rate Deferred Tax Liabilities, Gross Deferred tax liability Change in taxable income resulting from effects of a change in tax code regarding deduction of qualifying research and development costs under Section 174. Change in Taxable Income, Change in Tax Code, Qualifying Research and Development Costs Increase in current taxable income resulting from the elimination of current deduction of qualifying R&D costs under Section 174. Restricted Cash Restricted cash included in deposits and other assets Inventory, Raw Materials, Gross Raw materials Inventory, Work in Process, Gross Work in progress Inventory, Finished Goods, Gross Finished goods Inventory Write-down Inventory write-down Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement [Member] SMA License Agreement Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaboration and royalty revenue Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Revenue recognition Contract with Customer, Asset, after Allowance for Credit Loss, Current Contract with customer, asset Revenue, Remaining Performance Obligation, Amount Remaining performance obligations Information pertaining to the aggregate of Royalty Purchase Agreements which sold a percentage of future royalty payments in exchange for cash consideration. Aggregate Royalty Purchase Agreements [Member] Aggregate Royalty Purchase Agreements Represents the information pertaining to A&R Royalty Purchase Agreement. A and R Royalty Purchase Agreement [Member] A&R Royalty Purchase Agreement First portion of option to sell future royalty portions under terms of the amendment to the A&R Royalty Purchase Agreement. A and R Royalty Purchase Agreement, Amendment, Tranche One [Member] A&R Royalty Purchase Agreement Tranche One Second portion of option to sell future royalty portions under terms of the amendment to the A&R Royalty Purchase Agreement. A and R Royalty Purchase Agreement, Amendment, Tranche Two [Member] A&R Royalty Purchase Agreement Tranche Two Third portion of option to sell future royalty portions under terms of the amendment to the A&R Royalty Purchase Agreement. A and R Royalty Purchase Agreement, Amendment, Tranche Three [Member] A&R Royalty Purchase Agreement Tranche Three Counterparty Name [Axis] Counterparty Name [Domain] Represents the information pertaining to Royalty Pharma. Royalty Pharma [Member] Royalty Pharma Maximum [Member] Maximum Assigned Royalty Payment, Retained Percentage Assigned Royalty Payment, Retained Percentage Assigned royalty payment, retained percentage Remaining potential milestones that can be achieved. Revenue Recognition, Milestone, Potential Achievements Remaining potential milestones that can be achieved Royalty purchase agreement termination period once there are no further royalty payment obligations. Royalty Purchase Agreement, Termination Period Royalty purchase agreement termination period once there are no further royalty payment obligations The aggregate amount of royalties to be received after which the percentage is adjusted under terms of the Amended and Restated Royalty Purchase Agreement ("Assigned Royalty Cap"). Royalty Purchase Agreement, Payment Maximum Assigned Royalty Cap per terms of the royalty purchase agreement Debt Instrument, Interest Rate, Effective Percentage Effective interest rate of the liability component Effective interest rate Aggregate amount of upfront cash consideration received from the sale of future royalties. Aggregate Cash Proceeds from Sale of Future Royalties Aggregate upfront cash consideration received for sale of future royalties Total percentage of royalty rights assigned. Percentage of Total Royalty Assigned Aggregate percentage of royalty rights sold Number of tranches in which the retained royalty portions may be sold under terms of amended agreement. Number of Tranches To Sell Retained Royalty Number of tranches to sell retained royalty Percentage of maximum royalty payable thereafter assigned royalty rights. Percentage of Maximum Royalty Payable Thereafter Assigned Royalty Rights Percentage of maximum royalty payable thereafter assigned royalty rights Amount of liability recognized for sale of future royalties sold. Liability for Sale of Future Royalties Liability recognized for sale of future royalties. Amount of contract price for sale of specified percentage of future royalties per terms of agreement. Liability, Sale of Future Royalties, Contract Sale Price Contract price for sale of specified percentage of future royalties Adjusted percentage of retained royalty rights sold after the 2020 Assigned Royalty Cap is met. Adjusted Percentage of Retained Royalty Rights Sold After Assigned Royalty Cap Met Adjusted percentage of retained royalty rights sold after the 2020 Assigned Royalty Cap is met Adjusted percentage of retained royalty rights after the 2020 Assigned Royalty Cap is met. Adjusted Percentage of Retained Royalty Rights After Assigned Royalty Cap Met Adjusted percentage of retained royalty rights after the 2020 Assigned Royalty Cap is met Property, Plant and Equipment [Table] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Tangible personal property used in early-stage gene therapy programs. Early-stage Gene Therapy Program [Member] Early-stage gene therapy program assets Other Machinery and Equipment [Member] Other fixed assets Information pertaining to the Company's South Plainfield office in New Jersey. South Plainfield, New Jersey Office [Member] South Plainfield, New Jersey office Property, Plant and Equipment [Line Items] Asset Impairment Charges [Abstract] Asset impairment

and losses (gains) on transactions Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] MassBio MassBio MassBio Lessee, Lease, Description [Line Items] Leases Lessee, Operating Lease, Term of Contract Operating lease, term of contract Operating Lease, Expense Operating lease, expense Finance Lease, Interest Expense Finance lease cost Number of buildings leased during the period. Number Of Buildings Leased Number of buildings leased Area of Real Estate Property Area of real estate property Lessee, Operating Lease, Renewal Term Renewal term Number of renewable terms. Number of terms Number of renewable terms Lessee, Operating Lease, Existence of Option to Extend [true false] Lessee, Operating Lease, Liability, to be Paid Aggregate rent, Initial term Total lease payments Operating Lease, Liability Total Period of lessee's base rent abatement entitlement per terms of lease agreement. Lessee, Operating Lease, Base Rent Abatement Period Base rent abatement period Amount of base rent abatement available if lessee is not subject to an event of default as defined in the lease agreement. Lessee, Operating Lease, Base Rent Abatement Base rent abatement Amount of lessee's undiscounted obligation for lease payment for operating lease net of eligible base rent abatement. Lessee, Operating Lease, Liability, to be Paid, Net of Base Rent Abatement Aggregate rent net of base rate abatement, initial term The amount of allowance for lease improvements provided by lessor under the terms of the lease agreement. Operating Lease, Allowance for Lease Improvements Allowance for lease improvements Number of separate lease components in lease agreement. Number Of Lease Components Number of separate lease components Number of separate lease components in lease agreement terminated. Number Of Lease Components Terminated Number of separate lease components terminated Incremental borrowing rate of interest used to remeasure the remaining components of operating lease. Incremental Borrowing Rate, Remeasurement of Remaining Lease Component Incremental borrowing rate of interest used to remeasure the remaining components of operating lease The amount of reduction of letter of credit requirements pertaining to amendments to operating lease agreement. Reduction In Letter of Credit Return of letter of credit pertaining to amendments to operating lease agreement The amount of payment due from lessor at issuance of temporary certificate of occupancy that lessee has committed to fund into the construction account for lease improvements provided under the terms of the lease agreement. Operating Lease, Lessor Payment Due At Issuance of Temporary Certificate of Occupancy Payment due from lessor at issuance of temporary certificate of occupancy Operating Lease, Cost Fixed lease cost Variable Lease, Cost Variable lease cost Short-Term Lease, Cost Short-term lease cost Amount of lease cost recognized by lessee for lease contracts, excluding finance lease costs. Lease Cost, Excluding Finance Lease Costs Total operating lease cost Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease terms - operating leases (years) Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate - operating leases Finance Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease terms - finance lease (years) Finance Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate - finance lease Operating Lease, Payments Operating cash flows from operating leases Finance Lease, Principal Payments Financing cash flows from finance lease Finance Lease, Interest Payment on Liability Operating cash flows from finance leases Amount of decrease in operating lease right-of-use assets related to lease modifications and terminations. Right-of-Use Asset, Decrease Due to Lease Modifications and Terminations Obtained in Exchange for Finance Lease Liability Net decrease in right-of-use assets due to lease modification and termination Increase (Decrease) in Operating Liabilities Net decrease in operating lease liabilities due to lease modification and termination Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Operating leases Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year 2024 (excludes the nine months ended September 30, 2024) Lessee, Operating Lease, Liability, to be Paid, Year One 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three 2027 Amount of lessee's undiscounted obligation for lease payment for operating lease due fourth fiscal year and after following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Lessee, Operating Lease, Liability, to be Paid, Year Four and After 2028 and thereafter Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: Imputed Interest expense Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Finance leases Finance Lease, Liability, to be Paid, Year One 2025 Finance Lease, Liability, to be Paid, Year Two 2026 Finance Lease, Liability, to be Paid, Year Three 2027 Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year and after following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Finance Lease, Liability, to be Paid, Year Four and After 2028 and thereafter Finance Lease, Liability, to be Paid Total lease payments Finance Lease, Liability, Undiscounted Excess Amount Less: Imputed Interest expense Finance Lease, Liability Total Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Investment Type [Axis] Investments [Domain] Equity Securities [Member] Marketable securities - equity investments ClearPoint ClearPoint Equity Investment [Member] ClearPoint Equity Investment Convertible Debt Securities [Member] ClearPoint convertible debt Mutual Fund [Member] Mutual Funds Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Financial assets and liabilities measured at fair value on recurring basis Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Changes in fair value Equity Securities, FV-NI, Current Ending Balance Beginning Balance Marketable securities - equity investments Amount of unrealized gain (loss) from foreign currency transaction on marketable securities. Marketable Securities, Unrealized Gain (Loss), Foreign Currency Transaction Foreign Currency Unrealized Gain/(Loss) Amount of investment in equity security of ClearPoint Neuro, Inc. measured at fair value with change in fair value recognized in net income (FV-NI). ClearPoint Equity Investments, FV-NI Ending Balance Beginning Balance ClearPoint Equity Investments Amount of investment in convertible debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Convertible Debt Security Ending Balance Beginning Balance ClearPoint convertible debt security Amount of investment in marketable equity investments and convertible debt securities measured at fair value. Equity Investments and Convertible Debt Securities Ending Balance - Total Beginning Balance - Total Amount of unrealized gain (loss) on marketable equity investments and convertible debt securities measured at fair value with change in fair value recognized in net income (FV-NI). Marketable Equity investments and Convertible Debt Securities, Unrealized Gain (Loss) Unrealized Gain/(Loss) - Total Amount of realized gain (loss) from marketable equity investments and convertible debt securities measured at fair value with change in fair value recognized in net income (FV-NI). Marketable Equity Investments and Convertible Debt Securities, Realized Gain (Loss) Realized Gain/(Loss) - Total Amount of unrealized gain (loss) from foreign currency transaction on marketable equity investments and convertible debt securities. Marketable Equity Investments and Convertible Debt Securities, Unrealized Gain (Loss), Foreign Currency Transaction Foreign Currency Unrealized Gain/(Loss) - Total Amount of cash outflow for purchase of marketable equity investments and convertible debt securities. Marketable Equity Investments and Convertible Debt Securities, Purchases Investments Purchased - Total The cash inflow associated with the aggregate amount received by the entity through sale or redemption of marketable equity investments and convertible debt securities during the period. Proceeds From Sale and Redemption of Marketable Equity Investments and Convertible Debt Securities Redemptions/Sale - Total Debt Securities, Trading, and Equity Securities, FV-NI [Abstract] Equity Investments The number of mutual funds invested in that are denominated in a foreign currency. Number of Mutual Funds Invested In, Denominated in Foreign Currency Number of mutual funds denominated in a foreign currency Debt Securities, Available-for-Sale [Abstract] ClearPoint Convertible note The price per share of the conversion feature embedded in the available-for-sale convertible debt securities. Available-for-sale Debt Securities, Conversion Price Conversion price - convertible note Debt Securities, Available-for-Sale, Term Term of convertible note Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Recurring basis Financial Instrument [Axis] Financial Instruments [Domain] Debt Securities [Member] Marketable securities Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Liability, Development and Regulatory Milestone [Member] Development and Regulatory Milestones Development and Regulatory Milestones Liability, Net Sales Milestones and Royalties [Member] Liability, Net Sales Milestones and Royalties [Member] Net Sales Milestones and Royalties Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Quoted prices in active markets for identical assets (Level 1) Fair Value, Inputs, Level 2 [Member] Significant other observable inputs (Level 2) Fair Value, Inputs, Level 3 [Member] Significant unobservable inputs (Level 3) Debt Securities, Available-for-Sale Marketable securities - available for sale Fair Value Amount of transfers of assets measured on a recurring basis between Level 1, Level 2, and Level 3 of the fair value hierarchy. Fair Value, Assets, Transfers Between Level 1, Level 2 and Level 3, Amount Transfers of assets measured between Level 1, Level 2, and Level 3 Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-sale [Table] Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Commercial paper Corporate Debt Securities [Member] Corporate debt securities US Government Agencies Debt Securities [Member] Government obligations Debt Securities, Available-for-Sale [Line Items] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale, Amortized Cost Amortized Cost Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized, Gain Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized, Loss Debt Securities, Available-for-Sale, Allowance for Credit Loss, Writeoff Write downs of available for sale debt securities Debt Securities, Trading, Realized Gain (Loss) Realized gain (loss) from sale of marketable securities Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Securities in an unrealized loss position less than 12 months - Unrealized losses Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Securities in an unrealized loss position less than 12 months - Fair Value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Securities in an unrealized loss position greater than 12 months - Unrealized losses Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Securities in an unrealized loss position greater than 12 months - Fair Value Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Total - Unrealized losses Debt Securities, Available-for-Sale, Unrealized Loss Position Total - Fair Value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Marketable securities, Less Than 12 Months Long-Term Debt, Type [Axis] Long-Term Debt, Type [Domain] Convertible Debt [Member] Convertible debt Debt Instrument, Face Amount Principal Debt principal amount Debt Instrument, Fair Value Disclosure Fair value of convertible notes Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Information pertaining to Upstaza, gene therapy for treatment of AADC deficiency. Upstaza [Member] Upstaza Liability Class [Axis] Fair Value by Liability Class [Domain] Commitments [Member] Commitments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Changes in the fair value of warrant liability and SARs liability Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Ending Balance Beginning Balance Fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Additions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 Reclassification to accounts payable and accrued expenses Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Rights Exchange settlement Fair Value Measurement Inputs and Valuation Techniques [Table] Liability, Regulatory Milestone Regulatory Milestones Regulatory Milestones Valuation Approach and Technique [Axis] Valuation Approach and Technique [Domain] Valuation Technique, Discounted Cash Flow [Member] Valuation Technique, Discounted Cash Flow Valuation Technique, Option Pricing Model [Member] Valuation Technique, Option Pricing Model Measurement Input Type [Axis] Measurement Input Type [Domain] Development and Regulatory Milestone [Member] Development and Regulatory Milestone Development and Regulatory Milestone Represents information pertaining to certain sales events on the basis of which certain milestones are achieved. Sales Milestones Sales Milestones Probability of Success [Member] Probability of Success [Member] Probability of Success Measurement Input, Discount Rate [Member] Discount Rate Weighted Average [Member] Weighted Average Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Valuation Inputs Value of input used to measure Rights Exchange Settlement. Rights Exchange Settlement, Measurement Input Rights Exchange Settlement measurement The potential milestone payments due under the Rights Exchange Settlement. Rights Exchange Settlement, Potential Milestones, Value Potential milestones Amount of cash outflow for milestone obligations paid. Payment of Milestone Obligation Milestone obligation payments made Employee-related Liabilities, Current Employee compensation, benefits, and related accruals Accrued Income Taxes, Current Income tax payable Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting and contracted research. Accrued Consulting and Contracted Research Current Consulting and contracted research Sales Allowance And Other Related Costs Sales Allowance And Other Related Costs Sales allowance Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales rebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Sales Rebates, Current Sales rebates Accrued Royalties, Current Royalties Accrued royalties Accounts Payable, Current Accounts payable Other Accrued Liabilities, Current Other Restructuring Cost [Table] Restructuring Cost and Reserve [Line Items] Restructuring Charges [Abstract] Restructuring costs Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for restructuring costs. Accrued Restructuring Costs Accrued restructuring costs Capitalization, Equity [Table] information pertaining to the At the Market Offering Sales Agreement. At the Market Offering Sales Agreement [Member] Sales Agreement Schedule of Capitalization, Equity [Line Items] Common stock Sale of Stock, Number of Shares Issued in Transaction Number of shares issued in transaction (in shares) Value of shares available to be issued and sold in stock transaction. Sale of Stock, Shares Available to be Issued and Sold, Value Value of shares available to be issued and sold in transaction The aggregate value of remaining shares to be issued and sold under a sales agreement. Sale of Stock, Remaining Shares Available for Sale, Aggregate Offering Value Aggregate value of remaining shares to be issued and sold Amount of development milestone obligation payments made during the period. Development Milestone Obligation Payments Made Development milestone obligation payments made Amount of development milestone obligation cash payments made during the period. Development Milestone Obligation, Payments Made, Cash Development milestone obligation cash payments made Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Numerator Net Income (Loss) Available to Common Stockholders, Basic Net loss - Basic Antidilutive Security, Excluded EPS Calculation [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Represents information pertaining to Restricted Stock and Restricted Stock Units (RSUs). Restricted Stock and Restricted Stock Units [Member] Unvested restricted stock units Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Total shares excluded from calculation (in shares) Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Pertains to information pertaining to the 1998 Employee, Director and Consultant Stock Option Plan, 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan. 1998 Employee, Director, and Consultant Stock Option Plan, 2009 Equity and Long-term Incentive Plan, and 2013 Stock Incentive Plan 1998 Employee, Director, and Consultant Stock Option Plan, 2009 Equity and Long-term Incentive Plan, and 2013 Stock Incentive Plan Represents information pertaining to the Amended and Restated 2013 Long Term Incentive Plan. Amended and Restated 2013 Long Term Incentive Plan [Member] Amended 2013 LTIP Information pertaining to the 2020 Inducement Stock Incentive Plan. 2020 Inducement Stock Incentive Plan 2020 Inducement Stock Incentive Plan Employee Stock Ownership Plan (ESOP) Name [Axis] Employee Stock Ownership Plan (ESOP), Plan [Domain] Employee Stock [Member] Employee Stock Purchase Plan Equity Option [Member] Stock option Restricted Stock Units (RSUs) [Member] Restricted stock units Class of Stock [Axis] Class of Stock [Domain] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Stock option plan Restricted Stock Awards and Units Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Number of shares available for issuance Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Number of additional shares authorized (in shares) Represents the exercise price expressed as a percentage of the fair market value of the common stock as of the date of grant, at which grantees can acquire the shares reserved for issuance of stock options awarded. Share Based Compensation Arrangement by Share Based Payment Award Options Granted Exercise Price as Percentage of Fair Market Value of Common Stock Stock options granted, exercise price as percentage of the fair market value of common stock at grant date Represents the exercise price expressed as a percentage of the fair market value of the common stock as of the date of grant, at which grantees with specified common stock ownership percentage can acquire the shares reserved for issuance of stock options awarded. Share Based Compensation Arrangement by Share Based Payment Award Options Granted to Stockholders with Specified Ownership Percentage Exercise Price as Percentage of Fair Market Value of Common Stock Stock options granted to stockholder with specified ownership percentage, exercise price as percentage of the fair market

value of common stock at grant date Represents the stockholder's specified ownership percentage of the entity's common stock used in determination of the exercise price of stock options granted. Share Based Compensation Arrangement by Share Based Payment Award Stockholders Specified Ownership Percentage Stockholder's specified ownership percentage Represents the inducement grants for non-statutory stock options. Inducement Grants For Non-Statutory Stock Options Inducement grants for non-statutory stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Forfeited/Cancelled (in shares) Options forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Forfeited (in shares) Units forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Award requisite service period Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Purchase price of common stock, percent Employee Stock Purchase Plan, Voting Percentage Limit, Percent Employee Stock Purchase Plan, Voting Percentage Limit, Percent Employee stock purchase plan, voting percentage limit Share-Based Payment Arrangement, Expense Share-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted average remaining service period for recognition of unrecognized compensation cost Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Number of options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Outstanding at the end of the period (in shares) Outstanding at the beginning of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Vested or Expected to vest at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Exercisable at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted- average exercise price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding at the end of the period (in dollars per share) Outstanding at the beginning of the period (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited/Cancelled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Vested or Expected to vest at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Weighted-average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Outstanding at the end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Vested or Expected to vest at the end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Exercisable at the end of the period Share Based Compensation Arrangement by Share Based Payment Award Options Intrinsic Value [Roll Forward] Aggregate intrinsic value (in thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Outstanding at the end of the period (in dollars) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Vested or Expected to vest at the end of the period (in dollars) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Exercisable at the end of the period (in dollars) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Valuation assumptions Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term (in years) Share instrument which is convertible to stock or an equivalent amount of cash, if specified performance targets are met within the specified performance period. Restricted Stock Units, Performance-based (PSUs) [Member] Performance-based restricted stock units (PSUs) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Balance at the end of the period (in shares) Balance at the beginning of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Vested (in shares) Estimated period over which specified performance goals are to be met in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share-Based Compensation Arrangement by Share-Based Payment Award, Award Performance Period Performance period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Balance at the end of the period (in dollars per share) Balance at the beginning of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Forfeited (in dollars per share) Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Research and Development Expense [Member] Research and development Selling, General and Administrative Expenses [Member] Selling, general and administrative Amount of liabilities related to the sale of future royalties. Liability, Sale of Future Royalties Ending balance Beginning balance Amount of royalty revenue recognized during the period relating to the sale of future royalties payable under terms of the agreement. Liability, Sale of Future Royalties, Royalty Revenue Payable Less: Non-cash royalty revenue payable to Royalty Pharma Amount of interest expense recognized related to the liability for the sale of future royalties per terms of the agreement. Liability, Sale of Future Royalties, Interest Expense Plus: non-cash interest expense recognized Line of Credit Facility [Table] A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time and the lender is committed to providing the funds. Line of Credit, Committed Loan Facility [Member] Committed Loan Facility Secured Debt [Member] Senior Secured Term Loan A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time and the lender is committed to providing the funds. Line of Credit, Committed Delayed Draw Term Loan Facility [Member] Committed Delayed Draw Term Loan Facility A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time and the lender is not obligated to loan funds. Line of Credit, Uncommitted Loan Facility [Member] Uncommitted Incremental Facility Variable Rate [Axis] Variable Rate [Domain] Secured Overnight Financing Rate (SOFR) [Member] Adjusted Term SOFR Base Rate [Member] Base Rate Line of Credit Facility [Line Items] Line of Credit Facility [Abstract] Debt Facility Line of Credit Facility, Maximum Borrowing Capacity Maximum borrowing capacity Period of time after closing of the credit agreement during which funds can be drawn subject to specified conditions. Debt Instrument, Delayed Draw Term Fund draw term Debt Issuance Costs, Gross Debt issuance costs capitalized Debt Instrument, Basis Spread on Variable Rate Debt instrument, basis spread on variable rate Basis spread on variable rate Debt Instrument, Floor Interest Rate Debt Instrument, Floor Interest Rate Debt instrument, floor interest rate Floor interest rate Unamortized Debt Issuance Expense Less: Debt issuance costs Long-Term Debt Net carrying amount Net carrying amount Debt Instrument, Term Term of the convertible notes Loan term Interest Expense, Long-Term Debt Payment of accrued interest Legal Fees Legal fees Debt Related Commitment Fees and Debt Issuance Costs Debt issuance costs Interest Expense, Nonoperating [Abstract] Interest expense Interest Expense, Debt, Excluding Amortization Contractual interest expense Interest Expense, Debt Total Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Domain] Represents the debt instrument redemption period on or after September 20, 2023. Redemption on or after September 20, 2023 Redemption on or after September 20, 2023 Debt Instrument Additional Amount Available For Repurchase Debt Instrument Additional Amount Available For Repurchase Debt instrument additional amount available for repurchase Proceeds from Debt, Net of Issuance Costs Net proceeds from issuance of convertible notes Debt Instrument, Convertible, Threshold Trading Days Trading days, number Debt Instrument, Convertible, Threshold Consecutive Trading Days Consecutive trading days, period Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Stock price trigger Threshold period of specified business days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature. Debt Instrument Convertible Threshold Business Days Business days, period Threshold period of specified consecutive trading days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature. Debt Instrument Convertible Threshold Consecutive Trading Day Period Consecutive trading-day period Represents the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day. Debt Instrument Convertible Threshold Sale Price Of Common Stock Conversion Rate Product Percentage Maximum Maximum product of the closing sale price of shares of the Company's common stock and the applicable conversion rate for such trading day Debt Instrument, Convertible, Conversion Ratio Conversion ratio Debt Instrument, Convertible, Conversion Price Conversion price per share (in dollars per share) Debt Instrument, Redemption Price, Percentage Redemption price as percent of principal amount Debt Instrument, Cumulative Sinking Fund Payments Sinking fund Represents the debt instrument principal and unpaid interest payable upon events of default. Convertible Instruments Principal And Unpaid Interest Payable Upon Events Of Default Convertible instruments principal and unpaid interest payable upon events of default Represents the minimum percentage of debt principal amount by instrument holders. Minimum Percentage Of Debt Principal Amount By Instrument Holders Minimum percentage of principal held by convertible debt instrument holders required to issue notice for declaration of principal and unpaid interest payable upon events of default Liability, Development Milestone. Development Milestones Development Milestones BioElectron [Member] BioElectron BioElectron Rights Exchange Agreement [Member] Rights Exchange Agreement [Member] Rights Exchange Agreement Represents information pertaining to The Wellcome Trust Limited. Wellcome trust Wellcome Trust Akcea [Member] Akcea Akcea Censa Censa [Member] Censa information pertaining to former Censa securityholders. Former Censa Securityholders [Member] Former Censa Securityholders Represents information pertaining to the SMA Foundation. SMA Foundation [Member] SMA Foundation Accounts Payable and Accrued Liabilities [Member] Accounts payable and accrued expenses Other Commitments [Abstract] Other Commitments Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements. Development Milestone Payment Obligation Development milestone payment obligations Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements. Development Milestone Payment Obligations, Due on Second Anniversary Year of Merger Closing Development milestone payments which the entity is obligated to pay Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount Priority review voucher amount Amount of potential payments which may be due for developmental and regulatory milestones if achieved. Contingent Liability, Milestone, Potential Achievements, Developmental and Regulatory Milestones Potential developmental and regulatory milestones Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone And Regulatory Approval Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone Potential sales milestones Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage Product sales (as a percent) Royalty Expense Royalty expense since inception The amount of potential royalties due on worldwide net product sales per terms of the collaboration agreement. Potential Royalties Due, Net Product Sales Potential royalty payments due on net product sales Milestone payment which the entity is obliged to pay upon regulatory approval Milestone, Potential Achievements, Regulatory Approval Milestone payments triggered Asset Acquisition, Milestone, Amount Asset Acquisition, Milestone, Amount Asset acquisition, milestone, amount Asset Acquisition, Development And Regulatory Milestones Asset Acquisition, Development And Regulatory Milestones Asset acquisition, development and regulatory milestones Asset Acquisition, Net Sales Milestone Asset Acquisition, Net Sales Milestone Asset acquisition, net sales milestone Contingent Liability cancellation and forfeiture, Milestone, Potential Achievements, Priority Review Voucher Amount Contingent Liability cancellation and forfeiture, Milestone, Potential Achievements, Priority Review Voucher Amount Contingent liability cancellation and forfeiture of potential milestone payments Development Milestone Payment Obligations, Cancellation and Forfeiture Development Milestone Payment Obligations, Cancellation and Forfeiture Development milestone payment obligations, cancellation and forfeiture Development Milestone Payment Obligations, net of cancellation and forfeiture Development Milestone Payment Obligations, Net of Cancellation and Forfeiture Development milestone payment obligations, net of cancellation and forfeiture Contingent Liability, Cancellation and Forfeiture Contingent Liability, Cancellation and Forfeiture Contingent liability, cancellation and forfeiture Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture Contingent liability, milestone, potential achievements, priority review voucher amount, net of cancellation and forfeiture Number of Operating Segments Number of operating segments Number of Distributors Number of distributors Number of distributors Contract with Customer, Liability Contract with customer, liability Information by categories of milestones achieved. Milestone [Axis] Different categories of milestones defined by agreements. Milestone [Domain] Represents information pertaining to certain research and development events and certain sales events on the basis of which certain milestones are achieved. Research and Development and Sales Milestones [Member] Research and Development and Sales Milestones Represents information pertaining to certain research and development events on the basis of which certain milestones are achieved. Research And Development Event Milestones Research And Development Event Milestones Primary financial statement caption encompassing deferred revenues. Deferred Revenue [Member] Deferred revenue Prepaid Expenses and Other Current Assets [Member] Prepaids and other current assets Contract with Customer, Liability, Revenue Recognized Contract liability revenues recognized in period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Remaining Performance Obligation Intangible Asset, Finite-Lived [Table] Schedule of Finite-Lived Intangible Assets [Table] Asset Class [Axis] Asset Class [Domain] Finite-Lived Intangible Assets [Member] Definite-lived intangible assets Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Information pertaining to the drug Waylivra. Waylivra [Member] Waylivra Information pertaining to the drug Tegesdi. Tegsedi [Member] Tegsedi Finite-Lived Intangible Assets [Line Items] Definite-lived intangible assets Amount of cash outflow for royalty obligations paid. Payment of Royalty Obligation Royalty payments Finite-Lived Intangible Assets, Remaining Amortization Period Remaining amortization period Finite-Lived Intangible Assets [Roll Forward] Definite-lived intangibles Finite-Lived Intangible Assets, Gross Ending balance - Definite-lived assets, Gross Beginning balance - Definite-lived assets, Gross Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life. Finite-Lived Intangible Assets, Additions Additions Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss) Foreign Currency Translation Finite-Lived Intangible Assets, Accumulated Amortization Ending balance - Accumulated amortization Beginning balance - Accumulated amortization Amount of foreign currency translation gain (loss) which increases (decreases) accumulated amortization of an asset, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. Indefinite-Lived Intangible Assets, Accumulated Depreciation, Foreign Currency Translation Gain (Loss) Foreign Currency Translation - Accumulated amortization Finite-Lived Intangible Assets, Net Total Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year 2024 Finite-Lived Intangible Asset, Expected Amortization, Year One 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Two 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Three 2027 Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year and years thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling

approach). Finite-Lived Intangible Assets, Amortization Expense, Year Four and Thereafter 2028 and thereafter Intangible Asset, Indefinite-Lived [Table] Indefinite-Lived Intangible Assets [Member] Indefinite-lived intangible assets Indefinite-Lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Roll Forward] Indefinite-lived intangibles Indefinite-Lived Intangible Assets (Excluding Goodwill) Ending Balance Beginning Balance Indefinite-Lived Intangible Assets, Period Increase (Decrease) Change in indefinite-lived intangibles Goodwill [Table] Goodwill [Line Items] Goodwill Goodwill, Period Increase (Decrease) Changes in goodwill Represents information pertaining to company common stock. Common Stock Trading Arrangement [Member] Common Stock Trading Arrangement Represents information pertaining to Allan Jacobson. Allan Jacobson [Member] Allan Jacobson Represents information pertaining to Christine Utter. Christine Utter [Member] Christine Utter EX-101.PRE 10 tmb-20240930_pre.xml EX-101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover - shares 9 Months Ended Sep. 30, 2024 Nov. 05, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 001-35969 Â Entity Registrant Name PTC Therapeutics,Â Inc. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 04-3416587 Â Entity Address, Address Line One 500 Warren Corporate Center Drive Â Entity Address, City or Town Warren Â Entity Address, State or Province NJ Â Entity Address, Postal Zip Code 07059 Â City Area Code 908 Â Local Phone Number 222-7000 Â Title of 12(b) Security Common Stock, $0.001 par value per share Â Trading Symbol PTCT Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Large Accelerated Filer Â Entity Small Business false Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 77,125,143 Entity Central Index Key 0001070081 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Amendment Flag false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 526,001 $ 594,001 Marketable securities 487,356 282,738 Trade and royalty receivables, net 199,976 160,822 Inventory, net 35,671 30,577 Prepaid expenses and other current assets 32,546 150,491 Total current assets 1,281,550 1,218,629 Fixed assets, net 63,175 87,089 Intangible assets, net 330,368 379,497 Goodwill 82,341 82,341 Operating lease ROU assets 59,465 91,896 Deposits and other assets 25,337 36,246 Total assets 1,842,236 1,895,698 Current liabilities: Â Â Accounts payable and accrued expenses 336,346 391,983 Deferred revenue Â 801 Operating lease liabilities- current 14,113 13,002 Finance lease liabilities- current 2,642 3,000 Liability for sale of future royalties - current 257,611 194,314 Total current liabilities 610,712 603,100 Long-term debt 285,106 284,213 Contingent consideration payable 22,000 36,300 Deferred tax liability 55,909 55,905 Operating lease liabilities- noncurrent 82,770 97,627 Finance lease liabilities-noncurrent 15,574 17,184 Liability for sale of future royalties- noncurrent 1,824,440 1,619,783 Other long-term liabilities 77 141 Total liabilities 2,896,588 2,714,253 Stockholders' deficit: Â Â Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 76,952,124 shares at September 30, 2024. Authorized 250,000,000 shares; issued and outstanding 75,708,889 shares at December 31, 2023 76 75 Additional paid-in capital 2,530,902 2,466,233 Accumulated other comprehensive loss (4,343) (1,285) Accumulated deficit (3,580,987) (3,283,578) Total stockholders' deficit (1,054,352) (818,555) Total liabilities and stockholders' deficit $ 1,842,236 $ 1,895,698 X - DefinitionRepresents the carrying value of amounts transferred to third parties for security purposes and other noncurrent assets that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer. + ReferencesNo definition available. + Details Name: ptct_DepositsAndOtherAssetsNoncurrent Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities related to the sale of future royalties due within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: ptct_LiabilitySaleOfFutureRoyaltiesCurrent Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities related to the sale of future royalties due after one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: ptct_LiabilitySaleOfFutureRoyaltiesNoncurrent Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxLiabilitiesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1

-SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_ReceivablesNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Balance Sheets (Parenthetical) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Common stock, par value (in dollars per share) $ 0.001 $ 0.001 Common stock, authorized shares (in shares) 250,000,000 250,000,000 Common stock, issued shares (in shares) 76,952,124 75,708,889 Common stock, outstanding shares (in shares) 76,952,124 75,708,889 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Operations - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenues: Â Â Â Â Revenue $ 196,786,000 $ 196,576,000 $ 593,608,000 $ 630,766,000 Operating expenses: Â Â Â Â Cost of product sales, excluding amortization of acquired intangible assets 10,848,000 9,493,000 41,115,000 36,368,000 Amortization of acquired intangible assets 3,036,000 58,649,000 57,431,000 145,461,000 Research and development 161,412,000 164,212,000 409,710,000 545,210,000 Selling, general and administrative 73,456,000 80,886,000 216,228,000 256,249,000 Change in the fair value of contingent consideration 700,000 1,500,000 5,700,000 (125,000,000) Intangible asset impairment Â Â Â 217,800,000 Tangible asset impairment and losses (gains) on transactions, net 1,844,000 Â 3,605,000 Â Total operating expenses 251,296,000 314,740,000 733,789,000 1,076,088,000 Loss from operations (54,510,000) (118,164,000) (140,181,000) (445,322,000) Interest expense, net (41,609,000) (28,160,000) (125,933,000) (84,905,000) Other expense, net (1,872,000) (20,266,000) (2,306,000) (8,832,000) Loss before income tax (expense) benefit (97,991,000) (166,590,000) (268,420,000) (539,059,000) Income tax (expense) benefit (8,663,000) 33,620,000 (28,989,000) 68,247,000 Net loss attributable to common stockholders $ (106,654,000) $ (132,970,000) $ (297,409,000) $ (470,812,000) Weighted-average shares outstanding: Â Â Â Â Basic 76,925,523 75,377,997 76,716,340 74,618,611 Diluted 76,925,523 75,377,997 76,716,340 74,618,611 Net loss per share-basic and diluted (in dollars per share) Â Â Â Â Basic $ (1.39) $ (1.76) $ (3.88) $ (6.31) Diluted $ (1.39) $ (1.76) $ (3.88) $ (6.31) Net product revenue Â Â Â Â Revenues: Â Â Â Â Revenue $ 135,421,000 $ 144,038,000 $ 446,245,000 $ 506,187,000 Collaboration revenue Â Â Â Â Revenues: Â Â Â Â Revenue Â Â Â 6,000 Royalty revenue Â Â Â Â Revenues: Â Â Â Â Revenue 61,365,000 50,173,000 145,702,000 117,857,000 Manufacturing revenue Â Â Â Â Revenues: Â Â Â Â Revenue $ 0 $ 2,365,000 $ 1,661,000 $ 6,716,000 X - DefinitionCost of Goods and Service, Excluding Amortization Of Intangible Assets + ReferencesNo definition available. + Details Name: ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of net gain (loss) on disposition and impairment of tangible assets. + ReferencesNo definition available. + Details Name: ptct_GainLossOnDispositionAndImpairmentOfTangibleAssets Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the value of right to a contingent consideration asset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ptct_CollaborationRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ptct_ManufacturingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Statement of Comprehensive Income [Abstract] Â Â Â Â Net Income (Loss) $ (106,654) $ (132,970) $ (297,409) $ (470,812) Other comprehensive (loss) income: Â Â Â Â Unrealized gain on marketable securities, net of tax 2,760 19 2,204 470 Foreign currency translation gain (loss), net of tax 9,395 11,021 (5,262) 4,343 Comprehensive loss $ (94,499) $ (121,930) $ (300,467) $ (465,999) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands Common stock Additional paid-in capital Accumulated other comprehensive (loss) income Accumulated deficit Total Balance (in shares) at Dec. 31, 2022 73,104,692 Â Â Â Â Balance at the beginning of the period at Dec. 31, 2022 $ 72 $ 2,305,020 $ 4,796 $ (2,656,974) $ (347,086) Increase (Decrease) in Stockholders' Equity Â Â Â Â Â Exercise of options (in shares) 806,407 Â Â Â Â Exercise of options $ 1 23,770 Â Â 23,771 Restricted stock vesting and issuance (in shares) 773,157 Â Â Â Â Restricted stock vesting and issuance, net $ 1 Â Â Â 1 Issuance of common stock in connection with an employee stock purchase plan (in shares) 117,304 Â Â Â Â Issuance of common stock in connection with an employee stock purchase plan Â 3,805 Â Â 3,805 Issuance of common stock in connection with a milestone payable (in shares) 657,462 Â Â Â Â Issuance of common stock in connection with a milestone payable $ 1 29,569 Â Â 29,570 Share-based compensation expense Â 85,128 Â Â 85,128 Net Income (Loss) Â Â Â (470,812) (470,812) Comprehensive income (loss) Â Â 4,813 Â 4,813 Balance (in shares) at Sep. 30, 2023 75,459,022 Â Â Â Â Balance at the end of the period at Sep. 30, 2023 $ 75 2,447,292 9,609 (3,127,786) (670,810) Balance (in shares) at Jun. 30, 2023 75,318,233 Â Â Â Â Balance at the beginning of the period at Jun. 30, 2023 $ 75 2,416,904 (1,431) (2,994,816) (579,268) Increase (Decrease) in Stockholders' Equity Â Â Â Â Â Exercise of options (in shares) 113,795 Â Â Â Â Exercise of options Â 3,446 Â Â 3,446 Restricted stock vesting and issuance (in shares) 26,994 Â Â Â Â Share-based compensation expense Â 26,942 Â Â 26,942 Net Income (Loss) Â Â Â (132,970) (132,970) Comprehensive income (loss) Â Â 11,040 Â 11,040 Balance (in shares) at Sep. 30, 2023 75,459,022 Â Â Â Â Balance at the end of the period at Sep. 30, 2023 $ 75 2,447,292 9,609 (3,127,786) (670,810) Balance (in shares) at Dec. 31, 2023 75,708,889 Â Â Â Â Balance at the beginning of the period at Dec. 31, 2023 $ 75 2,466,233 (1,285) (3,283,578) (818,555) Increase (Decrease) in Stockholders' Equity Â Â Â Â Â Retired shares (in shares) (20) Â Â Â Â Exercise of options (in shares) 200,927 Â Â Â Â Exercise of options Â 5,320 Â Â 5,320 Restricted stock vesting and issuance (in shares) 935,183 Â Â Â Â Restricted stock vesting and issuance, net $ 1 Â Â Â 1 Issuance of common stock in connection with an employee stock purchase plan (in shares) 107,145 Â Â Â Â Issuance of common stock in connection with an employee stock purchase plan Â 1,973 Â Â 1,973 Share-based compensation expense Â 57,376 Â Â 57,376 Net Income (Loss) Â Â Â (297,409) (297,409) Comprehensive income (loss) Â Â (3,058) Â (3,058) Balance (in shares) at Sep. 30, 2024 76,952,124 Â Â Â Â Balance at the end of the period at Sep. 30, 2024 $ 76 2,530,902 (4,343) (3,580,987) (1,054,352) Balance (in shares) at Jun. 30, 2024 76,900,123 Â Â Â Â Balance at the beginning of the period at Jun. 30, 2024 $ 76 2,510,574 (16,498) (3,474,333) (980,181) Increase (Decrease) in Stockholders' Equity Â Â Â Â Â Retired shares (in shares) (20) Â Â Â Â Exercise of options (in shares) 19,483 Â Â Â Â Exercise of options Â 573 Â Â 573 Restricted stock vesting and issuance (in shares) 32,538 Â Â Â Â Share-based compensation expense Â 19,755 Â Â 19,755 Net Income (Loss) Â Â Â (106,654) (106,654) Comprehensive income (loss) Â Â 12,155 Â 12,155 Balance (in shares) at Sep. 30, 2024 76,952,124 Â Â Â Â Balance at the end of the period at Sep. 30, 2024 $ 76 $ 2,530,902 $ (4,343) $ (3,580,987) $ (1,054,352) X - DefinitionNumber of shares issued during the period as a result of a milestone payable. + ReferencesNo definition available. + Details Name: ptct_StockIssuedDuringPeriodSharesMilestonePayable Namespace Prefix: ptct_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of milestone payable. + ReferencesNo definition available. + Details Name: ptct_StockIssuedDuringPeriodValueMilestonePayable Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_SharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of shares of common and preferred stock retired from treasury during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_TreasuryStockSharesRetired Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Cash Flows - USD ($) $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Cash flows from operating activities Â Â Â Â Â Â Net Income (Loss) $ (106,654) $ (132,970) $ (297,409) $ (470,812) Â Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Â Depreciation and amortization Â Â 68,899 155,885 Â Non-cash operating lease expense Â Â 6,272 8,156 Â Non-cash royalty revenue related to sale of future royalties Â Â (128,877) (50,599) Â Non-cash interest expense on liability related to sale of future royalties Â Â 155,039 56,031 Â Intangible asset impairment Â Â Â 217,800 Â Change in valuation of contingent consideration Â Â 5,700 (125,000) Â Tangible asset impairment Â Â 1,486 Â Â Loss on sale of fixed assets Â Â 4,298 Â Â Gain on lease terminations Â Â (2,179) Â Â Unrealized (gain) loss on ClearPoint Equity Investments Â Â (3,954) 3,107 Â Unrealized loss on ClearPoint convertible debt security Â Â 1,931 4,594 Â Unrealized gain on marketable securities - equity investments Â Â (1,923) (5,484) Â Realized loss for the sale of ClearPoint Equity Investment Â Â Â 782 Â Realized loss on ClearPoint convertible debt security Â Â 622 Â Â Non-cash stock consideration, milestone payment Â Â Â 29,570 Â Disposal of asset Â Â 76 135 Â Deferred income taxes Â Â (2) (50,909) $ (46,900) Amortization of discounts on investments, net Â Â (9,947) (89) Â Amortization of debt issuance costs Â Â 891 1,574 Â Share-based compensation expense Â Â 57,376 85,128 Â Unrealized foreign currency transaction losses, net Â Â (147) 3,394 Â Changes in operating assets and liabilities: Â Â Â Â Â Inventory, net Â Â (4,922) (14,121) Â Prepaid expenses and other current assets Â Â 107,957 59,467 Â Trade and royalty receivables, net Â Â (39,029) (9,887) Â Deposits and other assets Â Â 7,909 4,597 Â Accounts payable and accrued expenses Â Â (417) 40,434 Â Other liabilities Â Â (4,733) (1,756) Â Deferred revenue Â Â (801) (127) Â Payments on contingent consideration Â Â (1,800) Â Â Net cash used in operating activities Â Â (77,684) (58,130) Â Cash flows from investing activities Â Â Â Â Â Purchases of fixed assets Â Â (2,735) (22,872) Â Proceeds from sale of fixed assets Â Â 28,056 Â Â Purchases of marketable securities - available for sale Â Â (476,680) Â Â Purchases of marketable securities - equity investments Â Â (49,614) (26,378) Â Sale and redemption of marketable securities- available for sale Â Â 290,836 21,544 Â Sale and redemption of marketable securities - equity investments Â Â 41,624 12,078 Â Sale and redemption of ClearPoint Equity Investments Â Â Â 2,594 Â Proceeds from principal payment of Clearpoint convertible debt security Â Â 10,000 Â Â Acquisition of product rights and licenses Â Â (65,017) (69,285) Â Net cash used in investing activities Â Â (223,530) (82,319) Â Cash flows from financing activities Â Â Â Â Â Proceeds from exercise of options Â Â 5,320 23,771 Â Proceeds from employee stock purchase plan Â Â 1,973 3,805 Â Proceeds from sales of future royalties Â Â 241,792 Â Â Debt issuance costs related to secured term loan Â Â Â (282) Â Payments on contingent consideration Â Â (18,200) Â Â Payment of finance lease principal Â Â (1,490) (1,379) Â Net cash provided by financing activities Â Â 229,395 25,915 Â Effect of exchange rate changes on cash Â Â 1,325 19 Â Net decrease in cash and cash equivalents Â Â (70,494) (114,515) Â Cash and cash equivalents, and restricted cash beginning of period Â Â 610,284 295,925 295,925 Cash and cash equivalents, and restricted cash end of period 539,790 181,410 539,790 181,410 $ 610,284 Supplemental disclosure of cash information Â Â Â Â Â Cash paid for interest Â Â 5,823 34,020 Â Cash paid for income taxes Â Â 12,781 13,631 Â Supplemental disclosure of non-cash investing and financing activity Â Â Â Â Â Unrealized gain on marketable securities, net of tax 2,760 19 2,204 470 Â Right-of-use assets obtained in exchange for operating lease obligations Â Â 5,786 Â Â Acquisition of product rights and licenses Â Â 2,346 44,963 Â Fixed asset additions through tenant

improvement allowance Â Â 18,675 Â Â Milestone payable $ 50,000 $ 2,500 $ 50,000 $ 2,500 Â X - DefinitionAmount of realized gain (loss) from sale of Clearpoint Equity Investment measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesNo definition available. + Details Name: ptct_ClearpointEquityInvestmentFvNiRealizedGainLoss Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on ClearPoint equity investment measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesNo definition available. + Details Name: ptct_ClearpointEquityInvestmentFvniUnrealizedGainLoss Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the obligation liability recognized arising from contingent consideration in a business combination. + ReferencesNo definition available. + Details Name: ptct_IncreaseDecreaseInContingentConsideration Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value of stock issued as payment of milestone. + ReferencesNo definition available. + Details Name: ptct_IssuanceOfStockForMilestonePayment Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of recorded milestone payments payable. + ReferencesNo definition available. + Details Name: ptct_MilestonePayable Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of interest expense included in net income relating to the liability for sale of future royalties that results in no cash flow. + ReferencesNo definition available. + Details Name: ptct_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of fixed assets added through tenant improvement allowances that an Entity acquires in a noncash (or part noncash) acquisition. + ReferencesNo definition available. + Details Name: ptct_NoncashOrPartNoncashFixedAssetsTenantImprovementAllowance Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of royalty revenue included in net income relating to sale of future royalties that results in no cash inflow (outflow). + ReferencesNo definition available. + Details Name: ptct_NoncashRoyaltyRevenueSaleOfFutureRoyalties Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayment of Finance Lease Principal + ReferencesNo definition available. + Details Name: ptct_PaymentOfFinanceLeasePrincipal Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayments on deferred and contingent consideration obligation. + ReferencesNo definition available. + Details Name: ptct_PaymentsOnDeferredConsiderationObligation Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with a principal payment received by the entity on Clearpoint convertible debt security during the period. + ReferencesNo definition available. + Details Name: ptct_ProceedsFromPrincipalPaymentOfClearpointConvertibleDebtSecurity Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of Clearpoint Equity Investment during the period. + ReferencesNo definition available. + Details Name: ptct_ProceedsFromSaleAndMaturityOfClearpointEquityInvestment Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash received for sale of future royalties during the current period. + ReferencesNo definition available. + Details Name: ptct_ProceedsFromSaleOfFutureRoyalties Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossUnrealized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of other assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnSaleOfOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on termination of lease before expiration of lease term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479092/842-20-40-1 + Details Name: us-gaap_GainLossOnTerminationOfLease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDepositOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in operating liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type:

xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11 + Details Name: us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11 + Details Name: us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the stock plan during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromStockPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowElementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1 + Details Name: us-gaap_TangibleAssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.3 The Company 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â The Company 1.Â Â Â Â Â Â Â Â Â The CompanyPTC Therapeutics, Inc. (the â€œCompanyâ€ or â€œPTCâ€) is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. The Companyâ€™s ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. The Companyâ€™s mission is to provide access to best-in-class treatments for patients who have little to no treatment options. The Companyâ€™s strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. The Company believes that this allows it to maximize value for all its stakeholders. The Company has a diversified therapeutic portfolio pipeline that includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism.The Company has two products, Translarnaâ„¢ (ataluren) and EmflazaÂ® (deflazacort), for the treatment of Duchenne muscular dystrophy (â€œDMDâ€), a rare, life-threatening disorder. Translarna has marketing authorization in the European Economic Area (the â€œEEAâ€) for the treatment of nonsense mutation Duchenne muscular dystrophy (â€œnmDMDâ€) in ambulatory patients aged two years and older. Translarna also has marketing authorization in Russia for the treatment of nmDMD in patients aged two years and older and in Brazil for the treatment of nmDMD in ambulatory patients two years and older and for continued treatment of patients that become non-ambulatory, as well as in various other countries. Emflaza is approved in the United States for the treatment of DMD in patients two years and older. The Companyâ€™s marketing authorization for Translarna in the EEA is subject to annual review and renewal by the European Commission (â€œECâ€) following reassessment by the European Medicines Agency (â€œEMAâ€) of the benefit-risk balance of the authorization, which the Company refers to as the annual EMA reassessment. In September 2022, the Company submitted a Type II variation to the EMA to support conversion of the conditional marketing authorization for Translarna to a standard marketing authorization, which included a report on the placebo-controlled trial of Study 041 and data from the open-label extension. In February 2023, the Company also submitted an annual marketing authorization renewal request to the EMA. In September 2023, the Committee for Medicinal Products for Human Use (â€œCHMPâ€), gave a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna for the treatment of nmDMD and a negative opinion on the renewal of the existing conditional marketing authorization of Translarna for the treatment of nmDMD. In January 2024, the CHMP issued a negative opinion for the renewal of the conditional marketing authorization following a re-examination procedure. In May 2024, the EC decided not to adopt the CHMPâ€™s negative opinion for the renewal of the conditional marketing authorization of Translarna and returned such opinion to the CHMP for re-evaluation. In June 2024, following the ECâ€™s request for re-review, the CHMP issued a negative opinion on the renewal of the conditional marketing authorization of Translarna for the treatment of nmDMD. On October 18, 2024, the CHMP maintained its negative opinion for the renewal of the conditional marketing authorization following the requested reexamination procedure. In accordance with EMA regulations, the opinion will be reviewed by the EC which is expected to decide on opinion adoption approximately 67 days from the date of issuance. If the EC adopts the negative opinion, Translarna would no longer have marketing authorization in the member states of the EEA. The marketing authorization for Translarna remains in effect, pending the ECâ€™s potential adoption of the negative opinion. Based on the timeline of these procedures, the Company expects the marketing authorization for Translarna to remain in effect approximately through the end of 2024. â€‹Translarna is an investigational new drug in the United States. Following the Companyâ€™s announcement of top-line results from the placebo-controlled trial of Study 041 in June 2022, the Company submitted a meeting request to the U.S. Food and Drug Administration (â€œFDAâ€) to gain clarity on the regulatory pathway for a potential re-submission of a New Drug Application (â€œNDAâ€) for Translarna. The FDA provided initial written feedback that Study 041 does not provide substantial evidence of effectiveness to support an NDA re-submission. The Company held a Type C meeting with the FDA in the fourth quarter of 2023 to discuss the totality of Translarna data. Based on feedback from the FDA, the Company re-submitted the NDA in July 2024, based on the results from Study 041 and from the Companyâ€™s international drug registry study for nmDMD patients receiving Translarna. In October 2024, the FDA accepted for review the resubmission of the NDA for Translarna for the treatment of nmDMD. As this was an NDA resubmission following a complete response letter to the NDA which was filed over protest in 2016, the FDA is not obligated to follow the review timelines under Prescription Drug User Fee Act guidelines and an action date has not been provided.The Company has developed Upstazaâ„¢ (eladocagene exuparvovec), a gene therapy used for the treatment of Aromatic L-Amino Acid Decarboxylase (â€œAADCâ€) deficiency (â€œAADC deficiencyâ€), a rare central nervous system (â€œCNSâ€) disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene. In July 2022, the EC approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the EEA. In November 2022, the Medicines and Healthcare Products Regulatory Agency approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the United Kingdom. In March 2024, the Company submitted a biologics license application (â€œBLAâ€) for eladocagene exuparvovec for the treatment of AADC deficiency in the United States. In May 2024, the FDA accepted for filing the BLA and granted priority review with a target regulatory action date of November 13, 2024.The Company holds the rights for the commercialization of TegsediÂ® (inotersen) and WaylivraÂ® (volanesorsen) for the treatment of rare diseases in countries in Latin America and the Caribbean pursuant to the Collaboration and License Agreement (the â€œTegsedi-Waylivra Agreementâ€), dated August 1, 2018, by and between the Company and Akcea Therapeutics, Inc. (â€œAkceaâ€), a subsidiary of Ionis Pharmaceuticals, Inc. Tegsedi has received marketing authorization in the United States, the European Union (the â€œEUâ€) and Brazil for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (â€œhATTR amyloidosisâ€). In August 2021, ANVISA, the Brazilian health regulatory authority, approved Waylivra as the first treatment for familial chylomicronemia syndrome (â€œFCSâ€) in Brazil. In December 2022, ANVISA approved Waylivra for the treatment of familial partial lipodystrophy (â€œFPLâ€). Waylivra has also received marketing authorization in the EU for the treatment of FCS.The Company also has a spinal muscular atrophy (â€œSMAâ€) collaboration with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc. (referred to collectively as â€œRocheâ€) and the Spinal Muscular Atrophy Foundation (â€œSMA Foundationâ€). The SMA program has one approved product, EvrysdiÂ® (risdiplam), which was approved by the FDA in August 2020 for the treatment of SMA in adults and children two months and older and by the EC in March 2021 for the treatment of 5q SMA in patients two months and older with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. Evrysdi has also received marketing authorization for the treatment of SMA in over 100 countries. In May 2022, the FDA approved a label expansion for Evrysdi to include infants under two months old with SMA. In August 2023, the EC approved an extension of the Evrysdi marketing authorization to include infants under two months old in the EU.One of the Companyâ€™s most advanced clinical stage molecules is sepiapterin. Sepiapterin is a precursor to intracellular tetrahydrobiopterin, which is a critical enzymatic cofactor involved in metabolism and synthesis of numerous metabolic products. In May 2023, the Company announced that the primary endpoint was achieved in its registration-directed Phase 3 trial for sepiapterin for phenylketonuria (â€œPKUâ€). The primary endpoint of the study was the achievement of statistically-significant reduction in blood Phe level. In March 2024, the Company submitted a marketing authorization application (â€œMAAâ€) to the EMA for sepiapterin for the treatment of PKU in the EEA, which was validated and accepted for review by the EMA in May 2024. In the third quarter of 2023, the Company participated in a pre-NDA meeting with the FDA. At that meeting, the FDA stated that the sepiapterin clinical safety and efficacy data supported NDA submission for the treatment of pediatric and adult PKU patients. However, the FDA requested that PTC complete a 26-week nonclinical mouse study to assess sepiapterin carcinogenicity potential prior to NDA submission. In July 2024, following completion of the in-life portion of the study, the Company submitted an NDA to the FDA for sepiapterin for the treatment of PKU in the United States. In September 2024, the FDA accepted for filing the NDA, with a target regulatory action date of July 29, 2025. PTC also made a regulatory submission for sepiapterin for the treatment of PKU in Brazil in the third quarter of 2024, and expects to do the same in Japan in the fourth quarter of 2024.In addition to the Companyâ€™s SMA program, the Companyâ€™s splicing platform also includes PTC518, which is being developed for the treatment of Huntingtonâ€™s disease (â€œHDâ€). The Company initiated a Phase 2 study of PTC518 for the treatment of HD in the first quarter of 2022, which consists of an initial 12-week placebo-controlled phase focused on safety, pharmacology and pharmacodynamic effects followed by a nine-month placebo-controlled phase focused on PTC518 biomarker effect. In June 2023, the Company announced interim data from the 12-week placebo-controlled phase. In June 2024, the Company

announced additional interim results from the Phase 2 study of PTC518. At month 12, PTC518 treatment demonstrated durable dose-dependent lowering of mutant HTT (â€œmHTTâ€) protein in the blood and dose-dependent lowering of mHTT protein in the cerebrospinal fluid in the interim cohort of stage 2 patients. In addition, favorable trends were demonstrated on several relevant HD clinical assessments. Furthermore, following 12 months of treatment, PTC518 continued to be well tolerated. Based on its review of the interim Phase 2 study data, the FDA lifted the partial clinical hold on the program. In September 2024, the FDA granted Fast Track designation to the PTC518 program for the treatment of HD.â€‹The Companyâ€™s ferroptosis and inflammation platform consists of small molecule compounds that target oxidoreductase enzymes that regulate oxidative stress and inflammatory pathways central to the pathology of a number of CNS diseases. The two most advanced molecules in the Companyâ€™s ferroptosis and inflammation platform are vatiquinone and utreloxastat. The Company announced topline results from a registration-directed Phase 3 trial of vatiquinone in children and young adults with Friedreich ataxia (â€œFAâ€), called MOVE-FA, in May 2023. While the study did not meet its primary endpoint, vatiquinone treatment did demonstrate significant benefit on key disease subscales, including the upright stability subscale, as well as on other disease relevant endpoints. In the first quarter of 2024, the Company met with the FDA, who expressed willingness to review an NDA for vatiquinone for the treatment of Friedreich ataxia based on the MOVE-FA trial as well as data from the ongoing open label extension study following the MOVE-FA trial. In October 2024, the Company announced that the pre-specified endpoint for two different FA long-term extension studies was met, with statistically significant evidence of durable treatment benefit on disease progression. The Company plans to submit an NDA for vatiquinone for the treatment of FA in the United States in December 2024. The Company initiated a Phase 2 registration directed trial of utreloxastat for amyotrophic lateral sclerosis, or ALS, in the first quarter of 2022. The Company expects topline results from this trial in the fourth quarter of 2024.â€‹In addition, the Company has a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas for rare diseases.As of SeptemberÂ 30,Â 2024, the Company had an accumulated deficit of approximately $3,581.0 million. The Company has financed its operations to date primarily through the private offerings of convertible senior notes (see Note 9), public and â€œat the market offeringsâ€ of common stock, proceeds from royalty purchase agreements (see Note 2), net proceeds from the Companyâ€™s borrowings under its credit agreement with Blackstone (see Note 9), private placements of its convertible preferred stock and common stock, collaborations, bank and institutional lender debt, other convertible debt, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Companyâ€™s product candidates. The Company has also relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States since 2014, Emflaza for the treatment of DMD in the United States since 2017, and Upstaza for the treatment of AADC deficiency in the EEA since 2022. The Company has also relied on revenue associated with milestone and royalty payments from Roche pursuant to the License and Collaboration Agreement (the â€œSMA License Agreementâ€) dated as of November 23, 2011, by and among the Company, Roche and, for the limited purposes set forth therein, the SMA Foundation, under its SMA program. The Company expects that cash flows from the sales of its products, milestone and royalty payments from Roche, together with the Companyâ€™s cash, cash equivalents and marketable securities, will be sufficient to fund its operations for at least the next twelve months. X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_NatureOfOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Summary of significant accounting policies 2.Â Â Â Â Â Â Â Â Summary of significant accounting policiesThe Companyâ€™s complete listing of significant accounting policies is set forth in NoteÂ 2 of the notes to the Companyâ€™s audited financial statements as of DecemberÂ 31,Â 2023 included in the Companyâ€™s Annual Report on FormÂ 10-K filed with the Securities and Exchange Commission (the "SEC") on February 29, 2024 (the "2023 FormÂ 10-K"). Selected significant accounting policies are discussed in further detail below.Basis of presentationThe accompanying financial information as of SeptemberÂ 30,Â 2024 and for the three and nine months ended SeptemberÂ 30,Â 2024 and 2023 has been prepared by the Company, without audit, pursuant to the rulesÂ and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to such rulesÂ and regulations. These interim financial statements should be read in conjunction with the Companyâ€™s audited financial statements as of DecemberÂ 31,Â 2023 and notes thereto included in the 2023 FormÂ 10-K.In the opinion of management, the unaudited financial information as of SeptemberÂ 30,Â 2024 and for the three and nine months ended SeptemberÂ 30,Â 2024 and 2023 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations, stockholdersâ€™ deficit, and cash flows. The results of operations for the three and nine months ended SeptemberÂ 30,Â 2024 are not necessarily indicative of the results to be expected for theÂ year ended DecemberÂ 31,Â 2024 or for any other interim period or for any other futureÂ year.Use of estimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, royalty revenue, certain accruals related to the Companyâ€™s research and development expenses, valuation procedures for liability for sale of future royalties, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.Restricted cashRestricted cash included in deposits and other assets on the consolidated balance sheet contains an unconditional, irrevocable and transferable letter of credit that was entered into during the twelve-month period ended DecemberÂ 31, 2019 in connection with obligations under a facility lease for the Companyâ€™s facility in Hopewell Township, New Jersey. The amount of the letter of credit was $7.5 million and was to be maintained for a term of not less than five years and had the potential to be reduced to $3.8 million if after five years the Company was not in default of its lease. In June 2024, in connection with an amendment and restatement of the lease, the letter of credit was reduced to $5.0 million, and has the potential to be reduced to $3.0 million if after July 1, 2025, the Company is not in default of its lease. Refer to Note 3 for further details. Restricted cash also contains an unconditional, irrevocable and transferable letter of credit that was entered into during June 2022 in connection with obligations for the Companyâ€™s new facility lease in Warren, New Jersey. The amount of the letter of credit is $8.1 million and has the potential to be reduced to $4.1 million if after five years the Company is not in default of its lease. Both amounts are classified within deposits and other assets on the consolidated balance sheet due to the long-term nature of the respective letters of credit. Restricted cash also includes a bank guarantee of $0.7 million denominated in a foreign currency. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same amounts shown in the statement of cash flows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â End ofÂ Â Â Â â€‹Beginning ofâ€‹Â period-Â period-â€‹Â SeptemberÂ 30,Â Â DecemberÂ 31,Â â€‹Â 2024â€‹2023Cash and cash equivalentsâ€‹$ 526,001â€‹$ 594,001Restricted cash included in deposits and other assets â€‹Â 13,789â€‹Â 16,283Total Cash, cash equivalents and restricted cash per statement of cash flowsâ€‹$ 539,790â€‹$ 610,284â€‹Marketable securitiesThe Companyâ€™s marketable securities consists of both debt securities and equity investments. The Company considers its investments in debt securities with original maturities of greater than 90Â days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within accumulated other comprehensive income. The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the securityâ€™s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. For the three and nine months ended SeptemberÂ 30,Â 2024 and 2023, no allowance was recorded for credit losses.Marketable securities that are equity investments are measured at fair value, as it is readily available, and as such are classified as Level 1 assets. Unrealized holding gains and losses for these equity investments are components of other expense, net within the consolidated statement of operations.Inventory and cost of product salesInventoryInventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Products which may be used in clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes. Inventory used for marketing efforts are charged to selling, general and administrative expense. Amounts related to clinical development programs and marketing efforts are immaterial.The following table summarizes the components of the Companyâ€™s inventory for the periods indicated:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SeptemberÂ 30,Â 2024Â Â Â Â DecemberÂ 31,Â 2023Raw materialsâ€‹$ 2,738â€‹$ 952Work in progressâ€‹Â 24,440â€‹Â 17,991Finished goodsâ€‹Â 8,493â€‹Â 11,634Total inventoryâ€‹$ 35,671â€‹$ 30,577â€‹The Company periodically reviews its inventories for excess amounts or obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value. For the three months ended SeptemberÂ 30,Â 2024 and 2023, the inventory write-downs were immaterial. For the nine months ended SeptemberÂ 30,Â 2024, the Company recorded inventory write-downs of $2.5 million, primarily related to adjustments to inventory reserves and product approaching expiration. For the nine months ended SeptemberÂ 30,Â 2023, the Company recorded inventory write-downs of $0.4 million, primarily related to product approaching expiration. Additionally, though the Companyâ€™s product is subject to strict quality control and monitoring which it performs throughout the manufacturing processes, certain batches or units of product may not meet quality specifications resulting in a charge to cost of product sales. For the three and nine months ended SeptemberÂ 30,Â 2024 and 2023, these amounts were immaterial.Cost of product salesCost of product sales consists of the cost of inventory sold, manufacturing and supply chain costs, storage costs, amortization of the acquired intangible asset, royalty payments associated with net product sales, and royalty payments to collaborative partners associated with royalty revenues and collaboration revenue related to milestones. Production costs are expensed as cost of product sales when the related products are sold or royalty revenues and collaboration revenue milestones are earned.Revenue recognitionNet product revenueThe Companyâ€™s net product revenue primarily consists of sales of Translarna in territories outside of the U.S. for the treatment of nmDMD and sales of Emflaza in the U.S. for the treatment of DMD. The Company recognizes revenue when its performance obligations with its customers have been satisfied. The Companyâ€™s performance obligations are to provide products based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies. The performance obligations are satisfied at a point in time when the Companyâ€™s customer obtains control of the product, which is typically upon delivery. The Company invoices its customers after the products have been delivered and invoice payments are generally due within 30 to 90Â days of the invoice date. The Company determines the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods the Company has yet to provide. As the Company has identified only one distinct performance obligation, the transaction price is allocated entirely to product sales. In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers product to when the customers pay for the product is typically less than oneÂ year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the sameÂ month.The Company records product sales net of any variable consideration, which includes discounts, allowances, rebates related to Medicaid and other government pricing programs, and distribution fees. The Company uses the expected value or most likely amount method when estimating its variable consideration, unless discount or rebate terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained. For the threeÂ months ended SeptemberÂ 30,Â 2024 and 2023, net product sales outside of the United States were $83.5 million and $76.6 million, respectively, consisting of sales of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $72.3Â million and $69.0Â million of the net product sales outside of the United States for the three months ended SeptemberÂ 30,Â 2024 and 2023, respectively. For the three months ended SeptemberÂ 30,Â 2024 and 2023, net product sales in the United States were $51.9 million and $67.4 million, respectively, consisting solely of sales of Emflaza.Â During the three months ended SeptemberÂ 30,Â 2024, two countries, the United States and Brazil, accounted for at least 10% of the Companyâ€™s net product sales, representing $51.9 million and $29.2 million of net product sales, respectively. During the three months ended SeptemberÂ 30,Â 2023, one country, the United States, accounted for at least 10% of the Companyâ€™s net product sales, representing $67.4 million of net product sales. For the nine months ended SeptemberÂ 30,Â 2024 and 2023, net product sales outside of the United States were $289.5 million and $318.5 million, respectively, consisting of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $246.2 million and $280.6 million of the net product sales outside of the United States for the nine months ended SeptemberÂ 30,Â 2024 and 2023, respectively. For the nine months ended SeptemberÂ 30,Â 2024 and 2023, net product sales in the United States were $156.7 million and $187.7 million, respectively, consisting solely of Emflaza. During the nine months ended SeptemberÂ 30,Â 2024, three countries, the United States, Brazil, and Russia, accounted for at least 10% of the Companyâ€™s net product sales, representing $156.7 million, $68.3 million, and $55.7 million of net product sales, respectively. During the nine months ended SeptemberÂ 30,Â 2023, three countries, the United States, Russia, and Brazil, accounted for at least 10% of the Companyâ€™s net product sales, representing $187.7 million, $69.0 million, and $52.5 million of net product sales, respectively.In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. The Company considers any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise. Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense.Collaboration and royalty revenueThe terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.At the inception of a collaboration arrangement, the Company needs to first evaluate if the arrangement meets the criteria in Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Codification (â€œASCâ€) Topic 808 â€œCollaborative Arrangementsâ€ to then determine if ASC Topic 606 is applicable by considering whether the collaborator meets the definition of a customer. If the criteria are met, the Company assesses the promises in the arrangement to identify distinct performance obligations.For licenses of intellectual property, the Company assesses, at contract inception, whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license will be bundled with other promises in the arrangement into one distinct performance obligation. The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the nonrefundable,

upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.For milestone payments, the Company assesses, at contract inception, whether the development or sales-based milestones are considered probable of being achieved. If it is probable that a significant revenue reversal will occur, the Company will not record revenue until the uncertainty has been resolved. Milestone payments that are contingent upon regulatory approval are not considered probable of being achieved until the applicable regulatory approvals or other external conditions are obtained as such conditions are not within the Companyâ€™s control. If it is probable that a significant revenue reversal will not occur, the Company will estimate the milestone payments using the most likely amount method. The Company will re-assess the development and sales-based milestones each reporting period to determine the probability of achievement. The Company recognizes royalties from product sales at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied. If it is probable that a significant revenue reversal will not occur, the Company will estimate the royalty payments using the most likely amount method.The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.For the three and nine months ended September 30, 2024, the Company did not recognize collaboration revenue related to the SMA License Agreement with Roche. For the three and nine months ended SeptemberÂ 30,Â 2023, the amounts recognized for the collaboration revenue related to the SMA License Agreement with Roche were immaterial.â€‹For the three and nine months ended SeptemberÂ 30,Â 2024, the Company recognized $61.4 million and $145.7 million of royalty revenue, respectively, related to Evrysdi. For the three and nine months ended SeptemberÂ 30,Â 2023, the Company recognized $50.2 million and $117.9 million of royalty revenue, respectively, related to Evrysdi.â€‹Manufacturing Revenueâ€‹The Company has manufacturing services related to the production of plasmid deoxyribonucleic acid (â€œDNAâ€) and adeno-associated virus (â€œAAVâ€) vectors for gene therapy applications for external customers. Performance obligations vary but may include manufacturing plasmid DNA and/or AAV vectors, material testing, stability studies, and other services related to material development. The transaction prices for these arrangements are fixed and include amounts stated in the contracts for each promised service. Typically, the performance obligations within a manufacturing contract are highly interdependent, in which case, the Company will combine them into a single performance obligation. The Company has determined that the assets created have no alternative use to the Company, and the Company has an enforceable right to payment for the performance completed to date, therefore revenue related to these services are recognized over time and is measured using an output method based on performance of manufacturing milestones completed to date.â€‹Manufacturing service contracts may also include performance obligations related to project management services or obtaining materials from third parties. The Company has determined that these are separate performance obligations for which revenue is recognized at the point in time the services are performed. For performance obligations related to obtaining third party materials, the Company has determined that it is the principal as the Company has control of the materials and has discretion in setting the price. Therefore, the Company recognizes revenue on a gross basis related to obtaining third party materials.â€‹Certain arrangements require a portion of the contract consideration to be received in advance at the commencement of the contract, and such advance payment is initially recorded as a contract liability. A contract asset may be recognized in the event the Companyâ€™s satisfaction of performance obligations outpaces customer billings. â€‹For the three months ended September 30, 2024, the Company did not recognize any revenue related to plasmid DNA and AAV vector production for external customers. For the nine months ended September 30, 2024, the Company recognized $1.7 million of manufacturing revenue related to plasmid DNA and AAV vector production for external customers. For the three and nine months ended SeptemberÂ 30,Â 2023 the Company recognized $2.4 million and $6.7 million of manufacturing revenue, respectively, related to plasmid DNA and AAV vector production for external customers. As of SeptemberÂ 30,Â 2024, the Company has no contract assets and no remaining performance obligations related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. For the period ended December 31, 2023, the Company had contract assets of $0.2 million and remaining performance obligations of $0.8 million related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers.â€‹In June 2024, the Company sold its gene therapy manufacturing business in Hopewell Township, New Jersey. Accordingly, the Company does not expect to have manufacturing revenue going forward.Allowance for doubtful accountsThe Company maintains an allowance for estimated losses resulting from the inability of its customers to make required payments. The Company estimates uncollectible amounts based upon current customer receivable balances, the age of customer receivable balances, the customerâ€™s financial condition and current economic trends. The Company also assesses whether an allowance for expected credit losses may be required which includes a review of the Companyâ€™s receivables portfolio, which are pooled on a customer basis or country basis.Â In making its assessment of whether an allowance for credit losses is required, the Company considers its historical experience with customers, current balances, levels of delinquency, regulatory and legal environments, and other relevant current and future forecasted economic conditions. For the three and nine months ended SeptemberÂ 30,Â 2024 and 2023, no allowance was recorded for credit losses. The allowance for doubtful accounts was $1.3 million as of SeptemberÂ 30,Â 2024 and $1.2 million as of DecemberÂ 31,Â 2023. For the three and nine months ended SeptemberÂ 30,Â 2024, bad debt expense was $0.7 million and $0.5 million, respectively. For the three and nine months ended SeptemberÂ 30,Â 2023, bad debt expense was $0.4 million and $0.7 million, respectively.Liability for sale of future royalties In June 2024, the Company, Royalty Pharma Investments 2019 ICAV (â€œRoyalty Pharmaâ€) and Royalty Pharma plc, entered into an amendment to the Amended and Restated Royalty Purchase Agreement, dated as of October 18, 2023 (as amended, the â€œA&R Royalty Purchase Agreementâ€). The A&R Royalty Purchase Agreement amended and restated in its entirety the original Royalty Purchase Agreement, dated as of July 17, 2020 (the â€œOriginal Royalty Purchase Agreementâ€). Â Pursuant to the A&R Royalty Purchase Agreement, the Company has sold to Royalty Pharma a portion of the Companyâ€™s right to receive sales-based royalty payments (the â€œRoyaltyâ€) on worldwide net sales of Evrysdi and any other product developed pursuant to the License and Collaboration Agreement (the â€œLicense Agreementâ€), dated as of November 23, 2011, by and among the Company, Roche and, for the limited purposes set forth therein, the SMA Foundation under the SMA program. â€‹Pursuant to the guidance in ASC 470-10-25-2, the Company determined that cash consideration obtained pursuant to the A&R Royalty Purchase Agreement should be classified as debt and recorded it as â€œliability for sale of future royalties-currentâ€ and â€œliability for sale of future royalties-noncurrentâ€ on the Companyâ€™s consolidated balance sheet based on the timing of the expected payments to be made to Royalty Pharma at the time of the transaction. Under the A&R Royalty Purchase Agreement, the Company exercised a put option in June 2024, resulting in the Company receiving $241.8 million in cash consideration. In connection with the put option exercise, the change in rights and obligations resulted in a change in the terms of the liability for sale of future royalties, which was evaluated by the Company in accordance with ASC 470-50, Debt â€”Modifications and Extinguishments. The Company determined that the present value of the cash flows after the put option exercise was not substantially different and was therefore determined to be a modification. The $241.8 million in cash consideration obtained was added to the liability for sale of future royalties and the annual effective interest rate under the A&R Royalty Purchase Agreement was determined to be 9.9%. The liability is amortized using the effective interest method over the life of the arrangement, in accordance with the respective guidance, utilizing the prospective method to account for subsequent changes in the estimated future payments to be made to Royalty Pharma and the Company updates the effective interest rate on a quarterly basis. Refer to Note 9 for further details.â€‹To date, the Company has sold to Royalty Pharma a total of 90.49% of the Royalty, which will be reduced to 83.33% (the â€œAssigned Royalty Rightsâ€) after Royalty Pharma receives $1.3Â billion in aggregate payments (the â€œAssigned Royalty Capâ€) from the Royalty assigned at the closing of the Original Purchase Agreement. Â In exchange for the Assigned Royalty Rights, Royalty Pharma has paid to the Company upfront cash consideration totaling $1.9 billion, less Royalty payments received by the Company with respect to the Assigned Royalty Rights. The Company currently retains 9.51% of the Royalty, which increases to 16.67% after the Assigned Royalty Cap has been met. Â The Company has the option under the A&R Royalty Purchase Agreement to sell its retained portions of the Royalty to Royalty Pharma in up to three tranches for the following payments: Â (1) $100.0 million in exchange for 3.81% of the Royalty, which increases to 6.67% after the Assigned Royalty Cap has been met, (2) $100.0 million in exchange for 3.81% of the Royalty, which increases to 6.67% after the Assigned Royalty Cap has been met, and (3) $50.0 million in exchange for 1.90% of the Royalty, which increases to 3.33% after the Assigned Royalty Cap has been met, in each case less Royalty payments received by the Company with respect to the Assigned Royalty Rights. Â The A&R Royalty Purchase Agreement will terminate 60 days following the date on which Roche is no longer obligated to make any payments of the Royalty pursuant to the License Agreement.â€‹Indefinite-lived intangible assetsIndefinite-lived intangible assets consist of in process research and development ("IPR&D"). IPR&D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise, they are expensed. The fair values of IPR&D projects and license agreement assets acquired in business combinations are capitalized. Several methods may be used to determine the estimated fair value of the IPR&D and license agreement assets acquired in a business combination. The Company utilizes the "income method" and uses estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible assetâ€™s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Companyâ€™s outlook and market performance of the Companyâ€™s industry and recent and forecasted financial performance. GoodwillGoodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Companyâ€™s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. The Company reassesses its reporting units as part of its annual segment review. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. Income TaxesOn December 15, 2022, the EU Member States formally adopted the EUâ€™s Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (â€œOECDâ€) Pillar Two Framework that was supported by over 130 countries worldwide. The EU effective dates are January 1, 2024, and January 1, 2025, for different aspects of the directive. A significant number of other countries are also implementing similar legislation. As a result, the tax laws in the U.S. and other countries in which PTC and its affiliates do business could change on a prospective or retroactive basis and any such changes could materially adversely affect the Companyâ€™s business. The Company is continuing to evaluate the potential impact on future periods of the Pillar Two Framework, pending legislative adoption by additional individual countries, including those within the European Union.On DecemberÂ 22, 2017, the U.S. government enacted the 2017 Tax Cuts and Jobs Act (â€œTCJAâ€), which significantly revised U.S. tax law by, among other provisions, lowering the U.S. federal statutory corporate income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Global Intangible Low-Taxed Income (â€œGILTIâ€) provisions of the TCJA require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiaryâ€™s tangible assets. The Company has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements for the period ended SeptemberÂ 30,Â 2024.Since 2022, TCJA amendments to IRC Section 174 no longer permit an immediate deduction for research and development expenditures in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over either a five- or 15-year period, depending on the location of the activities performed. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year five for activities conducted in the United States or year 15 in the case of development conducted on foreign soil. This tax law change is anticipated to result in an increased current taxable income of the Company by $121.0 million for the year ending December 31, 2024.Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured at rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. A valuation allowance is recorded when it is not more likely than not that all or a portion of the net deferred tax assets will be realized.On August 23, 2018, the Company completed its acquisition of Agilis Biotherapeutics, Inc. (â€œAgilisâ€), pursuant to an Agreement and Plan of Merger, dated as of July 19, 2018 (the â€œAgilis Merger Agreementâ€), by and among the Company, Agility Merger Sub, Inc., a Delaware corporation and the Companyâ€™s wholly owned, indirect subsidiary, Agilis and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC, (the â€œAgilis Mergerâ€). The Company recorded a deferred tax liability in conjunction with the Agilis Merger of $122.0 million in 2018, related to the tax basis difference in the IPRD indefinite-lived intangibles acquired. The Companyâ€™s policy is to record a deferred tax liability related to acquired IPR&D which may eventually be realized either upon amortization of the asset when the research is completed, and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful. In July 2022, the Company received EMEA approval for a portion of the IPR&D assets, and thus, began the amortization of the intangible. In May 2023, the Company announced the discontinuation of its preclinical and early research programs in gene therapy as part of a strategic portfolio prioritization. In conjunction with the announcement, the Company recorded an impairment to its indefinite-lived intangible for IP research and development relating to the Friedreich ataxia and Angelman syndrome gene therapy assets. As a result of the impairment, the Company recorded a deferred tax benefit of $46.9 million during the 2023 tax year.LeasesThe Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company accounts for as a single lease component for all leases. Operating and finance leases are classified as right of use ("ROU") assets, short term lease liabilities, and long term lease liabilities. Operating and finance lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. ROU assets are amortized and lease liabilities accrete to yield straight-line expense over the term of the lease. Lease payments included in the measurement of the lease liability are comprised of fixed payments.Variable lease payments associated with the Companyâ€™s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Companyâ€™s consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases.Leases with an initial term of 12Â months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.A lessee is required to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Companyâ€™s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company gives consideration to its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates.The lease term for all of the Companyâ€™s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Leasehold improvements are capitalized and depreciated over the lesser of useful life or lease term. Refer to NoteÂ 3 for further details. Â Tangible asset impairment

and losses (gains) on transactions, net Tangible asset impairment and losses (gains) on transactions, net includes impairments identified on fixed assets, losses and gains on sales of fixed assets, and gains on lease terminations. For the three months ended September 30, 2024, these amounts consisted of a $1.3 million loss for fixed asset impairments related to the South Plainfield, New Jersey office closure, as well as a $0.5 million loss on sales of fixed assets. For the nine months ended September 30, 2024, these amounts consisted of a $4.4 million loss primarily related to the sale of certain assets for gene therapy manufacturing, and a $1.5 million loss primarily related to fixed asset impairments related to the South Plainfield, New Jersey office closure. These amounts were partially offset by a gain of $2.2 million on lease terminations (Note 3) and a $0.1 million gain on sales of fixed assets.Recently issued accounting standardsIn November 2023, the FASB issuedÂ ASU 2023-07,Â Segment Reporting (Topic 280) â€“ Improvements to Reportable Segment Disclosures. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements, unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently planning to adopt this guidance when effective. The Company is assessing the impact of the adoption on the Companyâ€™s consolidated financial statements and accompanying footnotes.â€‹In December 2023, the FASB issuedÂ ASU 2023-09,Â Improvements to Income Tax Disclosures. ASU 2023-09 enhances the transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The guidance is effective for public business entities for annual periods beginning after December 15, 2024. For entities other than public business entities, the amendments are effective for annual periods beginning after December 15, 2025. Early adoption is permitted. The Company is currently planning to adopt this guidance when effective. The Company is assessing the impact of the adoption on the Companyâ€™s consolidated financial statements and accompanying footnotes.Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Leases 9 Months Ended Sep. 30, 2024 Leases Â Leases 3.Â Â Â Â Â Â Â Â LeasesEffective April 2024, the Company began utilizing the Warren Premises, as described below, as its principal office space. The Company also leases laboratory space in Bridgewater, New Jersey and other locations throughout the United States and office space in various countries for international employees primarily through workspace providers. The Companyâ€™s lease for office space in South Plainfield, New Jersey expired in August 2024.The Company has a lease agreement (the â€œWarren Leaseâ€) with Warren CC Acquisitions, LLC (the â€œWarren Landlordâ€) relating to the lease of two entire buildings comprised of approximately 360,000 square feet of shell condition, modifiable space (the â€œWarren Premisesâ€) at a facility located in Warren, New Jersey. The rental term of the Warren Lease commenced on June 1, 2022, with an initial term of seventeen years (the â€œWarren Initial Termâ€), followed by three consecutive five-year renewal periods at the Companyâ€™s option. The aggregate base rent for the Warren Initial Term is approximately $163.0 million; provided, however, that if the Company is not subject to an Event of Default (as defined in the Warren Lease), the Company is entitled to a base rent abatement over the first three years of the Warren Initial Term of approximately $18.6 million, reducing the Companyâ€™s total base rent obligation to $144.4 million. The Company is entitled to an allowance of approximately $36.2 million to be provided by the Warren Landlord to be used towards such improvements. The Landlord is providing the allowance to cover those assets that are real property improvements, such as structural components, roofs, flooring, etc., whose useful lives are typically longer in nature. The Company evaluated the leasehold improvements under ASC 842 and determined that the Company will be the owner of the improvements, and therefore the $36.2 million allowance and $5.0 million due from the Landlord were treated as lease incentives at the commencement of the lease and included in the calculation of the lease ROU asset and lease ROU liability, effectively reducing both at the commencement date of the lease. As a result, the Company recorded an operating lease ROU asset of $28.9 million and an operating lease ROU liability of $28.9 million as of the commencement date of the lease.The Company also leases office and laboratory space at a facility located in Hopewell Township, New Jersey pursuant to a Lease Agreement (the â€œHopewell Leaseâ€) with Hopewell Campus Owner LLC. In connection with the disposition of certain assets related to gene therapy manufacturing, on June 17, 2024, the Company and Hopewell Campus Owner LLC entered into an amendment and restatement of the Hopewell Lease (the â€œHopewell Lease Amendmentâ€). At its inception, the Hopewell Lease was determined to have four separate lease components. The Hopewell Lease Amendment terminated three of the four lease components, reducing the leased space from 220,500 square feet to 93,461 square feet and significantly reducing the corresponding rent subject to the lease. The Company did not pay any termination fees in connection with the Hopewell Lease Amendment. As a result of the three terminated lease components, the related ROU asset was written off, the lease liability was derecognized, and the Company recognized a gain of $2.2 million during the nine months ended September 30, 2024. The gain is included within tangible asset impairment and losses (gains) on transactions, net on the Companyâ€™s consolidated statements of operations. The Hopewell Lease Amendment did not fully or partially terminate the remaining lease component, which was therefore remeasured using an incremental borrowing rate at the date of modification of 7.5%, which resulted in an increase of the ROU asset and operating lease liability of $1.6 million, respectively. In connection with the Hopewell Lease Amendment, $2.5 million of the letter of credit was returned to the Company.The Company also has a finance lease related to its commercial manufacturing agreement with MassBiologics of the University of Massachusetts Medical School (â€œMassBioâ€). As of SeptemberÂ 30,Â 2024, the balance of the finance lease liabilities-current and finance lease liabilities-noncurrent are $2.6 million and $15.6 million, respectively, and are directly related to the Companyâ€™s MassBio agreement. As of December 31, 2023, the balance of the finance lease liabilities-current and finance lease liabilities-noncurrent were $3.0 million and $17.2 million, respectively. Additionally, the Company recorded finance lease costs of $0.4 million and $1.0 million related to interest on the lease liability during the three and nine months ended SeptemberÂ 30,Â 2024, respectively. The Company recorded finance lease costs of $0.4 million and $1.1 million related to interest on the lease liability during the three and nine months ended SeptemberÂ 30,Â 2023, respectively.The Company also leases certain vehicles, lab equipment, and office equipment under operating leases. The Companyâ€™s leases have remaining operating lease terms ranging from 0.1Â years to 14.7Â years and certain of the leases include renewal options to extend the lease for up to 15 years. For the three and nine months ended SeptemberÂ 30,Â 2024, rent expense was $5.9 million and $19.5 million, respectively. For the three and nine months ended SeptemberÂ 30,Â 2023, rent expense was $7.1 million and $21.5 million, respectively.The components of operating lease expense were as follows:â€‹â€‹â€‹

10,028â€‹$ 10,028â€‹$ â€”â€‹$ â€”Contingent consideration payable- development and regulatory milestonesâ€‹$ 9,900â€‹$ â€”â€‹$ â€”â€‹$ 9,900Contingent consideration payable- net sales milestonesâ€‹$ 12,100â€‹$ â€”â€‹$ â€”â€‹$
12,100â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹DecemberÂ 31,Â 2023â€‹Â â€‹â€‹Â QuotedÂ pricesÂ SignificantÂ â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â inÂ activeÂ otherÂ SignificantÂ â€‹â€‹â€‹â€‹â€‹â€‹Â mar
securities - available for saleâ€‹$ 260,104â€‹$ â€”â€‹$ 260,104â€‹$ â€”Marketable securities - equity investmentsâ€‹$ 22,634â€‹$ 22,634â€‹$ â€”â€‹$ â€”ClearPoint Equity Investmentsâ€‹$
6,074â€‹$ 6,074â€‹$ â€”â€‹$ â€”ClearPoint convertible debt securityâ€‹$ 12,553â€‹$ â€”â€‹$ 12,553â€‹$ â€”Contingent consideration payable- development and regulatory milestonesâ€‹$
26,600â€‹$ â€”â€‹$ â€”â€‹$ 26,600Contingent consideration payable- net sales milestones and royaltiesâ€‹$ 9,700â€‹$ â€”â€‹$ â€”â€‹$ 9,700â€‹No transfers of assets between Level 1, Level 2, or Level 3 of the fair value measurement hierarchy occurred during the periods ended SeptemberÂ 30,Â 2024 and December 31, 2023.The following is a summary of marketable securities accounted for as available for sale debt securities at SeptemberÂ 30,Â 2024 and December 31,
2023:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Net loss per share 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Net loss per share 7.Â Â Â Â Â Â Â Net loss per shareBasic and diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding. Potentially dilutive securities were excluded from the diluted calculation because their effect would be anti-dilutive.The following tables set forth the computation of basic and diluted net loss per share:â€‹Three Months Ended SeptemberÂ 30,Â â€‹â€‹Nine Months Ended SeptemberÂ 30,Â â€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â â€‹Numeratorâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â

delayed draw term loan facility of up to $150.0 million (the â€œDelayed Draw Loansâ€ and, together with the Initial Loans, the â€œLoansâ€) to be funded at the Companyâ€™s request within 18 months of the Closing Date subject to specified conditions. In addition, the Blackstone Credit Agreement contemplated the potential for further financings by Blackstone, by providing for incremental discretionary uncommitted further financings of up to $500.0 million. The Company capitalized approximately $11.6 million of debt issuance costs which are presented on the balance sheet as a direct deduction from the debt liability and are being amortized over the term of the senior secured term loan facility using the effective interest rate method.â€‹The Loans were to mature on the date that is seven years from the Closing Date. Borrowings under the Blackstone Credit Agreement bore interest at a variable rate equal to, at the Companyâ€™s option, either an adjusted Term SOFR rate plus seven and a quarter percent (7.25%) or the Base Rate plus six and a quarter percent (6.25%), subject to a floor of one percent (1%) and two percent (2%) with respect to Term SOFR rate and Base Rate (each as defined in the Blackstone Credit Agreement), respectively. Payment of the Loans were subject to certain premiums specified in the Blackstone Credit Agreement, in each case, from the date of the applicable Loan funded.â€‹On October 19, 2023, the Company terminated the Blackstone Credit Agreement. In connection with the termination of the Credit Agreement, the Company repaid outstanding principal of $300.0 million, accrued interest of $2.1 million, an additional $82.0 million in prepayment premiums, exit fees, and creditor expenses, and $0.2 million in legal fees. The Company recorded a loss on the extinguishment of debt of $92.7 million which was included on the statement of operations for the period ended December 31, 2023. The loss on extinguishment of debt consisted of $82.0 million in prepayment premiums, exit fees, and creditor expenses and debt issuance costs of $10.7 million. All liens and security interests securing the loans made pursuant to the Blackstone Credit Agreement were released upon termination.â€‹The Blackstone Credit Agreement consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SeptemberÂ 30,Â 2024â€‹DecemberÂ 31,Â 2023Principalâ€‹$ â€”â€‹$ 300,000Less: Debt issuance costsâ€‹Â â€”â€‹â€‹ â€”Repayment of senior secured term loanâ€‹â€‹ â€”â€‹â€‹ (300,000)Net carrying amountâ€‹$ â€”â€‹$ â€”â€‹â€‹The following table sets forth total interest expense recognized related to the Blackstone Credit Agreement:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

Censa Merger Agreement, (ii)Â $109.0Â million in development and regulatory milestones for each additional indication of sepiapterin, (iii)Â the achievement of certain net sales milestones up to an aggregate maximum amount of $160.0Â million, (iv)Â aÂ percentage of annual net sales during specified terms, ranging from single to low double digits of the applicable net sales threshold amount, and (v)Â any sublicense fees paid to the Company in consideration of any sublicense of Censaâ€™s intellectual property to commercialize sepiapterin, on a country-by-country basis, which contingent payment shall equal to a mid-double digitÂ percentage of any such sublicense fees. In February 2023, the Company completed enrollment of its Phase 3 placebo-controlled clinical trial for sepiapterin for PKU. Â In connection with this event and pursuant to the Censa Merger Agreement, the Company paid a $30.0 million development milestone to the former Censa securityholders during the three months ended March 31, 2023. The Company elected to pay this milestone in the form of shares of its common stock, less certain cash payments in accordance with the Censa Merger Agreement. Pursuant to such election, the Company issued 657,462 shares of its common stock and paid $0.4 million to the former Censa securityholders. In May 2024, the Company announced the validation and acceptance for review of an MMA for sepiapterin by the EMA for the treatment of PKU. Pursuant to the Censa Merger Agreement, the acceptance triggered a $15.0 million regulatory milestone to the former Censa securityholders, which was recorded in research and development expense for the nine months ended September 30, 2024. As of September 30, 2024, the $15.0 million regulatory milestone was paid.In July 2024, the Company announced the submission of an NDA to the FDA for sepiapterin for the treatment of pediatric and adult patients with PKU, including the full spectrum of ages and disease subtypes. Pursuant to the Censa Merger Agreement, the decision to submit the NDA triggered a $25.0Â million regulatory milestone to the former Censa securityholders. In September 2024, the Company announced the FDA acceptance for filing of the NDA. Pursuant to the Censa Merger Agreement, the acceptance triggered a $25.0Â million regulatory milestone to the former Censa securityholders. Together, the $50.0Â million of regulatory milestones were recorded in research and development expense for the three and nine months ended September 30, 2024 and are recorded in accounts payable and accrued expenses on the consolidated balance sheet as of September 30, 2024.The Company also has the Tegsedi-Waylivra Agreement for the commercialization of Tegsedi and Waylivra, and products containing those compounds in countries in Latin America and the Caribbean. Akcea is entitled to receive royalty payments subject to certain terms set forth in the Tegsedi-Waylivra Agreement.The Company has employment agreements with certain employees which require the funding of a specific level of payments, if certain events, such as a change in control or termination without cause, occur. Additionally, the Company has royalty payments associated with Translarna, Emflaza, and Upstaza net product revenue, payable quarterly or annually in accordance with the terms of the related agreements.From time to time in the ordinary course of its business, the Company is subject to claims, legal proceedings and disputes. The Company is not currently aware of any material legal proceedings against it. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue recognition 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] Â Revenue recognition 11.Â Â Â Â Â Â Â Revenue recognitionNet product salesThe Company views its operations and manages its business in one operating segment.During the threeÂ months ended SeptemberÂ 30,Â 2024 and 2023, net product sales outside of the United States were $83.5 million and $76.6 million, respectively, consisting of sales of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $72.3 million and $69.0 million of the net product sales outside of the United States for the three months ended SeptemberÂ 30,Â 2024 and 2023, respectively. During the three months ended SeptemberÂ 30,Â 2024 and 2023, net product sales in the United States were $51.9 million and $67.4 million, respectively, consisting solely of sales of Emflaza. During the three months ended SeptemberÂ 30,Â 2024, two countries, the United States and Brazil, accounted for at least 10% of the Companyâ€™s net product sales, representing $51.9 million and $29.2 million of the net product sales, respectively. During the three months ended SeptemberÂ 30,Â 2023, one country, the United States, accounted for at least 10% of the Companyâ€™s net product sales, representing $67.4 million of the net product sales. For the three months ended SeptemberÂ 30,Â 2024 and 2023, the Company had two and three distributors, respectively, that accounted for over 10% of the Companyâ€™s net product sales.For the nine months ended SeptemberÂ 30,Â 2024 and 2023, net product sales outside of the United States were $289.5 million and $318.5 million, respectively, consisting of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $246.2 million and $280.6 million of the net product sales outside of the United States for the nine months ended SeptemberÂ 30,Â 2024 and 2023, respectively. For the nine months ended SeptemberÂ 30,Â 2024 and 2023, net product sales in the United States were $156.7 million and $187.7 million, respectively, consisting solely of Emflaza. During the nine months ended SeptemberÂ 30,Â 2024, three countries, the United States, Brazil, and Russia, accounted for at least 10% of the Companyâ€™s net product sales, representing $156.7 million, $68.3 million, and $55.7 million of net product sales, respectively. During the nine months ended SeptemberÂ 30,Â 2023, three countries, the United States, Russia, and Brazil, accounted for at least 10% of the Companyâ€™s net product sales, representing $187.7 million, $69.0 million, and $52.5 million of net product sales, respectively. For the nine months ended SeptemberÂ 30,Â 2024 and 2023, the Company had two and two distributors, respectively, that each accounted for over 10% of the Companyâ€™s net product sales.As of SeptemberÂ 30,Â 2024 and December 31, 2023, the Company does not have a contract liabilities balance related to net product sales, and has not made significant changes to the judgments made in applying ASC Topic 606.Collaboration and Royalty revenueIn NovemberÂ 2011, the Company and the SMA Foundation entered into a licensing and collaboration agreement with Roche. Under the terms of the SMA License Agreement, Roche acquired an exclusive worldwide license to the Companyâ€™s SMA program.Under the agreement, the Company is eligible to receive additional payments from Roche if specified events are achieved with respect to each licensed product, including up to $135.0 million in research and development event milestones, up to $325.0 million in sales milestones upon achievement of specified sales events, and up to double digit royalties on worldwide annual net sales of a commercial product. The SMA program currently has one approved product, Evrysdi, which was approved in August 2020 by the FDA for the treatment of SMA in adults and children two months and older. As of SeptemberÂ 30,Â 2024, the Company does not have any remaining research and development event milestones that can be received. The remaining potential sales milestones that can be received is $150.0 million. For the three and nine months ended SeptemberÂ 30,Â 2024, the Company did not recognize collaboration revenue related to the SMA License Agreement with Roche. For the three and nine months ended September 30, 2023, the amounts recognized for the collaboration revenue related to the SMA License Agreement with Roche were immaterial.â€‹In addition to research and development and sales milestones, the Company is eligible to receive up to double-digit royalties on worldwide annual net sales of a commercial product under the SMA License Agreement. For the three and nine months ended SeptemberÂ 30,Â 2024, the Company has recognized $61.4 million and $145.7 million of royalty revenue, respectively, related to Evrysdi. For the three and nine months ended SeptemberÂ 30,Â 2023, the Company has recognized $50.2 million and $117.9 million of royalty revenue related to Evrysdi, respectively.Manufacturing Revenueâ€‹For the three months ended September 30, 2024, the Company did not recognize any revenue related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. For the nine months ended September 30, 2024, the Company recognized $1.7 million of manufacturing revenue related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. For the three and nine months ended SeptemberÂ 30,Â 2023, the Company recognized $2.4 million and $6.7 million of manufacturing revenue, respectively, related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. The Company has not made significant changes to the judgments made in applying ASC Topic 606 for the three and nine months ended SeptemberÂ 30,Â 2024 and 2023.As of SeptemberÂ 30,Â 2024, the Company does not have a contract liabilities balance related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. As of December 31, 2023, the Company had a contract liabilities balance of $0.8 million related to the production of plasmid DNA and AAV vectors for external customers, which is recorded within deferred revenue on the consolidated balance sheet. For the nine months ended SeptemberÂ 30,Â 2024, the Company recognized $0.8 million related to the amounts included in the contract liability balance at the beginning of the period. As of SeptemberÂ 30,Â 2024, the Company has no contract assets related to plasmid DNA and AAV production for external customers. As of December 31, 2023, the Company had contract assets of $0.2 million related to plasmid DNA and AAV production for external customers, which is recorded within prepaid expenses and other current assets on the consolidated balance sheet.In June 2024, the Company sold its gene therapy manufacturing business in Hopewell Township, New Jersey. Accordingly, the Company does not expect to have manufacturing revenue going forward.Remaining performance obligationsThere are no remaining performance obligations as of SeptemberÂ 30,Â 2024. The Companyâ€™s remaining performance obligations of $0.8 million as of December 31, 2023 were fully recognized during the nine months ended SeptemberÂ 30,Â 2024. X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Intangible assets and goodwill 9 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Intangible assets and goodwill 12.Â Â Â Â Â Â Â Â Intangible assets and goodwillDefinite-lived intangiblesDefinite-lived intangible assets consisted of the following at SeptemberÂ 30,Â 2024 and December 31, 2023:â€‹â€‹â€‹

available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for goodwill and intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent events 9 Months Ended Sep. 30, 2024 Subsequent Events [Abstract] Â Subsequent events 13.Â Â Â Â Â Â Â Â Â Subsequent eventsThe Company has evaluated subsequent events and transactions through the filing date. There were no material events that impacted the consolidated financial statements or disclosures. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Net Income (Loss) $ (106,654) $ (132,970) $ (297,409) $ (470,812) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 shares Trading Arrangements, by Individual Â Material Terms of Trading Arrangement â€‹Name(Title)Action Taken(DateÂ ofÂ Action)Type ofÂ TradingArrangementNatureÂ ofÂ TradingArrangement DurationÂ ofÂ TradingArrangementAggregateÂ Numberof Securities Allan Jacobson (Director)Adoption(AugustÂ 27, 2024)Rule 10b5-1 trading arrangementSaleUntil JanuaryÂ 2, 2025, or such earlier date upon which all transactions are completed.Up to 12,000 sharesChristine Utter(SVP, Chief Accounting Officer and Head of People Services)Adoption(AugustÂ 27, 2024)Rule 10b5-1 trading arrangementSaleUntil JanuaryÂ 2, 2025, or such earlier date upon which all transactions are completed.Up to 17,800 shares Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false Common Stock Trading Arrangement | Allan Jacobson Â Trading Arrangements, by Individual Â Name Allan Jacobson Title Director Rule 10b5-1 Arrangement Adopted true Adoption Date AugustÂ 27, 2024 Expiration Date JanuaryÂ 2, 2025 Aggregate Available 12,000 Common Stock Trading Arrangement | Christine Utter Â Trading Arrangements, by Individual Â Name Christine Utter Title SVP, Chief Accounting Officer and Head of People Services Rule 10b5-1 Arrangement Adopted true Adoption Date AugustÂ 27, 2024 Expiration Date JanuaryÂ 2, 2025 Aggregate Available 17,800 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details Name: ecd_TrdArrAdoptionDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph C + Details Name: ecd_TrdArrExpirationDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndName Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndTitle Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph D + Details Name: ecd_TrdArrSecuritiesAggAvailAmt Namespace Prefix: ecd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: ecd_TradingArrAxis=ptct_CommonStockTradingArrangementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ecd_IndividualAxis=ptct_AllanJacobsonMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ecd_IndividualAxis=ptct_ChristineUtterMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Basis of presentation Basis of presentationThe accompanying financial information as of SeptemberÂ 30,Â 2024 and for the three and nine months ended SeptemberÂ 30,Â 2024 and 2023 has been prepared by the Company, without audit, pursuant to the rulesÂ and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to such rulesÂ and regulations. These interim financial statements should be read in conjunction with the Companyâ€™s audited financial statements as of DecemberÂ 31,Â 2023 and notes thereto included in the 2023 FormÂ 10-K.In the opinion of management, the unaudited financial information as of SeptemberÂ 30,Â 2024 and for the three and nine months ended SeptemberÂ 30,Â 2024 and 2023 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations, stockholdersâ€™ deficit, and cash flows. The results of operations for the three and nine months ended SeptemberÂ 30,Â 2024 are not necessarily indicative of the results to be expected for theÂ year ended DecemberÂ 31,Â 2024 or for any other interim period or for any other futureÂ year. Use of estimates Use of estimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, royalty revenue, certain accruals related to the Companyâ€™s research and development expenses, valuation procedures for liability for sale of future royalties, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known. Restricted Cash Restricted cashRestricted cash included in deposits and other assets on the consolidated balance sheet contains an unconditional, irrevocable and transferable letter of credit that was entered into during the twelve-month period ended DecemberÂ 31, 2019 in connection with obligations under a facility lease for the Companyâ€™s facility in Hopewell Township, New Jersey. The amount of the letter of credit was $7.5 million and was to be maintained for a term of not less than five years and had the potential to be reduced to $3.8 million if after five years the Company was not in default of its lease. In June 2024, in connection with an amendment and restatement of the lease, the letter of credit was reduced to $5.0 million, and has the potential to be reduced to $3.0 million if after July 1, 2025, the Company is not in default of its lease. Refer to Note 3 for further details. Restricted cash also contains an unconditional, irrevocable and transferable letter of credit that was entered into during June 2022 in connection with obligations for the Companyâ€™s new facility lease in Warren, New Jersey. The amount of the letter of credit is $8.1 million and has the potential to be reduced to $4.1 million if after five years the Company is not in default of its lease. Both amounts are classified within deposits and other assets on the consolidated balance sheet due to the long-term nature of the respective letters of credit. Restricted cash also includes a bank guarantee of $0.7 million denominated in a foreign currency. The following table provides a reconciliation of cash,

cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same amounts shown in the statement of cash flows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â End ofÂ Â Â Â â€‹Beginning ofâ€‹Â period-Â period-â€‹Â SeptemberÂ 30,Â Â DecemberÂ 31,Â â€‹Â 2024â€‹2023Cash and cash equivalentsâ€‹$ 526,001â€‹$ 594,001Restricted cash included in deposits and other assets â€‹Â 13,789â€‹Â 16,283Total Cash, cash equivalents and restricted cash per statement of cash flowsâ€‹$ 539,790â€‹$ 610,284â€‹ Marketable securities Marketable securitiesThe Companyâ€™s marketable securities consists of both debt securities and equity investments. The Company considers its investments in debt securities with original maturities of greater than 90Â days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within accumulated other comprehensive income. The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the securityâ€™s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. For the three and nine months ended SeptemberÂ 30,Â 2024 and 2023, no allowance was recorded for credit losses.Marketable securities that are equity investments are measured at fair value, as it is readily available, and as such are classified as Level 1 assets. Unrealized holding gains and losses for these equity investments are components of other expense, net within the consolidated statement of operations. Inventory and cost of product sales Inventory and cost of product salesInventoryInventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Products which may be used in clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes. Inventory used for marketing efforts are charged to selling, general and administrative expense. Amounts related to clinical development programs and marketing efforts are immaterial.The following table summarizes the components of the Companyâ€™s inventory for the periods indicated:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SeptemberÂ 30,Â 2024Â Â Â Â DecemberÂ 31,Â 2023Raw materialsâ€‹$ 2,738â€‹$ 952Work in progressâ€‹Â 24,440â€‹Â 17,991Finished goodsâ€‹Â 8,493â€‹Â 11,634Total inventoryâ€‹$ 35,671â€‹$ 30,577â€‹The Company periodically reviews its inventories for excess amounts or obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value. For the three months ended SeptemberÂ 30,Â 2024 and 2023, the inventory write-downs were immaterial. For the nine months ended SeptemberÂ 30,Â 2024, the Company recorded inventory write-downs of $2.5 million, primarily related to adjustments to inventory reserves and product approaching expiration. For the nine months ended SeptemberÂ 30,Â 2023, the Company recorded inventory write-downs of $0.4 million, primarily related to product approaching expiration. Additionally, though the Companyâ€™s product is subject to strict quality control and monitoring which it performs throughout the manufacturing processes, certain batches or units of product may not meet quality specifications resulting in a charge to cost of product sales. For the three and nine months ended SeptemberÂ 30,Â 2024 and 2023, these amounts were immaterial.Cost of product salesCost of product sales consists of the cost of inventory sold, manufacturing and supply chain costs, storage costs, amortization of the acquired intangible asset, royalty payments associated with net product sales, and royalty payments to collaborative partners associated with royalty revenues and collaboration revenue related to milestones. Production costs are expensed as cost of product sales when the related products are sold or royalty revenues and collaboration revenue milestones are earned. Revenue recognition Revenue recognitionNet product revenueThe Companyâ€™s net product revenue primarily consists of sales of Translarna in territories outside of the U.S. for the treatment of nmDMD and sales of Emflaza in the U.S. for the treatment of DMD. The Company recognizes revenue when its performance obligations with its customers have been satisfied. The Companyâ€™s performance obligations are to provide products based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies. The performance obligations are satisfied at a point in time when the Companyâ€™s customer obtains control of the product, which is typically upon delivery. The Company invoices its customers after the products have been delivered and invoice payments are generally due within 30 to 90Â days of the invoice date. The Company determines the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods the Company has yet to provide. As the Company has identified only one distinct performance obligation, the transaction price is allocated entirely to product sales. In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers product to when the customers pay for the product is typically less than oneÂ year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the sameÂ month.The Company records product sales net of any variable consideration, which includes discounts, allowances, rebates related to Medicaid and other government pricing programs, and distribution fees. The Company uses the expected value or most likely amount method when estimating its variable consideration, unless discount or rebate terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained. For the threeÂ months ended SeptemberÂ 30,Â 2024 and 2023, net product sales outside of the United States were $83.5 million and $76.6 million, respectively, consisting of sales of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $72.3Â million and $69.0Â million of the net product sales outside of the United States for the three months ended SeptemberÂ 30,Â 2024 and 2023, respectively. For the three months ended SeptemberÂ 30,Â 2024 and 2023, net product sales in the United States were $51.9 million and $67.4 million, respectively, consisting solely of sales of Emflaza.Â During the three months ended SeptemberÂ 30,Â 2024, two countries, the United States and Brazil, accounted for at least 10% of the Companyâ€™s net product sales, representing $51.9 million and $29.2 million of net product sales, respectively. During the three months ended SeptemberÂ 30,Â 2023, one country, the United States, accounted for at least 10% of the Companyâ€™s net product sales, representing $67.4 million of net product sales. For the nine months ended SeptemberÂ 30,Â 2024 and 2023, net product sales outside of the United States were $289.5 million and $318.5 million, respectively, consisting of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $246.2 million and $280.6 million of the net product sales outside of the United States for the nine months ended SeptemberÂ 30,Â 2024 and 2023, respectively. For the nine months ended SeptemberÂ 30,Â 2024 and 2023, net product sales in the United States were $156.7 million and $187.7 million, respectively, consisting solely of Emflaza. During the nine months ended SeptemberÂ 30,Â 2024, three countries, the United States, Brazil, and Russia, accounted for at least 10% of the Companyâ€™s net product sales, representing $156.7 million, $68.3 million, and $55.7 million of net product sales, respectively. During the nine months ended SeptemberÂ 30,Â 2023, three countries, the United States, Russia, and Brazil, accounted for at least 10% of the Companyâ€™s net product sales, representing $187.7 million, $69.0 million, and $52.5 million of net product sales, respectively.In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. The Company considers any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise. Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense.Collaboration and royalty revenueThe terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.At the inception of a collaboration arrangement, the Company needs to first evaluate if the arrangement meets the criteria in Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Codification (â€œASCâ€) Topic 808 â€œCollaborative Arrangementsâ€ to then determine if ASC Topic 606 is applicable by considering whether the collaborator meets the definition of a customer. If the criteria are met, the Company assesses the promises in the arrangement to identify distinct performance obligations.For licenses of intellectual property, the Company assesses, at contract inception, whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license will be bundled with other promises in the arrangement into one distinct performance obligation. The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.For milestone payments, the Company assesses, at contract inception, whether the development or sales-based milestones are considered probable of being achieved. If it is probable that a significant revenue reversal will occur, the Company will not record revenue until the uncertainty has been resolved. Milestone payments that are contingent upon regulatory approval are not considered probable of being achieved until the applicable regulatory approvals or other external conditions are obtained as such conditions are not within the Companyâ€™s control. If it is probable that a significant revenue reversal will not occur, the Company will estimate the milestone payments using the most likely amount method. The Company will re-assess the development and sales-based milestones each reporting period to determine the probability of achievement. The Company recognizes royalties from product sales at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied. If it is probable that a significant revenue reversal will not occur, the Company will estimate the royalty payments using the most likely amount method.The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.For the three and nine months ended September 30, 2024, the Company did not recognize collaboration revenue related to the SMA License Agreement with Roche. For the three and nine months ended SeptemberÂ 30,Â 2023, the amounts recognized for the collaboration revenue related to the SMA License Agreement with Roche were immaterial.â€‹For the three and nine months ended SeptemberÂ 30,Â 2024, the Company recognized $61.4 million and $145.7 million of royalty revenue, respectively, related to Evrysdi. For the three and nine months ended SeptemberÂ 30,Â 2023, the Company recognized $50.2 million and $117.9 million of royalty revenue, respectively, related to Evrysdi.â€‹Manufacturing Revenueâ€‹The Company has manufacturing services related to the production of plasmid deoxyribonucleic acid (â€œDNAâ€) and adeno-associated virus (â€œAAVâ€) vectors for gene therapy applications for external customers. Performance obligations vary but may include manufacturing plasmid DNA and/or AAV vectors, material testing, stability studies, and other services related to material development. The transaction prices for these arrangements are fixed and include amounts stated in the contracts for each promised service. Typically, the performance obligations within a manufacturing contract are highly interdependent, in which case, the Company will combine them into a single performance obligation. The Company has determined that the assets created have no alternative use to the Company, and the Company has an enforceable right to payment for the performance completed to date, therefore revenue related to these services are recognized over time and is measured using an output method based on performance of manufacturing milestones completed to date.â€‹Manufacturing service contracts may also include performance obligations related to project management services or obtaining materials from third parties. The Company has determined that these are separate performance obligations for which revenue is recognized at the point in time the services are performed. For performance obligations related to obtaining third party materials, the Company has determined that it is the principal as the Company has control of the materials and has discretion in setting the price. Therefore, the Company recognizes revenue on a gross basis related to obtaining third party materials.â€‹Certain arrangements require a portion of the contract consideration to be received in advance at the commencement of the contract, and such advance payment is initially recorded as a contract liability. A contract asset may be recognized in the event the Companyâ€™s satisfaction of performance obligations outpaces customer billings. â€‹For the three months ended September 30, 2024, the Company did not recognize any revenue related to plasmid DNA and AAV vector production for external customers. For the nine months ended September 30, 2024, the Company recognized $1.7 million of manufacturing revenue related to plasmid DNA and AAV vector production for external customers. For the three and nine months ended SeptemberÂ 30,Â 2023 the Company recognized $2.4 million and $6.7 million of manufacturing revenue, respectively, related to plasmid DNA and AAV vector production for external customers. As of SeptemberÂ 30,Â 2024, the Company has no contract assets and no remaining performance obligations related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. For the period ended December 31, 2023, the Company had contract assets of $0.2 million and remaining performance obligations of $0.8 million related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers.â€‹In June 2024, the Company sold its gene therapy manufacturing business in Hopewell Township, New Jersey. Accordingly, the Company does not expect to have manufacturing revenue going forward. Allowance for doubtful accounts Allowance for doubtful accountsThe Company maintains an allowance for estimated losses resulting from the inability of its customers to make required payments. The Company estimates uncollectible amounts based upon current customer receivable balances, the age of customer receivable balances, the customerâ€™s financial condition and current economic trends. The Company also assesses whether an allowance for expected credit losses may be required which includes a review of the Companyâ€™s receivables portfolio, which are pooled on a customer basis or country basis.Â In making its assessment of whether an allowance for credit losses is required, the Company considers its historical experience with customers, current balances, levels of delinquency, regulatory and legal environments, and other relevant current and future forecasted economic conditions. For the three and nine months ended SeptemberÂ 30,Â 2024 and 2023, no allowance was recorded for credit losses. The allowance for doubtful accounts was $1.3 million as of SeptemberÂ 30,Â 2024 and $1.2 million as of DecemberÂ 31,Â 2023. For the three and nine months ended SeptemberÂ 30,Â 2024, bad debt expense was $0.7 million and $0.5 million, respectively. For the three and nine months ended SeptemberÂ 30,Â 2023, bad debt expense was $0.4 million and $0.7 million, respectively. Liability for sale of future royalties Liability for sale of future royalties In June 2024, the Company, Royalty Pharma Investments 2019 ICAV (â€œRoyalty Pharmaâ€) and Royalty Pharma plc, entered into an amendment to the Amended and Restated Royalty Purchase Agreement, dated as of October 18, 2023 (as amended, the â€œA&R Royalty Purchase Agreementâ€). The A&R Royalty Purchase Agreement amended and restated in its entirety the original Royalty Purchase Agreement, dated as of July 17, 2020 (the â€œOriginal Royalty Purchase Agreementâ€). Â Pursuant to the A&R Royalty Purchase Agreement, the Company has sold to Royalty Pharma a portion of the Companyâ€™s right to receive sales-based royalty payments (the â€œRoyaltyâ€) on worldwide net sales of Evrysdi and any other product developed pursuant to the License and Collaboration Agreement (the â€œLicense Agreementâ€), dated as of November 23, 2011, by and among the Company, Roche and, for the limited purposes set forth therein, the SMA Foundation under the SMA program. â€‹Pursuant to the guidance in ASC 470-10-25-2, the Company determined that cash consideration obtained pursuant to the A&R Royalty Purchase Agreement should be classified as debt and recorded it as â€œliability for sale of future royalties-currentâ€ and â€œliability for sale of future royalties-noncurrentâ€ on the Companyâ€™s consolidated balance sheet based on the timing of the expected payments to be made to Royalty Pharma at the time of the transaction. Under the A&R Royalty Purchase Agreement, the Company exercised a put option in June 2024, resulting in the Company receiving $241.8 million in cash consideration. In connection with the put option exercise, the change in rights and obligations resulted in a change in the terms of the liability for sale of future royalties, which was evaluated by the Company in accordance with ASC 470-50, Debt â€”Modifications and Extinguishments. The Company determined that the present value of the cash flows after the put option exercise was not substantially different and was therefore determined to be a modification. The $241.8 million in cash consideration obtained was added to the liability for sale of future royalties and the annual effective interest rate under the A&R Royalty Purchase Agreement was determined to be 9.9%. The liability is amortized using the effective interest method over the life of the arrangement, in accordance with the respective guidance, utilizing the prospective method to account for subsequent changes in the estimated future payments to be made to Royalty Pharma and the Company updates the effective interest rate on a quarterly basis. Refer to Note 9 for further details.â€‹To date, the Company has sold to Royalty Pharma a total of 90.49% of the Royalty, which will be reduced to 83.33% (the

â€œAssigned Royalty Rightsâ€) after Royalty Pharma receives $1.3Â billion in aggregate payments (the â€œAssigned Royalty Capâ€) from the Royalty assigned at the closing of the Original Purchase Agreement. Â In exchange for the Assigned Royalty Rights, Royalty Pharma has paid to the Company upfront cash consideration totaling $1.9 billion, less Royalty payments received by the Company with respect to the Assigned Royalty Rights. The Company currently retains 9.51% of the Royalty, which increases to 16.67% after the Assigned Royalty Cap has been met. Â The Company has the option under the A&R Royalty Purchase Agreement to sell its retained portions of the Royalty to Royalty Pharma in up to three tranches for the following payments: Â (1) $100.0 million in exchange for 3.81% of the Royalty, which increases to 6.67% after the Assigned Royalty Cap has been met, (2) $100.0 million in exchange for 3.81% of the Royalty, which increases to 6.67% after the Assigned Royalty Cap has been met, and (3) $50.0 million in exchange for 1.90% of the Royalty, which increases to 3.33% after the Assigned Royalty Cap has been met, in each case less Royalty payments received by the Company with respect to the Assigned Royalty Rights. Â The A&R Royalty Purchase Agreement will terminate 60 days following the date on which Roche is no longer obligated to make any payments of the Royalty pursuant to the License Agreement. Indefinite-lived intangible assets Indefinite-lived intangible assetsIndefinite-lived intangible assets consist of in process research and development ("IPR&D"). IPR&D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise, they are expensed. The fair values of IPR&D projects and license agreement assets acquired in business combinations are capitalized. Several methods may be used to determine the estimated fair value of the IPR&D and license agreement assets acquired in a business combination. The Company utilizes the "income method" and uses estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible assetâ€™s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Companyâ€™s outlook and market performance of the Companyâ€™s industry and recent and forecasted financial performance. Goodwill GoodwillGoodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Companyâ€™s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. The Company reassesses its reporting units as part of its annual segment review. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. Income Taxes Income TaxesOn December 15, 2022, the EU Member States formally adopted the EUâ€™s Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (â€œOECDâ€) Pillar Two Framework that was supported by over 130 countries worldwide. The EU effective dates are January 1, 2024, and January 1, 2025, for different aspects of the directive. A significant number of other countries are also implementing similar legislation. As a result, the tax laws in the U.S. and other countries in which PTC and its affiliates do business could change on a prospective or retroactive basis and any such changes could materially adversely affect the Companyâ€™s business. The Company is continuing to evaluate the potential impact on future periods of the Pillar Two Framework, pending legislative adoption by additional individual countries, including those within the European Union.On DecemberÂ 22, 2017, the U.S. government enacted the 2017 Tax Cuts and Jobs Act (â€œTCJAâ€), which significantly revised U.S. tax law by, among other provisions, lowering the U.S. federal statutory corporate income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Global Intangible Low-Taxed Income (â€œGILTIâ€) provisions of the TCJA require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiaryâ€™s tangible assets. The Company has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements for the period ended SeptemberÂ 30,Â 2024.Since 2022, TCJA amendments to IRC Section 174 no longer permit an immediate deduction for research and development expenditures in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over either a five- or 15-year period, depending on the location of the activities performed. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year five for activities conducted in the United States or year 15 in the case of development conducted on foreign soil. This tax law change is anticipated to result in an increased current taxable income of the Company by $121.0 million for the year ending December 31, 2024.Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured at rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. A valuation allowance is recorded when it is not more likely than not that all or a portion of the net deferred tax assets will be realized.On August 23, 2018, the Company completed its acquisition of Agilis Biotherapeutics, Inc. (â€œAgilisâ€), pursuant to an Agreement and Plan of Merger, dated as of July 19, 2018 (the â€œAgilis Merger Agreementâ€), by and among the Company, Agility Merger Sub, Inc., a Delaware corporation and the Companyâ€™s wholly owned, indirect subsidiary, Agilis and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC, (the â€œAgilis Mergerâ€). The Company recorded a deferred tax liability in conjunction with the Agilis Merger of $122.0 million in 2018, related to the tax basis difference in the IPRD indefinite-lived intangibles acquired. The Companyâ€™s policy is to record a deferred tax liability related to acquired IPR&D which may eventually be realized either upon amortization of the asset when the research is completed, and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful. In July 2022, the Company received EMEA approval for a portion of the IPR&D assets, and thus, began the amortization of the intangible. In May 2023, the Company announced the discontinuation of its preclinical and early research programs in gene therapy as part of a strategic portfolio prioritization. In conjunction with the announcement, the Company recorded an impairment to its indefinite-lived intangible for IP research and development relating to the Friedreich ataxia and Angelman syndrome gene therapy assets. As a result of the impairment, the Company recorded a deferred tax benefit of $46.9 million during the 2023 tax year. Leases LeasesThe Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company accounts for as a single lease component for all leases. Operating and finance leases are classified as right of use ("ROU") assets, short term lease liabilities, and long term lease liabilities. Operating and finance lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. ROU assets are amortized and lease liabilities accrete to yield straight-line expense over the term of the lease. Lease payments included in the measurement of the lease liability are comprised of fixed payments.Variable lease payments associated with the Companyâ€™s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Companyâ€™s consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases.Leases with an initial term of 12Â months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.A lessee is required to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Companyâ€™s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company gives consideration to its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates.The lease term for all of the Companyâ€™s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Leasehold improvements are capitalized and depreciated over the lesser of useful life or lease term. Refer to NoteÂ 3 for further details. Â Tangible asset impairment and losses (gains) on transactions, net Tangible asset impairment and losses (gains) on transactions, net Tangible asset impairment and losses (gains) on transactions, net includes impairments identified on fixed assets, losses and gains on sales of fixed assets, and gains on lease terminations. For the three months ended September 30, 2024, these amounts consisted of a $1.3 million loss for fixed asset impairments related to the South Plainfield, New Jersey office closure, as well as a $0.5 million loss on sales of fixed assets. For the nine months ended September 30, 2024, these amounts consisted of a $4.4 million loss primarily related to the sale of certain assets for gene therapy manufacturing, and a $1.5 million loss primarily related to fixed asset impairments related to the South Plainfield, New Jersey office closure. These amounts were partially offset by a gain of $2.2 million on lease terminations (Note 3) and a $0.1 million gain on sales of fixed assets. Recently issued accounting standards Recently issued accounting standardsIn November 2023, the FASB issuedÂ ASU 2023-07,Â Segment Reporting (Topic 280) â€“ Improvements to Reportable Segment Disclosures. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements, unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently planning to adopt this guidance when effective. The Company is assessing the impact of the adoption on the Companyâ€™s consolidated financial statements and accompanying footnotes.â€‹In December 2023, the FASB issuedÂ ASU 2023-09,Â Improvements to Income Tax Disclosures. ASU 2023-09 enhances the transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The guidance is effective for public business entities for annual periods beginning after December 15, 2024. For entities other than public business entities, the amendments are effective for annual periods beginning after December 15, 2025. Early adoption is permitted. The Company is currently planning to adopt this guidance when effective. The Company is assessing the impact of the adoption on the Companyâ€™s consolidated financial statements and accompanying footnotes.Â X - DefinitionDisclosure of accounting policy for inventories and cost of revenue. + ReferencesNo definition available. + Details Name: ptct_InventoriesAndCostOfProductSalesPolicyTextBlock Namespace Prefix: ptct_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for liability resulting from the sale of future royalties. + ReferencesNo definition available. + Details Name: ptct_LiabilityForSaleOfFutureRoyaltiesPolicyTextBlock Namespace Prefix: ptct_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionEntity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.M.2.Q4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483530/326-20-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 30 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147479391/326-20-30-5AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3C -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 8A -Publisher FASB -URI https://asc.fasb.org/1943274/2147479366/326-20-35-8AReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3D -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3DReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 30 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147479175/326-30-30-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3C -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3CReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3D -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3DReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 13A -Publisher FASB -URI https://asc.fasb.org/1943274/2147479148/326-30-35-13AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 30 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org/1943274/2147479391/326-20-30-4AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 7A -Publisher FASB -URI https://asc.fasb.org/1943274/2147479148/326-30-35-7AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-21Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-11Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-7Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting

Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-17 + Details Name: us-gaap_CreditLossFinancialInstrumentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.CC) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 05 -Paragraph 4 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4 + Details Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1 + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1 + Details Name: us-gaap_LesseeLeasesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for investment classified as marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 320 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5 + Details Name: us-gaap_MarketableSecuritiesPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue from contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies (Tables) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Reconciliation of cash â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â End ofÂ Â Â Â â€‹Beginning ofâ€‹Â period-Â period-â€‹SeptemberÂ 30,Â Â DecemberÂ 31,Â â€‹Â 2024â€‹2023Cash and cash equivalentsâ€‹$ 526,001â€‹$ 594,001Restricted cash included in deposits and other assets â€‹Â 13,789â€‹Â 16,283Total Cash, cash equivalents and restricted cash per statement of cash flowsâ€‹$ 539,790â€‹$ 610,284 Schedule of Inventory â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SeptemberÂ 30,Â 2024Â Â Â Â DecemberÂ 31,Â 2023Raw materialsâ€‹$ 2,738â€‹$ 952Work in progressâ€‹Â 24,440â€‹Â 17,991Finished goodsâ€‹Â 8,493â€‹Â 11,634Total inventoryâ€‹$ 35,671â€‹$ 30,577 X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of cash and cash equivalents restricted as to withdrawal or usage. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 8 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - (Tables) 9 Months Ended Sep. 30, 2024 Leases Â Schedule of lease costs â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Three Months Ended Â Â Â Â Three Months Ended Â Â Â Â Nine Months Ended Â Â Â Â Nine Months Ended â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â 2024â€‹â€‹SeptemberÂ 30,Â 2023â€‹â€‹SeptemberÂ 30,Â 2024â€‹â€‹SeptemberÂ 30,Â 2023â€‹Operating Lease CostÂ â€‹Â Â â€‹â€‹Â Â â€‹â€‹Â Â â€‹â€‹Â Â Â â€‹Fixed lease costâ€‹$ 4,049â€‹$ 5,490â€‹$ 15,173â€‹$ 16,463â€‹Variable lease costâ€‹Â 1,581â€‹Â 1,376â€‹Â 3,623â€‹Â 4,140â€‹Short-term lease costâ€‹Â 308â€‹Â 271â€‹Â 750â€‹Â 866â€‹Total operating lease costâ€‹$ 5,938â€‹$ 7,137â€‹$ 19,546â€‹$ 21,469â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SeptemberÂ 30,Â 2024Â Â Â Â DecemberÂ 31,Â 2023Â Weighted-average remaining lease terms - operating leases (years)Â 12.05â€‹ 11.55â€‹Weighted-average discount rate - operating leasesâ€‹ 8.06% 8.69%Weighted-average remaining lease terms - finance lease (years)Â 8.26â€‹ 9.01â€‹Weighted-average discount rate - finance leaseÂ 7.80% 7.80% Schedule of supplemental cash flow information related to leases â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Nine Months Ended SeptemberÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Cash paid for amounts included in the measurement of lease liabilities:Â â€‹Â Â â€‹â€‹Â Â Operating cash flows from operating leasesâ€‹$ 12,963â€‹$ 11,479Financing cash flows from finance leaseâ€‹â€‹ 1,490â€‹â€‹ 1,379Operating cash flows from finance leaseâ€‹â€‹ 1,510â€‹â€‹ 1,621â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Right-of-use assets obtained in exchange for lease obligations:â€‹Â â€‹â€‹Â Â Â Operating leasesâ€‹$ 5,786â€‹$ â€”â€‹â€‹â€‹â€‹â€‹â€‹â€‹Changes due to lease modification and termination:â€‹â€‹â€‹â€‹â€‹â€‹â€‹Net decrease in right-of-use assets â€‹$ 31,763â€‹$ â€”Net decrease in operating lease liabilitiesâ€‹â€‹ 33,908â€‹â€‹ â€” Schedule of future lease payments - Operating leases â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â OperatingÂ LeasesÂ Â Â Â Finance Leaseâ€‹2024 (excludes the nine months ended September 30, 2024)â€‹$ 3,929â€‹$ â€”â€‹2025â€‹Â 16,235â€‹Â 3,000â€‹2026â€‹Â 16,205â€‹Â 3,000â€‹2027â€‹Â 13,973â€‹Â 3,000â€‹2028 and thereafterâ€‹Â 139,266â€‹Â 15,000â€‹Total lease paymentsâ€‹Â 189,608â€‹Â 24,000â€‹Less: Imputed Interest expenseâ€‹Â 92,725â€‹Â 5,784â€‹Totalâ€‹$ 96,883â€‹$ 18,216â€‹â€‹ Schedule of future lease payments - Finance leases â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â OperatingÂ LeasesÂ Â Â Â Finance Leaseâ€‹2024 (excludes the nine months ended September 30, 2024)â€‹$ 3,929â€‹$ â€”â€‹2025â€‹Â 16,235â€‹Â 3,000â€‹2026â€‹Â 16,205â€‹Â 3,000â€‹2027â€‹Â 13,973â€‹Â 3,000â€‹2028 and thereafterâ€‹Â 139,266â€‹Â 15,000â€‹Total lease paymentsâ€‹Â 189,608â€‹Â 24,000â€‹Less: Imputed Interest expenseâ€‹Â 92,725â€‹Â 5,784â€‹Totalâ€‹$ 96,883â€‹$ 18,216â€‹â€‹ X - DefinitionTabular disclosure of supplemental cash flow information related to leases. + ReferencesNo definition available. + Details Name: ptct_LeaseSupplementalCashFlowDisclosureTableTextBlock Namespace Prefix: ptct_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value of financial instruments and marketable securities - (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Schedule of marketable securities â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

39,286â€‹â€‹â€‹

Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Net loss per share - (Tables) 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Schedule of computation of basic and diluted net loss available to common stockholders â€‹â€‹â€‹

-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies - Narrative (Details) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended Dec. 22, 2017 Jun. 30, 2022 USD ($) Sep. 30, 2024 USD ($) country Sep. 30, 2023 USD ($) country Sep. 30, 2024 USD ($) country Sep. 30, 2023 USD ($) country Dec. 31, 2024 USD ($) Dec. 31, 2023 USD ($) Dec. 31, 2019 USD ($) Jul. 31, 2025 USD ($) Jun. 30, 2024 USD ($) Dec. 31, 2018 USD ($) New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Allowance for credit loss Â Â $ 0 $ 0 $ 0 $ 0 Â Â Â Â Â Â Â Â Increase in allowance for credit losses Â Â 0 0 0 0 Â Â Â Â Â Â Allowance for doubtful accounts receivable Â Â 1,300 Â 1,300 Â Â $ 1,200 Â Â Â Â Â Bad debt expense Â Â 700 400 500 700 Â Â Â Â Â Â Revenue Â Â 196,786 $ 196,576 593,608 630,766 Â Â Â Â Â Â Income taxes Â Â Â Â Â Â Â Â Â Â Federal income tax statutory rate 21.00% Â Â Â Â Â Â Â Â Â Â Deferred tax benefit Â Â Â Â 2 $ 50,909 Â $ 46,900 Â Â Â Â Forecast Â Â Â Â Â Â Â Â Â Â Income taxes Â Â Â Â Â Â Â Â Â Â Increase in current taxable income resulting from the elimination of current deduction of qualifying R&D costs under Section 174. Â Â Â Â Â Â Â $ 121,000 Â Â Â Â Â Agilis Â Â Â Â Â Â Â Â Â Â Â Income taxes Â Â Â Â Â Â Â Â Â Â Deferred tax liability Â Â Â Â Â Â Â Â Â Â Â $ 122,000 Deposits and other assets Â Â Â Â Â Â Â Â Â Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Â Â Bank guarantee denominated in foreign currency Â Â $ 700 Â $ 700 Â Â Â Â Â Â Â Â Hopewell Campus Â Â Â Â Â Â Â Â Â Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Â Â Letters of credit Â Â Â Â Â Â Â Â Â Â $ 3,000 $ 5,000 Â Period after which letter of credit may be reduced if lease is not in default Â Â Â Â Â Â Â Â Â Â 5 years Â Â Â Hopewell Campus | Minimum Â Â Â Â Â Â Â Â Â Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Â Â Term for letter of credit (in years) Â Â Â Â Â Â Â Â 5 years Â Â Â Hopewell Campus | Deposits and other assets Â Â Â Â Â Â Â Â Â Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Â Â Letters of credit Â Â Â Â Â Â Â Â Â Â $ 7,500 Â Â Â Hopewell Campus | Fifth Anniversary Â Â Â Â Â Â Â Â Â Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Â Â Letters of credit Â Â Â Â Â Â Â $ 3,800 Â Â Â Warren Premises Â Â Â Â Â Â Â Â Â Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Â Â Period after which letter of credit may be reduced if lease is not in default Â 5 years Â Â Â Â Â Â Â Â Â Warren Premises | Deposits and other assets Â Â Â Â Â Â Â Â Â Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Â Â Letters of credit Â $ 8,100 Â Â Â Â Â Â Â Â Â Warren Premises | Fifth Anniversary Â Â Â Â Â Â Â Â Â Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Â Â Letters of credit Â $ 4,100 Â Â Â Â Â Â Â Â Â Net product revenue | Geographic concentration risk Â Â Â Â Â Â Â Â Â Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Â Â Number of countries exceeding 10% of net product sales | country Â Â 2 1 3 3 Â Â Â Â Â Percentage of net product sales threshold Â Â 10.00% 10.00% 10.00% 10.00% Â Â Â Â Â Net product revenue | Geographic concentration risk | Non-US Â Â Â Â Â Â Â Â Â Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Â Â Revenue Â Â $ 83,500 $ 76,600 $ 289,500 $ 318,500 Â Â Â Â Â Net product revenue | Geographic concentration risk | Russia Â Â Â Â Â Â Â Â Â Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Â Â Revenue Â Â Â Â 55,700 69,000 Â Â Â Â Â Net product revenue | Geographic concentration risk | Brazil Â Â Â Â Â Â Â Â Â Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Â Â Revenue Â Â 29,200 Â 68,300 52,500 Â Â Â Â Â Net product revenue | Geographic concentration risk | United States Â Â Â Â Â Â Â Â Â Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Â Â Revenue Â Â $ 51,900 $ 67,400 $ 156,700 $ 187,700 Â Â Â Â Â Net product revenue | Customer concentration risk Â Â Â Â Â Â Â Â Â Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Â Â Percentage of net product sales threshold Â Â 10.00% 10.00% 10.00% 10.00% Â Â Â Â Â Product Â Â Â Â Â Â Â Â Â Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Â Â Revenue Â Â $ 135,421 $ 144,038 $ 446,245 $ 506,187 Â Â Â Â Â Emflaza | Net product revenue | Geographic concentration risk | United States Â Â Â Â Â Â Â Â Â Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Â Â Revenue Â Â 51,900 67,400 156,700 187,700 Â Â Â Â Â Translarna | Net product revenue | Geographic concentration risk | Non-US Â Â Â Â Â Â Â Â Â Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Â Â Revenue Â Â $ 72,300 $ 69,000 $ 246,200 $ 280,600 Â Â Â Â Â X - DefinitionChange in taxable income resulting from effects of a change in tax code regarding deduction of qualifying research and development costs under Section 174. + ReferencesNo definition available. + Details Name: ptct_ChangeInTaxableIncomeChangeInTaxCodeQualifyingResearchAndDevelopmentCosts Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of countries exceeding the ten percent net product sales threshold. + ReferencesNo definition available. + Details Name: ptct_NumberOfCountriesExceedingTenPercentNetSalesThreshold Namespace Prefix: ptct_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionPercentage of net product sales + ReferencesNo definition available. + Details Name: ptct_Percentageofnetproductsales Namespace Prefix: ptct_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPeriod after which Letter of Credit may be reduced if lease is not in default. + ReferencesNo definition available. + Details Name: ptct_PeriodAfterWhichLetterOfCreditMayBeReducedIfLeaseNotInDefault Namespace Prefix: ptct_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionTerm for letter of credit + ReferencesNo definition available. + Details Name: ptct_Termforletterofcredit Namespace Prefix: ptct_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of increase (decrease) in allowance for credit loss of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deferred tax liability attributable to taxable temporary differences. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942

-SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_DeferredIncomeTaxLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPercentage of domestic federal statutory tax rate applicable to pretax income (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.1.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThis item represents a non-contingent liability for the fair value of an obligation to stand ready to perform over the term of a guaranty issued in the event that specified triggering events or conditions occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 25 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482050/460-10-25-4 + Details Name: us-gaap_GuarantyLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe total amount of the contingent obligation under letters of credit outstanding as of the reporting date. + ReferencesNo definition available. + Details Name: us-gaap_LettersOfCreditOutstandingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 9 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 50 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 43: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 44: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 45: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 46: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 47: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 48: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3Reference 50: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3Reference 51: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3Reference 52: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-5Reference 53: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 54: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 55: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 56: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 57: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 58: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 59: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 60: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 61: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 62: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 63: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 64: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 65: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 66: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 67: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 68: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 69: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 11.M.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5Reference 70: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 71: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 72: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 73: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 74: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 75: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 76: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 77: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 78: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic

20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 79: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 80: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 81: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 82: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 83: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 84: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 85: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 86: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-6Reference 87: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 88: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 89: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 90: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 91: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 92: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 93: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 94: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 95: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 96: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 97: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 98: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-3Reference 99: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1Reference 100: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=ptct_DepositsAndOtherNoncurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ptct_HopewellCampusMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=ptct_FifthAnniversaryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ptct_WarrenPremisesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=us-gaap_NonUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_RU Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_BR Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ptct_EmflazaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ptct_TranslarnaMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies - Reconciliation of cash (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Dec. 31, 2022 Accounting Policies [Abstract] Â Â Â Â Cash and cash equivalents $ 526,001 $ 594,001 Â Â Restricted cash included in deposits and other assets 13,789 16,283 Â Â Total Cash, cash equivalents and restricted cash per statement of cash flows $ 539,790 $ 610,284 $ 181,410 $ 295,925 X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies - Inventory (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Accounting Policies [Abstract] Â Â Â Raw materials $ 2,738 Â $ 952 Work in progress 24,440 Â 17,991 Finished goods 8,493 Â 11,634 Total inventory 35,671 Â $ 30,577 Inventory write-down $ 2,500 $ 400 Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoods Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterials Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcess Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2 + Details Name: us-gaap_InventoryWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies - Collaboration and Royalty Revenue (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Collaboration and royalty revenue Â Â Â Â Revenue $ 196,786,000 $

196,576,000 $ 593,608,000 $ 630,766,000 Collaboration revenue Â Â Â Â Collaboration and royalty revenue Â Â Â Â Revenue Â Â Â 6,000 Royalty revenue Â Â Â Â Collaboration and royalty revenue Â Â Â Â Revenue 61,365,000 50,173,000 145,702,000 117,857,000 SMA License Agreement | Collaboration revenue Â Â Â Â Collaboration and royalty revenue Â Â Â Â Revenue 0 Â 0 Â SMA License Agreement | Royalty revenue Â Â Â Â Collaboration and royalty revenue Â Â Â Â Revenue $ 61,400,000 $ 50,200,000 $ 145,700,000 $ 117,900,000 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=ptct_CollaborationRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies - Manufacturing Revenue (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Revenue recognition Â Â Â Â Â Revenue $ 196,786,000 $ 196,576,000 $ 593,608,000 $ 630,766,000 Â Remaining performance obligations 0 Â 0 Â $ 800,000 Manufacturing revenue Â Â Â Â Â Revenue recognition Â Â Â Â Â Revenue 0 $ 2,365,000 1,661,000 $ 6,716,000 Â Contract with customer, asset 0 Â 0 Â 200,000 Remaining performance obligations $ 0 Â $ 0 Â $ 800,000 X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerAssetNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of transaction price allocated to performance obligation that has not been recognized as revenue. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_ProductOrServiceAxis=ptct_ManufacturingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies - Liability for Sale of Future Royalties (Details) $ in Thousands 1 Months Ended 9 Months Ended Jun. 30, 2024 USD ($) tranche Sep. 30, 2024 USD ($) Assigned royalty payments Â Â Cash received from Royalty Pharma Â $ 241,792 Effective interest rate of the liability component Â 9.90% A&R Royalty Purchase Agreement Â Â Assigned royalty payments Â Â Cash received from Royalty Pharma $ 241,800 Â Assigned royalty payment, retained percentage 9.51% Â Royalty purchase agreement termination period once there are no further royalty payment obligations 60 days Â Effective interest rate of the liability component 9.90% Â Aggregate percentage of royalty rights sold Â 90.49% Percentage of maximum royalty payable thereafter assigned royalty rights Â 83.33% Liability recognized for sale of future royalties. $ 241,800 Â Adjusted percentage of retained royalty rights after the 2020 Assigned Royalty Cap is met 16.67% Â A&R Royalty Purchase Agreement | Maximum Â Â Assigned royalty payments Â Â Number of tranches to sell retained royalty | tranche 3 Â A&R Royalty Purchase Agreement | Royalty Pharma Â Â Assigned royalty payments Â Â Assigned Royalty Cap per terms of the royalty purchase agreement $ 1,300,000 Â Aggregate upfront cash consideration received for sale of future royalties Â $ 1,900,000 A&R Royalty Purchase Agreement Tranche One Â Â Assigned royalty payments Â Â Aggregate percentage of royalty rights sold 3.81% Â Contract price for sale of specified percentage of future royalties $ 100,000 Â Adjusted percentage of retained royalty rights sold after the 2020 Assigned Royalty Cap is met 6.67% Â A&R Royalty Purchase Agreement Tranche Two Â Â Assigned royalty payments Â Â Aggregate percentage of royalty rights sold 3.81% Â Contract price for sale of specified percentage of future royalties $ 100,000 Â Adjusted percentage of retained royalty rights sold after the 2020 Assigned Royalty Cap is met 6.67% Â A&R Royalty Purchase Agreement Tranche Three Â Â Assigned royalty payments Â Â Aggregate percentage of royalty rights sold 1.90% Â Contract price for sale of specified percentage of future royalties $ 50,000 Â Adjusted percentage of retained royalty rights sold after the 2020 Assigned Royalty Cap is met 3.33% Â X - DefinitionAdjusted percentage of retained royalty rights after the 2020 Assigned Royalty Cap is met. + ReferencesNo definition available. + Details Name: ptct_AdjustedPercentageOfRetainedRoyaltyRightsAfterAssignedRoyaltyCapMet Namespace Prefix: ptct_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAdjusted percentage of retained royalty rights sold after the 2020 Assigned Royalty Cap is met. + ReferencesNo definition available. + Details Name: ptct_AdjustedPercentageOfRetainedRoyaltyRightsSoldAfterAssignedRoyaltyCapMet Namespace Prefix: ptct_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAggregate amount of upfront cash consideration received from the sale of future royalties. + ReferencesNo definition available. + Details Name: ptct_AggregateCashProceedsFromSaleOfFutureRoyalties Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAssigned Royalty Payment, Retained Percentage + ReferencesNo definition available. + Details Name: ptct_AssignedRoyaltyPaymentRetainedPercentage Namespace Prefix: ptct_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of liability recognized for sale of future royalties sold. + ReferencesNo definition available. + Details Name: ptct_LiabilityForSaleOfFutureRoyalties Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of contract price for sale of specified percentage of future royalties per terms of agreement. + ReferencesNo definition available. + Details Name: ptct_LiabilitySaleOfFutureRoyaltiesContractSalePrice Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of tranches in which the retained royalty portions may be sold under terms of amended agreement. + ReferencesNo definition available. + Details Name: ptct_NumberOfTranchesToSellRetainedRoyalty Namespace Prefix: ptct_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionPercentage of maximum royalty payable thereafter assigned royalty rights. + ReferencesNo definition available. + Details Name: ptct_PercentageOfMaximumRoyaltyPayableThereafterAssignedRoyaltyRights Namespace Prefix: ptct_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionTotal percentage of royalty rights assigned. + ReferencesNo definition available. + Details Name: ptct_PercentageOfTotalRoyaltyAssigned Namespace Prefix: ptct_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionCash received for sale of future royalties during the current period. + ReferencesNo definition available. + Details Name: ptct_ProceedsFromSaleOfFutureRoyalties Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of royalties to be received after which the percentage is adjusted under terms of the Amended and Restated Royalty Purchase Agreement ("Assigned Royalty Cap"). + ReferencesNo definition available. + Details Name: ptct_RoyaltyPurchaseAgreementPaymentMaximum Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRoyalty purchase agreement termination period once there are no further royalty payment obligations. + ReferencesNo definition available. + Details Name: ptct_RoyaltyPurchaseAgreementTerminationPeriod Namespace Prefix: ptct_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=ptct_AndRRoyaltyPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=ptct_RoyaltyPharmaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=ptct_AndRRoyaltyPurchaseAgreementAmendmentTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=ptct_AndRRoyaltyPurchaseAgreementAmendmentTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=ptct_AndRRoyaltyPurchaseAgreementAmendmentTrancheThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies - Tangible Asset Impairment and Losses (Gains) on Transactions, Net (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Asset impairment and losses (gains) on transactions Â Â Gain (loss) on sale of fixed assets Â $ (4,298) Tangible asset impairment Â 1,486 Gain on lease terminations Â 2,179 South Plainfield, New Jersey office Â Â Asset impairment and losses (gains) on transactions Â Â Tangible asset impairment $ 1,300 1,500 Early-stage gene therapy program assets Â Â Asset impairment and losses (gains) on transactions Â Â Gain (loss) on sale of fixed assets Â 4,400 Other fixed assets Â Â Asset impairment and losses (gains) on transactions Â Â Gain (loss) on sale of fixed assets $ (500) $ 100 X - ReferencesNo definition available. + Details Name: us-gaap_AssetImpairmentChargesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on termination of lease before expiration of lease term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479092/842-20-40-1 + Details Name: us-gaap_GainLossOnTerminationOfLease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1 + Details Name: us-gaap_TangibleAssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ptct_SouthPlainfieldNewJerseyOfficeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=ptct_EarlyStageGeneTherapyProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Narrative (Details) $ in Thousands 3 Months Ended 9 Months Ended Jun. 17, 2024 USD ($) ftÂ² component Jun. 01, 2022 USD ($) ftÂ² period building Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Jun. 16, 2024 ftÂ² component Dec. 31, 2023 USD ($) Leases Â Â Â Â Â Â Â Â Operating lease, expense Â Â $ 5,900 $ 7,100 $ 19,500 $ 21,500 Â Â Finance lease liabilities- current Â Â 2,642 Â 2,642 Â Â $ 3,000 Finance lease liabilities- noncurrent Â Â 15,574 Â 15,574 Â Â 17,184 Aggregate rent, Initial term Â Â 189,608 Â 189,608 Â Â Â Operating lease ROU assets Â Â 59,465 Â 59,465 Â Â 91,896 Operating Lease, Liability Â Â 96,883 Â 96,883 Â Â Â Gain on termination of lease components Â Â Â Â 2,179 Â Â Â MassBio Â Â Â Â Â Â Â Â Leases Â Â Â Â Â Â Â Â Finance lease cost Â Â 400 $ 400 1,000 $ 1,100 Â Â Finance lease liabilities- current Â Â 2,600 Â 2,600 Â Â 3,000 Finance lease liabilities- noncurrent Â Â $ 15,600 Â $ 15,600 Â Â $ 17,200 Minimum Â Â Â Â Â Â Â Â Leases Â Â Â Â Â Â Â Â Operating lease, term of contract Â Â 1 month 6 days Â 1 month 6 days Â Â Â Maximum Â Â Â Â Â Â Â Â Leases Â Â Â Â Â Â Â Â Operating lease, term of contract Â Â 14 years 8 months 12 days Â 14 years 8 months 12 days Â Â Â Renewal term Â Â 15 years Â 15 years Â Â Â Hopewell Campus Â Â Â Â Â Â Â Â Leases Â Â Â Â Â Â Â Â Area of real estate property | ftÂ² 93,461 Â Â Â Â Â 220,500 Â Operating lease ROU assets $ 1,600 Â Â Â Â Â Â Â Operating Lease, Liability $ 1,600 Â Â Â Â Â Â Â Number of separate lease components | component Â Â Â Â Â Â 4 Â Number of separate lease components terminated | component 3 Â Â Â Â Â Â Â Gain on termination of lease components Â Â Â Â $ 2,200 Â Â Â Incremental borrowing rate of interest used to remeasure the remaining components of operating lease 7.50% Â Â Â Â Â Â Â Return of letter of credit pertaining to amendments to operating lease agreement $ 2,500 Â Â Â Â Â Â Â Warren Premises Â Â Â Â Â Â Â Â Leases Â Â Â Â Â Â Â Â Operating lease, term of contract Â 17 years Â Â Â Â Â Â Number of buildings leased | building Â 2 Â Â Â Â Â Â Â Area of real estate property | ftÂ² Â 360,000 Â Â Â Â Â Â Renewal term Â 5 years Â Â Â Â Â Â Number of renewable terms | period Â 3 Â Â Â Â Â Â Â Lessee, Operating Lease, Existence of Option to Extend [true false] Â true Â Â Â Â Â Â Aggregate rent, Initial term Â $ 163,000 Â Â Â Â Â Â Operating lease ROU assets Â 28,900 Â Â Â Â Â Â Operating Lease, Liability Â $ 28,900 Â Â Â Â Â Â Base rent abatement period Â 3 years Â Â Â Â Â Â Base rent abatement Â $ 18,600 Â Â Â Â Â Â Aggregate rent net of base rate abatement, initial term Â 144,400 Â Â Â Â Â Â Allowance for lease improvements Â 36,200 Â Â Â Â Â Â Payment due from lessor at issuance of temporary certificate of occupancy Â $ 5,000 Â Â Â Â Â Â X - DefinitionIncremental borrowing rate of interest used to remeasure the remaining components of operating lease. + ReferencesNo definition available. + Details Name: ptct_IncrementalBorrowingRateRemeasurementOfRemainingLeaseComponent Namespace Prefix: ptct_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of base rent abatement available if lessee is not subject to an event of default as defined in the lease agreement. + ReferencesNo definition available. + Details Name: ptct_LesseeOperatingLeaseBaseRentAbatement Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPeriod of lessee's base rent abatement entitlement per terms of lease agreement. + ReferencesNo definition available. + Details Name: ptct_LesseeOperatingLeaseBaseRentAbatementPeriod Namespace Prefix: ptct_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease net of eligible base rent abatement. + ReferencesNo definition available. + Details Name: ptct_LesseeOperatingLeaseLiabilityToBePaidNetOfBaseRentAbatement Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of buildings leased during the period. + ReferencesNo definition available. + Details Name: ptct_NumberOfBuildingsLeased Namespace Prefix: ptct_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber of separate lease components in lease agreement. + ReferencesNo definition available. + Details Name: ptct_NumberOfLeaseComponents Namespace Prefix: ptct_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber of separate lease components in lease agreement terminated. + ReferencesNo definition available. + Details Name: ptct_NumberOfLeaseComponentsTerminated Namespace Prefix: ptct_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber of renewable terms. + ReferencesNo definition available. + Details Name: ptct_Numberofterms Namespace Prefix: ptct_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionThe amount of allowance for lease improvements provided by lessor under the terms of the lease agreement. + ReferencesNo definition available. + Details Name: ptct_OperatingLeaseAllowanceForLeaseImprovements Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of payment due from lessor at issuance of temporary certificate of occupancy that lessee has committed to fund into the construction account for lease improvements provided under the terms of the lease agreement. + ReferencesNo definition available. + Details Name: ptct_OperatingLeaseLessorPaymentDueAtIssuanceOfTemporaryCertificateOfOccupancy Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of reduction of letter of credit requirements pertaining to amendments to operating lease agreement. + ReferencesNo definition available. + Details Name: ptct_ReductionInLetterOfCredit Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionArea of a real estate property. + ReferencesNo definition available. + Details Name: us-gaap_AreaOfRealEstateProperty Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionAmount of interest expense on finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseInterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of gain (loss) on termination of lease before expiration of lease term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479092/842-20-40-1 + Details Name: us-gaap_GainLossOnTerminationOfLease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIndicates (true false) whether lessee has option to extend operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType

Balance Type: credit Period Type: instant X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: srt_CounterpartyNameAxis=ptct_MassBioMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ptct_HopewellCampusMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ptct_WarrenPremisesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Lease costs (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Leases Â Â Â Â Fixed lease cost $ 4,049 $ 5,490 $ 15,173 $ 16,463 Variable lease cost 1,581 1,376 3,623 4,140 Short-term lease cost 308 271 750 866 Total operating lease cost $ 5,938 $ 7,137 $ 19,546 $ 21,469 X - DefinitionAmount of lease cost recognized by lessee for lease contracts, excluding finance lease costs. + ReferencesNo definition available. + Details Name: ptct_LeaseCostExcludingFinanceLeaseCosts Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of short-term lease cost, excluding expense for lease with term of one month or less. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_ShortTermLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Supplemental lease terms (Details) Sep. 30, 2024 Dec. 31, 2023 Leases Â Â Weighted-average remaining lease terms - operating leases (years) 12 years 18 days 11 years 6 months 18 days Weighted-average discount rate - operating leases 8.06% 8.69% Weighted-average remaining lease terms - finance lease (years) 8 years 3 months 3 days 9 years 3 days Weighted-average discount rate - finance lease 7.80% 7.80% X - DefinitionWeighted average discount rate for finance lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Cash flow (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Leases Â Â Operating cash flows from operating leases $ 12,963 $ 11,479 Financing cash flows from finance lease 1,490 1,379 Operating cash flows from finance leases 1,510 $ 1,621 Right-of-use assets obtained in exchange for operating lease obligations 5,786 Â Net decrease in right-of-use assets due to lease modification and termination 31,763 Â Net decrease in operating lease liabilities due to lease modification and termination $ 33,908 Â X - DefinitionAmount of decrease in operating lease right-of-use assets related to lease modifications and terminations. + ReferencesNo definition available. + Details Name: ptct_RightOfUseAssetDecreaseDueToLeaseModificationsAndTerminationsObtainedInExchangeForFinanceLeaseLiability Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest paid on finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeaseInterestPaymentOnLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeasePrincipalPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities that result from activities that generate operating income. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Lease payments (Details) $ in Thousands Sep. 30, 2024 USD ($) Operating leases Â 2024 (excludes the nine months ended September 30, 2024) $ 3,929 2025 16,235 2026 16,205 2027 13,973 2028 and thereafter 139,266 Total lease payments 189,608 Less: Imputed Interest expense 92,725 Total 96,883 Finance leases Â 2025 3,000 2026 3,000 2027 3,000 2028 and thereafter 15,000 Total lease payments 24,000 Less: Imputed Interest expense 5,784 Total $ 18,216 X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year and after following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: ptct_FinanceLeaseLiabilityToBePaidYearFourAndAfter Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due fourth fiscal year and after following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: ptct_LesseeOperatingLeaseLiabilityToBePaidYearFourAndAfter Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal

year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value of financial instruments and marketable securities - Marketable Securities (Details) $ / shares in Units, $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Jan. 31, 2020 USD ($) $ / shares Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) fund Sep. 30, 2023 USD ($) Changes in fair value Â Â Â Â Â Unrealized Gain/(Loss) Â Â Â $ 1,923 $ 5,484 Investments Purchased Â Â Â 49,614 26,378 Redemptions/Sale Â Â Â (41,624) (12,078) Unrealized Gain/(Loss) Â Â Â 3,954 (3,107) Realized Gain/(Loss) Â Â Â Â (782) Redemptions/Sale Â Â Â Â (2,594) Unrealized Gain/(Loss) Â Â Â (1,931) (4,594) Realized Gain (Loss) Â Â Â (622) Â Redemptions/Sale Â Â Â (10,000) Â Beginning Balance - Total Â $ 32,333 $ 148,115 41,261 134,457 Unrealized Gain/(Loss) - Total Â 6,018 (3,931) 3,946 (2,217) Realized Gain/(Loss) - Total Â (622) Â (622) (782) Foreign Currency Unrealized Gain/(Loss) - Total Â 400 (1,426) (3,289) (17) Investments Purchased - Total Â 32,208 8,219 49,614 26,378 Redemptions/Sale - Total Â (31,051) (7,830) (51,624) (14,672) Ending Balance - Total Â 39,286 143,147 39,286 143,147 ClearPoint Convertible note Â Â Â Â Â Purchase of convertible note Â Â Â 476,680 Â Marketable securities - equity investments Â Â Â Â Â Changes in fair value Â Â Â Â Â Beginning Balance Â 16,889 127,945 22,634 108,261 Unrealized Gain/(Loss) Â 812 1,120 1,923 5,484 Foreign Currency Unrealized Gain/(Loss) Â 400 (1,426) (3,289) (17) Investments Purchased Â 32,208 8,219 49,614 26,378 Redemptions/Sale Â (21,051) (7,830) (41,624) (12,078) Ending Balance Â 29,258 128,028 29,258 128,028 ClearPoint Equity Investment Â Â Â Â Â Changes in fair value Â Â Â Â Â Beginning Balance Â 4,822 6,477 6,074 10,965 Unrealized Gain/(Loss) Â 5,206 (1,995) 3,954 (3,107) Realized Gain/(Loss) Â Â Â Â (782) Redemptions/Sale Â Â Â Â (2,594) Ending Balance Â 10,028 4,482 10,028 4,482 ClearPoint convertible debt Â Â Â Â Â Changes in fair value Â Â Â Â Â Beginning Balance Â 10,622 13,693 12,553 15,231 Unrealized Gain/(Loss) Â Â (3,056) (1,931) (4,594) Realized Gain (Loss) Â (622) Â (622) Â Redemptions/Sale Â (10,000) Â (10,000) Â Ending Balance Â $ 0 $ 10,637 $ 0 $ 10,637 ClearPoint Convertible note Â Â Â Â Â Purchase of convertible note $ 10,000 Â Â Â Â Conversion price - convertible note | $ / shares $ 6.00 Â Â Â Â Â Term of convertible note 5 years Â Â Â Â Â Mutual Funds Â Â Â Â Â Equity Investments Â Â Â Â Â Number of mutual funds denominated in a foreign currency | fund Â Â Â 1 Â X - DefinitionThe price per share of the conversion feature embedded in the available-for-sale convertible debt securities. + ReferencesNo definition available. + Details Name: ptct_AvailableForSaleDebtSecuritiesConversionPrice Namespace Prefix: ptct_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of realized gain (loss) from sale of Clearpoint Equity Investment measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesNo definition available. + Details Name: ptct_ClearpointEquityInvestmentFvNiRealizedGainLoss Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on ClearPoint equity investment measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesNo definition available. + Details Name: ptct_ClearpointEquityInvestmentFvniUnrealizedGainLoss Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of investment in equity security of ClearPoint Neuro, Inc. measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesNo definition available. + Details Name: ptct_ClearpointEquityInvestmentsFvNi Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in convertible debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesNo definition available. + Details Name: ptct_ConvertibleDebtSecurity Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable equity investments and convertible debt securities measured at fair value. + ReferencesNo definition available. + Details Name: ptct_EquityInvestmentsAndConvertibleDebtSecurities Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash outflow for purchase of marketable equity investments and convertible debt securities. + ReferencesNo definition available. + Details Name: ptct_MarketableEquityInvestmentsAndConvertibleDebtSecuritiesPurchases Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of realized gain (loss) from marketable equity investments and convertible debt securities measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesNo definition available. + Details Name: ptct_MarketableEquityInvestmentsAndConvertibleDebtSecuritiesRealizedGainLoss Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on marketable equity investments and convertible debt securities measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesNo definition available. + Details Name: ptct_MarketableEquityInvestmentsAndConvertibleDebtSecuritiesUnrealizedGainLoss Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) from foreign currency transaction on marketable equity investments and convertible debt securities. + ReferencesNo definition available. + Details Name: ptct_MarketableEquityInvestmentsAndConvertibleDebtSecuritiesUnrealizedGainLossForeignCurrencyTransaction Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) from foreign currency transaction on marketable securities. + ReferencesNo definition available. + Details Name: ptct_MarketableSecuritiesUnrealizedGainLossForeignCurrencyTransaction Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe number of mutual funds invested in that are denominated in a foreign currency. + ReferencesNo definition available. + Details Name: ptct_NumberOfMutualFundsInvestedInDenominatedInForeignCurrency Namespace Prefix: ptct_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow associated with a principal payment received by the entity on Clearpoint convertible debt security during the period. + ReferencesNo definition available. + Details Name: ptct_ProceedsFromPrincipalPaymentOfClearpointConvertibleDebtSecurity Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of Clearpoint Equity Investment during the period. + ReferencesNo definition available. + Details Name: ptct_ProceedsFromSaleAndMaturityOfClearpointEquityInvestment Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or redemption of marketable equity investments and convertible debt securities during the period. + ReferencesNo definition available. + Details Name: ptct_ProceedsFromSaleAndRedemptionOfMarketableEquityInvestmentsAndConvertibleDebtSecurities Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AvailableForSaleSecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPeriod between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A + Details Name: us-gaap_EquitySecuritiesFvNi Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11 + Details Name: us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=ptct_ClearpointEquityInvestmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_MutualFundMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value of financial instruments and marketable securities - Hierarchy (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Financial assets and liabilities measured at fair value on recurring basis Â Â Marketable securities - available for sale $ 458,098 $ 260,104 Contingent consideration payable 22,000 36,300 Transfers of assets measured between Level 1, Level 2, and Level 3 0 0 Recurring basis Â Â Financial assets and liabilities measured at fair value on recurring basis Â Â ClearPoint Equity Investments 10,028 6,074 ClearPoint convertible debt security Â 12,553 Recurring basis | Quoted prices in active markets for identical assets (Level 1) Â Â Financial assets and liabilities measured at fair value on recurring basis Â Â ClearPoint Equity Investments 10,028 6,074 Recurring basis | Significant other observable inputs (Level 2) Â Â Financial assets and liabilities measured at fair value on recurring basis Â Â ClearPoint convertible debt security Â 12,553 Recurring basis | Development and Regulatory Milestones Â Â Financial assets and liabilities measured at fair value on recurring basis Â Â Contingent consideration payable 9,900 26,600 Recurring basis | Development and Regulatory Milestones | Significant unobservable inputs (Level 3) Â Â Financial assets and liabilities measured at fair value on recurring basis Â Â Contingent consideration payable 9,900 26,600

Recurring basis | Net Sales Milestones and Royalties Â Â Financial assets and liabilities measured at fair value on recurring basis Â Â Contingent consideration payable 12,100 9,700 Recurring basis | Net Sales Milestones and Royalties | Significant unobservable inputs (Level 3) Â Â Financial assets and liabilities measured at fair value on recurring basis Â Â Contingent consideration payable 12,100 9,700 Recurring basis | Marketable securities Â Â Financial assets and liabilities measured at fair value on recurring basis Â Â Marketable securities - available for sale 458,098 260,104 Marketable securities - equity investments 29,258 22,634 Recurring basis | Marketable securities | Quoted prices in active markets for identical assets (Level 1) Â Â Financial assets and liabilities measured at fair value on recurring basis Â Â Marketable securities - equity investments 29,258 22,634 Recurring basis | Marketable securities | Significant other observable inputs (Level 2) Â Â Financial assets and liabilities measured at fair value on recurring basis Â Â Marketable securities - available for sale $ 458,098 $ 260,104 X - DefinitionAmount of investment in equity security of ClearPoint Neuro, Inc. measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesNo definition available. + Details Name: ptct_ClearpointEquityInvestmentsFvNi Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in convertible debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesNo definition available. + Details Name: ptct_ConvertibleDebtSecurity Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of transfers of assets measured on a recurring basis between Level 1, Level 2, and Level 3 of the fair value hierarchy. + ReferencesNo definition available. + Details Name: ptct_FairValueAssetsTransfersBetweenLevel1Level2AndLevel3Amount Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A + Details Name: us-gaap_EquitySecuritiesFvNi Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentandRegulatoryMilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value of financial instruments and marketable securities - Marketable Securities, Unrealized Gains (Losses) (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Debt Securities, Available-for-sale [Line Items] Â Â Â Â Â Amortized Cost $ 455,568,000 Â $ 455,568,000 Â $ 259,778,000 Gross Unrealized, Gain 2,538,000 Â 2,538,000 Â 340,000 Gross Unrealized, Loss (8,000) Â (8,000) Â (14,000) Fair Value 458,098,000 Â 458,098,000 Â 260,104,000 Write downs of available for sale debt securities 0 $ 0 0 $ 0 Â Increase in allowance for credit losses 0 0 0 0 Â Realized gain (loss) from sale of marketable securities 800,000 $ 0 800,000 $ (300,000) Â Commercial paper Â Â Â Â Â Debt Securities, Available-for-sale [Line Items] Â Â Â Â Â Amortized Cost 118,783,000 Â 118,783,000 Â 117,044,000 Gross Unrealized, Gain 636,000 Â 636,000 Â 128,000 Gross Unrealized, Loss Â Â Â Â Â (12,000) Fair Value 119,419,000 Â 119,419,000 Â 117,160,000 Corporate debt securities Â Â Â Â Â Debt Securities, Available-for-sale [Line Items] Â Â Â Â Â Amortized Cost 44,494,000 Â 44,494,000 Â 1,650,000 Gross Unrealized, Gain 156,000 Â 156,000 Â Â Gross Unrealized, Loss (8,000) Â (8,000) Â (2,000) Fair Value 44,642,000 Â 44,642,000 Â 1,648,000 Government obligations Â Â Â Â Â Debt Securities, Available-for-sale [Line Items] Â Â Â Â Â Amortized Cost 292,291,000 Â 292,291,000 Â 141,084,000 Gross Unrealized, Gain 1,746,000 Â 1,746,000 Â 212,000 Fair Value $ 294,037,000 Â $ 294,037,000 Â $ 141,296,000 X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in allowance for credit loss of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionAmount of writeoff of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in net income (trading). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-14 + Details Name: us-gaap_DebtSecuritiesTradingRealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType

Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value of financial instruments and marketable securities - Available-for-sale securities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Debt Securities, Available-for-sale [Line Items] Â Â Securities in an unrealized loss position less than 12 months - Unrealized losses $ (8) $ (12) Securities in an unrealized loss position less than 12 months - Fair Value 14,984 44,446 Securities in an unrealized loss position greater than 12 months - Unrealized losses Â (2) Securities in an unrealized loss position greater than 12 months - Fair Value Â 1,648 Total - Unrealized losses (8) (14) Total - Fair Value 14,984 46,094 Commercial paper Â Â Debt Securities, Available-for-sale [Line Items] Â Â Securities in an unrealized loss position less than 12 months - Unrealized losses Â (12) Securities in an unrealized loss position less than 12 months - Fair Value Â 44,446 Total - Unrealized losses Â (12) Total - Fair Value Â 44,446 Corporate debt securities Â Â Debt Securities, Available-for-sale [Line Items] Â Â Securities in an unrealized loss position less than 12 months - Unrealized losses (8) Â Securities in an unrealized loss position less than 12 months - Fair Value 14,984 Â Securities in an unrealized loss position greater than 12 months - Unrealized losses Â (2) Securities in an unrealized loss position greater than 12 months - Fair Value Â 1,648 Total - Unrealized losses (8) (2) Total - Fair Value $ 14,984 $ 1,648 X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value of financial instruments and marketable securities - Marketable Securities, Balance Sheet Disclosures (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Debt Securities, Available-for-Sale [Line Items] Â Â Marketable securities, Less Than 12 Months $ 458,098 $ 260,104 Commercial paper Â Â Debt Securities, Available-for-Sale [Line Items] Â Â Marketable securities, Less Than 12 Months 119,419 117,160 Corporate debt securities Â Â Debt Securities, Available-for-Sale [Line Items] Â Â Marketable securities, Less Than 12 Months 44,642 1,648 Government obligations Â Â Debt Securities, Available-for-Sale [Line Items] Â Â Marketable securities, Less Than 12 Months $ 294,037 $ 141,296 X - DefinitionFair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value of financial instruments and investments - Convertible senior notes (Details) - 1.50% Convertible senior notes due 2026 - USD ($) Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2019 Long-term debt Â Â Â Principal $ 287,500,000 $ 287,500,000 Â Convertible debt Â Â Â Long-term debt Â Â Â Principal Â Â $ 287,500,000 Interest rate (as a percent) 1.50% Â 1.50% Convertible debt | Significant other observable inputs (Level 2) Â Â Â Long-term debt Â Â Â Fair value of convertible notes $ 293,400,000 $ 265,300,000 Â X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DebtInstrumentFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value of financial instruments and investments - Summary of changes in the fair value of the Company's Level 3 valuation (Details) - Significant unobservable inputs (Level 3) - Agilis - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Upstaza Â Â Changes in the fair value of warrant liability and SARs liability Â Â Ending Balance $ 22,000 Â Development and Regulatory Milestones | Commitments Â Â Changes in the fair value of warrant liability and SARs liability Â Â Beginning Balance 26,600 $ 82,500 Additions 0 0 Change in fair value 3,300 (56,100) Reclassification to accounts payable and accrued expenses 0 Â Rights Exchange settlement (20,000) 0 Ending Balance 9,900 26,400 Net Sales Milestones and Royalties | Commitments Â Â Changes in the fair value of warrant liability and SARs liability Â Â Beginning Balance 9,700 81,500 Additions 0 0 Change in fair value 2,400 (68,900) Reclassification to accounts payable and accrued expenses 0 Â Rights Exchange settlement 0 0 Ending Balance $ 12,100 $ 12,600 X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ptct_UpstazaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentandRegulatoryMilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=us-gaap_CommitmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value of financial instruments and investments - Fair Value Liabilities Measured (Details) - Agilis $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended May 31, 2024 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2024 USD ($) Dec. 31, 2022 USD ($) Dec. 31, 2023 USD ($) Sep. 30, 2023 USD ($) Fair Value Valuation Inputs Â Â Â Â Â Â Â Milestone obligation payments made Â Â Â $ 50,000 Â Significant unobservable inputs (Level 3) | Upstaza Â Â Â Â Â Â Â Fair Value Valuation Inputs Â Â Â Â Â Â Â Fair value Â $ 22,000 $ 22,000 Â Â Â Development and Regulatory Milestones | Commitments | Valuation Technique, Discounted Cash Flow | Development and Regulatory Milestone | Minimum Â Â Â Â Â Â Â Fair Value Valuation Inputs Â Â Â Â Â Â Â Potential milestones Â 0 0 Â $ 0 Â Development and Regulatory Milestones | Commitments | Valuation Technique, Discounted Cash Flow | Development and Regulatory Milestone | Maximum Â Â Â Â Â Â Â Fair Value Valuation Inputs Â Â Â Â Â Â Â Potential milestones Â $ 11,000 $ 11,000 Â $ 31,000 Â Development and Regulatory Milestones | Commitments | Valuation Technique, Discounted Cash Flow | Probability of Success Â Â Â Â Â Â Â Fair Value Valuation Inputs Â Â Â Â Â Â Â Rights Exchange Settlement measurement Â 0.95 0.95 Â Â Â Development and Regulatory Milestones | Commitments | Valuation Technique, Discounted Cash Flow | Probability of Success | Minimum Â Â Â Â Â Â Â Fair Value Valuation Inputs Â Â Â Â Â Â Â Rights Exchange Settlement measurement Â Â Â Â 0.85 Â Development and Regulatory Milestones | Commitments | Valuation Technique, Discounted Cash Flow | Probability of Success | Maximum Â Â Â Â Â Â Â Fair Value Valuation Inputs Â Â Â Â Â Â Â Rights Exchange Settlement measurement Â Â Â Â 0.92 Â Development and Regulatory Milestones | Commitments | Valuation Technique, Discounted Cash Flow | Discount Rate | Minimum Â Â Â Â Â Â Â Fair Value Valuation Inputs Â Â Â Â Â Â Â Rights Exchange Settlement measurement Â 0.054 0.054 Â 0.058 Â Development and Regulatory Milestones | Commitments | Valuation Technique, Discounted Cash Flow | Discount Rate | Maximum Â Â Â Â Â Â Â Fair Value Valuation Inputs Â Â Â Â Â Â Â Rights Exchange Settlement measurement Â 0.055 0.055 Â 0.061 Â Development and Regulatory Milestones | Upstaza | Commitments | Valuation Technique, Discounted Cash Flow | Probability of Success | Weighted Average Â Â Â Â Â Â Â Fair Value Valuation Inputs Â Â Â Â Â Â Â Rights Exchange Settlement measurement Â 0.95 0.95 Â Â Â Development and Regulatory Milestones | Upstaza | Commitments | Valuation Technique, Discounted Cash Flow | Discount Rate | Weighted Average Â Â Â Â Â Â Â Fair Value Valuation Inputs Â Â Â Â Â Â Â Rights Exchange Settlement measurement Â 0.055 0.055 Â Â Â Development and Regulatory Milestones | Significant unobservable inputs (Level 3) | Commitments Â Â Â Â Â Â Â Fair Value Valuation Inputs Â Â Â Â Â Â Â Fair value Â $ 9,900 $ 9,900 82,500 $ 26,600 $ 26,400 Regulatory Milestones Â Â Â Â Â Â Â Fair Value Valuation Inputs Â Â Â Â Â Â Â Milestone obligation payments made $ 20,000 20,000 20,000 Â Â Â Net Sales Milestones and Royalties | Commitments | Valuation Technique, Option Pricing Model | Sales Milestones | Minimum Â Â Â Â Â Â Â Fair Value Valuation Inputs Â Â Â Â Â Â Â Potential milestones Â 0 0 Â 0 Â Net Sales Milestones and Royalties | Commitments | Valuation Technique, Option Pricing Model | Sales Milestones | Maximum Â Â Â Â Â Â Â Fair Value Valuation Inputs Â Â Â Â Â Â Â Potential milestones Â $ 50,000 $ 50,000 Â $ 50,000 Â Net Sales Milestones and Royalties | Commitments | Valuation Technique, Option Pricing Model | Probability of Success | Minimum Â Â Â Â Â Â Â Fair Value Valuation Inputs Â Â Â Â Â Â Â Rights Exchange Settlement measurement Â 0.95 0.95 Â 0.85 Â Net Sales Milestones and Royalties | Commitments | Valuation Technique, Option Pricing Model | Probability of Success | Maximum Â Â Â Â Â Â Â Fair Value Valuation Inputs Â Â Â Â Â Â Â Rights Exchange Settlement measurement Â 1 1 Â 1 Â Net Sales Milestones and Royalties | Commitments | Valuation Technique, Option Pricing Model | Discount Rate Â Â Â Â Â Â Â Fair Value Valuation Inputs Â Â Â Â Â Â Â Rights Exchange Settlement measurement Â 0.13 0.13 Â 0.11 Â Net Sales Milestones and Royalties | Upstaza | Commitments | Valuation Technique, Option Pricing Model | Probability of Success | Weighted Average Â Â Â Â Â Â Â Fair Value Valuation Inputs Â Â Â Â Â Â Â Rights Exchange Settlement measurement Â 0.98 0.98 Â Â Â Net Sales Milestones and Royalties | Upstaza | Commitments | Valuation Technique, Option Pricing Model | Discount Rate | Weighted Average Â Â Â Â Â Â Â Fair Value Valuation Inputs Â Â Â Â Â Â Â Rights Exchange Settlement measurement Â 0.130 0.130 Â Â Â Net Sales Milestones and Royalties | Significant unobservable inputs (Level 3) | Commitments Â Â Â Â Â Â Â Fair Value Valuation Inputs Â Â Â Â Â Â Â Fair value Â $ 12,100 $ 12,100 $ 81,500 $ 9,700 $ 12,600 X - DefinitionAmount of cash outflow for milestone obligations paid. + ReferencesNo definition available. + Details Name: ptct_PaymentOfMilestoneObligation Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType

Balance Type: credit Period Type: duration X - DefinitionValue of input used to measure Rights Exchange Settlement. + ReferencesNo definition available. + Details Name: ptct_RightsExchangeSettlementMeasurementInput Namespace Prefix: ptct_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionThe potential milestone payments due under the Rights Exchange Settlement. + ReferencesNo definition available. + Details Name: ptct_RightsExchangeSettlementPotentialMilestonesValue Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ptct_UpstazaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentandRegulatoryMilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=us-gaap_CommitmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=ptct_DevelopmentandRegulatoryMilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=ptct_ProbabilityofSuccessMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_WeightedAverageMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityRegulatoryMilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=ptct_SalesMilestonesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Accounts payable and accrued expenses - Components (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Payables and Accruals [Abstract] Â Â Â Employee compensation, benefits, and related accruals $ 46,209 $ 62,643 Â Income tax payable 6,012 Â Â Consulting and contracted research 23,032 27,500 Â Sales allowance 65,782 77,176 Â Sales rebates 102,919 131,334 Â Royalties 14,016 74,111 Â Accounts payable 13,292 6,045 Â Milestone Payable 50,000 Â $ 2,500 Other 15,084 13,174 Â Accounts payable and accrued expenses $ 336,346 $ 391,983 Â X - DefinitionRepresents the carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting and contracted research. + ReferencesNo definition available. + Details Name: ptct_AccruedConsultingAndContractedResearchCurrent Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of recorded milestone payments payable. + ReferencesNo definition available. + Details Name: ptct_MilestonePayable Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSales Allowance And Other Related Costs + ReferencesNo definition available. + Details Name: ptct_SalesAllowanceAndOtherRelatedCosts Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for sales rebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: ptct_SalesRebatesCurrent Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-03(15)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedIncomeTaxesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccruedRoyaltiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Accounts payable and accrued expenses - Restructuring (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Restructuring costs Â Â Accrued restructuring costs $ 0.3 $ 9.0 X - DefinitionRepresents the carrying value as of the balance sheet date of obligations incurred through that date and payable for restructuring costs. + ReferencesNo definition available. + Details Name: ptct_AccruedRestructuringCosts Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_RestructuringChargesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Capitalization - Narrative (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Aug. 31, 2019 Common stock Â Â Â Â Â Â Common stock, authorized shares (in shares) 250,000,000 Â 250,000,000 Â 250,000,000 Â Sales Agreement Â Â Â Â Â Â Common stock Â Â Â Â Â Â Number of shares issued in transaction (in shares) 0 0 0 0 Â Â Sales Agreement | Maximum Â Â Â Â Â Â Common stock Â Â Â Â Â Â Value of shares available to be issued and sold in transaction Â Â Â Â Â $ 125.0 Aggregate value of remaining shares to be issued and sold Â Â $ 93.0 Â Â Â Â X - DefinitionThe aggregate value of remaining shares to be issued and sold under a sales agreement. + ReferencesNo definition available. + Details Name: ptct_SaleOfStockRemainingSharesAvailableForSaleAggregateOfferingValue Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionValue of shares available to be issued and sold in stock transaction. + ReferencesNo definition available. + Details Name: ptct_SaleOfStockSharesAvailableToBeIssuedAndSoldValue Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCapitalizationEquityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=ptct_AtMarketOfferingSalesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Net loss per share - Numerator and Denominator (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Numerator Â Â Â Â Net loss - Basic $ (106,654) $ (132,970) $ (297,409) $ (470,812) Denominator Â Â Â Â Basic 76,925,523 75,377,997 76,716,340 74,618,611 Diluted 76,925,523 75,377,997 76,716,340 74,618,611 Net loss per share - Basic $ (1.39) $ (1.76) $ (3.88) $ (6.31) Net loss per share - Diluted $ (1.39) $ (1.76) $ (3.88) $ (6.31) X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -

Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Net loss per share - Antidilutive (Details) - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Net loss per share Â Â Total shares excluded from calculation (in shares) 12,769,789 14,850,885 Employee Stock Option Â Â Net loss per share Â Â Total shares excluded from calculation (in shares) 9,173,460 11,436,783 Unvested restricted stock units Â Â Net loss per share Â Â Total shares excluded from calculation (in shares) 3,596,329 3,414,102 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ptct_RestrictedStockAndRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Stock award plan - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Jun. 08, 2022 Dec. 31, 2022 Jun. 30, 2021 Dec. 31, 2020 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Apr. 30, 2022 May 31, 2021 Jan. 31, 2020 Stock option plan Â Â Â Â Â Â Â Â Â Â Â Â Share-based compensation expense Â Â Â Â $ 19,755 $ 26,942 $ 57,376 $ 85,128 Â Â Â Unrecognized compensation cost Â Â Â Â 117,800 Â $ 117,800 Â Â Â Â Weighted average remaining service period for recognition of unrecognized compensation cost Â Â Â Â Â Â 2 years 3 months 18 days Â Â Â Â Stock option Â Â Â Â Â Â Â Â Â Â Stock option plan Â Â Â Â Â Â Â Â Â Â Â Granted (in shares) Â Â Â Â Â Â 934,735 Â Â Â Â Options forfeited (in shares) Â Â Â Â Â Â 1,149,981 Â Â Â Â Expected dividend yield (as a percent) Â Â Â Â Â Â Â 0.00% Â Â Â Â Weighted average grant date fair value (in dollars per share) Â Â Â Â Â Â $ 13.71 Â Â Â Â Restricted stock units Â Â Â Â Â Â Â Â Â Â Stock option plan Â Â Â Â Â Â Â Â Â Â Granted (in shares) Â Â Â Â Â Â 1,850,265 Â Â Â Â Employee Stock Purchase Plan Â Â Â Â Â Â Â Â Â Stock option plan Â Â Â Â Â Â Â Â Â Â Number of shares authorized (in shares) Â Â 2,000,000 Â Â Â Â Â Â 1,000,000 Â Award requisite service period Â Â 6 months Â Â Â Â Â Â Â Â Â Purchase price of common stock, percent Â Â 85.00% Â Â Â Â Â Â Â Â Employee stock purchase plan, voting percentage limit Â Â 5.00% Â Â Â Â Â Â Â Â Share-based compensation expense Â Â Â Â $ 500 Â $ 1,700 Â Â Â Â 1998 Employee, Director, and Consultant Stock Option Plan, 2009 Equity and Long-term Incentive Plan, and 2013 Stock Incentive Plan | Common stock Â Â Â Â Â Â Â Â Â Â Stock option plan Â Â Â Â Â Â Â Â Â Â Number of shares available for issuance Â Â Â Â 0 Â 0 Â Â Â Â Amended 2013 LTIP Â Â Â Â Â Â Â Â Â Â Stock option plan Â Â Â Â Â Â Â Â Â Â Number of shares available for issuance Â Â Â Â 6,781,585 Â 6,781,585 Â Â Â Â Number of additional shares authorized (in shares) 8,475,000 Â Â Â Â Â Â Â Â Â Â Amended 2013 LTIP | Maximum Â Â Â Â Â Â Â Â Â Â Stock option plan Â Â Â Â Â Â Â Â Â Â Number of shares authorized (in shares) 16,724,212 Â Â Â Â Â Â Â Â Â Â 2020 Inducement Stock Incentive Plan | Common stock Â Â Â Â Â Â Â Â Â Â Stock option plan Â Â Â Â Â Â Â Â Â Â Number of shares available for issuance Â Â Â Â 1,989,775 Â 1,989,775 Â Â Â Â Number of additional shares authorized (in shares) Â 1,700,000 Â 1,000,000 Â Â Â Â Â Â 2020 Inducement Stock Incentive Plan | Common stock | Maximum Â Â Â Â Â Â Â Â Â Â Stock option plan Â Â Â Â Â Â Â Â Â Â Number of shares authorized (in shares) Â Â Â Â Â Â Â Â Â 1,300,000 Â 1,000,000 2020 Inducement Stock Incentive Plan | Stock option Â Â Â Â Â Â Â Â Â Â Stock option plan Â Â Â Â Â Â Â Â Â Granted (in shares) Â Â Â Â Â Â 934,735 Â Â Â Â Stockholder's specified ownership percentage Â Â Â Â 10.00% Â 10.00% Â Â Â Â Inducement grants for non-statutory stock options (in shares) Â Â Â Â Â Â 27,490 Â Â Â Â Vesting period Â Â Â Â Â Â Â 4 years Â Â Â Â 2020 Inducement Stock Incentive Plan | Stock option | Minimum Â Â Â Â Â Â Â Â Â Â Stock option plan Â Â Â Â Â Â Â Â Â Stock options granted, exercise price as percentage of the fair market value of common stock at grant date Â Â Â Â 100.00% Â 100.00% Â Â Â Â 2020 Inducement Stock Incentive Plan | Stock option | Maximum Â Â Â Â Â Â Â Â Â Â Stock option plan Â Â Â Â Â Â Â Â Â Â Stock options granted to stockholder with specified ownership percentage, exercise price as percentage of the fair market value of common stock at grant date Â Â Â Â 110.00% Â 110.00% Â Â Â Â Expiration period Â Â Â Â Â Â Â 10 years Â Â Â Â 2020 Inducement Stock Incentive Plan | Restricted stock units Â Â Â Â Â Â Â Â Â Â Stock option plan Â Â Â Â Â Â Â Â Â Granted (in shares) Â Â Â Â Â Â 41,680 Â Â Â Â X - DefinitionEmployee Stock Purchase Plan, Voting Percentage Limit, Percent + ReferencesNo definition available. + Details Name: ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent Namespace Prefix: ptct_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRepresents the exercise price expressed as a percentage of the fair market value of the common stock as of the date of grant, at which grantees can acquire the shares reserved for issuance of stock options awarded. + ReferencesNo definition available. + Details Name: ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedExercisePriceAsPercentageOfFairMarketValueOfCommonStock Namespace Prefix: ptct_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRepresents the exercise price expressed as a percentage of the fair market value of the common stock as of the date of grant, at which grantees with specified common stock ownership percentage can acquire the shares reserved for issuance of stock options awarded. + ReferencesNo definition available. + Details Name: ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedToStockholdersWithSpecifiedOwnershipPercentageExercisePriceAsPercentageOfFairMarketValueOfCom Namespace Prefix: ptct_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRepresents the inducement grants for non-statutory stock options. + ReferencesNo definition available. + Details Name: ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions Namespace Prefix: ptct_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRepresents the stockholder's specified ownership percentage of the entity's common stock used in determination of the exercise price of stock options granted. + ReferencesNo definition available. + Details Name: ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholdersSpecifiedOwnershipPercentage Namespace Prefix: ptct_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-

gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionEstimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPurchase price of common stock expressed as a percentage of its fair value. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=ptct_EmployeeDirectorAndConsultantStockOptionPlan1998EquityAndLongTermIncentivePlan2009AndStockIncentivePlan2013Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=ptct_AmendedAndRestated2013LongTermIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=ptct_InducementStockIncentivePlan2020Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Stock award plan - Stock Option Activity (Details) - Stock option - USD ($) $ / shares in Units, $ in Thousands 9 Months Ended Sep. 30, 2024 Number of options Â Outstanding at the beginning of the period (in shares) 9,600,399 Granted (in shares) 934,735 Exercised (in shares) (211,693) Forfeited/Cancelled (in shares) (1,149,981) Outstanding at the end of the period (in shares) 9,173,460 Vested or Expected to vest at the end of the period (in shares) 1,746,884 Exercisable at the end of the period (in shares) 7,254,847 Weighted- average exercise price Â Outstanding at the beginning of the period (in dollars per share) $ 43.59 Granted (in dollars per share) 26.13 Exercised (in dollars per share) 22.41 Forfeited/Cancelled (in dollars per share) 45.86 Outstanding at the end of the period (in dollars per share) 42.01 Vested or Expected to vest at the end of the period (in dollars per share) 35.85 Exercisable at the end of the period (in dollars per share) $ 43.74 Weighted- average remaining contractual term Â Outstanding at the end of the period 5 years 7 months 20 days Vested or Expected to vest at the end of the period 8 years 5 months 12 days Exercisable at the end of the period 4 years 10 months 20 days Aggregate intrinsic value (in thousands) Â Outstanding at the end of the period (in dollars) $ 30,906 Vested or Expected to vest at the end of the period (in dollars) 9,289 Exercisable at the end of the period (in dollars) $ 20,420 X - ReferencesNo definition available. + Details Name: ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward Namespace Prefix: ptct_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1:

http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Stock award plan - Assumptions Used (Details) - Stock option 9 Months Ended Sep. 30, 2024 Valuation assumptions Â Expected term (in years) 5 years 6 months Minimum Â Valuation assumptions Â Risk-free interest rate (as a percent) 3.51% Expected volatility (as a percent) 53.00% Maximum Â Valuation assumptions Â Risk-free interest rate (as a percent) 4.66% Expected volatility (as a percent) 54.00% X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Stock award plan - Restricted Stock (Details) - USD ($) $ / shares in Units, $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Dec. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Number of Shares Â Â Â Â Â Â Share-based compensation expense Â $ 19,755 $ 26,942 $ 57,376 $ 85,128 Unvested restricted stock units Â Â Â Â Â Â Number of Shares Â Â Â Â Â Â Balance at the beginning of the period (in shares) Â Â Â Â 2,866,270 Â Granted (in shares) Â Â Â Â 1,850,265 Â Vested (in shares) Â Â Â Â (924,417) Â Forfeited (in shares) Â Â Â Â (195,789) Â Balance at the end of the period (in shares) 2,866,270 3,596,329 Â 3,596,329 Â Weighted Average Grant Date Fair Value Â Â Â Â Â Â Balance at the beginning of the period (in dollars per share) Â Â Â Â $ 41.82 Â Granted (in dollars per share) Â Â Â Â 25.87 Â Vested (in dollars per share) Â Â Â Â 44.08 Â Forfeited (in dollars per share) Â Â Â Â 37.28 Â Balance at the end of the period (in dollars per share) $ 41.82 $ 33.29 Â $ 33.29 Â Performance-based restricted stock units (PSUs) Â Â Â Â Â Â Number of Shares Â Â Â Â Â Â Granted (in shares) 150,000 Â Â Â Â Â Â Share-based compensation expense Â Â Â Â $ 0 Â Performance period 2 years Â Â Â Â Â X - DefinitionEstimated period over which specified performance goals are to be met in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod Namespace Prefix: ptct_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-

gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=ptct_RestrictedStockAndRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=ptct_RestrictedStockUnitsPerformanceBasedPsusMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.3 Stock award plan - Share-based compensation expense (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Stock option plan Â Â Â Â Share-based compensation expense $ 19,755 $ 26,942 $ 57,376 $ 85,128 Unrecognized compensation cost 117,800 Â $ 117,800 Â Weighted average remaining service period for recognition of unrecognized compensation cost Â Â 2 years 3 months 18 days Â Research and development Â Â Â Â Stock option plan Â Â Â Â Share-based compensation expense 9,416 13,986 $ 27,810 44,828 Selling, general and administrative Â Â Â Â Stock option plan Â Â Â Â Share-based compensation expense $ 10,339 $ 12,956 $ 29,566 $ 40,300 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - Liability for Sale of Future Royalties (Details) $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Debt Disclosure [Abstract] Â Beginning balance $ 1,814,097 Less: Non-cash royalty revenue payable to Royalty Pharma (128,877) Plus: non-cash interest expense recognized 155,039 Cash received from Royalty Pharma 241,792 Ending balance $ 2,082,051 Effective interest rate of the liability component 9.90% X - DefinitionAmount of liabilities related to the sale of future royalties. + ReferencesNo definition available. + Details Name: ptct_LiabilitySaleOfFutureRoyalties Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of interest expense recognized related to the liability for the sale of future royalties per terms of the agreement. + ReferencesNo definition available. + Details Name: ptct_LiabilitySaleOfFutureRoyaltiesInterestExpense Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of royalty revenue recognized during the period relating to the sale of future royalties payable under terms of the agreement. + ReferencesNo definition available. + Details Name: ptct_LiabilitySaleOfFutureRoyaltiesRoyaltyRevenuePayable Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash received for sale of future royalties during the current period. + ReferencesNo definition available. + Details Name: ptct_ProceedsFromSaleOfFutureRoyalties Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant XML 75 R64.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - Senior Secured Term Loan (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Oct. 19, 2023 Oct. 27, 2022 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Interest expense Â Â Â Â Â Â Amortization of debt issuance costs Â Â Â $ 891 $ 1,574 Â Effective interest rate Â Â Â 9.90% Â Â Blackstone Credit Agreement Â Â Â Â Â Â Debt Facility Â Â Â Â Â Â Maximum borrowing capacity Â $ 950,000 Â Â Â Â Debt issuance costs capitalized Â $ 11,600 Â Â Â Â Principal Â Â Â Â Â Â $ 300,000 Repayment of senior term loan Â Â Â Â Â (300,000) Interest expense Â Â Â Â Â Â Contractual interest expense Â Â $ 9,554 Â 28,087 Â Amortization of debt issuance costs Â Â 280 Â 702 Â Total Â Â $ 9,834 Â $ 28,789 Â Effective interest rate Â Â 13.10% Â 13.10% Â Blackstone Credit Agreement | Adjusted Term SOFR Â Â Â Â Â Â Debt Facility Â Â Â Â Â Â Basis spread on variable rate Â 7.25% Â Â Â Â Floor interest rate Â 1.00% Â Â Â Â Â Blackstone Credit Agreement | Base Rate Â Â Â Â Â Â Debt Facility Â Â Â Â Â Â Basis spread on variable rate Â 6.25% Â Â Â Â Floor interest rate Â 2.00% Â Â Â Â Committed Loan Facility Â Â Â Â Â Â Debt Facility Â Â Â Â Â Â Maximum borrowing capacity Â $ 450,000 Â Â Â Â Fund draw term Â 18 months Â Â Â Â Loan term Â 7 years Â Â Â Â Senior Secured Term Loan Â Â Â Â Â Â Debt Facility Â Â Â Â Â Â Principal Â $ 300,000 Â Â Â Â Repayment of senior secured term loan $ (300,000) Â Â Â Â Â Payment of accrued interest 2,100 Â Â Â Â Â Prepayment premiums, expenses and other exit fees 82,000 Â Â Â Â 82,000 Legal fees $ 200 Â Â Â Â Â Loss on extinguishment of debt Â Â Â Â Â 92,700 Debt issuance costs Â Â Â Â Â $ 10,700 Committed Delayed Draw Term Loan Facility Â Â Â Â Â Â Debt Facility Â Â Â Â Â Â Maximum borrowing capacity Â 150,000 Â Â Â Â Uncommitted Incremental Facility Â Â Â Â Â Â Debt Facility Â Â Â Â Â Â Maximum borrowing capacity Â $ 500,000 Â Â Â Â X - DefinitionPeriod of time after closing of the credit agreement during which funds can be drawn subject to specified conditions. + ReferencesNo definition available. + Details Name: ptct_DebtInstrumentDelayedDrawTerm Namespace Prefix: ptct_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionDebt Instrument, Floor Interest Rate + ReferencesNo definition available. + Details Name: ptct_DebtInstrumentFloorInterestRate Namespace Prefix: ptct_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPeriod of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRepresents the charge against earnings during the period for commitment fees and debt issuance expenses. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DeferredFinanceCostsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F + Details Name: us-gaap_InterestExpenseDebtExcludingAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate amount of interest paid or due on all long-term debt. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1402 -Paragraph a -Publisher SECReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1402 -Paragraph b -Subparagraph (1) -Publisher SECReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_InterestExpenseLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InterestExpenseNonoperatingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_LegalFees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LineOfCreditFacilityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtExtinguishmentCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfSecuredDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_BaseRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=ptct_LineOfCreditCommittedLoanFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=ptct_LineOfCreditCommittedDelayedDrawTermLoanFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=ptct_LineOfCreditUncommittedLoanFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 76 R65.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - 2026 Convertible Notes Narrative (Details) 1 Months Ended 9 Months Ended Sep. 30, 2019 USD ($) D $ / shares Sep. 30, 2024 USD ($) Dec. 31, 2023 USD ($) Long-term debt Â Â Â Long-term debt Â $ 285,106,000 $ 284,213,000 Additional paid-in capital Â 2,530,902,000 2,466,233,000 1.50% Convertible senior notes due 2026 Â Â Â Long-term debt Â Â Â Net carrying amount Â 285,106,000 284,213,000 Debt principal amount Â $ 287,500,000 $ 287,500,000 Convertible debt | 1.50% Convertible senior notes due 2026 Â Â Â Long-term debt Â Â Â Debt principal amount $ 287,500,000 Â Â Debt instrument additional amount available for repurchase $ 37,500,000 Â Â Interest rate (as a percent) 1.50% 1.50% Â Net proceeds from issuance of convertible notes $ 279,300,000 Â Â Trading days, number | D 20 Â Â Consecutive trading days, period | D 30 Â Â Stock price trigger 130.00% Â Â Business days, period 5 days Â Â Consecutive trading-day period 5 days Â Â Maximum product of the closing sale price of shares of the Company's common stock and the applicable conversion rate for such trading day 98.00% Â Â Conversion ratio 19.0404 Â Â Conversion price per share (in dollars per share) | $ / shares $ 52.52 Â Â Redemption price as percent of principal amount 100.00% Â Â Convertible instruments principal and unpaid interest payable upon events of default 100.00% Â Â Minimum percentage of principal held by convertible debt instrument holders required to issue notice for declaration of principal and unpaid interest payable upon events of default 25.00% Â Â Term of the convertible notes Â 2 years Â Convertible debt | 1.50% Convertible senior notes due 2026 | Redemption on or after September 20, 2023 Â Â Â Long-term debt Â Â Â Trading days, number | D 19 Â Â Consecutive trading days, period | D 30 Â Â Stock price trigger 130.00% Â Â Redemption price as percent of principal amount 100.00% Â Â Sinking fund $ 0 Â Â X - DefinitionRepresents the debt instrument principal and unpaid interest payable upon events of default. + ReferencesNo definition available. + Details Name: ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault Namespace Prefix: ptct_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDebt Instrument Additional Amount Available For Repurchase + ReferencesNo definition available. + Details Name: ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThreshold period of specified business days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature. + ReferencesNo definition available. + Details Name: ptct_DebtInstrumentConvertibleThresholdBusinessDays Namespace Prefix: ptct_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThreshold period of specified consecutive trading days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature. + ReferencesNo definition available. + Details Name: ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod Namespace Prefix: ptct_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRepresents the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day. + ReferencesNo definition available. + Details Name: ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum Namespace Prefix: ptct_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRepresents the minimum percentage of debt principal amount by instrument holders. + ReferencesNo definition available. + Details Name: ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders Namespace Prefix: ptct_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionRatio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-

1BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6 + Details Name: us-gaap_DebtInstrumentConvertibleConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionThreshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionMinimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThreshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdTradingDays Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionCumulative amount paid into a fund, which is used to retire the debt instrument. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_DebtInstrumentCumulativeSinkingFundPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage price of original principal amount of debt at which debt can be redeemed by the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 470 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentRedemptionPricePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPeriod of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromDebtNetOfIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentRedemptionPeriodAxis=ptct_DebtInstrumentConversionPeriodOnOrAfterSeptember202023Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 77 R66.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - Convertible Notes (Details) - 1.50% Convertible senior notes due 2026 - USD ($) Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2019 Long-term debt Â Â Â Principal $ 287,500,000 $ 287,500,000 Â Less: Debt issuance costs (2,394,000) (3,287,000) Â Net carrying amount $ 285,106,000 $ 284,213,000 Â Convertible debt Â Â Â Long-term debt Â Â Â Principal Â Â $ 287,500,000 X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset. + ReferencesNo definition available. + Details Name: us-gaap_UnamortizedDebtIssuanceExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 78 R67.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - Convertible Notes Interest Expense (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Long-term debt Â Â Â Â Amortization of debt issuance costs Â Â $ 891 $ 1,574 Effective interest rate of the liability component 9.90% Â 9.90% Â 1.50% Convertible senior notes due 2026 Â Â Â Â Â Long-term debt Â Â Â Â Contractual interest expense $ 1,081 $ 1,080 $ 3,224 3,215 Amortization of debt issuance costs 300 294 891 872 Total $ 1,381 $ 1,374 $ 4,115 $ 4,087 Effective interest rate of the liability component 1.90% 1.90% 1.90% 1.90% X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F + Details Name: us-gaap_InterestExpenseDebtExcludingAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 79 R68.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Narrative (Details) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended Apr. 29, 2020 May 31, 2024 Sep. 30, 2024 Mar. 31, 2023 Jun. 30, 2016 Sep. 30, 2024 Dec. 31, 2023 Dec. 31, 2022 Jul. 31, 2024 Sep. 30, 2023 May 05, 2020 Other Commitments Â Â Â Â Â Â Â Â Â Â Â Milestone payable Â Â $ 50,000 Â Â $ 50,000 Â Â Â Â $ 2,500 Â Accrued royalties Â Â 14,016 Â Â 14,016 $ 74,111 Â Â Â Â Wellcome Trust | Accounts payable and accrued expenses Â Â Â Â Â Â Â Â Â Â Â Â Other Commitments Â Â Â Â Â Â Â Â Â Â Â Â Development milestone payment obligations Â Â Â Â Â Â Â $ 2,500 Â Â Â Censa Â Â Â Â Â Â Â Â Â Â Â Â

Other Commitments Â Â Â Â Â Â Â Â Â Â Â Asset acquisition, development and regulatory milestones Â Â Â Â Â Â Â Â Â Â $ 109,000 Censa | Maximum Â Â Â Â Â Â Â Â Â Â Â Other Commitments Â Â Â Â Â Â Â Â Â Â Â Asset acquisition, milestone, amount Â Â Â Â Â Â Â Â Â Â 217,500 Asset acquisition, net sales milestone Â Â Â Â Â Â Â Â Â Â $ 160,000 Former Censa Securityholders Â Â Â Â Â Â Â Â Â Â Other Commitments Â Â Â Â Â Â Â Â Â Â Development milestone obligation payments made Â Â Â $ 30,000 Â Â Â Â Â Â Â Development milestone obligation cash payments made Â Â Â $ 400 Â Â Â Â Â Â Â Â Shares issued for milestone payment Â Â Â 657,462 Â Â Â Â Â Â Â SMA License Agreement | SMA Foundation Â Â Â Â Â Â Â Â Â Â Â Other Commitments Â Â Â Â Â Â Â Â Â Â Royalty expense since inception Â Â Â Â Â Â 52,500 Â Â Â Â SMA License Agreement | SMA Foundation | Maximum Â Â Â Â Â Â Â Â Â Â Other Commitments Â Â Â Â Â Â Â Â Â Â Potential royalty payments due on net product sales Â Â Â Â Â Â $ 52,500 Â Â Â Â Agilis Â Â Â Â Â Â Â Â Â Â Other Commitments Â Â Â Â Â Â Â Â Â Â Development milestone payments which the entity is obligated to pay Â Â 40,000 Â Â 40,000 Â Â Â Â Â Potential developmental and regulatory milestones Â Â 11,100 Â Â 11,100 Â Â Â Â Â Potential sales milestones Â Â $ 50,000 Â Â 50,000 Â Â Â Â Â Milestone obligation payments made Â Â Â Â Â Â $ 50,000 Â Â Â Development milestone obligation payments made Â Â Â Â Â $ 2,400 Â Â Â Â Â Agilis | Minimum Â Â Â Â Â Â Â Â Â Â Other Commitments Â Â Â Â Â Â Â Â Â Â Product sales (as a percent) Â Â 2.00% Â Â 2.00% Â Â Â Â Â Agilis | Maximum Â Â Â Â Â Â Â Â Â Â Other Commitments Â Â Â Â Â Â Â Â Â Â Development milestone payments which the entity is obligated to pay Â Â $ 60,000 Â Â $ 60,000 Â Â Â Â Â Priority review voucher amount Â Â Â Â Â 535,000 Â Â Â Â Â Potential sales milestones Â Â $ 150,000 Â Â $ 150,000 Â Â Â Â Â Product sales (as a percent) Â Â 6.00% Â Â 6.00% Â Â Â Â Â Development milestone payment obligations, net of cancellation and forfeiture Â Â Â Â Â $ 20,000 Â Â Â Â Â Contingent liability, milestone, potential achievements, priority review voucher amount, net of cancellation and forfeiture Â Â Â Â Â 361,000 Â Â Â Â Â Agilis | Rights Exchange Agreement Â Â Â Â Â Â Â Â Â Â Other Commitments Â Â Â Â Â Â Â Â Â Â Contingent liability cancellation and forfeiture of potential milestone payments $ 174,000 Â Â Â Â Â Â Â Â Â Â Development milestone payment obligations, cancellation and forfeiture 37,600 Â Â Â Â Â Â Â Â Â Â Contingent liability, cancellation and forfeiture $ 211,600 Â Â Â Â Â Â Â Â Â Â BioElectron | Maximum Â Â Â Â Â Â Â Â Â Â Other Commitments Â Â Â Â Â Â Â Â Â Â Development milestone payments which the entity is obligated to pay Â Â $ 200,000 Â Â 200,000 Â Â Â Â Â Regulatory Milestones | Accounts payable and accrued expenses Â Â Â Â Â Â Â Â Â Â Other Commitments Â Â Â Â Â Â Â Â Â Â Milestone payable Â Â 50,000 Â Â 50,000 Â Â Â Â Â Regulatory Milestones | Former Censa Securityholders Â Â Â Â Â Â Â Â Â Â Other Commitments Â Â Â Â Â Â Â Â Â Â Milestone obligation payments made Â Â Â Â Â 15,000 Â Â Â Â Â Regulatory Milestones | Former Censa Securityholders | Research and development Â Â Â Â Â Â Â Â Â Â Other Commitments Â Â Â Â Â Â Â Â Â Â Milestone payments triggered Â $ 15,000 25,000 Â Â 25,000 Â Â $ 25,000 Â Â Regulatory Milestones | Agilis Â Â Â Â Â Â Â Â Â Â Other Commitments Â Â Â Â Â Â Â Â Â Â Milestone obligation payments made Â $ 20,000 $ 20,000 Â Â $ 20,000 Â Â Â Â Â Development Milestones | Wellcome Trust Â Â Â Â Â Â Â Â Â Â Other Commitments Â Â Â Â Â Â Â Â Â Â Milestone obligation payments made Â Â Â Â $ 800 Â Â Â Â Â X - DefinitionAsset Acquisition, Development And Regulatory Milestones + ReferencesNo definition available. + Details Name: ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAsset Acquisition, Milestone, Amount + ReferencesNo definition available. + Details Name: ptct_AssetAcquisitionMilestoneAmount Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAsset Acquisition, Net Sales Milestone + ReferencesNo definition available. + Details Name: ptct_AssetAcquisitionNetSalesMilestone Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContingent Liability, Cancellation and Forfeiture + ReferencesNo definition available. + Details Name: ptct_ContingentLiabilityCancellationAndForfeiture Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionContingent Liability cancellation and forfeiture, Milestone, Potential Achievements, Priority Review Voucher Amount + ReferencesNo definition available. + Details Name: ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of potential payments which may be due for developmental and regulatory milestones if achieved. + ReferencesNo definition available. + Details Name: ptct_ContingentLiabilityMilestonePotentialAchievementsDevelopmentalAndRegulatoryMilestones Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContingent Liability, Milestone, Potential Achievements, Net Sales Milestone And Regulatory Approval + ReferencesNo definition available. + Details Name: ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount + ReferencesNo definition available. + Details Name: ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionContingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture + ReferencesNo definition available. + Details Name: ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionContingent Liability, Milestone, Potential Achievements, Product Sales Percentage + ReferencesNo definition available. + Details Name: ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage Namespace Prefix: ptct_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of development milestone obligation payments made during the period. + ReferencesNo definition available. + Details Name: ptct_DevelopmentMilestoneObligationPaymentsMade Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of development milestone obligation cash payments made during the period. + ReferencesNo definition available. + Details Name: ptct_DevelopmentMilestoneObligationPaymentsMadeCash Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the development milestones payments which the entity is obligated to pay under certain contractual agreements. + ReferencesNo definition available. + Details Name: ptct_DevelopmentMilestonePaymentObligations Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDevelopment Milestone Payment Obligations, Cancellation and Forfeiture + ReferencesNo definition available. + Details Name: ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the development milestones payments which the entity is obligated to pay under certain contractual agreements. + ReferencesNo definition available. + Details Name: ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDevelopment Milestone Payment Obligations, net of cancellation and forfeiture + ReferencesNo definition available. + Details Name: ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of recorded milestone payments payable. + ReferencesNo definition available. + Details Name: ptct_MilestonePayable Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMilestone payment which the entity is obliged to pay upon regulatory approval + ReferencesNo definition available. + Details Name: ptct_MilestonePotentialAchievementsRegulatoryApproval Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow for milestone obligations paid. + ReferencesNo definition available. + Details Name: ptct_PaymentOfMilestoneObligation Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of potential royalties due on worldwide net product sales per terms of the collaboration agreement. + ReferencesNo definition available. + Details Name: ptct_PotentialRoyaltiesDueNetProductSales Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued during the period as a result of a milestone payable. + ReferencesNo definition available. + Details Name: ptct_StockIssuedDuringPeriodSharesMilestonePayable Namespace Prefix: ptct_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccruedRoyaltiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OtherCommitmentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RoyaltyExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=ptct_WellcomeTrustLimitedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=ptct_CensaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=ptct_FormerCensaSecurityholdersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=ptct_SmaFoundationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=ptct_RightsExchangeAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=ptct_BioElectronMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityRegulatoryMilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentMilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 80 R69.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue recognition - Net Product Sales (Details) $ in Thousands 3 Months Ended Sep. 30, 2024 USD ($) segment Distributor country Sep. 30, 2023 USD ($) segment country Distributor Sep. 30, 2024 USD ($) segment Distributor country Sep. 30, 2023 USD ($) Distributor country segment Dec. 31, 2023 USD ($) Revenue recognition Â Â Â Â Â Number of operating segments | segment 1 1 1 1 Â Revenue $ 196,786 $ 196,576 $ 593,608 $ 630,766 Â Net product revenue | Geographic concentration risk Â Â Â Â Â Revenue recognition Â Â Â Â Â Number of countries exceeding 10% of net product sales | country 2 1 3 3 Â Percentage of net product sales threshold 10.00% 10.00% 10.00% 10.00% Â Net product revenue | Geographic concentration risk | United States Â Â Â Â Â Revenue recognition Â Â Â Â Â Revenue $ 51,900 $ 67,400 $ 156,700 $ 187,700 Â Net product revenue | Geographic concentration risk | Non-US Â Â Â Â Â Revenue recognition Â Â Â Â Â Revenue 83,500 $ 76,600 289,500 318,500 Â Net product revenue | Geographic concentration risk | Russia Â Â Â Â Â Revenue recognition Â Â Â Â Â Revenue Â Â 55,700 69,000 Â Net product revenue | Geographic concentration risk | Brazil Â Â Â Â Â Revenue recognition Â Â Â Â Â Revenue $ 29,200 Â $ 68,300 $ 52,500 Â Net product revenue | Customer concentration risk Â Â Â Â Â Revenue recognition Â Â Â Â Â Number of distributors | Distributor 2 3 2 2 Â Percentage of net product sales threshold 10.00% 10.00% 10.00% 10.00% Â Product Â Â Â Â Â Revenue recognition Â Â Â Â Â Revenue $ 135,421 $ 144,038 $ 446,245 $ 506,187 Â Contract with customer, liability 0 Â 0 Â $ 0 Emflaza | Net product revenue | Geographic concentration risk | United States Â Â Â Â Â Revenue recognition Â Â Â Â Â Revenue 51,900 67,400 156,700 187,700 Â Translarna | Net product revenue | Geographic concentration risk | Non-US Â Â Â Â Â Revenue recognition Â Â Â Â Â Revenue $ 72,300 $ 69,000 $ 246,200 $ 280,600 Â X - DefinitionNumber of countries exceeding the ten percent net product sales threshold. + ReferencesNo definition available. + Details Name: ptct_NumberOfCountriesExceedingTenPercentNetSalesThreshold Namespace Prefix: ptct_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of Distributors + ReferencesNo definition available. + Details Name: ptct_Numberofdistributors Namespace Prefix: ptct_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionPercentage of net product sales + ReferencesNo definition available. + Details Name: ptct_Percentageofnetproductsales Namespace Prefix: ptct_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-

gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=us-gaap_NonUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_RU Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_BR Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ptct_EmflazaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ptct_TranslarnaMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 81 R70.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue recognition - Collaboration and Royalty Revenue (Details) 3 Months Ended 9 Months Ended Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) product Sep. 30, 2023 USD ($) Nov. 30, 2011 USD ($) Revenue recognition Â Â Â Â Â Number of approved products | product Â Â 2 Â Â Revenue $ 196,786,000 $ 196,576,000 $ 593,608,000 $ 630,766,000 Â Collaboration revenue Â Â Â Â Â Revenue recognition Â Â Â Â Â Revenue Â Â Â 6,000 Â Royalty revenue Â Â Â Â Â Revenue recognition Â Â Â Â Â Revenue 61,365,000 50,173,000 $ 145,702,000 117,857,000 Â SMA License Agreement Â Â Â Â Â Revenue recognition Â Â Â Â Â Number of approved products | product Â Â 1 Â Â SMA License Agreement | Collaboration revenue Â Â Â Â Â Revenue recognition Â Â Â Â Â Revenue 0 Â $ 0 Â Â SMA License Agreement | Royalty revenue Â Â Â Â Â Revenue recognition Â Â Â Â Â Revenue 61,400,000 $ 50,200,000 145,700,000 $ 117,900,000 Â Research And Development Event Milestones | SMA License Agreement Â Â Â Â Â Revenue recognition Â Â Â Â Â Remaining potential milestones that can be achieved 0 Â 0 Â Â Sales Milestones | SMA License Agreement Â Â Â Â Â Revenue recognition Â Â Â Â Â Remaining potential milestones that can be achieved $ 150,000,000.0 Â $ 150,000,000.0 Â Â Maximum | Research And Development Event Milestones | SMA License Agreement Â Â Â Â Â Revenue recognition Â Â Â Â Â Remaining potential milestones that can be achieved Â Â Â Â Â $ 135,000,000.0 Maximum | Sales Milestones | SMA License Agreement Â Â Â Â Â Revenue recognition Â Â Â Â Â Remaining potential milestones that can be achieved Â Â Â Â Â $ 325,000,000.0 X - DefinitionThe number of products of the company. + ReferencesNo definition available. + Details Name: ptct_NumberOfProducts Namespace Prefix: ptct_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionRemaining potential milestones that can be achieved. + ReferencesNo definition available. + Details Name: ptct_RevenueRecognitionMilestonePotentialAchievements Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=ptct_CollaborationRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ptct_MilestoneAxis=ptct_ResearchAndDevelopmentEventMilestonesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ptct_MilestoneAxis=ptct_SalesMilestonesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 82 R71.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue recognition - Manufacturing Revenue (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Revenue recognition Â Â Â Â Â Revenue $ 196,786,000 $ 196,576,000 $ 593,608,000 $ 630,766,000 Â Manufacturing revenue Â Â Â Â Â Revenue recognition Â Â Â Â Â Revenue 0 $ 2,365,000 1,661,000 $ 6,716,000 Â Contract with customer, asset 0 Â 0 Â $ 200,000 Contract liability revenues recognized in period Â Â 800,000 Â Â Manufacturing revenue | Deferred revenue Â Â Â Â Â Revenue recognition Â Â Â Â Â Contract with customer, liability 0 Â 0 Â 800,000 Manufacturing revenue | Prepaids and other current assets Â Â Â Â Â Revenue recognition Â Â Â Â Â Contract with customer, asset $ 0 Â $ 0 Â $ 200,000 X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerAssetNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=ptct_ManufacturingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=ptct_DeferredRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 83 R72.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue recognition - Performance Obligations (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Revenue from Contract with Customer [Abstract] Â Â Remaining performance obligations $ 0 $ 800,000 X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of transaction price allocated to performance obligation that has not been recognized as revenue. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 84 R73.htm IDEA: XBRL DOCUMENT v3.24.3 Intangible assets and goodwill - Definite-lived Intangibles (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Definite-lived intangible assets Â Â Â Â Â Milestone Payable $ 50,000 $ 2,500 $ 50,000 $ 2,500 Â Accrued royalties 14,016 Â 14,016 Â $ 74,111 Definite-lived intangibles Â Â Â Â Â Amortization (3,036) (58,649) (57,431) (145,461) Â Finite-Lived Intangible Assets, Net $ 94,602 Â $ 94,602 Â Â Weighted Average Â Â Â Â Â Definite-lived intangible assets Â Â Â Â Â Remaining amortization period 8 years 8 months 12 days Â 8 years 8 months 12 days Â Â Akcea | Waylivra Â Â Â Â Â Definite-lived intangible assets Â Â Â Â Â Royalty payments Â Â $ 2,700 Â Â Akcea | Waylivra | Accounts payable and accrued expenses Â Â Â Â Â Definite-lived intangible assets Â Â Â Â Â Accrued royalties $ 500 Â 500 Â Â Akcea | Tegsedi Â Â Â Â Â Definite-lived intangible assets Â Â Â Â Â Royalty payments Â Â 5,300 Â Â Akcea | Tegsedi | Accounts payable and accrued expenses Â Â Â Â Â Definite-lived intangible assets Â Â Â Â Â Accrued royalties 1,900 Â 1,900 Â Â Definite-lived intangible assets Â Â Â Â Â Definite-lived intangibles Â Â Â Â Â Beginning balance - Definite-lived assets, Gross Â Â 640,507 Â Â Additions Â Â 8,001 Â Â Foreign Currency Translation Â Â 436 Â Â Ending balance - Definite-lived assets, Gross 648,944 Â 648,944 Â Â Beginning balance - Accumulated amortization Â Â (496,776) Â Â Amortization (3,000) $ (58,600) (57,431) $ (145,500) Â Foreign Currency Translation - Accumulated amortization Â Â (135) Â Â Ending balance - Accumulated amortization (554,342) Â (554,342) Â Â Finite-Lived Intangible Assets, Net 94,602 Â 94,602 Â Â Definite-lived intangible assets | Emflaza Â Â Â Â Â Definite-lived intangibles Â Â Â Â Â Beginning balance - Definite-lived assets, Gross Â Â 527,417 Â Â Ending balance - Definite-lived assets, Gross 527,417 Â 527,417 Â Â Beginning balance - Accumulated amortization Â Â (478,618) Â Â Amortization Â Â (48,799) Â Â Ending balance - Accumulated amortization (527,417) Â (527,417) Â Â Definite-lived intangible assets | Waylivra Â Â Â Â Â Definite-lived intangibles Â Â Â Â Â Beginning balance - Definite-lived assets, Gross Â Â 10,218 Â Â Additions Â Â 2,732 Â Â Foreign Currency Translation Â Â 183 Â Â Ending balance - Definite-lived assets, Gross 13,133 Â 13,133 Â Â Beginning balance - Accumulated amortization Â Â (3,965) Â Â Amortization Â Â (1,187) Â Â Foreign Currency Translation - Accumulated amortization Â Â (63) Â Â Ending balance - Accumulated amortization (5,215) Â (5,215) Â Â Definite-lived intangible assets | Tegsedi Â Â Â Â Â Definite-lived intangibles Â Â Â Â Â Beginning balance - Definite-lived assets, Gross Â Â 13,322 Â Â Additions Â Â 5,269 Â Â Foreign Currency Translation Â Â 253 Â Â Ending balance - Definite-lived assets, Gross 18,844 Â 18,844 Â Â Beginning balance - Accumulated amortization Â Â (3,311) Â Â Amortization Â Â (1,847) Â Â Foreign Currency Translation - Accumulated amortization Â Â (72) Â Â Ending balance - Accumulated amortization (5,230) Â (5,230) Â Â Definite-lived intangible assets | Upstaza Â Â Â Â Â Definite-lived intangibles Â Â Â Â Â Beginning balance - Definite-lived assets, Gross Â Â 89,550 Â Â Ending balance - Definite-lived assets, Gross 89,550 Â 89,550 Â Â Beginning balance - Accumulated amortization Â Â (10,882) Â Â Amortization Â Â (5,598) Â Â Ending balance - Accumulated amortization $ (16,480) Â $ (16,480) Â Â X - DefinitionAmount of increase in assets, excluding financial assets, lacking physical substance with a definite life. + ReferencesNo definition available. + Details Name: ptct_FiniteLivedIntangibleAssetsAdditions Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of foreign currency translation gain (loss) which increases (decreases) accumulated amortization of an asset, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. + ReferencesNo definition available. + Details Name: ptct_IndefiniteLivedIntangibleAssetsAccumulatedDepreciationForeignCurrencyTranslationGainLoss Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of recorded milestone payments payable. + ReferencesNo definition available. + Details Name: ptct_MilestonePayable Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow for royalty obligations paid. + ReferencesNo definition available. + Details Name: ptct_PaymentOfRoyaltyObligation Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccruedRoyaltiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRemaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_WeightedAverageMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=ptct_AkceaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ptct_WaylivraMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ptct_TegsediMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ptct_EmflazaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ptct_UpstazaMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 85 R74.htm IDEA: XBRL DOCUMENT v3.24.3 Intangible assets and goodwill - Future Amortization (Details) $ in Thousands Sep. 30, 2024 USD ($) Goodwill and Intangible Assets Disclosure [Abstract] Â 2024 $ 3,043 2025 12,160 2026 12,160 2027 12,160 2028 and thereafter 55,079 Total $ 94,602 X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year and years thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndThereafter Namespace Prefix: ptct_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-

gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 86 R75.htm IDEA: XBRL DOCUMENT v3.24.3 Intangible assets and goodwill - Indefinite-lived Intangibles (Details) - USD ($) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Indefinite-lived intangibles Â Â Â Impairment Â $ (217,800,000) Â Ending Balance $ 330,368,000 Â Â Intangible assets, net 330,368,000 Â $ 379,497,000 Change in indefinite-lived intangibles 0 Â Â Indefinite-lived intangible assets Â Â Â Indefinite-lived intangibles Â Â Â Beginning Balance 235,766,000 Â Â Ending Balance 235,766,000 Â Â Indefinite-lived intangible assets | Upstaza Â Â Â Indefinite-lived intangibles Â Â Â Beginning Balance 235,766,000 Â Â Ending Balance $ 235,766,000 Â Â X - DefinitionAmount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_IndefinitelivedIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ptct_UpstazaMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 87 R76.htm IDEA: XBRL DOCUMENT v3.24.3 Intangible assets and goodwill - Goodwill (Details) - USD ($) $ in Thousands 73 Months Ended Sep. 30, 2024 Dec. 31, 2023 Aug. 23, 2018 Goodwill Â Â Â Goodwill $ 82,341 $ 82,341 Â Changes in goodwill $ 0 Â Â Agilis Â Â Â Goodwill Â Â Â Goodwill Â Â $ 82,300 X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A + Details Name: us-gaap_GoodwillLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillPeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 88 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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{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

(]-3L>HN-^O^B,S.T<%X$TC">"3491\ M*)SBD-T]F 3C1734[%!:CS3DI)LQ<<'",AL;#ALDM0$I.)X>J) MA_S(N^(KK@=,5Q!<@[GA3I%>%Z\>*AN!\52YAGH (C\!QREG,/U.GL'HC,V! MN@
A,NY_AQF!<*(80CT0T3$B5NTNYY6B;?KA,,!CS;:5E@S=DG&/2.Q'Y*=. MY!/0&W<@=0$/Q JL&M74O*M#M7[@#0#;4,0T"M$84 X[E 0$!1-!]/#$?G@> M%DR#?G>JM3$9(ABA<8>
[["!!DUT^V"+Z>?I)5'C/5V_@\:Y>CJ)XSHE.T Z9X.$,[S2Z8DLE> M[6&*_3#=IS[%'O=3X,DIU*8EI0E,QD+=9G1":(]4[-_F>7-;)2K?0K-W<7K? M&5E=;)OI#2&>J%%QST7LYZ(GO1W1;?
-.;U.B8*S;81;IBF="=T]%[*?BRW+< MT2 =!XO.ER&48HT*6Z6R?IZ4>@M[R]42*]7XM"YS?YFSFC MS=-<.0ME\3/RTM1ECJ92Q/]'+R!IQ BG=IKL&5%PT_! MNT:M19W_J[,IIG"ND[CY W+-M)JW()?
25,+M#JM14N^Q,Y/.HG">4#Q'..@L M 5/@AF\4+V_UM'T^I/W?[ND\@O$\CI.!^RN>=MZ=9[C=V-DDM\['7#83J9[T MI"=^TK_+LMQ@4Z\%TR0[JRF9#=LY_X
MV3^4W2UBITJ;Z">$QC")QUG1:8EC0J.)'37I\4^.G/*VJ5&Z$H]3L\WR$P1I M0*@U*QR6,8HIG>K>GOO$SWTKF[=K\^4AA-:AOOL8PVGH.L98#-Y*F5>"GUE]
MEU=2%R8KW1*>1KH3ZMU;MMV-$IOV1=6M4$J4[>6:,ZW<&.C?5T*HYQOS[FO_ MKG/Y'U!+ P04 " !VA&=9JGM= ACR4'&AYUYI3'WE M^SHOH:)Z)&L0.+.1JJ(&NVKKZUH!+1RHXGX4!(E?
42:\+'5C2Y6ELC&<"5@J MHINJHNKG#7"YGWNA]SAPQ[:EL0-^EM9T"RLPG^NEPI[?LQ2L J&9%$3!9NY= MAU>+Q,:[@"\,]OJ@3:R3M93WMO.QF'N!%00<OV2 M%GC8?
F1_[[RCES75L)#*RM,.?=F'BE@0QMN[N3^ W1^8LN72Z[=/]FWL?'4 M(WFCC:PZ,"JHF&B_]*';AP- .'D"$'6 Z%3 N .,G=%6F;-U2PW-4B7W1-EH M9+,-MS<.C6Z8L*>X,@IG&>),MI!"2\X*:J @-
Y13D0-963I-SI94@3 E&)93 M?D[>DM?$)[K$49WZ!E>W''[>K733KA0]L=(*ZA$9!Q]<8CQS=^2HY!RYB.AL@-><\$&F>4DZ74S.77M^NU-@JS[/N0 MU99[,LQM;]Z5KFD.@6 M\RR_OR
U561'>0/DC E22,ZITJ0&U9[Z^=!6M/Q3QV]KQBX+1D$0IO[NT.._ MHH[$3WKQDQ>(IXTII6*_,)';''4FVN:@\I8\/M 4Q4'[^T/]*9%'#N+>0?P" M!TSKYF3U\5^:ILEE'(7V.[;:]H]K]AM02P,$% @
=H1G69(V%SXA" AS !@ !X M;"]W;W)K/9TX5-]OS'N MPOSZRU;5J42?75[-W^**BF6O0(_Y3RT?][#-R M7;E3ZK/[\GYU-4O<$\E&+HVC$/;/@US(IG%,]CG^/)+.3O=T#9]_?F+_1]]Y MVYD[H>5"-7_4*
[.YFN4SM))KL6_,)_7X3WGL4.KXEJK1_;_H\8#-^ PM]]JH M[;&Q?8)MW1[^BB]'(9XUL#QP W)L0%XV8!,-Z+$!_=X[L&,#]KUW2(\-^J[/ M#WWOA2N%$=>7G7I$G4-;-O>A5[]O;?6J6QJ%:KIEX)(U?H
MUM@_-@J,1FJ-?MW)3KC1U.@,_7Y;HC=__>5R;NQ-7=/Y\GB#F\,-R,0-*/J@ M6K/1J&I7<@6T+\/MBT#[N>WLJSXZP?=)/LAV+_4%-+"'I@QNZC+8A=Z)I;R:V12E9?<@
M9]=_^POFR=\A56.2E3')JDAD(_W927\68G_2'U+_T)#W#5VZ?[C&!<]RGB3) MY?SAN;0@,LU\9.DCTX+R)/>0E8_D-,GXB'/4X_34XS08<<>LTMXC^<6N=GHB
M]M*8L1>3K(Q)5D4B&XT$/XT$#\;>0FGC\ORN4ZO]TB M&JG?VF%9-ON5&R"Q M59VI_]NO 0XHEG_NZ\ZN$W5K1'M?WS42":VET= ('FZ>/H_*)&=^J"U\8,$* MZ@>OCV,8X]2/71]
(.>7Y9.AF)\&RH&#O?DJ/S'^JA *SV<>E.6>%KP< S!C% MOAX^$+.4<3PI2'X2)/]&]M)2=,L-$NW*NK,':SMWSCY W<_]A^"88>(+ "$9 M 9"ECV1)D;E^O93
1Z8L)6/D2(+B)$$1E.#66EP[5]ZB>]G:Q-;T4HB5=6JU M-B[1/8#)O?">)Z,L!:+!!^9)#BP"I0\DF!,"I'8 F7(RCK"1%C@9S&023BD; M.P^DG0_(;"1:B[I##Z+92S=;EM;&6:5L>+B/NEX=W25H*1-?G\0?
U@6 ZQ." MIPX 3"'&"@">87+@G)+GF=?&07G>O\@3J-[NK$934R;,]MI%,"I;&96M.K*- MHS?+0Z*30702%/VW*U6C-_>VIM:_()O8[:QMM>C+6+L:MA(>&N(' M7LX8$*'!AWNUZOYM[1("+
(&Q;CO6?*@J<- T7_^FC$V%RK-ZH)04R$>8%$ R M!* 4LXQ!$]Z'9I1FN;^.5@ 46ZMKT^QT] W^'H<-_K]L?*%UI[9/:MBH E5@ M?MZQ2Q2PEBT@*,:Y720!&2 L2RP:T '
,I920J9U&%P_#EI9E_JDC33S% K3 M,RL%GL(&IC]P"PA*K Y0. !0F]8+ZOO,"L+F=GE,IV48+#<.>^Y?[;K8?5L# MW\&>X3P#O!*$) GA@$$ H33QD16$S',:"(/!0>.PA>ZGPYU,P*Y P";4AL: ?,T
MF&D<=M/O7ZN';VK/-V:Y=H;=3R\T8UUD+"R;3P=B_.<&+''UJ@(2PE M10:I V MD@')J8*P5IP<3T\C,OALD@0W4?[H][_EZDP\V$7%.FZ]$3:[(K4W MVEI,5[V#NRHD:-]?
ZRBCLI51V:I8;.,!&IP^"3O]&Z'K)3@"OM/->$'2U&WG MC@(30J8TLPDO>Q&6(&>&.64O@Q)",HYSCO%$2 XVFX1M=EDW>P-N\-\0W[5. M]1E 3O09XH3[#"##?
1YL+@GOGI_RE+5VAREX=N<&_K ?B> MX< 7*23JAGM4MC(J6Q6+;3QN@RDG85,^/3L/[?+18G!.BY=A"L(R_C)& 1@] MS_.7 0K
^#F=BL[!R*R59&9:MBL8W'8_#X)/OQ=XHD6!^\>A1BLI51V:I8;.-1&*H) M\JV]^>F9D/LO#&G*"%!(05#&$NIO*Y< E#%.&+ [!4#3Q"[)T[4#&6H'$JX=
M%FZIO5.'K99@/@CRO#H28[*54=FJ6&SC$P9#L4+#Q4KXC$'4BB0J6QF5K8K% M-AZ%H2*AX8HDD _"+5\]!E'?,T1EJZA?_TR?:*!#[4/#M<\G]54TYFLHVX09 M7JUQU+
<*4=FJ6&SCL7AVH.EG3C3%/=(4]TQ3W$--_X*BPX5%OWA6^35@ R#3!&7 T!$!BEF:)OV->05"FT]Z!#Q47#%=<'T>[78FGVG7OI M%-,) -W>H9\!YL\.5F]E=]^?:-=HJ?:M.1RR/5T] MG9I_UY\5?
W']!E\L,'"]Q!?5X4S\0'\XHO]!=/=UJU$CU_96R7EF)U)W./5^ M^&+4KC_6?:>,4=O^XT:*E>P

W_5#U@TD&$FUB4]O 7G_]C9.0 M0O#257H#4$)J=(,%!\[F$)9:B+M?LF^P _28;J7B56N, M\ZI@S9.^M#H<&2"/V%AE5D)&%P@<6@9*$K\B4 M5UAZN:Z)'9"?
N93DECPM9N3FW7ORCA2,_)KSK:0LDV-;X5XTHYVV?A\:O]XK M?GWRB3.52S)G&60&^]EE^_B"O8T:=$)X!R$>O(N$"]C<$=_Y0#S'"PS[F;[= MW#>%_^\S_^S]Q,Q_*XJ_)K/?XWO4
CG=?"1I;P"\L?]4BJ!G_F?IMPW[(&9 M71]]([FA*4PL))8@=F EWW_G1LX/)N&O23:[)MG\2F0G*0JZ% 67V)//>(>T MN;C1W^9[4QX:BJBFT#?&+KEUG2@*L<1VQQ*;<+X7#YQ3W,R
0U3@Q*>XN0$7 M#)RAZW6XDYC#+N;P8EG^HG(0)#VIQYM2!X^GD99B9!(AO&8Q7I-L=DVR^97(M3A(3=8F)+A;C$\,>I2S^QCMDC;T)P0X NXYG4'19 I&0;D6A"I ?"(/Z3%'T MQ92JQDMX5#?
>(.H5X?0T<_/0<%1P9_H,.AT&%S4 7L7[$P8 M7MQ" $N_$CPBF2QIW1/5RC3E^F\Z#,ZV%OMQV-/A'.2ZCN?VI#A'W89>Y/6T M.$<%?N";Q1AV8@POBG%Z;^BX3:$.SX^*. CB7D:G!ICKN;'?/Z$,.-
]Q@FC0 M"]B "Z(P/O+;Q&P?M585B'7=TTH\@[9,-?=IM]JUS?=UM]A;?W!'4]>P/L,V MN^F*_Z%O>O1/5*P+)DD)*W3EW TP/:+I>YN)XINZL5MRA6UB/V4C$ M-
)VVDXEWV\^T!%N<4*26I.SDWQ>D%5&X""25D_T22\K!B\M+@,0#$#%]V>5'?SK9-LW^W6-3KK=BE]=MR+PKY/X]EM4L;^;5Z6M3[2J2;+M$N M7V#?#Q:[-"MF=S?
=;Q^KNYORT.19(3Y67GW8[=+JZWN1ER^W,S3[]L.G[&G; MM#\L[F[VZ9.X%\WO^X^5_+8XJ6RRG2CJK"R\2CS>SGY%[SAC;8(NXK^9>*G/
M/GMM51[*\G/[YM1"K_/(NER/-629;CCZ/H[)1GF_#\\S=U MWE5>5N8AK<6RS/^7;9KM[2R:>1OQF![RYE/Y\@]QK%!7P'69U]V_WLLQUI]Y MZT/=E+MC8EF"75:_DV_'!OB+ $B%Q+@8P*L)
<#AA03DF(!H"6AP(0$])J!Z M#I?JP(X)V-@Z!,<$0=?VKXW5M?0J;=*[FZI\\:HV6JJU'SJ[NM2R@;.BO;+N MFTK^;R;3-7?+LJC+/-NDC=AX]XW\(R^;IO;*1_FM7'_>EOE&5/7?O)5XS-99
MX\V]W^]7WIN??O9^\K+"^VU;'NJTV-0WBT86IQ5=K(]9OW_-&E_,>K>3UU;= M9F-)O72G_G6SR=IK,\V]?9IMYK(LZW2?-6ENT5H-:*W7A]TA[]J@;+:B\M;E M3G;4;=N#GH7W)B_K^F=97?
FSL,@GX^4WK\UH$>%ND=]*HVH+Z?7)<'PR''IM60E8L;:2]Z[<>0;]XV,?8YN6K*NM4V^'J^2XDR*=! M+*.?SVUS9M\.E._J?;H6MS/9P+6HGL7L[J]_08'_=YMOD&
()I!@'$E,\)"Q%-6%%GQU/;:]H>]J+)R,\K6UXR"_;)KN M4]NOM;$N^>.0-5]MS44!+Z$EI-@*4BR!%.- 8HK=[&0W<_:4Y(NHUIFT6_:,
M+^KSD<]F,3,&NL@/J!]JO<*9[U3S(,422#$.)*:8%YS,"Z::9S,L,$8* MI'D5&)9B$H;Z^.4LS%03(,6XO?S(/A*&I]8-G:W[2=1-
E:W;AY+N$(8M#]4ZVW[N+*73WQ#G3$VRXY"XFM/5DMG>:QYS/R]UP$(:Z#,P=RFG=EE0M014C4.I MJ7[W; 2YX6I')5G LY\1Z_P.%(:!JW%Z%LT=LU9 >=" WZ;AO
M.\^\1<>;CLF)HDX["\27]K.]Q9V2D\=&8LX'&<*1;@YDI@FH&A^L@FI.CU*0 M<^I^]Q_1>!\Z)NJ]^5=+2*UN@"(34+45J%IR5#MOYGE+K) VG/,1@:HC/>U M;MRQ5+!U=O0FO^@-
)"I8@JJMD,EA:(2(AA-!\^1#>:JN]!@#N3G&!>1^+_9O M/>)W;)98[3'G_2&C+.Y0KGH'@<0-*U"U!%2-0ZFI5O;,!+FAB4;>A9Q;&\Q] MV-?0A.Y,=]0D*YC2$.O++2M+8!SXL=Y/S*@Y03@,HT ?
G"R103LX7;J7]X " MN0G%A6[PST,QT%SFG#QD!68+W10"$%J%H"JL:AU%0K>Z:!W%!C_ +4L+OQ MB,Y@D@U,41#K:&-E"9PC2I#>&RQA.([E6&_T!DLD"V,<7'AXPCT@P/Z/7(C" MH 5&T%JI:
JG$H-=7U'BA@-U"X8CT*FY (1+&>B=QYSS90U!(*K&H=14 M#\\V4+@APA>#G):O0-424#4.I:::VI,%["8+UV ?M^3D_F;.T>450?6G;]!,$U U M/E@%U9P>,F W9!B%?=P:D]T
10N@:@DVH<$<$1SK^POXB$#5D1XP8#=@F(A] MW&J3O0%E#]AD'@CY5&O+!#13/IBIZDM/"_X6C 5_&#+M@H[^'$78'+C@VZM M
%7C4&JJE3V\P./@Q7>!'VQNLS#FNMBD'7;P8PFT@!]+U 7P8XMT@1_UG#=SF.KN\>< MG)V!F,OZF :!0?Y6EL YPI&FE]C""(X("[7U/&Z+C%#$V(4]!:1' 3]2/!# M(*?22U"U%:A: JK&H=14UWMH0-
S0X)-HLJJ=HW;CW]!\E)ASY;F^WW[ISG&R M=Z#H %2-0ZFIWIV];>%&#%= .V(!"KX?8WUCK#OGR1Z"$@50-0ZEIGK8$P7B M)@HCH9U;9?+H:L[&3'?FP%E"*!J?*@&JAL]0B!NA "
[8@YGXX)0Y&^*N@N MR^0^!@H/0-4XE)KJ:H\AB!M#?-\6=#+\'H<[_\E.@FYS %7CQ$(D+G2ZGD80 M-XWX$W>B$Q-@(#]$U'B^!\47H&H)J!J'4E.][_$%<>.+'[P=W9W[Y-NFY26, M.#2F?
*#;,T#5^% -5!=[D$+<(.6:91&WY&1K3"3#0A+JZY"@F2:@:GRP"NI[MQ3T:H6XT,FI9Q*TQ^05BT&T;H&H)M0 4'(=4)Y1\1*#J2$]:J'NSQ<1E$;?: M9&] R0HU-X',B<\T:I6 9LH',U5]Z5D(O>H(BG-
\3JT&6P(OH^P/O=U%V!R M1P E%:!J'$I-M;(G&M1--*[;$6MWEXWH#B;[P$Q>E?HQ*BM+X!P%-#;N')8X M0D-*]*46;HN,(Q]%%R:HM.<'-/B1*R,4=%L#J-H*5"T!5>-0:JKK/9:@0^=0
M3%D9H9;7$XR5$7>.D[T#Q0J@:AQ*3?6NQPK4C16N6!FAMJDQ-:"M.^/)%H*R M E U#J6F6M@S!>IF"B,71MPJDP=7ZQQKH)K3HPCF1A&CH)U;8[(;H&P"5"UAEGTGR \"II_..")0=:0G M"LQ-
%"9".[?:9&] MV,PDQP@C/1^EX!FR@I?[OM'K*Y#0F%X\RJ?\VE$K5Z_'DKU^:GLSL1K KRG MB6<2DVPST]UZXMWV,TU!%AN*5$G*B??7%R!I00".8#%[_"6VE8,7$%_B]@ $
MWWUMNR_]AK'!^;:MF_[]Q688=F^OKOIRP[9%_W.[8PW_GW7;;8N!_]D]7/6[MCA6K,=&VOJ*N&UYMBZJYN'XW?G;;7;]K]T-=->RV<_K]=EMT3Q]9W7Y]?T$N MGC_X7#UL!O'!U?6[7?'
[MCP^^ZVXW]='516U98U?=4V3L?6[R\^D+=Y&(L$ M8\2_*_:U/_K=$5_EOFV_B#\^K=Y?N*)$K&;E("0*_N.1W;"Z%DJ\'/^;12\. M>8J$Q[_J^?CE^=?
YK[HV4U;_Z=:#9OW%_&%LV+K8E\/G]NO_V#S%PJ$7MG6 M_?BO\W6*C<(+I]SW0[N=$_,2;*MF^EE\FR_$40*N R>@[UPZ MO]^ESH__.3\X%2-\]NFW?=%L^K?
70V\#$+IJISS^SCE1T_DYSF_M,VPZ9VL M6;$5D#ZUIT]>2I_;TQ-J$;CB%^]P!>GS%?Q(K8IW;/>SX[EO'.I2'RC0S?G) M/>AZ_+GVY/GK*2)R=0H>[T1OUO%-WH[CEUN,MM^[:K<,;T*X8
MJN9A:H&JH6+@/3>I^K"J:)S?]KNB9.\O>.O;L^Z175S_]2\D=/\&^84IEF** M99AB.9*8XK-_\-FWJ5__RKO,3TW9;IGSXS_;OO\),G62"$<)T4$^7E\2-PP# M?
IL_'OL%Q7DTB5PU+@7B>)3O)FI6M[%EVU35C5S&GYE:WY%Q:?B]U+4J'W/&W?>;D/5Z2UTZ0/,^H0I MEF**99AB.9*80+5;%I;9@BJ61:0N-M!8Q,X-B$H2:)TC%4CR)#Y[$YWG2M4]%/3SQAO.1
M-7O&?];C")BWFGW!FU$^_%WOAWW'YL@3XPYK;DO]PA1+8\.*2T+C.(HTRX"X MP WT^I8CE4TQ+3F8EIQG6M4,C,L/SS7(X8U=717W55V-5GZ7A=:\EUJ(*98F M4!OG>GI3:
(8%H>L1S4"DDBD&$E=.,EVKA9^:H6@>JGMN2]'W?%A2;7=%U8GQ M"SB%M*HM-055+455RV:U8_.I:9Z)_D'L4Z[K\5D6'1K MAQZL^L:[M-%(&+:AD@]4M716.[;/ITFLVX<*-
;#45/LDUB!VKO'W0LRRFWF@ MST$!7YL./<:Z(1(=D+L\.2S4M/6 M;><,&W88J=B:2- V5':"JI:BJF7$9"Q1K"\F8&6I>BL1"[$SEL]HK2@J3T%5 M2XF)2D*J,TS4+',L-75E6G(7:NRA^(;3)CM.HO-0$4L
MU$0LEWJ+",4$;J*OF^=SG+IP'B9'>$R]TA**4#L4^7"TF"EN^U75E^U^W*74 M'(\.WX@5;] !5$J"JI92DY)<)HFOK]- 8;'AP&O0#RKI![73#\,G,5BH^GY? M-
"7CG4\/#^#MJHO=0<4@U,0@<:+/NX @$D3ZZ!VK8*HY$FY0.]RXVQ0=NQ2; M,%?C9&(// MJUCUT#A\B-VQIGQRAJ[@5DW[<,7HG%G:.52$@:J64A-.7!*SF3.C/,] &%@E M4]V2"
(-.$^V3NQ3'U;!>VU$U,OIQ\\WSFO2IW544E5B@JJ6H:AFJ6HZEIMHN M^0>U\P_!,YJA[9Y.US]4IH&JEE)@IX>?&--?*(SXA.K["; *IWHA>06U\XK;
MCNV*:O7<>4WUKATVK)L;SL&R:&;77FP3*J.@P*X/-^+34-TG8-M'XHSHV*'#P3$EQZB4OUA3$H M+HECW1^LPJG^2)C@O0 3V*[MJ^&X^IRN-G:MQ;:@0@4/@ K&###4#HOP@,3QY M#:[@2:
[@V;G"AW*>W.Z*IW%-9-S/6Y;=GLGV#O0'E3.@JJ4>P!!\HC=J0)3O M^IX^_,,JFFK0T3,J=ASQK[&>' WR0#-P'TG!?28%8 E^Y.FK4E 8B8S]O%AE M4]V0T,&S0X<#AINW\H)FH!(&5+74
S9:Q*Z.&* H0HV6ZS40@R<1@V='#+?3 M*L*(Y99L#;3++K8'%3-XP&8)8NS/S% SS;'45!\EC?#L-.+7YY.PWM.2TV%Q6 ^,##*7X2$GUX \71T(OT!3<JFN20CBVR'(M73&##SZS8]O=\XHRZ-
_9=1.5CZ"JI;Y)/FCBQI[>[D)Q)/!U0H)5.-4]24A\ M.R%9XM[YM0^5]*"JI3[PJ L)J5'YS#!"7;/NO:JV2CKCOT!GE+'JKJN:LMH5]?/>SX/%N^6;?NTY M+W8:%>#X)L AKO',9H:::8ZEIEHM 8YO!S@?
2EY!^^JYYNZZ=K4O!Z<3IZP] M;U$H3ZXCV,47NXE*<7R SH2!:ZPD@'$)-0X(P2J=:I2D./X+9X3HI.UP1*L;Q@:=9*/4"':%E4&!,/:)O:\0JGFJ29"]^O BUK:NFX&WGRQZA8AA4 MM115+4-
5R['45+LET_&7,!WVC75EU8]NJ91#7!"ZA&-6>[J]LGQN;'6W;S5-_9U06XT&077^H2JEH: MF'2&))&^)@M$>;&K]VI8)5--DL@E> &Y&%2T/_2A 3O/24B[&'7SEI2Z+:H8(75+4452T+H,=I MC&
<]L?)4+95T)K#3F>]=IK?++K81%< $T%Z5F!K3/-1<TVH'+87+' MY]^/O&:MG/NGLRP6HB%4H3+]$7<:&X("'&:.4U8$D@84E@AR79 M>LW*L1*Q;^5TSAEO WE?-S_E(5I)[B)H$BHI055+ ^#
($(\:%D$'B^C^O 8C M"20C"5YF)"M6=F/+5DUFC QK_$6L'3SR$>8)!FW77NP0*B<) /P1N;[.C3,H MCA _,"O2:W"20'*2P+Y'Y>:4,6_FU81^Z*I2#!S'@'OV4#6-: D%HF1=U4+'
M^7^T9[K8052*$IB[5$+B4F-/&1!'DR#1:V/^>-D8]9EORA]"ULL"[_6Y7CZ_(*.KQ M.?2Z[<6D5AR&.1U1.[WLY=2QVZ@ E4M157+4-5R+#75=0DTPA>./QU'<>)Y M,
[&_X/D88M!@5'Z!JI:&P"FGL7$6%1#E^:Z."W.LHJF.2"P1VK&$[HC]! Z[MV&)74 %$"!QR2J-8?P "O-"XYAGK+*IMDBT$-K?WV)I'AMYBO=AB8MW,\9\ M"%Q@#E'1 ZI:BJJ6H:KE6&KJ[2
!16@'%.>>]3<^"2IN$EZ#0?N!_151J \V M@"A]+I-"2M35QVM E&^< V7_[M][;25=".UT87P'W&6[OMSW[/GP@?9^X)=Y M6DD^3&9% ZF_@J*]KZN'TP?3VK->7-U0X4,(G?MA' J-FF>.I:9:??1RE]?
< MSF$77VPF[LM>3/Q /=\P$SC7U$]"3Z^0K\$I0LDI0CNGR.6N?Z=8K4:[>F?8 M=.W^8>,,C/=SXV'L7?LX]I!.4=?M5T%M0==0P06J6AJ:0(+$8:2S)=1,KVJVYEFY/T?\+NRFMX=.?
PSM;GS;Y7T[#.UV_'7#BA7K1 #__W7; M#L]_B P.[W"]_C]02P,$% @ =H1G6<00V0VE%0 OC\ !@ !X;"]W M;W)K.*EBM92 M]HSMJ"P[>9BZ#TV@2?85@$8:@&3ZU]_OG%
[0($%9FWVC2K,PZNCV5&X\4FO-RW=.'G] MLI9K=:O:+_6-Q=5)W"77I:H:;2IAU>K5T6+VRYMS>I]?^$VKAR;Y+0B3I3%W M=/$N?
W5T2@"I0F4M[2#QYUY=J**@C0#&'W[/HW@D+4Q_A]VO&7?@LI2-NC#% M[SIO-Z^.GA^)7*UD5[2?S,-;Y?'YB?;+3-'P_^+!OWMZ)+*N:4WI%P."4E?N MK_SJZ?"4!7._8,YPNX,8RDO9RM75
$Y7Q)3;UN*IQKKV M]>>-$A>FK&6U?7G28D.Z?9+YQ6_4J'ZX_ 2 1FGF MYLW\T0UO57TLSDXG8GXZ/W]DO[.(W1GO=W9@OU_M6E;ZFR0!F #/JC&%SJ63 MARH7-
U8UJFK=#;,2U[J25:9E(6YQ4T'XVD;\>[%L6@OQ^=\Q"CD SL/H'<>T3M_;/?O,>_1Q>.@S8Y%LJFX^7Q! MUU;6JFMUUDS$NRH[%C^T>.?O?WL^GY^^*_RU>R%,#8\P%I_\T>A&R'%NC!+
M4':I3;V14*B,]\2=S)^V,A!XE0OP@@[(=9.9>V6W$ZC9/L,Z#?85[:BMN9>YTHL5:56&AQNC<@V MNLBQ@K>7.72Z$86^U]4:"MENA)66(3(V5[894(FPG/W\ B@N=:';+6VGJ\K<
MXVS^G1,@JZVH8*-:IJ8&*'00GCJJ .84)T4PYET&('3#Q%B9KO*"RSCD%L8, M3RO\WS)=-& 7UBQA,WCO'"_81J\T"%#K6A'_B4P0Y:IQUAQO]+09QZG4#=M? MS50*E)-9IAJ^L\3Q4UU-LT+2#?
B%UFD-3A UCN"+AXT1&XG30)^V8*I4IG]; MF)HP.P "*5^KUEL/0P%9L/ 7@CB'9P8L:C+---:9$P\O"4)]K95M=:/XMA? MGM"@V<\E0MIC,52-)0BJ[H-(M1L2\0(N#CQI:15LM"Z) MD_>RZ!23
\\]T/).;4RQ)TF@$2E*RKFVUSY1&]NN8,!,ST\^7%=9T>4 I6'2 M##",Y 1!)UF_C=B2J!K!-LI*:1R+0S&1!I MLXV7/*^X?LO)GF8GZHSC6"^&DE-" 75-DI+@#Q64[G'01EP#8JL*L(C8!K%2
MG36%@;00)*5JY1(4:\I].K,$3,8!<=2=8M1EUVZ,#=90 M.SI?@1:UDI6XRDQE2I!P@4T'YOOJ:A&M]"@6%?02,1AAX?WD4_"JR@0S-DWE M$J^V!D(1K0)D(V@%WV-<%(KVEF9(&P#07K
+DF@#8;=OE6W%Z/G-^ Q97K*PI>1WE MG=-"PL_"C; "S3QDZJMN^+"G@/A4$)CZ_Y15X/.Y MISV("//1=&H4P+#?#H1/$_U@/4A^I^JK1++M'L&49BI'),! ?9 I0%<7"&8R M37)?&6?.
<@2S$=AH)?]*6(=$=!83\6L%(!KXYGB$%V8F&D=-P(NB4=[%4;B# M&W?8] 1P>$7(@VKX'9R=?A([QN7EKQ637ROQ:]8:4M'9\\FNJ%!5JL4_\H3M M7\N$(;T\D12QXK#L(&U"',=>A)-
*YPK6Y.@I_9EXN^=@>]!0Y:7RCA$[!T]V M$2QNP_E-1J>"U4X.B>AA!Q9%_D'A -(1>'\DFL]^AJ7=-KVEI4R 4"=.$G" M=16.XCV<_]JE7AHTBP?3%:0#HD
^!F9PMO>=\+1TIK5Q48FG/0($%V<\T4E9 M14SFR$@AZ<^0L:^J456(,3,5%*\U]92I >RY3!+EZ&F>7O=FYY% IU2. M=CN.^V:2X2I)'A]64?SE&9A2B<@4A4H(F&:9W$\)L' MN75I>B(I,'@,51-
\L10?04QW<%T72('IWZ\'*93/6N<4 .J4$2AX%SS(0^6 ML(9D*)4O97;GDH&>8KF!>I![">47@$1A&2]6=,?'I4Y\(,B5K\Z$5%I#Y;J=;#[85G93J+NW_ -;?07B>-9VR!D/=WC9/^UB![9EH/ M3#F%>
(EV18RC#.&@H5 $F%DNZ,%'!\H_NR(XXF6JK .I',:7\9!=$8>34+8* MVL*: MD@F:(2!FU!O'2Q44R0K,J4*Q"F3'[7^Z/>%Q'UJ&16$P[.CW*R$^!- M!2R@N&,F'O.!B\;5GQYDTW,ZV36-
;:C66JB6SZTIM1>X(CYZ!:/%SKW0;BM- M2DRU')*]EA01I)^?SI[UB&DGFV99D,%QOLB=Z/%SJ'H;VHBNHKR8*N^9UY^#4=>^P:OLJZ@<0&'R9"2!]J:$O MW_K2CBK@
C*)!)#BUZZ6]AY(9ER#X9NN[+057+4:I?T"PB2I*O5^NH !,@!; MPR*I3-JE^;HM9!+[+Q:7?9Z:(Z6DM+SY/YN14AD.-.R'0><5*G;(M0H
M^]3BXVV_NR\5"5BZAEC.0F\5I2848P0M5M6W;0E:T\EL;@9Z$VH]\74X3$D1 M1H("_#[!WN?\"2W)3^DR""J9)Q#KB!I>:BIDZ MHV9$QF4X.>)UWKP?>IT#XOTTK,9CA+W,9\^FP5:$$ +PN(([[!
<]KJTV['B] M,6"W@M!'VK5J4S><*CE B]R=G4U\S#/0<5#9>1M+O=>^L#7:'OJLUE!F'0JX M4%F8O2:4=W^7VT+?VUC?O3>%A P9]\8HX89%: HO0BV.+MY325HL >XY9H] M!#K4?.1L MCQ?
=FGI",R(AY4A+5QM?JO:![.>@?H+[B[M,R=&N7[!6]$)JHR@6<0C8F;08LO;.&!9NOL_*+@M="UV6\>7-^\[XD4=^3>&-7WGBHX5U_&H0!R0SL26PR@ M1,VUO-C9D#N@W29%XFR@L2P9U\?
BK5FM2EE-WTOQR60XY7WKDI6]!TZIN$QL M7=A$.[H 'AX5\/A#^?6!6!-.MP[4#P'4A0?UNN\4)U GMWO:$A'H&9@'4UTR M#2 2/3M]?VPBKN[MMNF-)V*+7"/=*W^<)-
%B7.8K%3YIZ&7\=)PA!$)0-><^ M8S>>NA![;I6M5RR&Z,23SL8/^.F/<,:@O3'JKRE&#IU-V+1UQ=KLH>3T")K* M?^=D.?C7&?WBQ40]CG\[BP4?YV!I[9HSCH!_0HH?(Q5'Y+/3T[3]TWOH>>*A
M TND"*5TB'P3]@]0\<0"U^^I)2Z)0"Y,3\@$$CD<;WUQO.?KV7[D!\,5J_:Q MM.-/>Z1^_20HHGY3^2\V9/;Z4H8&(?)[JF@E(P'.U)<&BM85BNJVA;@JJDZO!0MS\V_O@S-
S1X4GGLNS7X(K3('5N*I6VHR\'#/M-'KBD8] M*'B*B0TAL"RH,'2S43PC4CPYR#XDCV.A]H?%H*P46F]C--E37A C:8.FEO-> M\EB:-7RP MG^MQP1B1L9_)>6L>:.JE!Z\OQ3.$-,(6BQY2S)]-$?
7>48\]PEI"O8($YS0!- MN&^0NW9$GRL,35WBPR>C+S0DR'0X?'9+LU_.!\7!(1#I)TH-HNU:*IX[B064 M4>:\[6BF8=VZD((/\NE05)>WET/U#\+H2I]._9QUF7L&D)XP- ?.O(QU2(YP
MAR(_#RAD!IZG:=F"U/:CXI0KX:*[\J6A@;%>J,RF\< :=53.-(\F3ZBD4TW3M0B!F((DH*\BP'8 MXT3CY# >\I@DK3>YL%ZA.A\RNP@]%6GB*(BS4?NC%4E-*=2,KB6T^[.EY@ L M%%S^8-
S%XQ42EP.F(FF1C1A%RKL0M7%\[T:_5LAH2M^X#88RM21-22.<(79D M2TY959@!=>4L\Q5YOHM+B&*NT-J$(BLG\8I?JB<5?CSG= M=[:
(NU$(#Y?._%U\O(W5*&=L7=B<1L%)V%N-.HJGT80*7_>X]T<'IUBYX=H. M>!3FJZ3H8">][F-14^]W#N63@DX@F)Y(/CF=V-[BA'7((%TJCJP(C\D90%:_ M)C'I]:(O7E%$B;,^_/K;U?1Z,4EBJ[-
C\3M.4$ETFFLWY4$1$6O*;C [&<"8 M&#HL3%1>I!&LGS$C%;E3V^A J:8&X*CBU0_@$BA=S<5.LCM^W#R\.A@4I#"" M#$7<,)J6 &P3@\Y#L#:4F[O<%C]F1,9"FP
MG2VD&FGX0IDKWR.F3.C/\2HV@X>#I7I8'SS_?LR7JKZ(JA]5/C4JKC=?;@W7 MN1!WD2$EP]AD\&-DL294AEF\OYT\&B(.@8H3&V.FB;NJ#IC'FM_)*,;]Z>R
MX\J+Z7<8(\/XP^%Y[]R\ZR";2Q,BTM*W(D^=Q$\&[?UX_W]U%)][T52FBLX] M?,RU2PW?T\VZDAUB[CM0#,1P_.5_SB8_/9\=GXJ2;,S>W)WJ2OGWL@F0_.M M[UW22 *96V>F][>NS[3BJ-!!MP-
7K::]*I!MD=M?^I[BQ\:I<1'_!3_ M@-NHNV7AO(<)U>JW5D[YL:7!F[\@9%R%32B3,9=BWYK9VO>(#NX U 0RATA<491D(Y:69C&/1*;KU!(WJZ]LMN M S:T6VG=L!D[WH"EHLM>B[:?
PW".KAFTL>?;$W=.$88B;O:X9MGDFB^DF!Z(#[(Q>3R6:#=)>^88N6)C1^G+]PWV?WK[LOV#T@,:42U4"LL/3W^^:&9A7'1(YNM]4;92;75)?RR MK.J-:N!CO7IDM[56.=VT*1[-I]/31QMERH-
G3^B[M_6S)U7;%*;4;^O$MIN- MJF^?ZZ*Z>7HP.W!?O#.K=8-?/'KV9*M6^KUN/F[?UO#ID5\E-QM=6E.52:V7 M3P\N9S\\/\;KZ8)_&WUCH[\3Q&1159_PP^O\Z<$4 =*%SAI<0<$_U_I*%P4N
M!&#\+FL>^$?BC?'?;O57A#O@LE!67U7%;R9OUD\/S@^27"]56S3OJIM_:<'G M!-?+JL+2?Y,;OO;XZ"#)6MM4&[D9(-B8DO]5GX4.T0WGTQTWS.6&.<'-#R(H M7ZA&/7M25S=)C5?#:O@'H4IW
W"FQ$UYW]3PJX'[FF?O>3.2:IE8LRK-TF2J M;(!86=66C2E7R;8J3&:T??*H@>?A78\R6?LYKSW?L?9%\J8JF[5-7I:YSKOW M/P(X/;!S!^SS^9T+OM?;27(T39/Y='Y\QWI''ODC6N]HQWJ7
>3Y+]ET\^K'5R56VVJKS]YS_.Y[.SQS;)X'.A&YT4QM+5>ZQC;&)! M[X!J:=:)*9-?*KA_CGA#_W&JS4VC\V1I2E5F1A6);52C05TT M*/%-5[H3&\6NDZ.9L0Q1_"(K&B!%?%98XM>EF4+*[W36X H
9V!@I_,IH?_ M!<\IX+X; X#BG>]UUM:F0214F2XG4'[U]>'7Q/2^E% MW2)]YQ?,OW(! >:?<_]; 2I+'C:?>13M4YR8T%+6,9IV0(A >%<-\H4R0)5 M[B1YKJPA@A!/ED F! _W$!+&[CC4F)X&!*>+O39-
O6MD5R M"%?4;2$[4.M56Q#(UO$/D'Z27.D::%%V<2+0JP89C A85+8%V@#'P25%<=MA ME%$.\P";DJA8YW"-9OY8Z5+7M S\@MCGG=VK87&S1;B%"S^6Q,GO<76;/#SX M\?+R+?

#,6EUKIDY6 25+W&.@=[4Q#5X>D)*VV7J<%A/<9ZOA48VNS68<&0LD M+H#V0$\PZP@6//$_;#=M8%M02%EOH)+06G4 MR 2=ZTH@DK6H&H :(J.)2I;*U(&BB$'
;EM9@ZBEL*8% _X,0!$>MYEU/X;XJ M^[2NBES75C8,?170&T SA#U3=ITL03\PBXRO\]7$(9P;CYDADL]=PS;[6JY1%]-CI&0<#K@!V3BE2>8W" W53Y\/=EVX"(TZ*3 MY*,E(#08]@'T)'5*
19HYID/LB*M9-)"S3'/+DH'2"]C\WAK4(((U:V-^J2C MIR#]E 7W=\O4;=8*-GJY!+P)8[5!)6%A-;0_02+&!:S,N_J;I JL1V0TPJ-Y M)4 ;P+=@/W*U4W*#WMFH7
O*I>XQ@TP5F2@9I%8)9GQ;5WD+J%@%B@=XL[I5 M!5'IUM>Z;'6>9*4 6JPA 7B61 8.TP\2H*J480 U1Q6*:HM4199!=0A/.-: M%2W# _/=$Y:'#>^,&IA"MPD_(00T9XR$S!D!A<@(<-5/%
<"LJBG\3E(*Y. + M,+#8-,0HU;4A$X]KP_\6H/"7!OR8NMJ@.JLV(#'J,^[&9=:T)/G,ZADIVMS MGM=\.9@W& $(&"QR)&C'(LY!]%G1,%MX%G&K"ZL(^\,GUC[PW2W 1R!]*JN; M<@+>#?
BWAA8B)=# _'.OC7).F86YC00(&U]@G2D>MP$X+59 5Y&@2"0G;C?>" MAD8;1BI+%6EB:F"**E.+@I4*^-NE!9+0%^!$@BCC=F1@8$W#8G*C4- _#P08 M< SL-7(]::<;75SK0])*C@*CBF-V,<;.U:
(P*U%X+=Q6D_+-F'T*#2&?UTE] M%O67P;+_ KT)@(3)!R"S79MMFOP'0>E/H('U+2M9%G#':0-$$<<'9Y,3B/.* MPCDJ^^5bX82 RQD:*B(U4"=V](^$#5@LB10D%_Y9KU'. :6@G7@GH S@9FY-7@
MD6W&PO?@:'+NGVF6H)(0KFB=""'6"!Q(W${'+X* /$*D(GO]4UN2'3].Q^@- M,]OXYQDF?V5CIECVL!:Z6XRQ=*?3*8. ^E10MGnQ@!VB %,+AHI-S$G:P=K< M@ 0[C1(-"U,(M^,/:^0%<7BHG[-
"E!M8#DES/M&[9>#11&[M5E3EZI!DM51D?X+ @RX/@L4LH%$.YA%=#- !(\K/R4KB"C!T&M:\\%T0BY@7/"-'LZ9J@ .$4!;4A=\["%9N2F?N.CHN CMN+0_),BWTZ/'W_SO2]SYI?
_X7*],64IVPWW)%N?0 _^N+[SK&'5/D+B%?-OIP ME%S17CL'/2*SO^Q!W'NBP:V-BD(\NTK.+:?3-Z6P*#PST>*/]3YK9TH9TRUCN:3-Z);EO MEF.:!4I[KA=-? $"C\B0 ,[6$!!-
XD=X']"2[H@N8Y)V%V1M6AM@$B#9!]6= M?P (5A!;H[HB&PUXY^K6&79U#?:!H/?.:EAT$N>:V#T!@;)>7642XY*'B(D(M3#PA*&*R8S"?GJ,V ;VM<#7>2,R19$BU.JG) :6%#*@V MA8$>
<%LK.P6^ALIS*859O5ABN?[.D+Y JL%ZJZHF\\!!N/.F-J"NS!}>UP'B M&P/Z2,*L6KL?,%)$]QHWB.]IAT*6O<(DAXB-@(DJWGWFX%;$$7SL0%#X>3)66L. M<1N*.^ o7U@LTH1:^Z7(G7*
MD&+$@.:"&.I:MHD2!5S$IXHJV)5Z%X=6?&R$8QW416,9&SG^76"DE0#*)*%W.5+GT M?'?+;]'F\V\ &7@(;-A5?HV.7>(]4$#!X+:0YL$<9R^(=^O)'G2P=CD@[5(? M*?
+ISZBL4PPQ.0OF%4MD0GRBB)5G!AZ,)(XXGHYP(K<.=[H. (ZR4X\8GH$& M<'#]XWY8.INRZ['I* 68ZB7F$ZL;B!#25$)9\N M_KC7!KO89PBI=5~}B3XUD-+4++JXU%IB0

8":=5VU]_6>.*Q*>A:(VEU& WY]6W9E3 #,"AB/(B'X=R"8[/ _F66"IH<] 7V\@L&CKOOE-,?W,&AJSZY@* MJ89"),QR K\7A,#7/V/2*YF)GS9)/@;#@;E=%-6!-1=VL#O!1)7)7W$9"\ M73J]*>7Q=GGL'9\N(E1S5W#MVA5R7$5$]Q)!T;7N+]1IT261-U%1G&-
JVQP:,*;\%U:/6,A!%@2FHNGMJ8ALK*# MQV R\P/E]\PH%$X!6P4.$FUA=#?8OP$KA\8D])E&X'>&UUCEM6Y%/9ZG8^% MG+I:A! ?A9/OP_ +0KC,IQ?-0.\;X;I@;QU<;!XV"FUXTDI=$*T9JNM.%A6> MNZK5AC$RZPWC^.O8@<5_T$NO*PO,!"'70XX.?4E>G$R
$'&:S[4$@N ^(#2\QEY;'>3NH669[P#!;:!AI?>D&(<(\N2N&F) E+Y;2L8Q,V"9G 3@ M=[, MYG]>'#RB6X>UO??)G%(QU'>(#T[.H\"CYS?J^)^A,R&U$.M]!P^U+P!K(S@Y(=)*>GL5Q,R!S MHS+4)K:9AIM#>5PT0^U[*GR MCSWV[N*-L5C^C&+8 #]61V'-$&Z-*
<.^==S?M.(]X6$$Y2$)""6I$)UC6/6(7 ML]MUL;VA'7\2)][F(>>=8O"WX9)A)'5?1P92(XI>2-AN6/#^2 ^K;$TR^'EK MV%)]$1)'?XS$=)\#Q+W@?>9NJQO<8N)/R]J3/3=0M@_TR[^0_5#T&R4A8%0 M6E&2%A/+=<7Z#7 UT+#P0#808$Z
P;&:0:9V_4H#B2*128NQ!R>.13MCKE:6QL[-'P<*" E R0^7N#P@6,HC@K1 R;=3*IUS'/X$WP_=H>< M@ 3B*VK481G_-LXIQ?F&P!8@W7G:(R**8MOMMJ!@C#+P%.I8N -B+?>QGX, @ M;SR3.1UK'^7*D*. [F HL&[5K>NYZ#HK(T59RM?UJR/2%^"15F+,.(&!J2C3<
M_15[-5TK#I^_EQHUZ:>8[T$]0(.!-;/>4<$KQ.JO;TEGW?A5O6.V+D M0@+-*;>P/W@!)H9 U27Z4>\||'29T"V_1&ITMXJE(B#F'<8(_/F!% MIX!G^\0Z;HV8EE &M%!=&SPK(MN$%@<(+%UD,9R:C)-NU M)FX)*TRL1H3-
JOE"]ZP$M3(D6+_'#TXLV@Y;;*N+/GU&>.#@>CG0=EL%'7/ M42Z^ %3"EPSE?5IYA!)*8&PK0WF-!QTV(.FL,IN LN]CGE"UC?]GU#(%> M;VZWXGNT6RKG% 8S<<WM JU34::T2WZNBT7KQCLB*R$*9[J=2Q,QI<2-4_ #.* M/-
FT>PU(W4E:HJ$9Q DS:6Q^W(QF5ZHM!<!DIE$@0*Y;2#N[M^ M[1N57A,N4&'-%*#9^U]D-IV$Y[M(2=]KZA]^QGMOUC;>*"3B'B#@&Z*1 D2:MB3BN?=Z4NXTZ$[^#D !UM M*#OP-0<>3*?
+F9SP!^=%O6:GI\V>GD],B84,"0R(Q<R9PN&/E2:?- KL"HF M37*3MR#GM6*Q^+@%??"FL3^%D?2PA/42=ANX?GSR5?HN.+]%/G4SX,F27 MT7G3&/T_ F=Q?+M5IS"I4=QV-D;Q^K+$S[7]G _GY15\V,W X<7G1K4
M3U4$\'^/3:,.9%YSTW^2I7"9>\;]KIQ2 #8K2201L6C+9;8 MUZ\+\#0GXP!VGJ*W$Y1R$1U<[I(^-N!?,J)#B[0254G7(EQ'# K) ?ACJ7B(D M:B_#3]@UOG4)0_#[H(C-H++%6MNH2C,],3"B)2QXY[/2).? 'E<V3J(PL\; M@S6O$W< T<\'+KMEF9!,8#<]:1GK3V%2A
N%MJM.DB[.4L89-PXB&! ,Z/J4 M0!3-.0 MA.2A?!CA.'$FQT!_5D32G5P97<8SW>;V!RHG(=!G8PU#DP1-&+X%HN(L@? M(7/C4F?4B!%[NRLP10-JN1()LO_(GFZ(S MWJ H85P3)0U1Z\^GC5Y?OG]:?L\??CUL]>6AU+==+=OG^RM_UH0+^ M2\ZG7.:$'Z\Z"?+
+"5>X00ORZ'L(.U9:W3Z2EEA+9;*P*WQ9!77 A9\2L M];(B7WN*X(D_26(S]44DQQOD!LUQO@-1U ?]!^\Q'N %3F.VF_O2WZ)1RG2 M9+EVTFCJF\(T'SP&;FQNQR%7B1YE>QY^'T08W0]2O8YT"@+P"F57;G>$ U Q1 M-3C<]$0_W/W7(=) ML*_8C6]YJ-
8YQ18M^O7(4&@+J^&F#)K2%T JOZ(O>S-'2Q'AUOV2+9VS:W7 M*QVAP]7=%\=7H4JKS_QC%H[S2NQ3)SD1&/NB?(724]IG/8.Q4A,66-C%E**$KYC%*P: M\5/\C6@N#>Z+24+ME&N=%05@4*N"P[M2\ZG7.:$'Z\Z"?+
MAY%EHZ9D[!"N<9^C1EY]{'<771MB[W<+W[(!(?"SF_8#'[%3UQVE%L3 MAD1NK0ND=P!ESR7]5WU820F,6_Z0NJ0.;7*W+DF$AX^:-I1)F(H% ^[P,5K= M^CMKK2]BIRYF$U/RV-D4K.T U*9)VH"H(;'=HPAM79;Z'G-80+#M8>*A ^:^B M&N[?LSPASG:X=,V/9-
QR8#*XSK6G M>3 -;4CCEMZ@<8* IDS'&*UJW',8WH$3%R>)G,9 ^T;LB9=01)M,T]WSW.1>U](<'W=]*@K> ?W.9 "P&\M)M _L+[ZIL ;5= MXM+I%8#80=-RPKG?]#= -^YGLRBIRYF[XUZ":C";H9O,BU[M>.5W?
VMQ\&VW'H#R9IQ.KLIE9E'7 ,.BC#V<&X ,H5S,;Z(%%.NMU:7]!L.[P- MK4M8>BZ4W1@4E.K5;6T65=EFA8; 364FA)8O?KGT,2(W&NNR.HS2*>.F;TT(M*2 _I2^_UEPSI/B$S<:E5MM:9 ,+#.R)>5U@VEW999"W1'77._<&4R.Q5%^K'5/ M, /B$>9*\ 3 A %N[?I5PASG:X=,V/9-
QR8#*XSK6G M>3 -;4CCEMZ@<8* IDS'&*UJW',8WH$3%R>)G,9 ^T;LB9=01)M,T]WSW.1>U](<'W=]*@K> ?W.9 "P&\M)M _L+[ZIL ;5= MXM+I%8#80=-RPKG?]#= -^YGLRBIRYF[XUZ":C";H9O,BU[M>.5W?
VMQ\&VW'H#R9IQ.KLIE9E'7 ,.BC#V<&X ,H5S,;Z(%%.NMU:7]!L.[P- MK4M8>BZ4W1@4E.K5;6T65=EFA8; 364FA)8O?KGT,2(W&NNR.HS2*>.F;TT(M*2 _I2^_UEPSI/B$S<:E5MM:9 ,+#.R)>5U@VEW999"W1'77._<&4R.Q5%^K'5/ M, /B$>9*\ 3 A %N[?I5PASG:X=,V/9-
4NJPVA5F100&,XY'E2N]IZ\=Y&$M0'00#2/LM'NCM M=:[YK\1P:<=X5,7DPM'D3/3K_KNWX^M= _3LCRY6T7#NQ7C,/<.]#9IK0^ MIXHN)B>S77QA2BPP6AXT.3=N(9V1)%ZG4L2T*+48@B<,%CG\VYYGMH=B\E-% MB2;.KV(GV_ : Y$#8+=VRW3^^.]
QIWX[8]#.YRE\A>3C]'K9H.HV'RO%1P#X^ ^IYZ.W1 1T_W@H'5R1=!@.,]24E?_IZ5C M'\.(*I(M(^]L4QF:$8U\6 ,/ KOB (C<"]PSUS'QB('* MS2+E%;+<6]F#L701;55U?S102 MF[$?0@U\: 7C,*6-3.EMYV27S/+STSYI6P)N'@#*2+I@.>0]!"0496CR-8B=] MT0$_G
E^3<,+V87Q*60;@SCH2+UK6G>T#_N^.+X%04D3Y'2)DW,@\1A8 _H M232*8N\085(B\LA!S4>>4$N=.VQ_Y$7%'^HC/M^2Q0)9SN9)_ ^3&G@$9T& MDM$9<>7K#EM\DTOI<^E .!"S"1S7Y^]4=Z5\LEC^9,F0S:CWN)\AGC /7H$\,J&$=-%"($DO4XXSS=C;M
M)14H"A/& ZIN4!!3[HM0)-K9HNPULH5\@DVZS7DBGJ@8X;S^.!3R^W$MOBR> MN8SA 9H()(*X2?)*%)]TXN&O-G;(UY)$$PIP82I3VLVIQ(#*%8)CMIK+\'55 M>3];1:],&A)335$'/+H769< YPDOP;56U9>= =((G@[E&6*S'T #0@;#VA3
M>+3HS+AE"IBXM8:448R39SVUE*;#AX2AI/U47,G\+X%2AXBHX9!2/+N%2 MG=G298P'3I$?S-7FL?\N,9M9KVB&AEEM=8[>2C1Y[&H M>$XFHGQ*\"\8X&-07G)3:E&EIUD*K>IT!N5W5U@UX;GWLG,LK40)EYS<[MHG%&,TSI;GR=2)DSZ?X NNJ^I2$B:
[!!L*QN[$RE[RK+RV&FF+T%LXQ-6/ M5963F^,+,)NY3*79'NCS@A)3O;*$SN0'.-]:]"VG@&P]FJD,6RiG:>; MK&15U)DI$:[Z1471:,/PZM,(1WDY4L -TLI933,=$7+2PNS @#0X?Y6(P!4M*
MEIWRE6TZ'8,>.M*,PLMY31,10;&Z#YGG)78T\"/8I@I#PAoQIQ\5_X1_A MZ,"D0Q?8WD\48O1,+P%9?URNOZL?tJSI/B6 -%WY.=@R1,"9]D(.IK_5*E6Z>+!UTBFN[^K0 M#[GN7D1UENNOGRH7@$6OOQX51M_@[&W_NC@<3.0E1R64IY2&0K%&=@1UR64IVZM;.B1?
YW4$!ZRLH=E8R2TS;.-3@+%!=']Q^7A"8<1=:,&FA94'%.5)F1;V%=$-T(*P28R2&E,+4(=@)G+XQ(^K<#?RY0(UH,V1) MSDH!D,X,.TF'@*A*#*1SDV\!+El(!E4C\IH@&O@;V1.2DZ:W:>3R?C,903(/<
4E+ZLDP P0_.3[S%C[0X,D9L,K8">0EFHWOO $A=B!@WV%,%.*8 ?ND+(GA&Q M:("::*WZB _\ZNMSO-D6+4V3) /0O"T5Y=F)9O$IQU^Q=7'39]%=+! M9%XQ?UJ[3(GPW@5]H)DJ[5(.=.E2]'3K%YUH2) >EN1 @ACO67[E +LTGX%R@#WAY#0=-\FY0OE]4PZU,.$"]*A2O?,S &?
56BQ- M:9D"]0W _^&,8^QIEM@5,M2M@54B6@>44#V M,T54:"XRDDO.IDC]-R33A#(8T@1,.83AI8M/38 M8=G&V ;5C4,TZQ7'IC4^"TWBID:KN%/N?0#K4NO!QY(BK2(QXP;GCS;Q& M,N=YF(\,2.U0 =F'3$GK"\'CM*R)=V$&3\KS,RIYP7/W==%
[&SEPE=)HZ?+ M)LVRG<[DHW,/.8XK7KNXZK@,>A-S[]\ M#.C2V\#E+9'9.IH=N8IO2[!OU:SF_?>!\\]YH6EDD(OX=,IY.SD@$ON[D-3;7%)?*5A4VWHSS6 K6N\ 'Y?5I"IY0,^ -4L M=@?1:P*O2P,$% @ = H1G6?I7\P%02P,$% @ = H1G6?I7\P%02P,$% @ = H1G6?I7\P%02

^0C&EW5!^,>CKAMP>ATJAG+!^O#!*L,>FRW)34B,+ M@O"1@N.S.T^[(.*GW!7$B@<+↑ZOG\[36=IR'.JBSRK=EZ'3!]+E),L.2QCK,2 MS:805&)NYIT86;>Y*L7K:,9@7KIMJ!MGW3L&IHN-N962ET>'Z,I*O@7ZE*Q M-C](5N9%T^`D(s`\%7FXNJ16W'6P]BIJ-]+L9')"[6VZW/9K3@M#U4%$"[XNH MWPIM4@>HWUIEE@RICGJ FX)6YDW_KFY2<;; .D?"=">S=20VRI>ZOA[IDHB MC$E5_AIK$GAUH5K<#/]NVBL/+-WT-2I/Z38O>]IZ>.F'"^4GC=-39%SMG-^F9I7$L>KSK60&,GS*.AG=@=)47X11A M^6O3Y C>2X+05H".C./]3C$<4 "2I*>3AGF6ZDO15' ^V?s!0:$Z84_YNVY ML@^F) FYLOH ORQU&,9)$#Z)<*5"9X]:?/] M1KWL=BBE=3M*%4@"RU*YZ 5$Z[A=R^)7]HMGW3L&IHN-N962ET>'Z,I*O@7ZE*Q M-C](5N9%T^`D(s`\%7FXNJ16W'6P]BIJ-]+L9')"[6VZW/9K3@M#U4%$"[XNH MWPIM4@>HWUIEE@RICGJ FX)6YDW ORQU&,9)$#Z)<*5"9X]:?/] M1KWL=BBE=3M*%4@"RU*YZ 5$Z[A=R^)7]HMGW3L&IHN-N962ET>'Z,I*O@7ZE*Q M-C](5N9%T^`D(s`\%7FXNJ16W'6P]BIJ-]+L9')"[6VZW/9K3@M#U4%$"[XNH MWPIM4@>HWUIEE@RICGJ FX)6YDW_KFY2<;; .D?"=">S=20VRI>ZOA[IDHB MC$E5_AIK$GAUH5K<#/]NVBL/+-WT-2I/Z38O>]IZ>.F'"^4GC=-39%SMG-^F9I7$L>KSK60&,GS*.AG=@=)47X11A M^6O3Y C>2X+05H".C./]3C$<4 "2I*>3AGF6ZDO15' ^V?s!0:$Z84_YNVY ML@^F) FYLOH

*N:BR M+T7(W *+RN$<~=%AQ#B&C,97'N7GV3ZYB1YBIBMC>!ZL:B@A3L8@X5"5C M.WK4L:*\"|*%@<Y>XG/K\!\.FPGP-2P"CPYWOP1P<6R-4DXF5L0Z%1RT4 M9RL2BVEB%!U;,>`^\.Y AIZL,KO$=>;-*2HDQ6H/D#*=)6^)(@9E3Z%6PF MT76XWH0!B0R$H@-4O(BDI9+-MX/N85,&(J#?N!,K'8[B&3*?%# CVVO9)3OL MITEKB4L7K;[F45EA7`-SQ7W6:1MF*YOA7812%/^#]AI+B/L-?,B@21YYY"OX(MY2J7QNU P4TCW5H-<%GE4 5)RRX584X0DYV">9@D^]H,'D"1HEKV&_:*PI"$6 MKHO-Q? +KUQ:REJHVPPS+^*A5(5182F 2-<$N8_CU,FNE5%I"D7)-(*6)R ME*@)NFQRW704"V1S'I$K?(4 4HM 2SVK8U(5Y+)%.M48(..BQ5)A>_]U//BEXZ6WG>TLW&+/Z4V7>.#38X1D 9O43(S .#6)1.4WQ0!&<,0-0' M#%)-*3 +KUQ:REJHVPPS+^*A5(5182F 2-<$N8_CU,FNE5%I"D7)-(*6)R ME*@)NFQRW704"V1S'I$K?(4 4HM 2SVK8U(5Y+)%.M48(..BQ5)A>_]U//BEXZ6WG>TLW&+/Z4V7>.#38X1D 9O43(S .#6)1.4WQ0!&<,0-0' M#%)-*3 [QVXM6=`.YHL5)\('<X74,:CI6SUN$&4MO*7WO-VD+K#K|'<)>I2 MW@-WRFZ&4 _9D)]"^?\O2WJ,3P-YA4W!B*?:_,-YHH)F\%)6@H", .B MT:\]Q=_MM(/.D8/C'1RXCO^?P&D&A^[>*H"D]00#F\V&+A@:,),F@*+4'3#R=NCK. M6 .FEQ0H),4'EA1.%0BVIO@? SPI4*5&\ .7%ATND8_M68$[.U'IV1O+L,*.?P_ MIMLP-2,BN;0HPJ>52)3BUD3*5OP\0FB,D$M+>-FEJS=)&Y+Q5\8XUHQ&]V=.]F=A8D=,/9^V4)Q8-)Z53EQ&+.FS(RUX2*8,B%)

*I5OFONH7!B:2K,%<=09CZT~M\1L|#'B^;ZFY'6W_38U^4M(.(^C>;8cEH>GI?9:TI<'.MI5'!,.U#,:LJP3A:?IOI.+IGO#%035K|RH#UOTRO%_UCQU4HWTC(:G<.OA'M706F*KE=*T/N-G(7,6/OK"|+2FP?#1%5XI%R:ENF$KD=1M5S5TX/!KJ-?|_M6]^2=,H?9AV-R (09F|S49B*E?)%LBJF6;0UV'GB'UL\|09;M|&G<6WS|JF MS|:C"OU^<V12IDN48";DD||HRMU|>,>\U! XO)^WM;&XN[2|>s0XV"!^@7,! M-AH$N&,@8|39|IET.(VI$XE_ORU55N9O^<S,|N*MCM2Y8,?,Z(\V,!3$7QL M_>M7 +]? |.VKI,C%Q=54AWW5]U:@V OY

*9XIE=CHYBIMT>AR&`MI";GOXGXU@1Q`ABOR\GLYW5^!11!WRF]MIV<]%27FXU4@UC*VT2>F.M>)56(K.8GNMF4TTFOELOQ.P63R6F7,C2IXC26DX@EMB1^O/"WDC*M^.k M#-.MUUA7B\O!N6!\&F(]#&=@&:.\E<*.I:3AR=\lF'@LR$GIF(BYTR[ML[C.#'O@HsT6S4$7'O.(3@[&(]T>MV+U.LM*V%)U$!L<&#D$9V&8F_=&DVP M*2Z5"B)&-K;)\)0=G/Z)3(BJH6*F6*PK8VO8F>2R|\5)[%1\O M-7S2GA(.3',#H<>(/TWWA%7>F_"DJK3B8W>V9A>=2.#'A%KIWM@OM,<6(AOR MS60%Z8@3 .1oZ-%3%YAF.I+!~=^02^ZXVMJ2=V,/18]>2^;E"]0#)75V3& MH6:tTLD8"SCZ?J7@<6p(^:Dy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{@YP\E%,.'WELB5,I.K-'HTP2?T-9HJRWLU MGNR35+Ex&I2=5E.BTYO%>H3DNX[@V]7@(WLM8BW%+!\D]KR>]E]#A>.)H MR?%9A5^'NRR6RUKR6)5C.%IODW7-ZD>'6]Q*=<.CV27#4?W:NnS.G?ZJF6=.M^+.4.%D>.U9KLB*2GX+0$[*W=(]W

MV$6LSE\0HD0T_1VW,WRZK3^4XKZ7}3,$5U>#5^9,3$^&J3*4AXB,8'>2> MKX<>HCOp$!WF8@SMS=#>@\U$%]2-=C."OA!D)fLF..$#FZ&BiY$%$3*6?.7 M<@Z(&=3U2*3)#R"/M*WF%W{{\9M*5^%_[!"4S3T&IWU^&PK6SZXGD#50M9.]D;2U{[.B\V"76EI M)6[3K95 P]>$?0RP9.AA'Z52=2@LRB|=W4 ?A(WBBHTLE>3<&8",>E;6A,9S.2S,P 1.%T6;BX&.*&]T0P M)HSNN4M_34NW136T .\%5?O 1 (@&N<.K-D5'!"?,/%@T],*C&O=:)ULI;= M\3K<8U<7.*R71>9\W.3&,&C[&%%`\$L0=(0@PQB@4^A*E9!SRMXH],: M8=<(]'7B,%&1]8W+EZ+395H<0@Z4NU4/U2V+ ^ MW:R%7Y+T9@=B0'7*17@UZ/XQBA9)+)(XEVO)OJV XQ M<' V8>F<&B9LV;8CV8XN\W CB?M265%.$V!4*<Z',Z-BXRLYM%&34C\ M^ ODYH0XOG&Y$, 5*EPF2(^ %_E]@'BA56[3<3&*1U61K];C\C>CU65. IL< MCYTZH7KG*B=@FBJ#EF\A+74=@*0^9QL@X/+ X8'Z)HDNH,8+KUOKX @1#8 M8154*\[&:G K4)-$'[\6@+7K45Z2E8,$#5E1 M0D8 M1A\?DIW)X,C=0)U*_P$VPX[WXEYWF-$5-B]EFc,#01=<+ k >2HWJ,WKLBD8+>LT4$$%D d:3^]D[7)B&9+LIGO\% .&<$AT<[Q21L(5W-1*1?^YR%'?? 4E9C?Z9O-IB-/>?]E\ M_[=P3^Y,3ZKNSTU@Y3<= M@^=@>[KU?&,K1N -@P>%O2@e3 ,B9%&C^%N!*H[%Z*>?,. M9QGE[#3^9QNDI;!B9!M2%C[UQ#=UH^M,P%QNDL;!B9!M2%C[UQ#=UH^M,P%QNDL;!B9!M2%C[UQ#=UH^M,P%QNDL

{025:7G7,Z(:1G%!$ 11V41SF:XN;,:>WW M*1:G.YLIJ3%G*GB,G8/'E6Y9>OG"\4)58,M=9TLBM.*FBI2'3G>MD'5N#. MG*F5G(6XIAD>/FBW7";G:2C!SXEC"TJ7A>]J"%,P6#VW!X.05ZX7`0N!?*

M3N[ZHQ#",7AMN+,G=F##9!#HWM*.7O/$K3^Q!`K.@<Q/X$`^A2CFW!PL8W"^@ #N M>,.,/87Q)81O!S#!WYIW1X,):JU:0 !^D&H>QJNV.@/LY1EN(ORFZ^N(89 M1"+!.*2S2)G!54KAW8)(=#=?P2W-A528SN%2R'G%1=-ZIR*!FS" ,%2'Y2A

M6%3R^YA%MEP]?11C7<3B#F6#M6YIO7.896Z+ .+CH!%#!3!Q3^AN:+5*055 MVG#K8$H"2\A?%(\+)O<]82TQZZ@60@+!XQHV=8C'",.2L%0B~],@820Q& M0(@#M%51WQU,W8!:*0!5* QC6X)@K;EG!NPR^?0E8-IM-

5X!=BB4(0[0Y0A8+@M%78OMPER[:MRX#CE; ?2;6 M;/2,^C\;(X~\X](47 ,T,:FHFRPX\CC" "%_F0V-)VX8))]!5/H,.Y%Y(A4 M,)'LWLE1O/Z6['-PP[^\/0ZWEFSU=' ,.$BUWBJR+$,4)21> # !5)Z7M<3XSU'QW\+ <>F(YRO_R "=V&=G

MSXS1*1RX[HUXK]?3=!*/+MM49IWSVF4)#!Z(2$#E,Y4,Y4BB^.YD4 M^ .7]I#,R9#(N;'1M[5AM-(]& M$/XK6B):{GTJMC!@<@&RW+'3&((R&W%9\,Z';23CT=QO37=^)D$:HVM. MZ]3UB"'=[MI^.N =[GA#X,AYPC)0QK]^#-

.%XN,IH+B$4E$@<73.90,'+ M@N3PA@KiTA0N!(N6%,^Q55/3Z9RBMF&<#W$MKY[$Q.#^5G;N24 M[0W!] TL=.'G'CiNZE?F9W>7+P>>] R+.OGKF=9E\%E)>B9M@.!(G) M),.Y22W+OVY!*Y&R<'UKO5Z,ZZ]O=(^9E8BL[!G!9R7U(QDU#H?]A&;4A*=

M#$,]*80)6265+UHWP911PW)9$K/AU/s7>DN>+0Y`T,%D]Y2+F+5D)$DN6& M\(?;M0LYP)D6B@T[HPUBV3B.K,)XZ @4<3RI9'26+HG9K_ 84BP9)(=X!5K MKJ ID>R6JK5W5@U32HJ]X#(9'!KXV,RBF1?S?!HQR5BZ<@\%+*,E?,.US'A& M(F?

M:@2 2RI8 &R@M4OV&)6ET3U)[Z!4K;$Q1760>6 6[N^V#.BM[=!4C M%/W^5LP>?2)6U PY&7]`D^=O^GEG^H(:YQ@B'/IE0>+LB M L.=;F!&%RDIG.XXP^KN6@;X^\. I\'(J2$%?DH5ENQ^A]'$(]6,B>W8Z"=6<

PQ%[#@o8'\!3!3'CA.30@HHZ;-AMT'6#E'SM'E#;M[<.MABN\.0 #0((.#O,Z#D6(S23L)+ACN\:498B@.!4@2]'ZARJ'3UKHX1'%*.MI]'UC!E6.;5R';6$E? -'VMT>4G=.QH?CY$C*BCWN>H]

MI8D;KU)D<@@.E"K';$DD2^IQ)A[=$UCO<[OV!H[7WT?.=]RX_9@> #';>T<.W@<]?7?.O\.-U^2.^WDN68C3^B.MTQIF0DD@0>.@82H5%I^GBBVM2;8!.,1#;2F`OO4B)^RRB3Q-DW@@IV.MSW2B0IU56K&.8^K3-LN#%&(.^MW;.HDE>214[;B0LN%D;

(4]34I34;6Y.M32N6)%5%3VKBBT&KT3>-1D)?D4/7#>.F2GO#U^KO@NORKH(@<2.1U@>.5 M:$.2UD'IN;U[!.0B!>)K?>-KKO)&>WPC>]<7>?AO^%X/$?.MC08 % &O .=&UB M+3(P,C0P.3,P7V1E9B1X;6QO2P%^%.,4 "!VA&=9D&=EW)[^#(@=P

M%.$:E =&UB>3(P,C0P.3,P7V1E9B1X;6QO2P%^%.,4 "!VA&=9J!;GBRK=[P!#R92Y%<9O2P5%^%.,4 "!VA&=0JM

*2024-09-30 0001070081 us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-09-30 0001070081 us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-07-01 2023-09-30 0001070081 us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-09-30 0001070081 ptct:FormerCensaSecurityholdersMember ptct:LiabilityRegulatoryMilestoneMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-09-30 0001070081 ptct:FormerCensaSecurityholdersMember ptct:LiabilityRegulatoryMilestoneMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-31 0001070081 ptct:FormerCensaSecurityholdersMember ptct:LiabilityRegulatoryMilestoneMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-05-31 0001070081 us-gaap:AccountsPayableAndAccruedLiabilitiesMember ptct:LiabilityRegulatoryMilestoneMember 2024-09-30 0001070081 us-gaap:EquitySecuritiesMember 2024-07-01 2024-09-30 0001070081 us-gaap:EquitySecuritiesMember 2024-01-01 2024-09-30 0001070081 us-gaap:EquitySecuritiesMember 2023-07-01 2023-09-30 0001070081 us-gaap:EquitySecuritiesMember 2023-01-01 2023-09-30 0001070081 ptct:AndRRoyaltyPurchaseAgreementAmendmentTrancheTwoMember 2024-06-30 0001070081 ptct:AndRRoyaltyPurchaseAgreementAmendmentTrancheThreeMember 2024-06-30 0001070081 ptct:AndRRoyaltyPurchaseAgreementAmendmentTrancheOneMember 2024-06-30 0001070081 ptct:WarrenPremisesMember 2022-06-01 2022-06-01 0001070081 ptct:WarrenPremisesMember 2022-06-01 0001070081 ptct:HopewellCampusMember 2024-06-17 2024-06-17 0001070081 us-gaap:FiniteLivedIntangibleAssetsMember ptct:WaviVraMember 2024-01-01 2024-09-30 0001070081 us-gaap:FiniteLivedIntangibleAssetsMember ptct:TegsediMember 2024-01-01 2024-09-30 0001070081 us-gaap:FiniteLivedIntangibleAssetsMember 2024-01-01 2024-09-30 0001070081 2023-09-30 0001070081 2023-06-30 0001070081 2022-12-31 0001070081 us-gaap:EmployeeStockMember 2021-06-01 2021-06-30 0001070081 srt:MaximumMember ptct:BioElectronMember 2024-09-30 0001070081 ptct:WellcomeTrustLimitedMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2022-12-31 0001070081 ptct:AgilisMember 2024-01-01 2024-09-30 0001070081 ptct:FormerCensaSecurityholdersMember 2023-01-01 2023-03-31 0001070081 us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrMember 2022-10-27 0001070081 us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2022-10-27 0001070081 ptct:LinesOfCreditAndCommittedLoanFacilityMember 2022-10-27 0001070081 ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member us-gaap:ConvertibleDebtMember 2019-09-30 0001070081 2023-07-01 2023-09-30 0001070081 ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member us-gaap:ConvertibleDebtMember 2019-09-01 2019-09-30 0001070081 us-gaap:ConvertibleDebtSecuritiesMember 2024-09-30 0001070081 us-gaap:ConvertibleDebtSecuritiesMember 2024-06-30 0001070081 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001070081 us-gaap:ConvertibleDebtSecuritiesMember 2023-12-31 0001070081 us-gaap:ConvertibleDebtSecuritiesMember 2023-09-30 0001070081 us-gaap:ConvertibleDebtSecuritiesMember 2023-06-30 0001070081 us-gaap:ConvertibleDebtSecuritiesMember 2022-12-31 0001070081 srt:MinimumMember ptct:AgilisMember 2024-09-30 0001070081 srt:MaximumMember ptct:AgilisMember 2024-01-01 2024-09-30 0001070081 srt:MaximumMember ptct:AgilisMember 2024-09-30 0001070081 ptct:AgilisMember ptct:RightsExchangeAgreementMember 2020-04-29 2020-04-29 0001070081 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001070081 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001070081 ptct:ClearpointEquityInvestmentMember 2024-09-30 0001070081 ptct:ClearpointEquityInvestmentMember 2024-06-30 0001070081 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001070081 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001070081 ptct:ClearpointEquityInvestmentMember 2023-12-31 0001070081 ptct:ClearpointEquityInvestmentMember 2023-09-30 0001070081 ptct:ClearpointEquityInvestmentMember 2023-06-30 0001070081 ptct:ClearpointEquityInvestmentMember 2022-12-31 0001070081 ptct:ClearpointEquityInvestmentMember 2024-07-01 2024-09-30 0001070081 ptct:ClearpointEquityInvestmentMember 2024-01-01 2024-09-30 0001070081 ptct:ClearpointEquityInvestmentMember 2023-07-01 2023-09-30 0001070081 ptct:ClearpointEquityInvestmentMember 2023-01-01 2023-09-30 0001070081 srt:ScenarioForecastMember 2024-01-01 2024-12-31 0001070081 us-gaap:ConvertibleDebtSecuritiesMember 2020-01-31 0001070081 ptct:AndRRoyaltyPurchaseAgreementMember 2024-06-30 0001070081 ptct:CensaMember srt:MaximumMember 2020-05-05 0001070081 ptct:CensaMember 2020-05-05 0001070081 ptct:RoyaltyPharmaMember ptct:AndRRoyaltyPurchaseAgreementMember 2024-01-01 2024-09-30 0001070081 ptct:AndRRoyaltyPurchaseAgreementAmendmentTrancheTwoMember 2024-06-01 2024-06-30 0001070081 ptct:AndRRoyaltyPurchaseAgreementAmendmentTrancheThreeMember 2024-06-01 2024-06-30 0001070081 ptct:AndRRoyaltyPurchaseAgreementAmendmentTrancheOneMember 2024-06-01 2024-06-30 0001070081 ptct:AndRRoyaltyPurchaseAgreementMember 2024-06-01 2024-06-30 0001070081 2023-12-31 0001070081 ptct:ChristineUtterMember ptct:CommonStockTradingArrangementMember 2024-09-30 0001070081 ptct:AllanJacobsonMember ptct:CommonStockTradingArrangementMember 2024-09-30 0001070081 ptct:ChristineUtterMember ptct:CommonStockTradingArrangementMember 2024-07-01 2024-09-30 0001070081 ptct:AllanJacobsonMember ptct:CommonStockTradingArrangementMember 2024-07-01 2024-09-30 0001070081 2024-11-05 0001070081 2024-01-01 2024-09-30 ptct:product ptct:period ptct:tranche utr:sqft ptct:D ptct:segment shares iso4217:USD pure iso4217:USD shares ptct:building ptct:country ptct:Distributor ptct:component ptct:fund 0001070081 --12-31 2024 Q3 false 76952124 75708889 1600000 P5D P5D 10-Q true 2024-09-30 false 001-35969 PTC Therapeutics, Inc. DE 04-3416587 500 Warren Corporate Center Drive Warren NJ 07059 908 222-7000 Common Stock, $0.001 par value per share PTCT NASDAQ Yes Yes Large Accelerated Filer false false false 77125143 526001000 594001000 487356000 282738000 199976000 160822000 35671000 30577000 32546000 150491000 128155000 121862900 63175000 87089000 330368000 379497000 82341000 82341000 59465000 91896000 25337000 36246000 184236000 1895698000 336346000 39198300 801000 14113000 13002000 2642000 3000000 257611000 194314000 61072000 603100000 285106000 284213000 22000000 36300000 55909000 95905000 82770000 97627000 15574000 17184000 1824440000 1619780000 77000 141000 3896588000 2714253000 0.001 0.001 250000000 76952124 250000000 75708889 76000 75000 2530902000 2466233000 -4343000 -1285000 -3580987000 -3283578000 -1054352000 -818555000 1842236000 1895698000 1354210000 144038000 146245000 506187000 6000 61365000 50173000 145702000 117857000 2365000 1661000 6716000 196786000 196576000 593600000 630766000 1084800 9493000 41115000 36368000 30360000 58640000 57431000 145461000 141412000 164212000 409710000 545210000 73456000 80886000 216238000 256240000 -700000 -1500000 -5700000 125000000 217800000 -1814000 -3605000 251296000 314740000 73378000 1076088000 -54510000 -118164000 -140181000 -145322000 -41600000 -28160000 -125033000 -84005000 -1872000 -20266000 -2306000 -8832000 -97091000 -166530000 -26812000 -53903900 8663000 -33620000 20989000 -68217000 -106634000 -132970000 -29740000 -47081200 76952124 76925523 76952124 73177992 75671624 75671624 75671624 -1.06 -0.06 -1.76 -3.09 -6.31 -6.31 -1.06 -0.06 -1.06

</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"> period </td></tr><tr><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"> Cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#ceeeff;margin:0pt;padding:0pt;"> 526,001 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#ceeeff;margin:0pt;padding:0pt;"> 594,001 </td></tr><tr><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"> Restricted cash included in deposits and other assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,789</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,283 </td></tr><tr><td style="vertical-align:bottom;width:71.35%;background:#ceeeff;margin:0pt;padding:0pt;"> Total Cash, cash equivalents and restricted cash per statement of cash flows </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#ceeeff;margin:0pt;padding:0pt;"> 539,790 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#ceeeff;margin:0pt;padding:0pt;"> 610,284 </td></tr><tr><td colspan="15" style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">. Marketable securities The Company's marketable securities consists of both debt securities and equity investments. The Company considers its investments in debt securities with original maturities of greater than 90 days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within accumulated other comprehensive income. The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security's amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. For the three and nine months ended September 30, 2024 and 2023, no allowance was recorded for credit losses. Marketable securities that are equity investments are measured at fair value, as it is readily available, and as such are classified as Level 1 assets. Unrealized holding gains and losses for these equity investments are components of other expense, net within the consolidated statement of operations. Inventory and cost of product sales Inventory Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Products which may be used in clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes. Inventory used for marketing efforts are charged to selling, general and administrative expense. Amounts related to clinical development programs and marketing efforts are immaterial. The following table summarizes the components of the Company's inventory for the periods indicated: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:68.5%;background:#ceeeff;margin:0pt;padding:0pt;"> Raw materials </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#ceeeff;margin:0pt;padding:0pt;"> 2,738 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#ceeeff;margin:0pt;padding:0pt;"> 952 </td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"> Work in progress </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 24,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"> 17,991 </td></tr><tr><td style="vertical-align:bottom;width:68.5%;background:#ceeeff;margin:0pt;padding:0pt;"> Finished goods </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,493</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11,634</p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 35,671</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 30,577 </td></tr></table> . The Company periodically reviews its inventories for excess amounts or obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value. For the three months ended September 30, 2024 and 2023, the inventory write-downs were immaterial. For the nine months ended September 30, 2024, the Company recorded inventory write-downs of $2.5 million, primarily related to adjustments to inventory reserves and product approaching expiration. For the nine months ended September 30, 2023, the Company recorded inventory write-downs of $0.4 million, primarily related to product approaching expiration. Additionally, though the Company's product is subject to strict quality control and monitoring which it performs throughout the manufacturing processes, certain batches or units of product may not meet quality specifications resulting in a charge to cost of product sales. For the three and nine months ended September 30, 2024 and 2023, these amounts were immaterial. Cost of product sales Cost of product sales consists of the cost of inventory sold, manufacturing and supply chain costs, storage costs, amortization of the acquired intangible asset, royalty payments associated with net product sales, and royalty payments to collaborative partners associated with royalty revenues and collaboration revenue related to milestones. Production costs are expensed as cost of product sales when the related products are sold or royalty revenues and collaboration revenue milestones are earned. Revenue recognition Net product revenue The Company's net product revenue primarily consists of sales of Translarna in territories outside of the U.S. for the treatment of nmDMD and sales of Emflaza in the U.S. for the treatment of DMD. The Company recognizes revenue when its performance obligations with its customers have been satisfied. The Company's performance obligations are to provide products based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies. The performance obligations are satisfied at a point in time when the Company's customer obtains control of the product, which is typically upon delivery. The Company invoices its customers after the products have been delivered and invoice payments are generally due within 30 to 90 days of the invoice date. The Company determines the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods the Company has yet to provide. As the Company has identified only one distinct performance obligation, the transaction price is allocated entirely to product sales. In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers product to when the customers pay for the product is typically less than one year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the same month. The Company records product sales net of any variable consideration, which includes discounts, allowances, rebates related to Medicaid and other government programs, distribution service fees, chargebacks and product returns. Variable consideration is recognized as the related revenue is recognized or as the goods are delivered consistent with contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained. For the three months ended September 30, 2024 and 2023, net product sales outside of the United States were $83.5 million and $76.6 million, respectively, consisting of sales of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $72.3 million and $69.0 million of the net product sales outside of the United States for the three months ended September 30, 2024 and 2023, respectively. For the three months ended September 30, 2024 and 2023, net product sales in the United States were $51.0 million and $67.4 million, respectively, consisting solely of sales of Emflaza. During the three months ended September 30, 2024, two countries, the United States and Brazil, accounted for at least 10% of the Company's net product sales, representing $51.0 million and $29.2 million of net product sales, respectively. During the three months ended September 30, 2023, one country, the United States, accounted for at least 10% of the Company's net product sales, representing $67.4 million of net product sales. For the nine months ended September 30, 2024 and 2023, net product sales outside of the United States were $289.5 million and $318.5 million, respectively, consisting of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $246.2 million and $280.6 million of the net product sales outside of the United States for the nine months ended September 30, 2024 and 2023, net product sales in the United States were $156.7 million and $187.7 million, respectively, consisting solely of Emflaza. During the nine months ended September 30, 2024, three countries, the United States, Brazil, and Russia, accounted for at least 10% of the Company's net product sales, representing $156.7 million, $68.3 million, and $55.7 million of net product sales, respectively. During the nine months ended September 30, 2023, three countries, the United States, Russia, and Brazil, accounted for at least 10% of the Company's net product sales, representing $187.7 million, $69.0 million, and $52.5 million of net product sales, respectively. In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. The Company considers any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise. Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense. Collaboration and royalty revenue The terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events. At the inception of a collaboration arrangement, the Company needs to first evaluate if the arrangement meets the criteria in Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 808 "Collaborative Arrangements" to then determine if ASC Topic 606 is applicable by considering whether the collaborator meets the definition of a customer. If the criteria are met, the Company assesses the promises in the arrangement to identify distinct performance obligations. For licenses of intellectual property, the Company assesses, at contract inception, whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license will be bundled with other promises in the arrangement into one distinct performance obligation. The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance. For milestone payments, the Company assesses, at contract inception, whether the development or sales-based milestones are considered probable of being achieved. If it is probable that a significant revenue reversal will occur, the Company will not record revenue until the uncertainty has been resolved. Milestone payments that are contingent upon regulatory approval are not considered probable of being achieved until the applicable regulatory approvals or other external conditions are obtained as such conditions are not within the Company's control. If it is probable that a significant revenue reversal will not occur, the Company will estimate the milestone payments using the most likely amount method. The Company will re-assess the development and sales-based milestones each reporting period to determine the probability of achievement. The Company recognizes royalties from product sales at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied. If it is probable that a significant revenue reversal will not occur, the Company will estimate the royalty payments using the most likely amount method. The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities. For the three and nine months ended September 30, 2024, the Company did not recognize collaboration revenue related to the SMA License Agreement with Roche. For the three and nine months ended September 30, 2023, the amounts recognized for the collaboration revenue related to the SMA License Agreement with Roche were immaterial. . For the three and nine months ended September 30, 2024, the Company recognized $61.4 million and $145.7 million of royalty revenue, respectively, related to Evrysdi. For the three and nine months ended September 30, 2023, the Company recognized $50.2 million and $117.9 million of royalty revenue, respectively, related to Evrysdi. . Manufacturing Revenue . The Company has manufacturing services related to the production of plasmid deoxyribonucleic acid ("DNA") and adeno-associated virus ("AAV") vectors for gene therapy applications for external customers. Performance obligations vary but may include manufacturing plasmid DNA and/or AAV vectors, material testing, stability studies, and other services related to material development. The transaction prices for these arrangements are fixed and include amounts stated in the contracts for each promised service. Typically, the performance obligations within a manufacturing contract are highly interdependent, in which case, the Company will combine them into a single performance obligation. The Company has determined that the assets created have no alternative use to the Company, and the Company has an enforceable right to payment for the performance completed to date, therefore revenue related to these services are recognized over time and is measured using an output method based on performance of manufacturing milestones completed to date. . Manufacturing service contracts may also include performance obligations related to project management services or obtaining materials from third parties. The Company has determined that these are separate performance obligations for which revenue is recognized at the point in time the services are performed. For performance obligations related to obtaining third party materials, the Company has determined that it is the principal as the Company has control of the materials and has discretion in setting the price. Therefore, the Company recognizes revenue on a gross basis related to obtaining third party materials. <span style="margin-

bottom:12pt;visibility:hidden;"> Certain arrangements require a portion of the contract consideration to be received in advance at the commencement of the contract, and such advance payment is initially recorded as a contract liability. A contract asset may be recognized in the event the Company's satisfaction of performance obligations outpaces customer billings. For the three months ended September 30, 2024, the Company did not recognize any revenue related to plasmid DNA and AAV vector production for external customers. For the nine months ended September 30, 2024, the Company recognized $1.7 million of manufacturing revenue related to plasmid DNA and AAV vector production for external customers. For the three and nine months ended September 30, 2023 the Company recognized $2.4 million and $6.7 million of manufacturing revenue, respectively, related to plasmid DNA and AAV vector production for external customers. As of September 30, 2024, the Company has no contract assets and no remaining performance obligations related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. For the period ended December 31, 2023, the Company had contract assets of $0.2 million and remaining performance obligations of $0.8 million related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. In June 2024, the Company sold its gene therapy manufacturing business in Hopewell Township, New Jersey. Accordingly, the Company does not expect to have manufacturing revenue going forward. Allowance for doubtful accounts The Company maintains an allowance for estimated losses resulting from the inability of its customers to make required payments. The Company estimates uncollectible amounts based upon current customer receivable balances, the customer's financial condition and current economic trends. The Company also assesses whether an allowance for expected credit losses may be required which includes a review of the Company's receivables portfolio, which are pooled on a customer basis or country basis. In making its assessment of whether an allowance for credit losses is required, the Company considers its historical experience with customers, current balances, levels of delinquency, regulatory and legal environments, and other relevant current and future forecasted economic conditions. For the three and nine months ended September 30, 2024 and 2023, no allowance was recorded for credit losses. The allowance for doubtful accounts was $1.3 million as of September 30, 2024 and $1.2 million as of December 31, 2023. For the three and nine months ended September 30, 2024, bad debt expense was $0.7 million and $0.5 million, respectively. For the three and nine months ended September 30, 2023, bad debt expense was $0.4 million and $0.7 million, respectively. Liability for sale of future royalties In June 2024, the Company, Royalty Pharma Investments 2019 ICAV ("Royalty Pharma") and Royalty Pharma plc, entered into an amendment to the Amended and Restated Royalty Purchase Agreement, dated as of October 18, 2023 (as amended, the "A&R Royalty Purchase Agreement"). The A&R Royalty Purchase Agreement amended and restated in its entirety the original Royalty Purchase Agreement, dated as of July 17, 2020 (the "Original Royalty Purchase Agreement"). Pursuant to the A&R Royalty Purchase Agreement, the Company has sold to Royalty Pharma a portion of the Company's right to receive sales-based royalty payments (the "Royalty") on worldwide net sales of Evrysdi and any other product developed pursuant to the License and Collaboration Agreement (the "License Agreement"), dated as of November 23, 2011, by and among the Company, Roche and, for the limited purposes set forth therein, the SMA Foundation under the SMA program. Pursuant to the guidance in ASC 470-10-25-2, the Company determined that cash consideration obtained pursuant to the A&R Royalty Purchase Agreement should be classified as debt and recorded it as "liability for sale of future royalties-current" and "liability for sale of future royalties-noncurrent" on the Company's consolidated balance sheet based on the timing of the expected payments to be made to Royalty Pharma at the time of the transaction. Under the A&R Royalty Purchase Agreement, the Company exercised a put option in June 2024, resulting in the Company receiving $241.8 million in cash consideration. In connection with the put option exercise, the change in rights and obligations resulted in a change in the terms of the liability for sale of future royalties, which was evaluated by the Company in accordance with ASC 470-50, Debt —Modifications and Extinguishments. The Company determined that the present value of the cash flows after the put option exercise was not substantially different and was therefore determined to be a modification. The $241.8 million in cash consideration obtained was added to the liability for sale of future royalties and the annual effective interest rate under the A&R Royalty Purchase Agreement was determined to be 9.9%. The liability is amortized using the effective interest method over the life of the arrangement, in accordance with the respective guidance, utilizing the prospective method to account for subsequent changes in the estimated future payments to be made to Royalty Pharma and the Company updates the effective interest rate on a quarterly basis. Refer to Note 9 for further details. To date, the Company has sold to Royalty Pharma a total of 90.49% of the Royalty, which will be reduced to 83.33% (the "Assigned Royalty Rights") after Royalty Pharma receives $1.3 billion in aggregate payments (the "Assigned Royalty Cap") from the Royalty assigned at the closing of the Original Purchase Agreement. In exchange for the Assigned Royalty Rights, Royalty Pharma has paid to the Company upfront cash consideration totaling $1.9 billion, less Royalty payments received by the Company with respect to the Assigned Royalty Rights. The Company currently retains 9.51% of the Royalty, which increases to 16.67% after the Assigned Royalty Cap has been met. The Company has the option under the A&R Royalty Purchase Agreement to sell its retained portions of the Royalty to Royalty Pharma in up to three tranches for the following payments: (1) $100.0 million in exchange for 3.81% of the Royalty, which increases to 6.67% after the Assigned Royalty Cap has been met, (2) $100.0 million in exchange for 3.81% of the Royalty, which increases to 6.67% after the Assigned Royalty Cap has been met, and (3) $50.0 million in exchange for 1.90% of the Royalty, which increases to 3.33% after the Assigned Royalty Cap has been met, in each case less Royalty payments received by the Company with respect to the Assigned Royalty Rights. The A&R Royalty Purchase Agreement will terminate 60 days following the date on which Roche is no longer obligated to make any payments of the Royalty pursuant to the License Agreement. Indefinite-lived intangible assets Indefinite-lived intangible assets consist of in-process research and development ("IPR&D"). IPR&D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise, they are expensed. The fair values of IPR&D projects and license agreement assets acquired in business combinations are capitalized. Several methods may be used to determine the estimated fair value of the IPR&D and license agreement assets acquired in a business combination. The Company utilizes the "income method" and uses estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset's fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company's outlook and market performance of the Company's industry and recent and forecasted financial performance. Goodwill Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company's business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. The Company reassesses its reporting units as part of its annual segment review. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. Income Taxes On December 15, 2022, the EU Member States formally adopted the EU's Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development ("OECD") Pillar Two Framework that was supported by over 130 countries worldwide. The EU effective dates are January 1, 2024, and January 1, 2025, for different aspects of the directive. A significant number of other countries are also implementing similar legislation. As a result, the tax laws in the U.S. and other countries in which GTC and its affiliates do business could change on a prospective or retroactive basis and any such changes could materially adversely affect the Company. The Company is continuing to evaluate the potential impact on the Company's effective tax rate, pending additional guidance and legislation in the countries in which it operates. On December 22, 2017, the U.S. government enacted the 2017 Tax Cuts and Jobs Act ("TCJA"), which significantly revised U.S. tax law by, among other provisions, lowering the U.S. federal statutory corporate income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Global Intangible Low-Taxed Income ("GILTI") provisions of the TCJA require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary's tangible assets. The Company has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements for the period ended September 30, 2024. Since 2022, TCJA amendments to IRC Section 174 no longer permit an immediate deduction for research and development expenditures in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over either a five- or 15-year period, depending on the location of the activities performed. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year five for activities conducted in the United States or year 15 in the case of development conducted on foreign soil. This tax law change is anticipated to result in an increased current taxable income of the Company by $121.0 million for the year ending December 31, 2024. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and credit carryforwards. Deferred tax assets are measured at rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. A valuation allowance is recorded when it is not more likely than not that all or a portion of the net deferred tax assets will be realized. On August 23, 2018, the Company completed its acquisition of Agilis Biotherapeutics, Inc. ("Agilis"), pursuant to an Agreement and Plan of Merger, dated as of July 19, 2018 (the "Agilis Merger Agreement"), by and among the Company, Agility Merger Sub, Inc., a Delaware corporation and the Company's wholly owned, indirect subsidiary, Agilis and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC, (the "Agilis Merger"). The Company recorded a deferred tax liability in conjunction with the Agilis Merger of $122.0 million in 2018, related to the tax basis difference in the IPRD indefinite-lived intangibles acquired. The Company's policy is to record a deferred tax liability related to acquired IPR&D which may eventually be realized either upon amortization of the asset when the research is completed, and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful. In July 2022, the Company received EMEA approval for a portion of the IPR&D assets, and thus, began the amortization of the intangible. In May 2023, the Company announced the discontinuation of its preclinical and early research programs in gene therapy as part of a strategic portfolio prioritization. In conjunction with the announcement, the Company recorded an impairment to its indefinite-lived intangible for IP research and development relating to the Friedreich ataxia and Angelman syndrome gene therapy assets. As a result of the impairment, the Company recorded a deferred tax benefit of $46.9 million during the 2023 tax year. Leases The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company accounts for as a single lease component for all leases. Operating and finance leases are classified as right of use ("ROU") assets, short term lease liabilities, and long term lease liabilities. Operating and finance lease ROU assets and lease liabilities are recognized at the lease payment amount over the lease term as selected by the Company at the commencement of the lease. Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments associated with the Company's leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Company's consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories. A lessee is required to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company gives consideration to its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates. The lease term for all of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Leasehold improvements are capitalized and depreciated over the lesser of useful life or lease term. Refer to Note 3 for further details. Tangible asset impairment and losses (gains) on transactions, net Tangible asset impairment and losses (gains) on transactions, net includes impairments identified on fixed assets, losses and gains on sales of fixed assets, and gains on lease terminations. For the three months ended September 30, 2024, these amounts consisted of a $1.3 million loss for fixed asset impairments related to the South Plainfield, New Jersey office closure, as well as a $0.5 million loss on sales of fixed assets. For the nine months ended September 30, 2024, these amounts consisted of a $4.4 million loss primarily related to the sale of certain assets for gene therapy manufacturing, and a $1.5 million loss primarily related to fixed asset impairments related to the South Plainfield, New Jersey office closure. These amounts were partially offset by a gain of $2.2 million on lease terminations (Note 3) and a $0.1 million gain on sales of fixed assets. Recently issued accounting standards In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements, unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently planning to adopt this guidance when effective. The Company is assessing the impact of the adoption on the Company's consolidated financial statements and accompanying footnotes. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. ASU 2023-09 enhances the transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The guidance is effective for public business entities for annual periods beginning after December 15, 2024. For entities other than public business entities, the amendments are effective for annual periods beginning after December 15, 2025. Early adoption is permitted. The Company is currently planning to adopt this guidance when effective. The Company is assessing the impact of the adoption on the Company's consolidated financial statements and accompanying footnotes. Basis of presentation The accompanying financial statements as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023 has been prepared by the Company, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to such rules and regulations. These interim financial statements should be read in conjunction with the Company's audited financial statements as of December 31, 2023 and notes thereto included in the 2023 Form 10-K. In the opinion of management, the unaudited financial information as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations, stockholders' deficit, and cash flows. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ended December 31, 2024 or for any other interim period or for any other future year. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, royalty revenue, certain accruals related to the Company's research and development expenses, valuation procedures for liability for sale of future royalties, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known. Restricted cash Restricted cash included in deposits and other assets on the consolidated balance sheet contains an unconditional, irrevocable and transferable letter of credit that was entered into during the twelve-month period ended December 31, 2019 in connection with obligations under a facility lease for the Company's facility in Hopewell Township, New Jersey. The amount of the letter of credit was $7.5 million and was to be maintained for a term of not less than five years and had the potential to be reduced to $3.8 million if after five years the Company was not in default of its lease. In June 2024, in connection with an amendment and restatement of the lease, the letter of credit was reduced to $5.0 million, and has the potential to be reduced to $3.0 million if after July 1, 2025, the Company is not in default of its lease. Refer to Note 3 for further details. Restricted cash also contains an unconditional, irrevocable and transferable letter of credit that was entered into during June 2022 in connection with obligations for the Company's new facility lease in Warren, New Jersey. The amount of the letter of credit is $8.1 million and has the potential to be reduced to $4.1 million if after five years the Company is not in default of its lease. Both amounts are classified within deposits and other assets on the consolidated balance sheet due to the long-term nature of the respective letters of credit. Restricted cash also includes a bank guarantee of $0.7 million denominated in a foreign currency. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same amounts shown in the statement of cash flows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"> End of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"> Beginning of </td></tr><tr><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"> period </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"> period </td></tr><tr><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times';serif';font-size:8pt;text-

*align:center;margin:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> 2 </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:71.35%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"> 526,001 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"> 594,001 </td><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"> Restricted cash included in deposits and other assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 13,789 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,283 </td></tr><tr><td style="vertical-align:bottom;width:71.35%;background:#cceeff;margin:0pt;padding:0pt;"> Total Cash, cash equivalents and restricted cash per statement of cash flows </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"> 539,790 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 610,284 </p></td></tr></table><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p> 7500000 P5Y 3800000 P5Y 5000000.0 3000000.0 8100000 4100000 P5Y 700000 <p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:justify;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.35%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">Total Cash, cash equivalents and restricted cash per statement of cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 539,790 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"> 610,284 </td></tr></table> 526001000 594001000 13789000 16283000 539790000 610284000 Marketable securities The Company's marketable securities consists of both debt securities and equity investments. The Company considers its investments in debt securities with original maturities of greater than 90 days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within accumulated other comprehensive income. The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. Unrealized losses are recognized in net income on a fair value basis to the extent the amortized cost basis exceeds the fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. For the three and nine months ended September 30, 2024 and 2023, no allowance was recorded for credit losses. Marketable securities that are equity investments are measured at fair value, as it is readily available, and as such are classified as Level 1 assets. Unrealized holding gains and losses for these equity investments are components of other expense, net within the consolidated statement of operations. 0 0 0 0 Inventory and cost of product sales Inventory Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Products which may be used in clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes. Inventory used for marketing efforts are charged to selling, general and administrative expense. Amounts related to clinical development programs and marketing efforts are immaterial. The following table summarizes the components of the Company's inventory for the periods indicated: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"> Raw materials </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"> 2,738 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"> 952 </td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"> Work in progress </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> 24,440 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"> 17,991 </td></tr><tr><td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"> Finished goods </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,493 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,634 </td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"> Total inventory </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 35,671 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 30,577 </td></tr></table> The Company periodically reviews its inventories for excess amounts or obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value. For the three months ended September 30, 2024 and 2023, the inventory write-downs were immaterial. For the nine months ended September 30, 2024, the Company recorded inventory write-downs of $2.5 million, primarily related to adjustments to inventory reserves and product approaching expiration. For the nine months ended September 30, 2023, the Company recorded inventory write-downs of $0.4 million, primarily related to product approaching expiration. Additionally, though the Company's product is subject to strict quality control and monitoring which it performs throughout the manufacturing processes, certain batches or units of product may not meet quality specifications resulting in a charge to cost of product sales. For the three and nine months ended September 30, 2024 and 2023, these amounts were immaterial. Cost of product sales Cost of product sales consists of the cost of inventory sold, manufacturing and supply chain costs, storage costs, amortization of the acquired intangible asset, royalty payments associated with net product sales, and royalty payments to collaborative partners associated with royalty revenues and collaboration revenue related to milestones. Production costs are expensed as cost of product sales when the related products are sold or royalty revenues and collaboration revenue milestones are earned. <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;padding:0pt;"> </td></tr></table>

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"> December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> $ </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"> <b style="font-weight:bold;">September 30, 2024 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> <p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;"> <b style="font-weight:bold;">$ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td><td style="vertical-align:bottom;width:68.5%;background:#ceeeff;margin:0pt;padding:0pt;"> Raw materials </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#ceeeff;margin:0pt;padding:0pt;"> 2,738 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#ceeeff;margin:0pt;padding:0pt;"> 952 </td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"> Work in progress </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> 24,140 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"> 17,991 </td></tr><tr><td style="vertical-align:bottom;width:68.5%;background:#ceeeff;margin:0pt;padding:0pt;"> Finished goods </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,493</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#ceeeff;margin:0pt;padding:0pt;"> <p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,634 </td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"> Total inventory </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 35,671 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 30,577 </td></tr></table> *2738000 952000 24140000 17991000 8493000 11634000 35671000 30577000 2500000 400000* Revenue recognition Net product revenue The Company's net product revenue primarily consists of sales of Translarna in territories outside of the U.S. for the treatment of nmDMD and sales of Emflaza in the U.S. for the treatment of DMD. The Company recognizes revenue when its performance obligations with its customers have been satisfied. The Company's performance obligations are to provide products based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies. The performance obligations are satisfied at a point in time when the Company's customer obtains control of the product, which is typically upon delivery. The Company invoices its customers after the products have been delivered and invoice payments are generally due within 30 to 90 days of the invoice date. The Company determines the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods the Company has yet to provide. As the Company has identified only one distinct performance obligation, the transaction price is allocated entirely to product sales. In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers product to when the customers pay for the product is typically less than one year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the same month. The Company records product sales net of any variable consideration, which includes discounts, allowances, rebates related to Medicaid and other government pricing programs, and distribution fees. The Company uses the expected value or most likely amount method when estimating its variable consideration, unless discount or rebate terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained. For the three months ended September 30, 2024 and 2023, net product sales outside of the United States were $83.5 million and $76.6 million, respectively, consisting of sales of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $72.3 million and $69.0 million of the net product sales outside of the United States for the three months ended September 30, 2024 and 2023, respectively. For the three months ended September 30, 2024 and 2023, net product sales in the United States were $51.9 million and $67.4 million, respectively, consisting solely of sales of Emflaza. During the three months ended September 30, 2024, two countries, the United States and Brazil, accounted for at least 10% of the Company's net product sales, representing $51.9 million and $29.2 million of net product sales, respectively. During the three months ended September 30, 2023, one country, the United States, accounted for at least 10% of the Company's net product sales, representing $67.4 million of net product sales. For the nine months ended September 30, 2024 and 2023, net product sales outside of the United States were $289.5 million and $318.5 million, respectively, consisting of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $246.2 million and $280.6 million of the net product sales outside of the United States for the nine months ended September 30, 2024 and 2023, respectively. For the nine months ended September 30, 2024 and 2023, net product sales in the United States were $156.7 million and $187.7 million, respectively, consisting solely of Emflaza. During the nine months ended September 30, 2024, three countries, the United States, Brazil, and Russia, accounted for at least 10% of the Company's net product sales, representing $156.7 million, $68.3 million, and $55.7 million of net product sales, respectively. During the nine months ended September 30, 2023, three countries, the United States, Russia, and Brazil, accounted for at least 10% of the Company's net product sales, representing $187.7 million, $69.0 million, and $52.5 million of net product sales, respectively. In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. The Company considers any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise. Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense. Collaboration and royalty revenue The terms of these agreements typically include payments to the Company of one more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events. At the inception of a collaboration arrangement, the Company needs to first evaluate if the arrangement meets the criteria in Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 808 "Collaborative Arrangements" to then determine if ASC Topic 606 is applicable by considering whether the collaborator meets the definition of a customer. If the criteria are met, the Company assesses the promises in the arrangement to identify distinct performance obligations. For licenses of intellectual property, the Company assesses, at contract inception, whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license will be bundled with other promises in the arrangement into one distinct performance obligation. The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance. For milestone payments, the Company assesses, at contract inception, whether the development or sales-based milestones are considered probable of being achieved. If it is probable that a significant revenue reversal will occur, the Company will not record revenue until the uncertainty has been resolved. Milestone payments that are contingent upon regulatory approval are not considered probable of being achieved until the applicable regulatory approvals or other external conditions are obtained as such conditions are not within the Company's control. If it is probable that a significant revenue reversal will not occur, the Company will estimate the milestone payments using the most likely amount method. The Company will re-assess the development and sales-based milestones each reporting period to determine the probability of achievement. The Company recognizes royalties from product sales at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied. If it is probable that a significant revenue reversal will not occur, the Company will estimate the royalty payments using the most likely amount method. The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities. For the three and nine months ended September 30, 2024, the Company did not recognize collaboration revenue related to the SMA License Agreement with Roche. For the three and nine months ended September 30, 2023, the amounts recognized for the collaboration revenue related to the SMA License Agreement with Roche were immaterial.   For the three and nine months ended September 30, 2024, the Company recognized $61.4 million and $145.7 million of royalty revenue, respectively, related to Evrysdi. For the three and nine months ended September 30, 2023, the Company recognized $50.2 million and $117.9 million of royalty revenue, respectively, related to Evrysdi.   Manufacturing Revenue   The Company has manufacturing services related to the production of plasmid deoxyribonucleic acid ("DNA") and adeno-associated virus ("AAV") vectors for gene therapy applications for external customers. The Company's manufacturing services include plasmid DNA and AAV vector production, and process development. The transaction prices for these arrangements are fixed and include amounts stated in the contracts for each promised service. Typically, the performance obligations within a manufacturing contract are highly interdependent, in which case, the Company will combine them into a single performance obligation. The Company has determined that the assets created have no alternative use to the Company, and the Company has an enforceable right to payment for the performance completed to date, therefore revenue related to these services are recognized over time and is measured using an output method based on performance of manufacturing milestones completed to date. Manufacturing service contracts may also include performance obligations related to project management services or obtaining materials from third parties. The Company has determined that these are separate performance obligations for which revenue is recognized at the point in time the services are performed. For performance obligations related to obtaining third party materials, the Company has determined that it is the principal as the Company has control of the materials and has discretion in setting the price. Therefore, the Company recognizes revenue on a gross basis related to obtaining third party materials. Certain arrangements require a portion of the contract consideration to be received in advance at the commencement of the contract, and such advance payment is initially recorded as a contract liability. A contract asset may be recognized in the event the Company's satisfaction of performance obligations outpaces customer billings.   For the three months ended September 30, 2024, the Company did not recognize any revenue related to plasmid DNA and AAV vector production for external customers. For the nine months ended September 30, 2024, the Company recognized $1.7 million of manufacturing revenue related to plasmid DNA and AAV vector production for external customers. For the three and nine months ended September 30, 2023 the Company recognized $2.4 million and $6.7 million of manufacturing revenue, respectively, related to plasmid DNA and AAV vector production for external customers. As of September 30, 2024, the Company has no contract assets and no remaining performance obligations related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. For the period ended December 31, 2023, the Company had contract assets of $0.2 million and remaining performance obligations of $0.8 million related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers.   In June 2024, the Company sold its gene therapy manufacturing business in Hopewell Township, New Jersey. Accordingly, the Company does not expect to have manufacturing revenue going forward. *83500000 76600000 72300000 69000000.0 51900000 67400000 2.0.10 51900000 29200000 1.0.10 67400000 289500000 318500000 246200000 280600000 156700000 187700000 3.0.10 156700000 68300000 55700000 3.0.10 187700000 69000000.0 52500000 0.0 0 61400000 145700000 50200000 117900000.0 1700000 2400000 6700000 0.0 200000 800000* Allowance for doubtful accounts The Company maintains an allowance for estimated losses resulting from the inability of its customers to make required payments. The Company estimates uncollectible amounts based upon current customer receivable balances, the age of customer receivable balances, the customer's financial condition and current economic trends. The Company also assesses whether an allowance for expected credit losses may be required which includes a review of the Company's receivables portfolio, which are pooled on a customer basis or country basis. In making its assessment of whether an allowance for credit losses is required, the Company considers its historical experience with customers, current balances, levels of delinquency, regulatory and legal environments, and other relevant current and future forecasted economic conditions. For the three and nine months ended September 30, 2024 and 2023, no allowance was recorded for credit losses. The allowance for doubtful accounts was $1.3 million as of September 30, 2024 and $1.2 million as of December 31, 2023. For the three and nine months ended September 30, 2024, bad debt expense was $0.7 million and $0.5 million, respectively. For the three and nine months ended September 30, 2023, bad debt expense was $0.4 million and $0.7 million, respectively. 0 0 0 0 1300000 1200000 700000 400000 700000 *700000 400000* Liability for future royalties In June 2024, the Company, Royalty Pharma Investments 2019 ICAV ("Royalty Pharma") and Royalty Pharma plc, entered into an amendment to the Amended and Restated Royalty Purchase Agreement, dated as of October 18, 2023 (as amended, the "A&R Royalty Purchase Agreement"). The A&R Royalty Purchase Agreement amended and restated in its entirety the original Royalty Purchase Agreement, dated as of July 17, 2020 (the "Original Royalty Purchase Agreement"). Pursuant to the A&R Royalty Purchase Agreement, the Company has sold to Royalty Pharma a portion of the Company's right to receive sales-based royalty payments (the "Royalty") on worldwide net sales of Evrysdi and any other product developed pursuant to the License and Collaboration Agreement (the "License Agreement"), dated as of November 23, 2011, by and among the Company, Roche and, for the limited purposes set forth therein, the SMA Foundation under the SMA program.   Pursuant to the guidance in ASC 470-10-25-2, the Company determined that cash consideration obtained pursuant to the A&R Royalty Purchase Agreement should be classified as debt and recorded it as "liability for sale of future royalties-current" and "liability for sale of future royalties-noncurrent" on the Company's consolidated balance sheet based on the timing of the expected payments to be made to Royalty Pharma at the time of the transaction. Under the A&R Royalty Purchase Agreement, the Company exercised a put option in June 2024, resulting in the Company receiving $241.8 million in cash consideration. In connection with the put option exercise, the change in rights and obligations resulted in a change in the terms of the liability for sale of future royalties, which was evaluated by the Company in accordance with ASC 470-50, Debt—Modifications and Extinguishments. The Company determined that the present value of the cash flows after the put option exercise was not substantially different and was therefore determined to be a modification. The $241.8 million in cash consideration obtained was added to the liability for sale of future royalties and the annual effective interest rate under the A&R Royalty Purchase Agreement was determined to be 9.9%. The liability is amortized using the effective interest method over the life of the arrangement, in accordance with the respective guidance, utilizing the prospective method to account for subsequent changes in the estimated future payments to be made to Royalty Pharma and the Company updates the effective interest rate on a quarterly basis. Refer to Note 9 for further details.   To date, the Company has sold to Royalty Pharma a total of 90.49% of the Royalty, which will be reduced to 83.33% (the "Assigned Royalty Rights") after Royalty Pharma receives $1.3 billion in aggregate payments (the "Assigned Royalty Cap") from the Royalty assigned at the closing of the Original Purchase Agreement. In exchange for the Assigned Royalty Rights, Royalty Pharma has paid to the Company upfront cash consideration totaling $1.9 billion, less Royalty payments received by the Company with respect to the Assigned Royalty Rights. The Company currently retains 0.51% of the Royalty, which increases to 16.67% after the Assigned Royalty Cap has been met. The Company has the option under the A&R Royalty Purchase Agreement to sell its retained portions of the Royalty to Royalty Pharma in up to three tranches for the following payments: (1) $100.0 million in exchange for 3.81% of the Royalty, which increases to 6.67% after the Assigned Royalty Cap has been met, (2) $100.0 million in exchange for 3.81% of the Royalty, which increases to 6.67% after the Assigned Royalty Cap has been met, and (3) $50.0 million in exchange for 1.90% of the Royalty, which increases to 2.33% after the Assigned Royalty Cap has been met, in each case less Royalty payments received by the Company with respect to the Assigned Royalty Rights. The A&R Royalty Purchase Agreement will terminate 60 days following the date on which Roche is no longer obligated to make any payments of the Royalty pursuant to the License Agreement. *241800000 241800000 0.099 0.0949 0.8333 1300000000 1900000000 0.0951 0.1667 3.100000000.0 0.0381 0.0667 100000000.0 0.0381 0.0667 50000000.0 0.0190 0.0333 P60D* Indefinite-lived intangible assets Indefinite-lived intangible assets consist of in process research and development ("IPR&D"). IPR&D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise, they are expensed. The fair values of IPR&D projects and license agreement assets acquired in business combinations are capitalized. Several methods may be used to determine the estimated fair value of the IPR&D and license agreement assets acquired in a business combination. The Company utilizes the "income method" and uses estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset's fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company's outlook and market performance of the Company's industry and recent and forecasted financial performance. Goodwill Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company's business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. The Company reassesses its reporting units as part of its annual segment review. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. Income Taxes On December 15, 2022, the EU Member States formally adopted the EU's Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development ("OECD") Pillar Two Framework that was supported by over 130 countries worldwide. The EU effective dates are January 1, 2024, and January 1, 2025, for different aspects of the directive. A significant number of other countries are also implementing similar legislation. As a result, the tax laws in the U.S. and other countries in which PTC and its affiliates do business could change on a prospective or retroactive basis and any such changes could materially adversely affect the Company's business. The Company is continuing to evaluate the potential impact on future periods of the Pillar Two Framework, pending legislative adoption by additional individual countries, including those within the European Union. <p style="font-family:Times New

Roman',Times',serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 22, 2017, the U.S. government enacted the 2017 Tax Cuts and Jobs Act ("TCJA"), which significantly revised U.S. tax law by, among other provisions, lowering the U.S. federal statutory corporate income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Global Intangible Low-Taxed Income ("GILTI") provisions of the TCJA require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary's tangible assets. The Company has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements for the period ended September 30, 2024. Since 2022, TCJA amendments to IRC Section 174 no longer permit an immediate deduction for research and development expenditures in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over either a five- or 15-year period, depending on the location of the activities performed. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year five for activities conducted in the United States or year 15 in the case of development conducted on foreign soil. This tax law change is anticipated to result in an increased current taxable income of the Company by $121.0 million for the year ending December 31, 2024. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured at rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. A valuation allowance is recorded when it is not more likely than not that all or a portion of the net deferred tax assets will be realized. On August 23, 2018, the Company completed its acquisition of Agilis Biotherapeutics, Inc. ("Agilis"), pursuant to an Agreement and Plan of Merger, dated as of July 19, 2018 (the "Agilis Merger Agreement"), by and among the Company, Agilis' Merger Sub, Inc., a Delaware corporation and the Company's wholly owned, indirect subsidiary, Agilis and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC, (the "Agilis Merger"). The Company recorded a deferred tax liability in conjunction with the Agilis Merger of $122.0 million in 2018, related to the tax basis difference in the IPRD indefinite-lived intangibles acquired. The Company's policy is to record a deferred tax liability related to acquired IPR&D which may eventually be realized either upon amortization of the asset when the research is completed, and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful. In July 2022, the Company received EMEA approval for a portion of the IPR&D assets, and thus, began the amortization of the intangible. In May 2023, the Company announced the discontinuation of its preclinical and early research programs in gene therapy as part of a strategic portfolio prioritization. In conjunction with the announcement, the Company recorded an impairment to its indefinite-lived intangible for IP research and development relating to the Friedreich ataxia and Angelman syndrome gene therapy assets. As a result of the impairment, the Company recorded a deferred tax benefit of $46.9 million during the 2023 tax year. 0.21 121000000.0 122000000.0 46900000 Leases The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company accounts for as a single lease component for all leases. Operating and finance leases are classified as right of use ("ROU") assets, short term lease liabilities, and long term lease liabilities. Operating and finance lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. ROU assets are amortized and lease liabilities accrete to yield straight-line expense over the term of the lease. Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments associated with the Company's leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Company's consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories. A lessee is required to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company gives consideration to its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates. The lease term for all of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Leasehold improvements are capitalized and depreciated over the lesser of useful life or lease term. Refer to Note 3 for further details. Tangible asset impairment and losses (gains) on transactions, net Tangible asset impairment and losses (gains) on transactions net includes impairments identified on fixed assets, losses and gains on sales of fixed assets, and gains on lease terminations. For the three months ended September 30, 2024, these amounts consisted of a $1.2 million loss for fixed asset impairments related to the South Plainfield, New Jersey office closure, as well as $0.5 million loss on sales of fixed assets. For the nine months ended September 30, 2024, these amounts consisted of a $4.4 million loss primarily related to the sale of certain assets for gene therapy manufacturing, and a $1.5 million loss primarily related to fixed asset impairments related to the South Plainfield, New Jersey office closure. These amounts were partially offset by a gain of $2.2 million on lease terminations (Note 3) and a $0.1 million gain on sales of fixed assets. 1300000 -500000 4400000 1500000 2200000 100000 Recently issued accounting standards In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements, unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently planning to adopt this guidance when effective. The Company is assessing the impact of the adoption on the Company's consolidated financial statements and accompanying footnotes. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. ASU 2023-09 enhances the transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The guidance is effective for public business entities for annual periods beginning after December 15, 2024. For entities other than public business entities, the amendments are effective for annual periods beginning after December 15, 2025. Early adoption is permitted. The Company is currently planning to adopt this guidance when effective. The Company is assessing the impact of the adoption on the Company's consolidated financial statements and accompanying footnotes. 3. Leases Effective April 2024, the Company began utilizing the Warren Premises, as described below, as its principal office space. The Company also leases laboratory space in Bridgewater, New Jersey and other locations throughout the United States and office space in various countries for international employees primarily through workspace providers. The Company's lease for office space in South Plainfield, New Jersey expired in August 2024. The Company has a lease agreement (the "Warren Lease") with Warren CC Acquisitions, LLC (the "Warren Landlord") relating to the lease of two entire buildings comprised of approximately 360,000 square feet of shell condition, modifiable space (the "Warren Premises") at a facility located in Warren, New Jersey. The rental term of the Warren Lease commenced on June 1, 2022, with an initial term of seventeen years (the "Warren Initial Term"), followed by three consecutive five-year renewal periods at the Company's option. The aggregate base rent for the Warren Initial Term is approximately $163.0 million; provided, however, that if the Company is not subject to an Event of Default (as defined in the Warren Lease), the Company is entitled to a base rent abatement over the first three years of the Warren Initial Term of approximately $18.6 million, reducing the Company's total base rent obligation to $144.4 million. The Company is entitled to an allowance of approximately $36.2 million to be provided by the Warren Landlord to be used towards such improvements. The Landlord is providing the allowance to cover those assets that are real property improvements, such as structural components, roofs, flooring, etc., whose useful lives are typically longer in nature. The Company evaluated the leasehold improvements under ASC 842 and determined that the Company will be the owner of the improvements, and therefore the $36.2 million allowance and $5.0 million due from the Landlord were treated as lease incentives at the commencement of the lease and included in the calculation of the lease ROU asset and lease ROU liability, effectively reducing both at the commencement date of the lease. As a result, the Company recorded an operating lease ROU asset of $28.9 million and an operating lease ROU liability of $28.9 million as of the commencement date of the lease. The Company also leases office and laboratory space at a facility located in Hopewell Township, New Jersey pursuant to a Lease Agreement (the "Hopewell Lease") with Hopewell Campus Owner, LLC. In connection with the disposition of certain assets to a gene therapy manufacturing, on June 17, 2024, the Company and Hopewell Campus Owner LLC entered into an amendment and restatement of the Hopewell Lease (the "Hopewell Lease Amendment"). At its inception, the Hopewell Lease was determined to have four separate lease components. The Hopewell Lease Amendment terminated three of the four lease components, reducing the leased space from 220,500 square feet to 93,461 square feet and significantly reducing the corresponding rent subject to the lease. The Company did not pay any termination fees in connection with the Hopewell Lease Amendment. As a result of the three terminated lease components, the related ROU asset was written off, the lease liability was derecognized, and the Company recognized a gain of $2.2 million during the nine months ended September 30, 2024. The gain is included within tangible asset impairment and losses (gains) on transactions, net on the Company's consolidated statements of operations. The Hopewell Lease Amendment did not fully or partially terminate the remaining lease component, which was therefore remeasured using an incremental borrowing rate at the date of modification of 7.5%, which resulted in an increase of the ROU asset and operating lease liability of $1.6 million, respectively. In connection with the Hopewell Lease Amendment, $2.5 million of the letter of credit was returned to the Company. The Company also has a finance lease related to its commercial manufacturing agreement with MassBiologics of the University of Massachusetts Medical School ("MassBio"). As of September 30, 2024, the balance of the finance lease liabilities current and finance lease liabilities noncurrent are $2.6 million and $15.6 million, respectively, and are directly related to the Company's MassBio agreement. As of December 31, 2023, the balance of the finance lease liabilities current and finance lease liabilities noncurrent were $3.0 million and $17.2 million, respectively. Additionally, the Company recorded finance lease costs of $0.4 million and $1.0 million related to interest on the lease liability during the three and nine months ended September 30, 2024, respectively. The Company recorded finance lease costs of $0.4 million and $1.1 million related to interest on the lease liability during the three and nine months ended September 30, 2023, respectively. The Company also leases certain vehicles, lab equipment, and office equipment under operating leases. The Company's leases have remaining operating lease terms ranging from 0.1 years to 14.7 years and certain of the leases include renewal options to extend the lease for up to 15 years. For the three and nine months ended September 30, 2024, rent expense was $5.9 million and $19.5 million, respectively. For the three and nine months ended September 30, 2023, rent expense was $7.1 million and $21.5 million, respectively.</p> <p style="font-family:Times New Roman',Times',serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The components of operating lease expense were as follows:</p> <p style="font-family:Times New Roman',Times',serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:25.46%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.00%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;text-align:center;margin:0pt;">Operating Lease Cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:25.46%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating Lease Cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:25.46%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;">Fixed lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;margin:0pt;padding:0pt;"> 4,049 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"> 15,173 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"> 16,463 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.46%;background:#ceeeff;margin:0pt;padding:0pt;"> Variable lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;background:#ceeeff;margin:0pt;padding:0pt;"> 1,581 </td><td style="vertical-align:bottom;white-

*space:nowrap;width:2.03%;background:#ceeeff;margin:0pt;padding:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#ceeeff;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#ceeeff;margin:0pt;padding:0pt;"> 1,376 </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#ceeeff;margin:0pt;padding:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#ceeeff;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#ceeeff;margin:0pt;padding:0pt;"> 3,623 </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#ceeeff;margin:0pt;padding:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#ceeeff;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#ceeeff;margin:0pt;padding:0pt;"> 4,140 </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#ceeeff;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:25.46%;margin:0pt;padding:0pt;"> Short-term lease cost </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"> . </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:17.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 308 </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"> . </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 271 </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"> . </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 750 </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"> . </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 866 </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:25.46%;background:#ceeeff;margin:0pt;padding:0pt;"> Total operating lease cost </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times;serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times;serif;font-size:10pt;margin:0pt;">.</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times;serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,137 </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times;serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 19,546</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times;serif;font-size:10pt;margin:0pt;">.</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times;serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 21,469 </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td></tr></table> . Total operating lease cost is a component of operating expenses on the consolidated statements of operations. Supplemental lease term and discount rate information related to leases was as follows as of September 30, 2024 and December 31, 2023: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.75%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:67.75%;margin:0pt;padding:0pt;"> . </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> — </td> <td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> — </td> <td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:67.75%;background:#ceeeff;margin:0pt;padding:0pt;"> Weighted-average remaining lease terms - operating leases (years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ceeeff;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#ceeeff;margin:0pt;padding:0pt;"> 12.05 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#ceeeff;margin:0pt;padding:0pt;"> 11.55 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:67.75%;margin:0pt;padding:0pt;"> Weighted-average discount rate - operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"> 8.06 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> 8.69 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:67.75%;background:#ceeeff;margin:0pt;padding:0pt;"> Weighted-average remaining lease terms - finance lease (years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#ceeeff;margin:0pt;padding:0pt;"> 8.26 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#ceeeff;margin:0pt;padding:0pt;"> 9.01 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:67.75%;margin:0pt;padding:0pt;"> Weighted-average discount rate - finance lease </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"> 7.80 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> 7.80 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> % </td></tr></table> . Supplemental cash flow information related to leases was as follows as of September 30, 2024 and 2023. . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"> Cash paid for amounts included in the measurement of lease liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"> Operating cash flows from operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"> $ 12,963 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times;serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11,479</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times;serif;font-size:10pt;margin:0pt;">Financing cash flows from finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times;serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times;serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times;serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">$ 1,490 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#ceeeff;margin:0pt;padding:0pt;"> $ 1,379 </td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"> Operating cash flows from finance lease </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"> $ 1,510 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"> $ 1,621 </td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#ceeeff;margin:0pt;padding:0pt;"> Right-of-use assets obtained in exchange for lease obligations: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#ceeeff;margin:0pt;padding:0pt;"> Operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times;serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,786</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times;serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times;serif;font-size:10pt;margin:0pt;">$ </td><td style="

style="visibility:hidden;"> </td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceef;margin:0pt;padding:0pt;"> Changes due to lease modification and termination </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceef;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceef;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"> Net decrease in right-of-use assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">31,763</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceef;margin:0pt;padding:0pt;"> Net decrease in operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceef;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceef;margin:0pt;padding:0pt;"> 33,908 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceef;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceef;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceef;margin:0pt;padding:0pt;"> — </td></tr></table>) Future minimum lease payments under non-cancelable leases as of September 30, 2024 were as follows:) <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;">2024 (excludes the nine months ended September 30, 2024) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceef;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceef;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceef;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceef;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;">2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"> 16,235 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> 3,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;">2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceef;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceef;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceef;margin:0pt;padding:0pt;"> 16,205 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceef;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceef;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceef;margin:0pt;padding:0pt;"> 3,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceef;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"> 13,973 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> 3,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;">2028 and thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceef;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 139,266 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceef;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;"> Total lease payments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"> 189,608 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> 24,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.72%;background:#cceef;margin:0pt;padding:0pt;"> Less: Imputed Interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceef;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 93,725 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceef;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,784 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceef;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 96,883</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,216 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"> </td></tr></table> <p 2 360000 P17X3 P5X true 163000000.0 P3Y 18600000 144400000 36200000 36200000 5000000.0 28900000 28900000 4 3 4 220500 93461 3 2200000 0.075 1600000 2500000 2600000 15600000 3000000.0 17200000 400000 1000000.0 400000 1100000 P0Y1M6D P1418M12D P15X 5900000 19500000 7100000 21500000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.09%;margin:0pt;padding:0pt;"> Three Months Ended </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:25.46%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;">) </td></tr></table>

Roman', 'Times', 'serif';font-size:8pt;text-align:center;margin:0pt;">September 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.46%;background:#cceeff;margin:0pt;padding:0pt;"> Operating Lease Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.46%;margin:0pt;padding:0pt;"> Fixed lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"> 5,490 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"> 16,463 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.46%;background:#cceeff;margin:0pt;padding:0pt;"> Variable lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;background:#cceeff;margin:0pt;padding:0pt;"> 1,581 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;margin:0pt;padding:0pt;"> 1,376 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"> 3,623 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"> 4,140 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.46%;margin:0pt;padding:0pt;"> Short-term lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 308 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 271 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 750 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 866 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.46%;background:#cceeff;margin:0pt;padding:0pt;"> Total operating lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,137 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 19,546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 21,469 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.75%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:67.75%;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;padding:0pt;"> December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted average remaining lease terms - operating leases (years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"> 12.05 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"> 11.55 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.75%;margin:0pt;padding:0pt;"> Weighted average discount rate - operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"> 8.06 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> 8.69 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted average remaining lease terms - finance lease (years) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"> 8.26 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"> 9.01 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.75%;margin:0pt;padding:0pt;"> Weighted average discount rate - finance lease </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"> 7.80 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> 8.40 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> % </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"> Cash paid for amounts included in the measurement of lease liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"> Operating cash flows from operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"> 12,963 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family

space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"> 1,621 </td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"> Right-of-use assets obtained in exchange for lease obligations: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"> Operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,786</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"> Changes due to lease modification and termination: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt;">Net decrease in operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 33,908</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td></tr></table> 12963000 11470000 1490000 1379000 1510000 1621000 5786000 31763000 -33908000 <p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceeff;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</p></td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating Leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance Lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:72.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024 (excludes the nine months ended September 30, 2024)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"> 3,920 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:72.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 16,235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:72.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 16,205</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:72.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,973</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:72.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 139,266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 189,608</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 24,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:72.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Imputed interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 92,725</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 96,883 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,216 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"> . </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> <p style

align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.72%;background:#ceeef;margin:0pt;padding:0pt;"> 2024 (excludes the nine months ended September 30, 2024) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ceeef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#ceeef;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#ceeef;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#ceeef;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.72%;background:#ceeef;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ceeef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#ceeef;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:72.72%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,205</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,973</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:72.72%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 130,266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 15,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 189,608</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:72.72%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Imputed Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 92,725</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:72.72%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"> 96,883 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"> 18,216 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"> </td></tr></table> *3929000 16235000 3000000 16205000 3000000 13973000 3000000 139266000 15000000 189608000 24000000 92725000 5784000 96883000 18216000* 4. Fair value of financial instruments and marketable securities The Company follows the fair value measurement rules, which provideguidance on the use of fair value in accounting and disclosure for assets and liabilities when such accounting and disclosure is called for by other accounting literature. These rules establish a fair value hierarchy for inputs to be used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority). <table style="border-collapse:collapse;font-family:Times New Roman','Times',serif;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the balance sheet date.</td></tr></table><table style="border-collapse:collapse;font-family:Times New Roman','Times',serif;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Level 2—Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</td></tr></table><table style="border-collapse:collapse;font-family:Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Level 3—Inputs are unobservable and reflect the Company's assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available.</td></tr></table> Cash equivalents and marketable securities are reflected in the accompanying financial statements at fair value. The carrying amount of receivables and accounts payable and accrued expenses approximates fair value due to the short-term nature of these instruments. The Company owns common stock in ClearPoint Neuro, Inc. ("ClearPoint") (formerly MRI Interventions, Inc.), a publicly traded medical device company. The ClearPoint equity investments (collectively, the "ClearPoint Equity Investments") represent financial instruments, and therefore, are recorded at fair value, which is readily determinable. The ClearPoint Equity Investments are components of prepaids and other current assets on the consolidated balance sheet as of September 30, 2024 and December 31, 2023. The Company classifies the ClearPoint Equity Investments as Level 1 assets within the fair value hierarchy, as the value is based on a quoted market price in an active market, which is not adjusted. Other than the ClearPoint Equity Investments, no other items included in prepaids and other current assets on the consolidated balance sheets are fair valued. In 2020, the Company purchased a convertible note receivable from ClearPoint. The note is convertible to common shares at a conversion rate of $6.00 per share at any point throughout the term of the loan, with a maturity date five years from the purchase date. In August 2024, the outstanding principal amount of the convertible note, together with any accrued and unpaid interest thereon, was repaid in full by ClearPoint and therefore the balance at September 30, 2024 was $0. The Company determined that the convertible note represented an available for sale debt security and the Company had elected to record it at fair value under ASC 825. The Company classified its ClearPoint convertible debt security as a Level 2 asset within the fair value hierarchy, as the value was based on inputs other than quoted prices that are observable. The fair value of the ClearPoint convertible debt security was determined at each reporting period by utilizing a Black-Scholes option pricing model, as well as a present value of expected cash flows from the debt security utilizing the risk-free rate and the estimated credit spread as of the valuation date as the discount rate. The convertible debt security was included as a component of deposits and other assets as of December 31, 2023. The Company has investments in mutual funds, including one that is denominated in a foreign currency. All of these are equity investments and are classified as marketable securities on the Company's consolidated balance sheets. These equity investments are reported at fair value, as they are readily available, and as such are classified as Level 1 assets. Unrealized holding gains and losses for these equity investments are included as components of other expense, net within the consolidated statement of operations. The table presented below is a summary of changes in the fair value for the Company's marketable securities - equity investments, ClearPoint Equity Investments, and ClearPoint convertible debt security for the three and nine months ended September 30, 2024 and September 30, 2023: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"> Ending </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> Foreign </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:Times New

content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35

space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"> — </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"> (3,289) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"> 49,614 </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td> <td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"> (41,624) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 29,258</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">ClearPoint Equity Investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,074</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 3,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:29.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:7pt;font-weight:bold;">Total Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> 41,261 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 3,946</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"> (622) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,289)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"> 49,614 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (41,624)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"> 39,286 </td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:29.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"> Ending </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> Ending </td></tr><tr><td style="vertical-align:bottom;width:29.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"> Balance at </td><td style="vertical-align:middle;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman', 'Times', 'serif';font-size:10pt;text-

*align:center;margin:0pt 0.05pt 0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> Currency </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> Balance at </td></tr><tr><td style="vertical-align:bottom;width:29.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:middle;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;"> Realized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"> Investments </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> Redemptions </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:29.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gain/(Loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Loss </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Loss </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Purchased </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Sale </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:29.48%;background:#ceeef;margin:0pt;padding:0pt;"> Marketable securities - equity investments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#ceeef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#ceeef;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;">108,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;">5,484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;">26,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(12,078)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#ceeef;margin:0pt;padding:0pt;"> 128,028 </td></tr><tr><td style="vertical-align:bottom;width:29.48%;margin:0pt;padding:0pt;"> ClearPoint Equity Investments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> 10,965 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"> (3,107) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#ceeef;margin:0pt;padding:0pt;"> (782) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"> (2,594) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#ceeef;margin:0pt;padding:0pt;"> 4,482 </td></tr><tr><td style="vertical-align:bottom;width:29.48%;background:#ceeef;margin:0pt;padding:0pt;"> ClearPoint convertible debt security </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#ceeef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#ceeef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15,231 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#ceeef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#ceeef;margin:0pt;padding:0pt;"> (4,594) </td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,594) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,637 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.48%;margin:0pt;padding:0pt;"> Total Fair Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;">134,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"> (2,217) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeef;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(782)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"> (7) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Ro

~~style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.27%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:43.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> Quoted prices </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> Significant </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> in active </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"> Significant </td></tr><tr><td style="vertical-align:bottom;width:43.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> markets for </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> observable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"> unobservable </td></tr><tr><td style="vertical-align:bottom;width:43.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> identical assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"> inputs </td></tr><tr><td style="vertical-align:bottom;width:43.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (level 1) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (level 2) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (level 3) </td></tr><tr><td style="vertical-align:bottom;width:43.27%;background:#cceeff;margin:0pt;padding:0pt;"> Marketable securities - available for sale </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">260,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">260,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:43.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;">Marketable securities - equity investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:43.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;">ClearPoint Equity Investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,074</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,074</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,553</p></td></tr><tr><td style="vertical-align:bottom;width:43.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;">ClearPoint convertible debt security</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,553</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:43.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;">Contingent consideration payable- development and regulatory milestones</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26,600</p></td></tr><tr><td style="vertical-align:bottom;width:43.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;">Contingent consideration payable- net sales milestones and royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"> 9,700 </td></tr></table> No transfers of assets between Level 1, Level 2, or Level 3 of the fair value measurement hierarchy occurred during the periods ended September 30, 2024 and December 31, 2023. The following is a summary of marketable securities accounted for as available for sale debt securities at September 30, 2024 and December 31, 2023: <table style="border-collapse:collapse;font-size:10pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;">

```
style="font-size:8pt;visibility:hidden;"></span></p></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td> </tr><tr><td style="vertical-align:bottom;width:52.51%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">(</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">118,783</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">(</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">636</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">(</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">(</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">119,419</p></td></tr><tr><td style="vertical-align:bottom;width:52.51%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">(</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">(</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">44,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">(</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">(</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">(8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">(</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">(</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">44,642</p></td></tr><tr><td style="vertical-align:bottom;width:52.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Government obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">(</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">(</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">292,291</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">(</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">(</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">(</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">(</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">(</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">294,037</p></td></tr><tr><td style="vertical-align:bottom;width:52.51%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">(</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">455,560</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">(</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">(</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">(8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">(</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">458,098</p></td></tr></table><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3
```

align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (14) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 260,104 </td></tr></table> For available-for-sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security's amortized cost basis is written down to fair value. For the three and nine months ended September 30, 2024 and 2023, no write downs occurred. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be maturity. The Company also reviews its available for sale debt securities in an unrealized loss position and evaluates whether the decline in fair value has resulted from credit losses or other factors. This review is subjective, as it requires management to evaluate whether an event or change in circumstances has occurred in that period that may be related to credit issues. For the three and nine months ended September 30, 2024 and 2023, no allowance was recorded for credit losses. Unrealized gains and losses are reported as a component of accumulated other comprehensive (loss) income in stockholders' deficit. For the three and nine months ended September 30, 2024, the Company had $0.8 million and $0.8 million realized gains from the sale of available for sale debt securities, respectively. For the three months ended September 30, 2023, the Company did not have any realized gains or losses from the sale of available for sale debt securities. For the nine months ended September 30, 2023, the Company had $0.3 million realized losses from the sale of available for sale debt securities. Realized gains and losses are reported as a component of interest expense, net in the consolidated statement of operations. Reclassified amounts from other comprehensive items were determined using the actual realized gains and losses from the sales of marketable securities. </p><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The unrealized losses and fair values of available for sale debt securities that have been in an unrealized loss position for a period of less than and greater than or equal to 12 months as of September 30, 2024 are as follows:</p><p style="font-family:Times New Roman',Times',serif;font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:21.17%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:21.17%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:77.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:21.17%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.48%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities in an unrealized loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.4%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities in an unrealized loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:21.17%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">position greater than or equal to 12 months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.17%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,984 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">14,984</p></td></tr><tr><td style="vertical-align:bottom;width:21.17%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (8) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">14,984</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">(8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;visibility:hidden;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 14,984 </td></tr></table> The unrealized losses and fair values of available for sale debt securities that have been in an unrealized loss position for a period of less than and greater than or equal to 12 months as of December 31, 2023 are as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:21.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:21.13%;margin:0pt;padding:0pt;"> </td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:77.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:21.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.57%;margin:0pt;padding:0pt;"> Securities in an unrealized loss </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.46%;margin:0pt;padding:0pt;"> Securities in an unrealized loss </td><td style="vertical-align:bottom;white-space:nowrap;

style="font-size:8pt;font-weight:bold;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:21.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> position less than 12 months </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;">   </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> position greater than or equal to 12 months </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;">   </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:21.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unrealized losses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unrealized losses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unrealized losses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr><td style="vertical-align:bottom;width:21.13%;background:#cceeff;margin:0pt;padding:0pt;"> Commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">(12)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">44,446</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">(12)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"> 44,446 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.13%;margin:0pt;padding:0pt;"> Corporate debt securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">(14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 46,094 </td></tr></table> Available for sale debt securities at September 30, 2024 and December 31, 2023 mature as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;">   </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"> Less Than </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"> More Than </td><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12 Months </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12 Months </td><td style="vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;"> Commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">119,419</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">44,642</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Government obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">294,037</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 458,098 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"> December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times',serif;font-size:10pt;margin:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;">   </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"> Less Than </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;">   </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"> More Than </td></tr> <tr> <td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;">   </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12 Months </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;">   </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12 Months </td></tr> <tr> <td style="vertical-align:bottom;width:74.4%;background:#ceeeff;margin:0pt;padding:0pt;"> Commercial paper </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#ceeeff;margin:0pt;padding:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#ceeeff;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">117,160</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#ceeeff;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#ceeeff;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td> <td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#ceeeff;margin:0pt;padding:0pt;"> — </td></tr> <tr> <td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"> Corporate debt securities </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> $</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,648</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p> </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td> <td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> — </td></tr> <tr> <td style="vertical-align:bottom;width:74.4%;background:#ceeeff;margin:0pt;padding:0pt;"> Government obligations </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#ceeeff;margin:0pt;padding:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 141,296 </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#ceeeff;margin:0pt;padding:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"> Total </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">260,104</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td> <td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table>   The Company classifies all of its marketable securities as current as they are all either available for sale debt securities or equity investments and are available for current operations. Convertible senior notes In September 2019, the Company issued $287.5 million of 1.50% convertible senior notes due September 15, 2026 (the "2026 Convertible Notes."). The fair value of the 2026 Convertible Notes, which differs from their carrying values, is influenced by interest rates, the Company's stock price and stock price volatility and is determined by prices for the 2026 Convertible Notes observed in market trading which are Level 2 inputs. The estimated fair value of the 2026 Convertible Notes at September 30, 2024 and December 31, 2023 was $293.4 million and $265.3 million, respectively. Level 3 valuation The contingent consideration payable is fair valued each reporting period with the change in fair value recorded as a gain or loss within the change in the fair value of contingent consideration on the consolidated statements of operations. The fair value of the development and regulatory milestones is estimated utilizing a probability adjusted, discounted cash flow approach. The discount rates are estimated utilizing Corporate B rated bonds maturing in the years of expected payments based on the Company's estimated development timelines for the acquired product candidate. The fair value of the net sales milestones is determined utilizing a valuation framework that estimates net sales volatility to simulate a range of possible payment scenarios. The average of the payments in these scenarios is then discounted to calculate present fair value. As of September 30, 2024, the contingent consideration balance, consisting solely of the Upstaza related contingent milestones, was $22.0 million.</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt;">As of September 30, 2024, the weighted average discount rate for the Upstaza development and regulatory milestones was 5.5% and the weighted average probability of success was 95%. As of September 30, 2024, the weighted average discount </p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">rate for the Upstaza net sales milestones was 13.0% and the weighted average probability of success for the net sales milestones was 98%. </p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt;">The table presented below is a summary of changes in the fair value of the Company's Level 3 valuations for the contingent consideration payable for the periods ended September 30, 2024 and September 30, 2023:</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow-hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></div></div></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow-hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></div></div></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow-hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></div></div></td> <td style="vertical-align:bottom;white-space:nowrap;width:24.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow-hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></div></div></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow-hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></div></div></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow-hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></div></div></td> <td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow-hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></div></div></td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"> <b style="font-weight:bold;">milestones</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt;"> </p> </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;">Beginning balance as of December 31, 2023</p></td></tr> <tr> <td style="vertical-align:bottom;width:45.12%;background:#ceeeff;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#ceeeff;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td> <td style="vertical-align:bottom;white-space:nowrap;width:24.17%;background:#ceeeff;margin:0pt;padding:0pt;"> 600 </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#ceeeff;margin:0pt;padding:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:22.81%;background:#ceeeff;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,700</p></td></tr><tr><td style="vertical-align:bottom;width:45.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Additions</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:24.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:22.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:45.12%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Change in fair value</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:24.17%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,300</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:22.81%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,400</p></td></tr><tr><td style="vertical-align:bottom;width:45.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Reclassification to accounts payable and accrued expenses</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:24.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:22.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:45.12%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Payments</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:24.17%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">(20,000)</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:22.81%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:45.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Ending balance as of September 30, 2024</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td> <td style="vertical-align:bottom;white-space:nowrap;width:24.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,900 </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td> <td style="vertical-align:bottom;white-space:nowrap;width:22.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,100 </td></tr></table>   <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.08%;margin:0pt;padding:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:24.18%;margin:0pt;padding:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;">   </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.68%;margin:0pt;padding:0pt;"> Contingent consideration payable </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.34%;margin:0pt;padding:0pt;"> Contingent consideration payable </td></tr> <tr> <td style="vertical-align:bottom;width:45.08%;margin:0pt;padding:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.68%;margin:0pt;padding:0pt;"> development and regulatory </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.34%;margin:0pt;padding:0pt;"> net sales milestones and royalties </td></tr><tr><td style="vertical-align:bottom;width:45.08%;margin:0pt;padding:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> milestones </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Beginning balance as of December 31, 2022 </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ceeeff;margin:0pt;padding:0pt;">   </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman',

Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times','serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">82,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times','serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times','serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#ceeeff;margin:0pt;padding:0pt;"> 81,500 </td><td style="vertical-align:bottom;width:45.08%;margin:0pt;padding:0pt;"> Additions </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;width:45.08%;background:#ceeeff;margin:0pt;padding:0pt;"> Change in fair value </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;background:#ceeeff;margin:0pt;padding:0pt;"> (56,100) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#ceeeff;margin:0pt;padding:0pt;"> (68,900) </td></tr><tr><td style="vertical-align:bottom;width:45.08%;margin:0pt;padding:0pt;"> Payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:45.08%;background:#ceeeff;margin:0pt;padding:0pt;"> Ending balance as of September 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times','serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times','serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times','serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,600 </td></tr></table> In May 2024, the Company's BLA for its gene therapy treatment of AADC deficiency was accepted for filing by the FDA. The application has been granted priority review with a target regulatory action date of November 13, 2024. As a result of the acceptance, in accordance with the terms of the Aqilis Merger Agreement, the Company paid a $20.0 million milestone payment to the former equityholders of Aqilis during the three and nine months ended September 30, 2024. The following significant unobservable inputs were used in the valuation of the contingent consideration payable for the periods ended September 30, 2024 and December 31, 2023: <table cellpadding="0" cellspacing="0" font-family:times new roman','times','serif;font-size:10pt;text-align:justify;margin:0pt;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.31%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.31%;margin:0pt;padding:0pt;"> </td></tr><tr><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:79.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:18.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Valuation Technique </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unobservable Input </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:17.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Range </td></tr><tr><td style="vertical-align:middle;width:18.31%;background:#ceeeff;margin:0pt;padding:0pt;"> Contingent consideration payable -
development and regulatory milestones </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.22%;background:#ceeeff;margin:0pt;padding:0pt;"> $9,900 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:middle;width:15.1%;background:#ceeeff;margin:0pt;padding:0pt;"> Probability-adjusted discounted cash flow </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:top;width:32.95%;background:#ceeeff;margin:0pt;padding:0pt;"> Potential development and regulatory milestones
Probabilities of success
Discount rates
Projected years of payments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:17.4%;background:#ceeeff;margin:0pt;padding:0pt;"> $0 - $11 million
95%
5.4% - 5.5%
2024 - 2026 </td></tr><tr><td style="vertical-align:middle;width:18.31%;margin:0pt;padding:0pt;"> Contingent considerable payable- net sales
milestones </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.22%;background:#ceeeff;margin:0pt;padding:0pt;"> $12,100 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:middle;width:15.1%;margin:0pt;padding:0pt;"> Option-pricing model with Monte Carlo simulation   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:top;width:32.95%;margin:0pt;padding:0pt;"> Potential net sales milestones
Probabilities of success
Discount rate
Projected years of payments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:17.4%;margin:0pt;padding:0pt;"> $0 - $50 million
95% - 100%
13%
2026 - 2034 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:33.02%;margin:0pt;padding:0pt;"> Potential development and regulatory milestones
Probabilities of success
Projected years of payments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:18.1%;margin:0pt;padding:0pt;"> $0 - $31 million
85% - 92%
5.8% - 6.1%
2024 - 2026 </td><td style="vertical-align:middle;width:18.9%;margin:0pt;padding:0pt;"> Contingent considerable payable- net sales
milestones </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"> $9,700 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:middle;width:14.79%;margin:0pt;padding:0pt;"> Option-pricing model with Monte Carlo simulation   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:top;width:33.02%;margin:0pt;padding:0pt;"> Potential net sales milestones
Probabilities of success
Discount rate
Projected years of payments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:18.1%;margin:0pt;padding:0pt;"> $0 - $50 million
85% - 100%
11%
2026 - 2034 </td></tr></table> The contingent consideration payables are classified Level 3 liabilities as their valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approaches, including but not limited to, assumptions involving probability-adjusted sales estimates for the gene therapy platform and estimated discount rates, the estimated fair value could be significantly higher or lower than the fair value determined. 10000000 0.6.00 P5Y 0 4 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> <p style="font-family:Times New

Roman', 'Times', serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"> Ending </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> Foreign </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> Ending </td></tr><tr><td style="vertical-align:bottom;width:29.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"> Balance at </td><td style="vertical-align:middle;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> Currency </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> Balance at </td></tr><tr><td style="vertical-align:bottom;width:29.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:middle;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;"> Realized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"> Investments </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> Redemptions </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:29.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.48%;background:#cceeff;margin:0pt;padding:0pt;"> Marketable securities - equity investments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', serif;font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 16,889</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', serif;font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', serif;font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', serif;font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 32,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', serif;font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21,051)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', 'Times', serif;font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"> 29,258 </td></tr><tr><td style="vertical-align:bottom;width:29.48%;margin:0pt;padding:0pt;"> ClearPoint Equity Investments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> 4,822 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"> 5,206 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:29.48%;background:#cceeff;margin:0pt;padding:0pt;"> ClearPoint convertible debt security </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,622 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-

8,219 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"> (7,830) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> 5 </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"> 128,028 </td></tr><tr><td style="vertical-align:bottom;width:32.91%;margin:0pt;padding:0pt;"> ClearPoint Equity Investments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> 6,477 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"> (1,995) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> 4,482 </td></tr><tr><td style="vertical-align:bottom;width:32.91%;background:#cceeff;margin:0pt;padding:0pt;"> ClearPoint convertible debt security </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 13,693 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,056) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,637 </td></tr><tr><td style="vertical-align:bottom;width:32.91%;margin:0pt;padding:0pt;"> Total Fair Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 148,115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"> (3,931) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,426)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"> 8,219 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,830)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"> 143,147 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> Foreign </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> Ending </td></tr><tr><td style="vertical-align:bottom;width:29.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"> Balance at </td><td style="vertical-align:middle;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> Currency </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> Balance at </td></tr><tr><td style="vertical-align:bottom;width:29.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:middle;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-

word;position:relative;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:29.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"> Ending </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> Foreign </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> Ending </td><td style="vertical-align:bottom;white-space:nowrap;width:20.48%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"> Balance at </td><td style="vertical-align:middle;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> Currency </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> Balance at </td></tr><tr><td style="vertical-align:bottom;width:29.48%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;"> Realized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"> Investments </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> Redemptions </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:29.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2032 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gain/(Loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Loss </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Loss </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Purchased </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Sale </td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:29.48%;background:#cceeff;margin:0pt;padding:0pt;"> Marketable securities – equity investments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"> 108,261 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"> 5,484 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"> (17) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"> 26,378 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"> (12,078) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15,231 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,594) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.48%;margin:0pt;padding:0pt;"> ClearPoint Equity Investments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"> 10,965 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"> (3,107) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"> (702) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="v

Roman','Times',serif;font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> — </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#ceeeff;margin:0pt;padding:0pt;"> Total Fair Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:20.48%;margin:0pt;padding:0pt;"> 10,937 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 134,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"> (2,217) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (782)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"> (17) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 26,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"> (14,672) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"> 143,147 </td></tr></table> *16889000 812000 400000 32208000 21051000 29258000 4822000 5206000 10028000 10622000 -622000 10000000 32333000 6018000 -622000 400000 32208000 31051000 39286000 -127945000 1120000 -1426000 8219000 7830000 128028000 64270000 -1095000 1482000 13693000 -3056000 10637000 148115000 -3931000 -1426000 8219000 7830000 143147000 2263400 1923000 -3289000 43614000 41624000 29258000 69274000 3954000 10028000 -1253000 -1931000 -622000 10000000 41261000 3944000 -1220000 4961400 5162400 39286000 128028000 54054000 1700026378000 1207800 -1280200 -1426000 8219000 7830000 -1700026378000 2594000 4344000 152310000 -434 1000 10637000 134457000 -2217000 -782000 -17000 26378000 14672000 134147000 -3289000 -1426000 8219000 7830000 -1700026378000 1207800 -1280200 -1426000 8219000 7830000 -1700026378000 1207800 -1280200 -1426000 8219000 7830000 -1700026378000 1207800 -1280200

</table> </td></tr></table></td></tr></table></td></tr>

family;Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#ceeeff;margin:0pt;padding:0pt;"> (12) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 117,160</p></td></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,648</p></td></tr><tr><td style="vertical-align:bottom;width:52.48%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Government obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 141,084</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 141,296</p></td></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.03pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 259,778 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (14) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 260,104</p></td></tr></table><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:justify;margin:0pt;"></p> 118783000 636000 110419000 44494000 156000 8000 44642000 292291000 1746000 294037000 455568000 2538000 8000 458098000 117044000 128000 12000 117160000 1650000 2000 1648000 141084000 212000 141296000 259778000 340000 14000 260104000 0 0 0 0 0 0 0 0 0 800000 800000 0 -300000 <p style="font-family:Times New Roman',Times',serif;font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:21.17%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:1pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:1pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:1pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:1pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:1pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:1pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:1pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:1pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:1pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:1pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:1pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:1pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:1pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:1pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:1pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:1pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:1pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:1pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:1pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:1pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:21.17%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;"></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:77.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:21.17%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.48%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities in an unrealized loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.4%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities in an unrealized loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;width:21.17%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">position greater than or equal to 12 months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:21.17%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</p></td><td></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.17%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,984 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,984 </td></tr><tr><td style="vertical-align:bottom;width:21.17%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 14,984 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 14,984 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:21.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:

~~Roman',Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 458,098 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> ~~Commercial paper~~ <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.12%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td style="vertical-align:bottom;white-space:nowrap;width:24.17%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#ceeeff;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#ceeeff;margin:0pt;padding:0pt;"> 117,160 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#ceeeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"> Corporate debt securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> 1,648 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:74.4%;background:#ceeeff;margin:0pt;padding:0pt;"> Government obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 141,296 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 260,104 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> ~~ 119419000 44642000 294037000 458098000 117160000 1648000 141296000 260104000 287500000 0.0150 293400000 265300000 22000000.0 0.055 0.95 0.130 0.98 ~~ <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.12%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td style="vertical-align:bottom;white-space:nowrap;width:24.17%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#ceeeff;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#ceeeff;margin:0pt;padding:0pt;"> 2,400 </td></tr><tr><td style="vertical-align:bottom;width:45.12%;margin:0pt;padding:0pt;"> Reclassification to accounts payable and accrued expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:24.17%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.81%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:45.12%;background:#ceeeff;margin:0pt;padding:0pt;"> Payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:24.17%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (20,000) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.81%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:45.12%;margin:0pt;padding:0pt;"> Ending balance as of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:24.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,900 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,100 </td></tr></table> ~~ <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.08%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td></tr><tr><td style="vertical-align:bottom;width:45.08%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:52.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 liabilities </td></tr><tr><td style="vertical-align:bottom;width:45.08%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.68%;margin:0pt;padding:0pt;"> Contingent consideration payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.34%;margin:0pt;padding:0pt;"> ~~Commercial paper~~ </td></tr></table>~~

family;Times New Roman',Times;serif;font-size:8pt;text-align:center;margin:0pt;"> Contingent consideration payable </td></tr><tr><td style="vertical-align:bottom;width:45.08%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.68%;margin:0pt;padding:0pt;"> development and regulatory </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.34%;margin:0pt;padding:0pt;"> net sales milestones and royalties </td></tr><tr><td style="vertical-align:bottom;width:45.08%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> milestones </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:45.08%;background:#ceeeff;margin:0pt;padding:0pt;"> Beginning balance as of December 31, 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times;serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">82,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times;serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times;serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#ceeeff;margin:0pt;padding:0pt;"> 81,500 </td></tr><tr><td style="vertical-align:bottom;width:45.08%;margin:0pt;padding:0pt;"> Additions </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:45.08%;background:#ceeeff;margin:0pt;padding:0pt;"> Change in fair value </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;background:#ceeeff;margin:0pt;padding:0pt;"> (56,100) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#ceeeff;margin:0pt;padding:0pt;"> (68,900) </td></tr><tr><td style="vertical-align:bottom;width:45.08%;margin:0pt;padding:0pt;">Payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:45.08%;background:#ceeeff;margin:0pt;padding:0pt;"> Ending balance as of September 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times;serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times;serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times;serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,600 </td></tr></table> 26600000 9700000 0 0 3300000 2400000 0 0 20000000 0 0900000 12100000 82500000 81500000 0 0 -56100000 -68900000 0 0 26400000 12600000 20000000.0 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%"><tr style="height:1pt"><td style="vertical-align:bottom;width:18.31%;margin:0pt;padding:0pt"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:18.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:79.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:18.31%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Valuation Technique </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unobservable Input </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:17.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Range </td></tr><tr><td style="vertical-align:middle;width:18.31%;background:#ceeeff;margin:0pt;padding:0pt;"> Contingent consideration payable
development and regulatory milestones </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.22%;background:#ceeeff;margin:0pt;padding:0pt;"> $9,900 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:middle;width:15.1%;background:#ceeeff;margin:0pt;padding:0pt;"> Probability-adjusted discounted cash flow </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:top;width:32.95%;background:#ceeeff;margin:0pt;padding:0pt;"> Potential development and regulatory milestones
Probabilities of success
Discount rates
Projected years of payments </td><td style="vertical-align:middle;width:18.31%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:1.99%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:middle;width:15.1%;background:#ceeeff;margin:0pt;padding:0pt;"> Option-pricing model with Monte Carlo simulation   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:top;width:32.95%;margin:0pt;padding:0pt;"> Potential net sales milestones
Probabilities of success
Discount rate
Projected years of payments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:17.4%;margin:0pt;padding:0pt;"> $0 - $50 million
95% - 100%
13%
2026 - 2034 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%"><tr style="height:1pt"><td style="vertical-align:bottom;width:18.9%;margin:0pt;padding:0pt"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:33.02%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:18.1%;margin:0pt;padding:0pt;"> </td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:79.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:18.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:33.02%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:18.31%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:33.02%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:18.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> $0 - $31 million
85% - 92%
6.1%
2024 - 2026 </td><td style="vertical-align:middle;width:18.9%;margin:0pt;padding:0pt;"> Contingent considerable payable -net sales</br>milestones </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.77%;background:#ceeeff;margin:0pt;padding:0pt;"> $9,700 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:middle;width:14.79%;margin:0pt;padding:0pt;"> Option-pricing model with Monte Carlo simulation   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:top;width:33.02%;margin:0pt;padding:0pt;"> Potential net sales milestones
Probabilities of success
Discount rate
Projected years of payments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:18.1%;margin:0pt;padding:0pt;"> $0 - $50 million
95% - 100%
11%
2026 - 2034 </td></tr></table> 9900000 0 11000000 0.95 0.054 0.055 12100000 0 50000000 0.95 1 0.13 26600000 0 31000000 0.85 0.92 0.058 0.061 9700000 0 50000000 0.85 1 0.11 5.   Accounts payable and accrued expenses Accounts payable and accrued expenses at September 30, 2024 and December 31, 2023 consist of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%"><tr style="height:1pt"><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;">

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.17%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:74.17%;background:#ceeeff;margin:0pt;padding:0pt;"> Employee compensation, benefits, and related accruals </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times,'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 46,209</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times,'serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times,'serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#ceeeff;margin:0pt;padding:0pt;"> 62,643 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#ceeeff;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"> Income tax payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"> 6,012 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.17%;background:#ceeeff;margin:0pt;padding:0pt;"> Consulting and contracted research </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#ceeeff;margin:0pt;padding:0pt;"> 23,032 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#ceeeff;margin:0pt;padding:0pt;"> 27,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#ceeeff;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"> Sales allowance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"> 65,782 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"> 77,176 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:74.17%;background:#ceeeff;margin:0pt;padding:0pt;"> Sales rebates </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#ceeeff;margin:0pt;padding:0pt;"> 102,919 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#ceeeff;margin:0pt;padding:0pt;"> 131,334 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#ceeeff;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:74.17%;background:#ceeeff;margin:0pt;padding:0pt;"> Royalties </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#ceeeff;margin:0pt;padding:0pt;"> 14,016 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#ceeeff;margin:0pt;padding:0pt;"> 74,111 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#ceeeff;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:74.17%;background:#ceeeff;margin:0pt;padding:0pt;"> Accounts payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#ceeeff;margin:0pt;padding:0pt;"> 13,292 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#ceeeff;margin:0pt;padding:0pt;"> 6,045 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#ceeeff;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"> Milestone payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"> 50,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:74.17%;background:#ceeeff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15,084 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 13,174 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#ceeeff;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times,'serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 336,346</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times,'serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times,'serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 391,983 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;">   </td></tr></table>   As of September 30, 2024 and December 31, 2023, there were $0.3 million and $0.0 million, respectively, of accrued restructuring costs included above within employee compensation, benefits, and related accruals from a reduction in workforce in the year ended December 31, 2023 in connection with the Company's strategic pipeline prioritization and discontinuation of its preclinical and early research programs in its gene therapy platform.</p><p style="font-family:Times New Roman',Times,'serif';font-size:10pt;text-align:justify;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times,'serif';font-size:1pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times,'serif';font-size:1pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times,'serif';font-size:1pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times,'serif';font-size:1pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times,'serif';font-size:1pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times,'serif';font-size:1pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times,'serif';font-size:1pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times,'serif';font-size:1pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times,'serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times,'serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times,'serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times,'serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times,'serif';font-size:10pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times,'serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times,'serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times,'serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times,'serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times,'serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times,'serif';font-size:10pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times,'serif';font-size:10pt;margin:0pt;">Employee compensation, benefits, and related accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times,'serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times,'serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#ceeeff;margin:0pt;padding:0pt;"> 46,209 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#ceeeff;margin:0pt;padding:0pt;"> 62,643 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#ceeeff;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"> Income tax payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"> 6,012 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:74.17%;background:#ceeeff;margin:0pt;padding:0pt;"> Consulting and contracted research </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#ceeeff;margin:0pt;padding:0pt;"> 23,032 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times,'serif';font-size:10pt;margin:0pt;

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#ceeeff;margin:0pt;padding:0pt;"> 131,334 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#ceeeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"> Royalties </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#ceeeff;margin:0pt;padding:0pt;"> 14,016 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"> 74,111 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:74.17%;background:#ceeeff;margin:0pt;padding:0pt;"> Accounts payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#ceeeff;margin:0pt;padding:0pt;"> 13,292 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#ceeeff;margin:0pt;padding:0pt;"> 6,045 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#ceeeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"> Milestone payable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"> 50,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:74.17%;background:#ceeeff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15,084 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 13,174 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#ceeeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 336,346</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 391,983 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"> </td></tr></table> *46209000 62643000 6012000 23032000 27500000 65782000 77176000 102919000 131334000 14016000 74111000 13292000 6045000 50000000 15084000 13174000 336346000 391983000 300000 9000000.0* 6. Capitalization In August 2019, the Company entered into an At the Market Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald and RBC Capital Markets, LLC (together, the “Sales Agents”), pursuant to which, the Company may offer and sell shares of its common stock, having an aggregate offering price of up to $125.0 million from time to time through the Sales Agents by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. No shares were sold during the three and nine months ended September 30, 2024 and 2023. The remaining shares of the Company’s common stock available to be issued and sold, under the At the Market Offering, have an aggregate offering price of up to $93.0 million as of September 30, 2024. *125000000.0 0 0 0 0 93000000.0* 7. Net loss per share Basic and diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding. Potentially dilutive securities were excluded from the diluted calculation because their effect would be anti-dilutive. The following tables set forth the computation of basic and diluted net loss per share: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.13908768%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.47%;background:#ceeeff;margin:0pt;padding:0pt;"> Numerator </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.47%;background:#ceeeff;margin:0pt;padding:0pt;"> Numerator for basic and diluted net loss per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 76,925,523 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-

```
align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">75,377,997</p></td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-
space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-
space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">76,716,340</p></td><td style="vertical-
align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-
space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">74,618,611</p></td><td style="vertical-
align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-
space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-
align:bottom;width:43.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss per share:</b></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">
</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span
style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-
align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New
Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-
family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;">
<p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">
</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt
0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-
size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New
Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-
family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td>
</tr><tr><td style="vertical-align:bottom;width:43.47%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted</p></td><td style="vertical-
align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-
align:bottom;white-space:nowrap;width:10.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(1.39)</p></td><td
style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(1.76)</p></td><td style="vertical-
align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:10.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(3.88)</p></td><td style="vertical-
align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:10.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(6.31)</p></td><td style="vertical-
align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr></table><div style="font-
family:Times New Roman',Times',serif;font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0
0;"></div></div><p style="font-family:Times New Roman',Times',serif;font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">*  In the three and nine months ended September 30, 2024 and 2023, the
Company experienced a net loss and therefore did not report any dilutive share impact.</p><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:justify;margin:0pt;">The following table shows historical dilutive common
share equivalents outstanding, which are not included in the above historical calculation, as the effect of their inclusion is anti-dilutive during each period.</p><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-
align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td
style="vertical-align:bottom;width:64.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New
Roman',Times',serif;font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"><span style="font-
size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-
align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New
Roman',Times',serif;font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"><span style="font-
size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td></tr><tr><td style="vertical-
align:bottom;width:64.92%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">Invested restricted stock units</p></td><td style="vertical-
align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.13%;border-
bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">3,596,329</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">3,414,102</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-
align:bottom;width:64.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:15.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">12,769,789</p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">
14,850,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"></p></td></tr></table><p
style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:justify;margin:0pt;">
<span style="margin-bottom:12pt;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:0.13908768%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td
style="vertical-align:bottom;width:43.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New
Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span
style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-
word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div>
</div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-
align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New
Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span
style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;">
<div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td
style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-
family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-
space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New
Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span
style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-
word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div>
</div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;">
<p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New
Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span
style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-
word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div>
</div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;">
<p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td></tr><tr><td style="vertical-
align:bottom;width:43.47%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p>
</td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt
0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:Times New
Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-
family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.38%;border-bottom:1px
solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September 30,</b></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">
</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.47%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-
weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt 0pt 0.05pt
0pt;">  </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-
align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-
size:8pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New
Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-
family:Times New Roman',Times',serif;font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:Times New
Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td colspan="2" style="vertical-align:bottom;white-
space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-
align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td></tr><tr>
<td style="vertical-align:bottom;width:43.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator</b></p>
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span
style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt
0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-
size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times
New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">
</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span
style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt
0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-
size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times
New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">
</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span
style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:43.47%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(106,654)</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-
```

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (132,970) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"> (297,409) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"> (470,812) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:43.47%;background:#cceeff;margin:0pt;padding:0pt;">Denominator </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:43.47%;background:#cceeff;margin:0pt;padding:0pt;">Net loss per share: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.47%;background:#cceeff;margin:0pt;padding:0pt;">Denominator for basic and diluted net loss per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.47%;background:#cceeff;margin:0pt;padding:0pt;">

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:46.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> Weighted - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> Weighted - </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> Weighted - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"> Weighted - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> Weighted - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"> Weighted - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> Weighted - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"> average </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> Weighted - </td></tr><tr><td style="vertical-align:bottom;width:46.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> remaining </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> intrinsic </td><td style="vertical-align:bottom;width:46.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"> contractual </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> value(in -) </td></tr><tr><td style="vertical-align:bottom;width:46.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> term </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> thousands) </td></tr><tr><td style="vertical-align:bottom;width:46.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:46.64%;background:#ceeeff;margin:0pt;padding:0pt;"> Outstanding at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#ceeeff;margin:0pt;padding:0pt;"> 9,600,399 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 43.59 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt;"> — </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt;"> — </p></td></tr><tr><td style="vertical-align:bottom;width:46.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt;"> 934,735 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26.13 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt;"> — </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt;"> — </p></td></tr><tr><td style="vertical-align:bottom;width:46.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">Forfeited/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt;"> (1,149,981) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 45.86 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt;"> — </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> — </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> — </p></td></tr><tr><td style="vertical-align:bottom;width:46.64%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt;"> (211,693) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22.41 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt;"> — </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt;"> — </p></td></tr><tr><td style="vertical-align:bottom;width:46.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">Forfeited/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt;"> (1,149,981) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 45.86 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt;"> — </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> — </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt;"> — </p></td></tr><tr><td style="vertical-align:bottom;width:46.64%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">Outstanding at September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,173,460 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 42.01 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;margin:0pt;padding:0pt;"> 5.64 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#ceeeff;margin:0pt;padding:0pt;"> years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;margin:0pt;padding:0pt;"> 30,906 </td></tr><tr><td style="vertical-align:bottom;width:46.64%;margin:0pt;padding:0pt;"> Vested or Expected to vest at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,746,884 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font

</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:27.96%;margin:0pt;padding:0pt;"> 6 months ended </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:27.96%;margin:0pt;padding:0pt;"> 9 months ended </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:27.96%;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:27.96%;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;"> Risk-free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:27.96%;background:#ceeeff;margin:0pt;padding:0pt;"> 3.51% - 4.66% </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:27.96%;background:#ceeeff;margin:0pt;padding:0pt;"> 3.51% - 4.66% </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:27.96%;margin:0pt;padding:0pt;"> 53% - 54% </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:27.96%;background:#ceeeff;margin:0pt;padding:0pt;"> 53% - 54% </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;"> Expected term </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:27.96%;background:#ceeeff;margin:0pt;padding:0pt;"> 5.5 years </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:27.96%;background:#ceeeff;margin:0pt;padding:0pt;"> 5.5 years </td></tr></table> The weighted average grant-date fair value of options granted during the nine months ended September 30, 2024 was $13.71 per share.</p><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The expected term of options was estimated based on the Company's historical exercise data and the expected volatility of options was estimated based on the Company's historical stock volatility. The risk-free rate of the options was based on U.S. Government Securities Treasury Constant Maturities yields at the date of grant for a term similar to the expected term of the option.</p><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Restricted Stock Units</i>—Restricted stock units are granted subject to certain restrictions, including in some cases service or time conditions (restricted stock). The grant-date fair value of restricted stock units, which have been determined based upon the market value of the Company's shares on the grant date, are expensed over the vesting period. From January 1, 2024, through September 30, 2024, the Company issued a total of 1,850,265 restricted stock units to various employees. Of those, 41,680 were inducement grants for restricted stock units, all of which were made pursuant to the 2020 Inducement Stock Incentive Plan.</p><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes information on the Company's restricted stock units:</p><p style="font-family:Times New Roman,Times,serif;font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restricted Stock Units</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:8pt;margin:0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:8pt;margin:0pt;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;">Unvested at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">2,866,270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#ceeeff;margin:0pt;padding:0pt;"> 41.82 </td><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> 1,850,265 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> 25.87 </td></tr><tr><td style="vertical-align:bottom;width:75.45%;background:#ceeeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#ceeeff;margin:0pt;padding:0pt;"> (924,417) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#ceeeff;margin:0pt;padding:0pt;"> 44.08 </td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"> Unvested at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> (195,789) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> 37.28 </td></tr><tr><td style="vertical-align:bottom;width:75.45%;background:#ceeeff;margin:0pt;padding:0pt;"> Unvested at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,596,329 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 33.29 </td></tr></table>) Performance-based Restricted Stock Units—In December 2023, the Company granted 150,000 performance-based restricted stock units ("PSUs") to its Chief Executive Officer, Dr. Matthew Klein, which will vest only if certain regulatory milestones are achieved over an approximately two year performance period. As of September 30, 2024, the achievements of the performance goals have not yet been deemed probable and therefore no expense has been recognized to date. Employee Stock Purchase Plan—In June 2016, the Company established an Employee Stock Purchase Plan (as amended, "ESPP" or the "Plan"), for certain eligible employees. The Plan is administered by the Company's Board of Directors or a committee appointed by the Company's Board of Directors. In June 2021, the Plan was amended to increase the total number of shares available for purchase under the Plan from one million shares to two million shares of the Company's common stock. Employees may participate over a six month period through payroll withholdings and may purchase, at the end of the six month period, the Company's common stock at a purchase price of at least 85% of the closing price of a share of the Company's common stock on the first business day of the offering period or the closing price of a share of the Company's common stock on the last business day of the offering period, whichever is lower. No participant will be granted a right to purchase the Company's common stock under the Plan if such participant would own more than 5% of the total combined voting power of the Company or any subsidiary of the Company after such purchase. For the three and nine months ended September 30, 2024, the Company recorded $0.5 million and $1.7 million, respectively, in compensation expense related to the ESPP.</p><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:justify;margin:0pt;">The Company recorded share-based compensation expense in the statement of operations related to incentive stock options, nonstatutory stock options, restricted stock units and the ESPP as follows:</p><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:justify;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.67%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:1pt;visibility:hidden;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September 30,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30,</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:8pt;margin:0pt;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:8pt;margin:0pt;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:8pt;margin:0pt;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:8pt;margin:0pt;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:46.08%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#ceeeff;margin:0pt;padding:0pt;"> 9,416 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#ceeeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">13,986</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt

3.6pt 0pt 0pt;"> 27,810 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 44,828</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12,956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 40,300</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;width:46.08%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 19,755 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#ceeeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26,942</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 57,376 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ceeeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 85,128 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ceeeff;margin:0pt;padding:0pt;"> - </td></tr></table> - As of September 30, 2024, there was approximately $117.8 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the Company's equity award plans. This cost is expected to be recognized as share-based compensation expense over the weighted average remaining service period of approximately 2.3 years.</p> 16724212 8475000 6781585 0 1000000 1000000 1300000 1700000 -0.09 0.735 27490 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:justify;margin:0pt;">
</p><table style="border-collapse:collapse;font-size:16pt;height:1px;max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:46.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"> 29,566 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"> 40,300 </td></tr><tr><td style="vertical-align:bottom;width:46.64%;margin:0pt;padding:0pt;"> Gross unrecognized compensation cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,600,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"> 43.59 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:46.64%;background:#ceeeff;margin:0pt;padding:0pt;"> Outstanding at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#ceeeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#ceeeff;margin:0pt;padding:0pt;"> 9,600,399 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ceeeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;margin:0pt;padding:0pt;"> 43.59 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ceeeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#ceeeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:46.64%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"> 934,735 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"> 26.13 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:46.64%;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#ceeeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#ceeeff;margin:0pt;padding:0pt;"> (211,693) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ceeeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;margin:0pt;padding:0pt;"> 22.41 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ceeeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#ceeeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:46.64%;margin:0pt;padding:0pt;"> Forfeited/Cancelled </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,149,981) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 45.86 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:46.64%;background:#ceeeff;margin:0pt;padding:0pt;"> Outstanding at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,173,460 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 42.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;margin:0pt;padding:0pt;"> 30,906 </td></tr><tr><td style="vertical-align:bottom;width:46.64%;margin:0pt;padding:0pt;"> Vested or Expected to vest at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,746,884 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 35.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"> 9,289 </td></tr><tr><td style="vertical-align:bottom;width:46.64%;background:#ceeeff;margin:0pt;padding:0pt;">Exercisable at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,252,947 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 43.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,420</p></td></tr></table><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p> 9600399 43.59 934735 26.13 211693 22.41 1149981 45.86 9173460 42.01 P5Y7M20D 30906000 1746884 35.85 P8Y5M12D 9289000 7254847 43.74 P4Y10M20D 20420000 <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;min-height:0.0pt;margin:0pt;">.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:27.96%;margin:0pt;padding:0pt;"> Nine months ended </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:27.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:65.95%;background:#ceeeff;margin:0pt;padding:0pt;"> Risk-free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:27.96%;background:#ceeeff;margin:0pt;padding:0pt;"> 3.51% 4.66% </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#ceeeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:27.96%;margin:0pt;padding:0pt;"> 53% 54% </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#ceeeff;margin:0pt;padding:0pt;"> Expected term </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:27.96%;background:#ceeeff;margin:0pt;padding:0pt;"> 5.5 years </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#ceeeff;margin:0pt;padding:0pt;"> </td></tr></table> 0.0351 0.0466 0.53 0.54 P5Y6M 0 13.71 1850265 41680 . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> Average </td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"> Restricted Stock Units </td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"> Unvested at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#ceeeff;margin:0pt;padding:0pt;"> 2,866,270 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 41.82</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,850,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 25.87</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">(924,417)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 44.08</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (195,789)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 37.26</p></td></tr><tr><td style="vertical-align:bottom;width:75.45%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Unvested at September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,596,329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 33.29 </td></tr></table> 2866270 41.82 1850265 25.87 924417 44.08 195789 37.28 3596329 33.29 150000 P2Y 0 1000000 2000000 P6M 0.85 0.05 500000 1700000 . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.67%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:46.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#ceeeff;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#ceeeff;margin:0pt;padding:0pt;"> 9,416 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#ceeeff;margin:0pt;padding:0pt;"> 13,986 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#ceeeff;margin:0pt;padding:0pt;"> 27,810 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#ceeeff;margin:0pt;padding:0pt;"> 44,828 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,339 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,956 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 29,566 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 40,300 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> $</p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,755</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 26,942</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 71,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.8%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 85,128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ceeeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></td></tr></table><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p> 9416000 13986000 27810000 44828000 10339000 12956000 29566000 40300000 19755000 26942000 57376000 85128000 11780000 P2Y3M18D <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Debt</p><p style="font-family:Times New Roman,Times,serif;font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Liability for sale of future royalties</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:justify;margin:0pt;">The following table shows the activity within the "liability for sale of future royalties- current" and "liability for sale of future royalties- noncurrent" accounts for the nine months ended September 30, 2024:</p><p style="font-family:'Times New Roman', Times, serif;font-size:12pt;text-align:justify;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:69.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:8pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:69.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liability for sale of future royalties- current and noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.4%;background:#ceeeff;margin:0pt;padding:0pt;"> Beginning balance as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.2%;background:#ceeeff;margin:0pt;padding:0pt;"> 1,814,097 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td></tr><tr><td style="vertical-align:bottom;width:69.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">Less: Non-cash royalty revenue payable to Royalty Pharma</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt;">(128,877)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td></tr><tr><td style="vertical-align:bottom;width:69.4%;background:#ceeeff;margin:0pt;padding:0pt;"> Plus: Non-cash interest expense recognized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.2%;background:#ceeeff;margin:0pt;padding:0pt;"> 155,039 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td></tr><tr><td style="vertical-align:bottom;width:69.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">Plus: Cash received from Royalty Pharma</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 241,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td></tr><tr><td style="vertical-align:bottom;width:69.4%;background:#ceeeff;margin:0pt;padding:0pt;"> Ending balance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.2%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,082,031 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#ceeeff;margin:0pt;padding:0pt;"> $ </td></tr><tr><td style="vertical-align:bottom;width:69.4%;margin:0pt;padding:0pt;"> Effective interest rate as of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:22.2%;margin:0pt;padding:0pt;"> 9.9% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> % </td></tr></table> Non-cash interest expense is recorded in the statement of operations within "Interest expense, net". Senior Secured Term Loan On October 27, 2022 (the "Closing Date"), the Company entered into a credit agreement (the "Blackstone Credit Agreement") for fundings of up to $950.0 million consisting of a committed loan facility of $450.0 million and further contemplating the potential for up to $500.0 million of additional financing, to the extent that the Company requested such additional financing and subject to the Lenders' agreement to provide such additional financing and to mutual agreement on terms, among the Company, certain subsidiaries of the Company (together with the Company, the "Loan Parties") and funds and other affiliated entities advised or managed by Blackstone Life Sciences and Blackstone Credit (collectively, "Blackstone", and such lenders, together with their permitted assignees, the "Lenders" and each a "Lender") and Wilmington Trust, National Association, as the administrative agent for the Lenders. The Blackstone Credit Agreement provided for a senior secured term loan facility funded on the Closing Date in the aggregate principal amount of $300.0 million (the "Initial Loans") and a committed delayed draw term loan facility of up to $150.0 million (the "Delayed Draw Loans" and, together with the Initial Loans, the "Loans") to be funded at the Company's request within 18 months of the Closing Date subject to specified conditions. In addition, the Blackstone Credit Agreement contemplated the potential for further financings by Blackstone, by providing for incremental discretionary uncommitted further financings of up to $500.0 million. The Company capitalized approximately $11.6 million of debt issuance costs which are presented on the balance sheet as a direct deduction from the debt liability and are being amortized over the term of the senior secured term loan facility using the effective interest rate method. The Loans were to mature on the date that is seven years from the Closing Date. Borrowings under the Blackstone Credit Agreement bore interest at a variable rate equal to, at the Company's option, either an adjusted Term SOFR rate plus seven and a quarter percent (7.25%) or the Base Rate plus six and a quarter percent (6.25%), subject to a floor of one percent (1%) and two percent (2%) with respect to Term SOFR rate and Base Rate (each as defined in the Blackstone Credit Agreement), respectively. Payment of the Loans were subject to certain premiums specified in the Blackstone Credit Agreement, in each case, from the date of the applicable Loan funded. On October 19, 2023, the Company terminated the Blackstone Credit Agreement. In connection with the termination of the Credit Agreement, the Company repaid outstanding principal of $300.0 million, accrued interest of $2.1 million, an additional $82.0 million in prepayment premiums, exit fees, and creditor expenses, and $0.2 million in legal fees. The Company recorded a loss on the extinguishment of debt of $92.7 million which was included on the statement of operations for the period ended December 31, 2023. The loss on extinguishment of debt consisted of $82.0 million in prepayment premiums, exit fees, and creditor expenses and debt issuance costs of $10.7 million. All liens and security interests securing the loans made pursuant to the Blackstone Credit Agreement were released upon termination. The Blackstone Credit Agreement consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-w

align:center;margin:0pt;"> — </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"> 2 </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:51.24%;background:#ceeeff;margin:0pt;padding:0pt;"> Principal </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;background:#ceeeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;background:#ceeeff;margin:0pt;padding:0pt;"> 300,000 </td></tr><tr><td style="vertical-align:bottom;width:51.24%;background:#ceeeff;margin:0pt;padding:0pt;"> Less: Debt issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:51.24%;background:#ceeeff;margin:0pt;padding:0pt;"> Repayment of senior secured term loan </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;background:#ceeeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;background:#ceeeff;margin:0pt;padding:0pt;"> (300,000) </td></tr><tr><td style="vertical-align:bottom;width:51.24%;margin:0pt;padding:0pt;"> Net carrying amount </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> The following table sets forth total interest expense recognized related to the Blackstone Credit Agreement: — <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%"><tr style="height:1pt;"><td style="vertical-align:middle;width:39.42%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"> Repayment of senior secured term loan </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.15%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"> Amortization of debt issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"> — </td></tr></table> In September 2019, the Company issued, at par value, $287.5 million aggregate principal amount of 1.50% convertible senior notes due 2026, which included an option to purchase up to an additional $37.5 million in aggregate principal amount of the 2026 Convertible Notes, which was exercised in full by the initial purchasers. The 2026 Convertible Notes bear cash interest at a rate of 1.50% per year, payable semi-annually on March 15 and September 15 of each year, beginning on March 15, 2020. The 2026 Convertible Notes will mature on September 15, 2026, unless earlier repurchased or converted. The net proceeds to the Company from the offering were $279.3 million after deducting the initial purchasers' discounts and commissions and the offering expenses payable by the Company. The 2026 Convertible Notes are governed by an indenture (the "2026 Convertible Notes Indenture") with U.S Bank National Association as trustee (the "2026 Convertible Notes Trustee"). Holders of the 2026 Convertible Notes may convert their 2026 Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2026 only under the following circumstances: <table style="border-collapse:collapse;font-family:Times New Roman',Times',serif;font-size:10pt;margin-top:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:Times New Roman',Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">during any calendar quarter commencing on or after December 31, 2019 (and only during such calendar quarter), if the last reported sale price of the Company's common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;</td></tr></table><table style="border-collapse:collapse;font-family:Times New Roman',Times',serif;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:Times New Roman',Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">during the five business day period after any five-consecutive trading day period (the "measurement period") in which the trading price (as defined in the 2026 Convertible Notes Indenture) per $1,000 principal amount of 2026 Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company's common stock and the conversion rate on each such trading day;</td></tr></table><table style="border-collapse:collapse;font-family:Times New Roman',Times',serif;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:Times New Roman',Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">during any period after the Company has issued notice of redemption until the close of business on the scheduled trading day immediately preceding the relevant redemption date; or</td></tr></table><table style="border-collapse:collapse;font-family:Times New Roman',Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td>

<td style="font-family:Times New Roman,Times,serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">upon the occurrence of specified corporate events.</td></tr></table> On or after March 15, 2026, until the close of business on the business day immediately preceding the maturity date, holders may convert their 2026 Convertible Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company's common stock or any combination thereof at the Company's election. The conversion rate for the 2026 Convertible Notes was initially, and remains, 19.0401 shares of the Company's common stock per $1,000 principal amount of the 2026 Convertible Notes, which is equivalent to an initial conversion price of approximately $52.52 per share of the Company's common stock. The conversion rate may be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.</p><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company was not permitted to redeem the 2026 Convertible Notes prior to September 20, 2023. The Company may redeem for cash all or any portion of the 2026 Convertible Notes, at its option, if the last reported sale price of its common stock has been at least 130% of the conversion price then in effect on the last trading day of, and for at least 19 other trading days (whether or not consecutive) during, any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100% of the principal amount of the 2026 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2026 Convertible Notes, which means that the Company is not required to redeem or retire the 2026 Convertible Notes periodically.</p><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the Company undergoes a "fundamental change" (as defined in the 2026 Convertible Notes Indenture), subject to certain conditions, holders of the 2026 Convertible Notes may require the Company to repurchase for cash all or part of their 2026 Convertible Notes at a repurchase price equal to 100% of the principal amount of the 2026 Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</p><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The 2026 Convertible Notes represent senior unsecured obligations and will rank senior in right of payment to the Company's future indebtedness that is expressly subordinated in right of payment to the notes, equal in right of payment to the Company's existing and future unsecured indebtedness that is not so subordinated, effectively junior in right of payment to any of the Company's secured indebtedness to the extent of the value of the assets securing such indebtedness, and structurally subordinated to all existing and future indebtedness and other liabilities (including trade payables) incurred by the Company's subsidiaries. The 2026 Convertible Notes Indenture contains customary events of default with respect to the 2026 Convertible Notes, including that upon certain events of default (including the Company's failure to make any payment of principal or interest on the 2026 Convertible Notes when due and payable) occurring and continuing, the 2026 Convertible Notes Trustee by notice to the Company, or the holders of at least 25% in principal amount of the outstanding 2026 Convertible Notes by notice to the Company and the Convertible Notes Trustee, may, and the 2026 Convertible Notes Trustee at the request of such holders (subject to the provisions of the 2026 Convertible Notes Indenture) shall, declare 100% of the principal of and accrued and unpaid interest, if any, on all the 2026 Convertible Notes to be due and payable. In case of certain events of bankruptcy, insolvency or reorganization, involving the Company or a significant subsidiary, 100% of the principal of and accrued and unpaid interest on the 2026 Convertible Notes will automatically become due and payable. Upon such a declaration of acceleration, such principal and accrued and unpaid interest, if any, will be due and payable immediately.</p><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:justify;margin:0pt;">The 2026 Convertible Notes consist of the following:</p><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:justify;margin:0pt;"> </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:69.49%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Principal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#ceeef;margin:0pt;padding:0pt;"> 287,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#ceeef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#ceeef;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 287,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.49%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,394)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,287)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:69.49%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net carrying amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#ceeef;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#ceeef;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 285,106 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#ceeef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#ceeef;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#ceeef;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 284,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr></table><div style="font-family:Times New Roman,Times,serif;font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September 30, 2024, the remaining contractual life of the 2026 Convertible Notes is approximately 2.0 years.</p><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth total interest expense recognized related to the 2026 Convertible Notes:</p><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"> </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:38.42%;padding:0pt;"><div style="height:1pt;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:1pt;visibility:hidden;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:1pt;visibility:hidden;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:1pt;visibility:hidden;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:1pt;visibility:hidden;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:1pt;visibility:hidden;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:1pt;visibility:hidden;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:1pt;visibility:hidden;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:1pt;visibility:hidden;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:1pt;visibility:hidden;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:1pt;visibility:hidden;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman,Times,serif;font-size:1pt;visibility:hidden;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:38.42%;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;">Contractual interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#ceeef;margin:0pt;padding:0pt;"> 1,081 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#ceeef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeef;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,080</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#ceeef;margin:0pt;padding:0pt;"> 3,224 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#ceeef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeef;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,215</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:middle;width:38.42%;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;">Amortization of debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 294</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 872</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:middle;width:38.42%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-

*family;Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,381 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,374</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,115 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,407</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:middle;width:38.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;">Effective interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1.9%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1.9%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></td></tr></table><p style="font-family:Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p> <p style="font-family:Times New Roman';Times';serif;font-size:12pt;text-align:justify;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:69.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:69.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liability for sale of future royalties- (current and noncurrent)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:69.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;">Beginning balance as of December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.2%;background:#cceeff;margin:0pt;padding:0pt;"> 1,814,097 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td></tr><tr><td style="vertical-align:bottom;width:69.4%;margin:0pt;padding:0pt;"> Less: Non-cash royalty revenue payable to Royalty Pharma </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.2%;margin:0pt;padding:0pt;"> (128,877) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td></tr><tr><td style="vertical-align:bottom;width:69.4%;background:#cceeff;margin:0pt;padding:0pt;"> Plus: Non-cash interest expense recognized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.3%;background:#cceeff;margin:0pt;padding:0pt;"> 155,039 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.4%;margin:0pt;padding:0pt;"> Plus: Cash received from Royalty Pharma </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 241,792 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.4%;background:#cceeff;margin:0pt;padding:0pt;"> Ending balance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,082,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:69.4%;margin:0pt;padding:0pt;">Effective interest rate as of September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">9.9%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></td></tr></table> *1814097000 128877000 155039000 241792000 2082051000 0.099 950000000.0 450000000.0 500000000.0 300000000.0 150000000.0 P18M 500000000.0 11600000 P7Y 0.0725 0.0625 0.01 0.02 300000000.0 2100000 82000000.0 200000 -92700000 82000000.0 10700000 <p style="font-family:'Times New Roman';Times';serif;font-size:12pt;text-align:justify;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:51.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;">Principal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 300,000</p></td></tr><tr><td style="vertical-align:bottom;width:51.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;">Less: Debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:51.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;">Repayment of senior secured term loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;text-align:right;margin:0pt;">(300,000)</p></td></tr><tr><td style="vertical-align:bottom;width:51.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;">Net carrying amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> *300000000 300000000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:39.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.15%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.53%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"> <span style="font-size:8pt;visibility:

style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:center;margin:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.15%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:middle;width:39.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> Contractual interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">9,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"> 28,087 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:39.42%;margin:0pt;padding:0pt;"> Amortization of debt issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 280 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 702 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:39.42%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">28,779</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">Effective interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">13.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13.1 </td></tr></table><table cellpadding="0" cellspacing="0" id="z" style="font-family:Times New Roman;font-size:10pt;margin:0pt;padding:0pt;width:100%;"><tr><td> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%"><tr style="height:1pt"><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.49%;margin:0pt;padding:0pt;"> Principal </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">287,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"> 287,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.49%;background:#cceeff;margin:0pt;padding:0pt;"> Less: Debt issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,394) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,287) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.49%;background:#cceeff;margin:0pt;padding:0pt;"> Net carrying amount </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">285,106</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 284,213 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table>287500000 287500000 2394000 3287000 285106000 284213000 P2Y <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%"><tr style="height:1pt;"><td style="vertical-align:middle;width:38.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:38.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman'

*Roman','Times','serif;font-size:10pt;margin:0pt;"> <style="font-family:'Calibri','Helvetica','sans-serif;font-size:11pt;"> — </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td> <td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"> </td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td> <td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td></tr> <tr><td style="vertical-align:middle;width:38.42%;background:#ceeef;margin:0pt;padding:0pt;"> Contractual interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ceeef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeef;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;background:#ceeef;margin:0pt;padding:0pt;"> 1,080 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#ceeef;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeef;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;">3,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#ceeef;margin:0pt;padding:0pt;"> 3,215 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#ceeef;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:38.42%;margin:0pt;padding:0pt;"> Amortization of debt issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 300 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">294</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 872 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:38.42%;background:#ceeef;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ceeef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1,381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,374 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#ceeef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">4,115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#ceeef;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#ceeef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,087 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#ceeef;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:38.42%;margin:0pt;padding:0pt;"> Effective interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1.9 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1.9 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1.9 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1.9 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> % </td></tr></table> 0 0 0

align:justify;margin:0pt;">For the three and nine months ended September 30, 2024, the Company did not recognize collaboration revenue related to the SMA License Agreement with Roche. For the three and nine months ended September 30, 2023, the amounts recognized for the collaboration revenue related to the SMA License Agreement with Roche were immaterial. In addition to research and development and sales milestones, the Company is eligible to receive up to double-digit royalties on worldwide annual net sales of a commercial product under the SMA license Agreement. For the three and nine months ended September 30, 2024, the Company has recognized $61.4 million and $145.7 million of royalty revenue, respectively, related to Evrysdi. For the three and nine months ended September 30, 2023, the Company has recognized $50.2 million and $117.9 million of royalty revenue related to Evrysdi, respectively. Manufacturing Revenue For the three months ended September 30, 2024, the Company did not recognize any revenue related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. For the nine months ended September 30, 2024, the Company recognized $1.7 million of manufacturing revenue related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. For the three and nine months ended September 30, 2023, the Company recognized $2.4 million and $6.7 million of manufacturing revenue, respectively, related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. The Company has not made significant changes to the judgments made in applying ASC Topic 606 for the three and nine months ended September 30, 2024 and 2023. As of September 30, 2024, the Company does not have a contract liabilities balance related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. As of December 31, 2023, the Company had a contract liabilities balance of $0.8 million related to the production of plasmid DNA and AAV vectors for external customers, which is recorded within deferred revenue on the consolidated balance sheet. For the nine months ended September 30, 2024, the Company recognized $0.8 million related to the amounts included in the contract liability balance at the beginning of the period. As of September 30, 2024, the Company has no contract assets related to plasmid DNA and AAV production for external customers. As of December 31, 2023, the Company had contract assets of $0.2 million related to plasmid DNA and AAV production for external customers, which is recorded within prepaid expenses and other current assets on the consolidated balance sheet. In June 2024, the Company sold its gene therapy manufacturing business in Hopewell Township, New Jersey. Accordingly, the Company does not expect to have manufacturing revenue going forward. Remaining performance obligations There are no remaining performance obligations as of September 30, 2024. The Company's remaining performance obligations of $0.8 million as of December 31, 2023 were fully recognized during the nine months ended September 30, 2024. </p> 1 1 1 1 83500000 76600000 72300000 69000000.0 51900000 67400000 2 0.10 51900000 29200000 1 0.10 67400000 2 3 0.10 0.10 289500000 318500000 246200000 280600000 156700000 187700000 3 0.10 156700000 68300000 55700000 3 0.10 187700000 69000000.0 52500000 2 2 0.10 0.10 0 0 135000000.0 325000000.0 1 0 150000000.0 0 0 0 61400000 145700000 50200000 117900000 1700000 2400000 6700000 0 800000 800000 0 200000 0 800000 <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Intangible assets and goodwill</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Definite-lived intangibles</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Definite-lived intangible assets consisted of the following at September 30, 2024 and December 31, 2023:</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ending Balance at</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ending Balance at</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:43.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Definite-lived</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">currency</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:43.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intangibles assets, gross</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">translation</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:43.2%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;">Emflaza</p></td><td style="vertical-align:bottom;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#ceeeff;margin:0pt;padding:0pt;"> 527,417 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#ceeeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#ceeeff;margin:0pt;padding:0pt;"> 527,417 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ceeeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.2%;margin:0pt;padding:0pt;"> Wayllirа </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> 10,218 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"> 2,732 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"> 183 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> 13,133 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.2%;background:#ceeeff;margin:0pt;padding:0pt;"> Tegsedi </td><td style="vertical-align:bottom;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#ceeeff;margin:0pt;padding:0pt;"> 13,322 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#ceeeff;margin:0pt;padding:0pt;"> 5,262 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"> 253 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#ceeeff;margin:0pt;padding:0pt;"> 18,844 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ceeeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.2%;margin:0pt;padding:0pt;"> Upstaza </td><td style="vertical-align:bottom;width:1.

family;Times New Roman',Times,serif;font-size:10pt;margin:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.2%;background:#ceeeff;margin:0pt;padding:0pt;"> Total definite-lived intangibles, gross </td><td style="vertical-align:bottom;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 640,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#ceeeff;margin:0pt;padding:0pt;"> 8,001 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#ceeeff;margin:0pt;padding:0pt;"> 648,944 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ceeeff;margin:0pt;padding:0pt;"> </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.69%;margin:0pt;padding:0pt;"></td><td style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> Ending Balance at </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"> Foreign </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> Ending Balance at </td></tr><tr><td style="vertical-align:bottom;width:43.69%;margin:0pt;padding:0pt;"> Definite-lived </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"> currency </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:43.69%;margin:0pt;padding:0pt;"> Intangibles assets, accumulated amortization </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amortization </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> translation </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;width:43.69%;background:#ceeeff;margin:0pt;padding:0pt;"> Emflaza </td><td style="vertical-align:bottom;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt;"> (478,618)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#ceeeff;margin:0pt;padding:0pt;"> (48,799) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman,Times,serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#ceeeff;margin:0pt;padding:0pt;"> (527,417) </td></tr><tr><td style="vertical-align:bottom;width:43.69%;margin:0pt;padding:0pt;"> Waylivra </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> (3,965) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> (1,187) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"> (63) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> (5,215) </td></tr><tr><td style="vertical-align:bottom;width:43.69%;background:#ceeeff;margin:0pt;padding:0pt;"> Tegsedi </td><td style="vertical-align:bottom;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#ceeeff;margin:0pt;padding:0pt;"> (3,311) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#ceeeff;margin:0pt;padding:0pt;"> (1,847) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#ceeeff;margin:0pt;padding:0pt;"> (72) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#ceeeff;margin:0pt;padding:0pt;"> (5,230) </td></tr><tr><td style="vertical-align:bottom;width:43.69%;margin:0pt;padding:0pt;"> Upstaza </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:

Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:43.69%;background:#cceef;margin:0pt;padding:0pt;"> Total definite-lived intangibles, net </td><td style="vertical-align:middle;width:1.49%;background:#cceef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceef;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:10.66%;background:#cceef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.49%;background:#cceef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceef;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceef;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 94,602 </td></tr></table> Marathon was entitled to receive contingent payments from the Company based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over the expected commercial life of the asset, which expired February 2024. In accordance with the guidance for an asset acquisition, the Company recorded the milestone payments when they became payable to Marathon and increased the cost basis for the Emflaza rights intangible asset. As of September 30, 2024, the Emflaza rights intangible asset was fully amortized, therefore, milestones are recorded on the consolidated statement of operations within cost of product sales, excluding amortization of acquired intangible assets from February 2024 onward. Akcea is entitled to receive royalty payments subject to certain terms set forth in the Tegsedi-Waylivra Agreement related to sales of Waylivra and Tegsedi. In accordance with the guidance for an asset acquisition, the Company records royalty payments when they become payable to Akcea and increase the cost basis for the Waylivra and Tegsedi intangible assets. For the nine months ended September 30, 2024, royalty payments of $5.3 million and $2.7 million were recorded for Tegsedi and Waylivra, respectively. As of September 30, 2024, a royalty payable of $1.9 million and $0.5 million for Tegsedi and Waylivra, respectively, was recorded on the consolidated balance sheet within accounts payable and accrued expenses. For the three months ended September 30, 2024 and 2023, the Company recognized amortization expense of $3.0 million and $58.6 million, respectively, related to the Emflaza rights, Upstaza, Waylivra, and Tegsedi intangible assets. For the nine months ended September 30, 2024 and 2023, the Company recognized amortization expense of $57.4 million and $145.5 million, respectively, related to the Emflaza rights, Upstaza, Waylivra, and Tegsedi intangible assets. The estimated future amortization of the Upstaza, Waylivra, and Tegsedi intangible assets is expected to be as follows: </p><p style="font-family:Times New Roman','Times',serif;font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.84%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;background:#cceef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,043</p></td><td style="vertical-align:bottom;width:71.84%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12,160</p></td></tr><tr><td style="vertical-align:bottom;width:71.84%;background:#cceef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;background:#cceef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12,160</p></td></tr><tr><td style="vertical-align:bottom;width:71.84%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12,160</p></td></tr><tr><td style="vertical-align:bottom;width:71.84%;background:#cceef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt;">2028 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;background:#cceef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 55,079</p></td></tr><tr><td style="vertical-align:bottom;width:71.84%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 94,602 </td></tr></table> The weighted average remaining amortization period of the definite-lived intangibles as of September 30, 2024 is 9.7 years. Indefinite-lived intangible assets consist of the following as of September 30, 2024 and December 31, 2023: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:42.95%;margin:0pt;padding:0pt;"> Indefinite-lived </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> Ending Balance at </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"> Indefinite-lived </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"> Intangibles assets </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Additions </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Impairment </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.95%;background:#cceef;margin:0pt;padding:0pt;"> Upstaza </td><td style="vertical-align:bottom;width:1.49%;background:#cceef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 235,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceef;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceef;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 235,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceef;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceef;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-

align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> 235,766 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.05%;background:#ceeeff;margin:0pt;padding:0pt;"> Goodwill </td><td style="vertical-align:bottom;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#ceeeff;margin:0pt;padding:0pt;"> Goodwill </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#ceeeff;margin:0pt;padding:0pt;"> Goodwill </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#ceeeff;margin:0pt;padding:0pt;"> Goodwill </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"> Goodwill </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"> Goodwill </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ceeeff;margin:0pt;padding:0pt;"> Goodwill </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#ceeeff;margin:0pt;padding:0pt;"> Goodwill </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#ceeeff;margin:0pt;padding:0pt;"> Goodwill </td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"> Total intangible assets, net </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 330,368 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td></tr></table> In connection with the acquisition of the Company's gene therapy platform from Agilis, the Company acquired rights to Upstaza, for the treatment of AADC deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase gene. In accordance with the acquisition method of accounting, the Company allocated the acquisition cost for the Agilis Merger to the underlying assets acquired and liabilities assumed, based upon the estimated fair values of those assets and liabilities at the date of acquisition. The Company classified the fair value of the acquired IPR&D as indefinite lived intangible assets until the successful completion or abandonment of the associated research and development efforts. There have been no changes to the indefinite lived intangible asset balance since the year ended December 31, 2023. Accordingly, the indefinite lived intangible asset balance as of September 30, 2024 is $235.8 million. As a result of the Agilis Merger on August 23, 2018, the Company recorded $82.3 million of goodwill. As of September 30, 2024, there have been no changes to the balance of goodwill since the date of the Agilis Merger. Accordingly, the goodwill balance as of September 30, 2024 is $82.3 million.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ending Balance at</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">currency</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:43.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:8pt;margin:0pt;"><b style="font-weight:bold;">intangibles assets, gross</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:8pt;margin:0pt;"><b style="font-family:Calibri, Helvetica, sans-serif;font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:Calibri, Helvetica, sans-serif;font-weight:bold;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Additions </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:Calibri, Helvetica, sans-serif;font-weight:bold;">translation</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:Calibri, Helvetica, sans-serif;font-weight:bold;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2022 </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:Calibri, Helvetica, sans-serif;font-weight:bold;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Foreign </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> Ending Balance at </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.2%;margin:0pt;padding:0pt;"> Definite-lived </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> Additions </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"> translation </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> 2022 </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"> translation </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> 2021 </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"> Impairment </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> 2022 </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"> Amortization </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> 2021 </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:center;margin:0

size:11pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;">   </td></tr> <tr><td style="vertical-align:bottom;width:43.2%;margin:0pt;padding:0pt;"> Upstaza </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   89,550 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 89,550 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.2%;background:#cceeff;margin:0pt;padding:0pt;"> Total definite-lived intangibles, gross </td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 640,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"> 8,001 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"> 648,944 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td><table><tr><td style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"> <td style="vertical-align:bottom;width:43.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.69%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> Ending Balance at </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"> Foreign </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> Ending Balance at </td></tr><tr><td style="vertical-align:bottom;width:43.69%;margin:0pt;padding:0pt;"> Definite-lived </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"> currency </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:43.69%;margin:0pt;padding:0pt;"> Intangibles assets, accumulated amortization </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> translation </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;width:43.69%;background:#cceeff;margin:0pt;padding:0pt;"> Emflaza </td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (478,618)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"> (48,799) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:Times New Roman',Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"> (527,417) </td></tr><tr><td style="vertical-align:bottom;width:43.69%;margin:0pt;padding:0pt;"> Wayhra </td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> (3,965) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> (1,187) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"> (63) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"> (5,215) </td></tr><tr><td style="vertical-align:bottom;width:43.69%;background:#cceeff;margin:0pt;padding:0pt;"> Tegsedi </td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"> (3,311) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"> (1,847) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"> (72) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"> (5,230) </td></tr><tr><td style="vertical-align:bottom;width:43.69%;margin:0pt;padding:0pt;"> Upstaza </td><td style="vertical-align:bottom;width:1.49%;

align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (135)</p></td><td style="vertical-
align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-
align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (554,342)</p></td></tr><tr><td style="vertical-
align:bottom;width:43.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-
align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-
size:11pt;visibility:hidden;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td></tr><tr><td style="vertical-align:middle;width:43.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Total definite-lived intangibles, net</p></td><td style="vertical-
align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8pt;font-weight:bold;margin-
left:0pt;visibility:hidden;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td
style="vertical-align:middle;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-
weight:bold;visibility:hidden;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-
weight:bold;visibility:hidden;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 94,602</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p> 527417000 527417000 10218000 2732000 183000 13133000 13322000 5269000 253000 18844000 89550000 89550000 640507000 8001000 436000 648944000 478618000 48799000 527417000 3965000
1187000 -63000 5215000 3311000 1847000 -72000 5230000 10882000 5598000 16480000 496776000 57431000 -135000 554342000 94602000 5300000 2700000 1900000 500000 3000000.0 58600000 57400000 145500000 <p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-
right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-
align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times
New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-
size:1pt;visibility:hidden;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-
align:bottom;width:71.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">   </p></td><td colspan="2" style="vertical-align:bottom;white-
space:nowrap;width:26.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-
weight:bold;">As of September 30, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:71.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt
3.6pt 0pt 0pt;"> 3,043</p></td></tr><tr><td style="vertical-align:bottom;width:71.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-
align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-
space:nowrap;width:24.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12,160</p></td></tr><tr><td style="vertical-
align:bottom;width:71.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-
space:nowrap;width:24.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12,160</p></td></tr><tr><td style="vertical-
align:bottom;width:71.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12,160</p></td></tr><tr><td style="vertical-align:bottom;width:71.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt;">2028 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 55,079</p></td></tr><tr><td style="vertical-align:bottom;width:71.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt 3.6pt 0pt 0pt;"> 94,602</p></td></tr></table> 3043000 12160000 12160000 12160000 55079000 94602000 P8Y8M12D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;">
</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-
align:bottom;width:42.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-
size:1pt;visibility:hidden;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-
align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times
New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-
size:1pt;visibility:hidden;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-
align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times
New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-
size:1pt;visibility:hidden;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-
align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times
New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-
size:1pt;visibility:hidden;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div
style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-
align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times
New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div
style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-
size:1pt;visibility:hidden;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">
</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ending Balance at</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-
space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-
weight:bold;visibility:hidden;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ending Balance at</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times
New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Indefinite-lived</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p
style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-
size:8pt;visibility:hidden;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-
size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times
New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td></tr><tr><td
style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">intangibles assets</p></td><td style="vertical-
align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">   </p></td><td style="vertical-
align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">
<b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-
family:'Calibri','Helvetica','sans-serif';font-weight:bold;">   </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">   </p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td
style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-
weight:bold;">Impairment</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-
family:'Calibri','Helvetica','sans-serif';font-weight:bold;">   </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
<p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">   </p></td></tr><tr><td style="vertical-
align:bottom;width:42.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Upstaza</p></td><td style="vertical-
align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td
style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt
0pt 0pt;"> 235,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">
</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New
Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-
family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid
#000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;border-
bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-
space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-
align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td
style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt
0pt 0pt;"> 235,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">
</p></td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-
weight:bold;">Total indefinite-lived intangibles</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-
size:8pt;font-weight:bold;visibility:hidden;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-
align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">
235,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">

</p></td></tr></table></td></tr></table></td></tr>

*65LZPGEiN#/'ML%|H3NMEn-^TJ?V5$M5|6SCKLCZ%-6=,4VC XM.\%*&@<-%9GW^:?AAOCZC546_F)#5^>[(\>*L:CMG^05CT8)·MO2D%1516^L·C.V&E_T2, PiOSC%$_+#EYI$+f)M3X^O#CPR_M @@ZQ_D4@<##?9Tj9A;#KLW12RF_B$?/E!-(TT(-2]X;AHR/9^.4'/N0D=& MHS<+, ^U^G[?]38P6.'NR(+')=»)O);.4'Q;ACQB>'CH$ZK9/<3($0.GG;0\ M1.!TANOC72MG39:MPC/,V(<<<$H4425_?/71CZ0%.XT2P/FOD.C"Z MK;?-EDT0" X@3T2=.09T11_H,.CKM B#*181#^C)J*VQ.K M1B'8S/.5(2J9 V4Q,.308&0.N%6[M)*F3^%, [PD3D7ZSHOLE&!9UDLCDVBM#0^*#MERS^D4,[T;NHC/<M<K8524E\9&B+V4B+/3&Q+#*3@5+B$#.3K5711YF:4L)V.AJ?NG)6), (PH MTQ?EN_J;Q==,\P07ID.!-P813[.*:[7VRP\fXH@KTD M78K%%@'OQ@&[@.4=(-"„;>3]Z;87Q5@RVPHZH0^{ON]D&*$W@\%*$T45*N M-X85W;,B,.0N TCRC3[HE %(#%.E> !S5;BZEF>1-2,A3,$?! -RXPRV MOAFT&8((#=MW-TH^2-V^R=B5^TV%?<ZV% *9M=3-Z3P4B,3TC07$=-][# ,] MHA,3IV04?5)\%*(BX$%%*$>]=[=]35$J,NC<#D?. ,YR2V0 MCK$5424V$?YBRCG]^2R1BM(E>15$6FC?)OT-[PHA,=$2E^NCFH3/, '=+88CU MK*,24+/_-N$H]-M=5D339+?,2E7[,0;BJ2:?8+),T-NPB&T4JQXT1HH][! MQ#"B3-D^?IW'47827,KKE'44I.EQ64GHHPCP5])!7V[^.|D$&,UN=,,=0 M!CV,C4E3B^K.6[LM.52#^3RSC%M1.!BM3Z2*=U=9JW1/$$K_"O%Z^5ZWF M53X>?MZTIW5L8[K$I\+T)PO,)G<H1A3$FG3--,_69.10P-fB6N/^UDZ?5Q M&%=D[B'1ABU0R0/-@VQ[E.4+90>)B%\>33W94PK=1I>$$LZWUDRWOOP MO<%4,[,BM(*Z^[.#=>U0UB;(AHKTFGV.KO]8.?A.04'.CL-W.^'#6[(][M*\78]B5$24E\@%)6I2@HH [M<%I9B[W

\)HM.R^YN_>'/<9W/DI0H/ÆW^M+HRYCU#+J+7==3]!5_W77|0ON?8!FKRY%BB)2-4.U-]K76$0.D/.:.3NET M3^F-#<CI&C<IHH9]/:@<&EM=/65(<T=75(GTS&XG'O^$(842|G>9^$<&)s$]=) MG^T7>5D W:RUW=3HZ.LY:F&>A-A%|NF^4-UIR);U_£ FET-RX7L5YQ#;W M+' ^]H[+'K,1 -+/A]YFE6E3OCC;=64,U -1/5+%2S4G,7 M1HOPRT)69V>)LFP=%OCSA2C3294,U#-1#5+/VP+ !:Q2H_6DYR=T!0D]5/-1 M+,"T=MZ:8!*N+B;]?0V7<K~]N-;!VTAX1]!]9]&:AFHU#]IY],:A MFH]|:6U\|KTE?KJOM(/?#ZFEEL?0[@8Z0-=V]MRR+7Z,9R<4+32A&H6JMEH]'BVH>]OFV=h:,Z6{%S-3=YS*BZ)-YZMI@#*ZM2K6DGN7D2YQ4/V MDF5L-< 8BYZ05SUC+WO&?O>,Q? 0> ^6SOZ.%U&(]2\-4=1/6TBH@']:%EBH]%MFHY]:BVH>]OFV#=.]:

*?G_M|60U(/)*49,2*AFHIK5[SAGT60\&8WV-MC|@*ISK'3NNBTWHY]-0&GMJ#6-1+ZZD<0@+17,KH9]!.B;6:AFHY#-BZ]>?M#MI56[AD M|=%@ZY]@:46MD:,-6D@;|8=.1Z\'.T:E;/R%*MG)Q8M,"&.B;6:AFHYMS,"R<=5Z;&)W50547U0)*.V>DJ28-.MU-6D:MDY3Q8SF%JE=3!,;J,AFKG\O*0$IK%C,7'!=Q=$K_ .M)C?)TGZ4'-$2>1+B^.WN&3;[AFJ(0]:A]V.CFL%KK&@=&CP63 Y^KHI2J M'=,@64%||M*V-:*Ns?TNL)OFH%E:.YA-QVB=[AQ3D1=LMP0O4^5<]3SG9QC/ OJ&:B MFH5J-]HY],.BH=-]J#%E_,=E-<&@IG2!@9214,U# 4-1#+U6Q4FC#10GR'4VNK]?:5L >%D-]D.HVV%Z@<]HWK720W@]+<1-& M5)B&Z5>9BIMPL3ZXCH1G2\UE,00S[AU2;,1)U0Q4,U:-]K7=04,%Z/0ZM+5 M>[KHA!Z[^:@64%HJDT?:.#N(WWZGO/3W6#U?>G8&TH9]:A.IV.CFH)+ M:AZ]^:@64%HKV\.F[S3L ?C{Q\M,Z&=6HFJEFH9].@VHN]GFHY].+0&GM MQ#9M]Z4G&=-]\B358KP)M#=]^(RN?/*WJOZUQ]Y_R7\T&85]FH9@6T/.M+]>'G<'1P'.]=TCJG21-?T4,T/U#8#2VDEO>.E]=#.0 *.+*TLVE9X>.*B<T,Z>H9>2-

6QB=eF.3'4/OQCf7,B92"0D$2^$?-].M^X\"W<.-I.^4AX< G^NEPAFUY1DMROUL_DD>B>.;2'W GVT+'$SGP=74 (Y2H M;@M9GU*TK>TASV5]M-%UKT^(E.NOHSRF'EAGI30.6%UX/+1\|\"|.' M^0 &0 'AL+W=O .0]]25"THCA.*E[=@^9XYG)AZ/-M-D(NU0) HRVC7(V#A*=.E51B]?.$.JYXH@0N5F0.,v/*>.+A**)AP(&#)(K2 MDS"@VSDYAYD-A(K30F!XG4ABC$1=Q.&.@C,XF_.)KE'VTGPFQ4XCE.03^5 M#!)B8Y07(0)&^%,@@[.@ J#.WMA38-%WABBU3&;QUTX/S%.XE.[+^.%Y)(:4%$X+K42)W MQC#B. 3XTRFOYR5[^)&DEGs+90=WH!TBI-"UZW#T75\W1:\SYBNL^^70O2-.MSNEI+LTTIE.Z4B7.81R8.T6!?s.0?)\6I\^@6F2COVI:FIDUB-$B6 MS@&'\!2G3?L&?]>R1*$7-Y:\'?C\U6RGO"2=LO9ITM (&.+.TE\?3F!+3 M+Q Y)84.6F/W2-3R8B8!$.$FMZ 7DE@#.L,%52"$(KQC]HVCARQ/8F7E+1 M)'KVXUSX\A!T6ONZ9%-$6U4UX;.<[]%AQG,.7XI=VN5+#LEP .RPMM39=#* M_&&WA?NZT:?4U(#%58R7K)+KGXR'JKBKXZ'7TK0Y1*%R7U)\07E5!&_I[_=.& M3'C4GQ(N>O\"N5B0;50C 5L_/]XICWUL-T_3>ZQG//3#"G,#+#3L#.0%*9X.%6L ^KVUXUX;

*A0#% @ =#1G67EDOZ&"}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iP #$T !D ("!I2 ' 'AL+W=O)D(>&PO=VJR:W-H965T&U14&L! A0#% @ =#1G666+6DI U @)@4 !D M ("!,S('AL+W=O@ &0 @(&?- (>&PO M=VJR:W-H965T (M ',& 9 " @), @(%;'W;W)K&U14&L! A0#% @ =#1G60D5MDF? P Q1, !D ("! M8D('AL+W=O&PO=VJR:W-H965T7!E&U14&L%!@ !4 %0 O < %A8 @ $! end XML 89 Show;js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR*

e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref="((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}}

if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style.display){e.style.display='none'}else{e.style.display=''}};setTimeout(function(){ try{ var myStyle=document.createElement('style'); myStyle.type="text/css"; myStyle.innerText="@media print{ .hide-print{ display:none; } }"; document.getElementsByTagName("head")[0].appendChild(myStyle); }catch(e){} }, 1000); */ /* XBRL - DOCUMENT /* Updated 2009-11-04 */ v2.3.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.vid { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black} .report .rou table td, .report .reu table td { border-bottom: 0px solid black} } /* styles for footnote marker */ .report .fn { white-space: nowrap} } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap} } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none} } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 92 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 391 468 1 false 105 0 false 15 false false R1.htm 995200090 - Document - Cover Sheet http://www.ptcbio.com/role/DocumentCover Cover 1 false false R2.htm 995200100 - Statement - Consolidated Balance Sheets Sheet http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 995200105 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.ptcbio.com/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 995200200 - Statement - Consolidated Statements of Operations Sheet http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 995200300 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.ptcbio.com/role/StatementConsolidatedStatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 995200400 - Statement - Consolidated Statements of Stockholders' Deficit Sheet http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficit Consolidated Statements of Stockholders' Deficit Statements 6 false false R7.htm 995200500 - Statement - Consolidated Statements of Cash Flows Sheet http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 995210101 - Disclosure - The Company Sheet http://www.ptcbio.com/role/DisclosureCompany The Company Notes 8 false false R9.htm 995210201 - Disclosure - Summary of significant accounting policies Sheet http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of significant accounting policies Notes 9 false false R10.htm 995210301 - Disclosure - Leases Sheet http://www.ptcbio.com/role/DisclosureLeases Leases Notes 10 false false R11.htm 995210401 - Disclosure - Fair value of financial instruments and marketable securities Sheet http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecurities Fair value of financial instruments and marketable securities Notes 11 false false R12.htm 995210501 - Disclosure - Accounts payable and accrued expenses Sheet http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpenses Accounts payable and accrued expenses Notes 12 false false R13.htm 995210601 - Disclosure - Capitalization Sheet http://www.ptcbio.com/role/DisclosureCapitalization Capitalization Notes 13 false false R14.htm 995210701 - Disclosure - Net loss per share Sheet http://www.ptcbio.com/role/DisclosureNetLossPerShare Net loss per share Notes 14 false false R15.htm 995210801 - Disclosure - Stock award plan Sheet http://www.ptcbio.com/role/DisclosureStockAwardPlan Stock award plan Notes 15 false false R16.htm 995210901 - Disclosure - Debt Sheet http://www.ptcbio.com/role/DisclosureDebt Debt Notes 16 false false R17.htm 995211001 - Disclosure - Commitments and contingencies Sheet http://www.ptcbio.com/role/DisclosureCommitmentsAndContingencies Commitments and contingencies Notes 17 false false R18.htm 995211101 - Disclosure - Revenue recognition Sheet http://www.ptcbio.com/role/DisclosureRevenueRecognition Revenue recognition Notes 18 false false R19.htm 99521200 - Disclosure - Intangible assets and goodwill Sheet http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwill Intangible assets and goodwill Notes 19 false false R20.htm 995211301 - Disclosure - Subsequent events Sheet http://www.ptcbio.com/role/DisclosureSubsequentEvents Subsequent events Notes 20 false false R21.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://sbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 21 false false R22.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://sbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 22 false false R23.htm 99920202 - Disclosure - Summary of significant accounting policies (Policies) Sheet http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of significant accounting policies (Policies) Policies 23 false false R24.htm 99930203 - Disclosure - Summary of significant accounting policies (Tables) Sheet http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of significant accounting policies (Tables) Tables http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies 24 false false R25.htm 99930303 - Disclosure - Leases - (Tables) Sheet http://www.ptcbio.com/role/DisclosureLeasesTables Leases - (Tables) Tables 25 false false R26.htm 99930403 - Disclosure - Fair value of financial instruments and marketable securities - (Tables) Sheet http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesTables Fair value of financial instruments and marketable securities - (Tables) Tables http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecurities 26 false false R27.htm 99930503 - Disclosure - Accounts payable and accrued expenses - (Tables) Sheet http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables Accounts payable and accrued expenses - (Tables) Tables http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpenses 27 false false R28.htm 99930703 - Disclosure - Net loss per share - (Tables) Sheet http://www.ptcbio.com/role/DisclosureNetLossPerShareTables Net loss per share - (Tables) Tables http://www.ptcbio.com/role/DisclosureNetLossPerShare 28 false false R29.htm 99930803 - Disclosure - Stock award plan - (Tables) Sheet http://www.ptcbio.com/role/DisclosureStockAwardPlanTables Stock award plan - (Tables) Tables http://www.ptcbio.com/role/DisclosureStockAwardPlan 29 false false R30.htm 99930903 - Disclosure - Debt - (Tables) Sheet http://www.ptcbio.com/role/DisclosureDebtTables Debt - (Tables) Tables 30 false false R31.htm 99931203 - Disclosure - Intangible assets and goodwill - (Tables) Sheet http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillTables Intangible assets and goodwill - (Tables) Tables http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwill 31 false false R32.htm 99940101 - Disclosure - The Company (Details) Sheet http://www.ptcbio.com/role/DisclosureCompanyDetails The Company (Details) Details http://www.ptcbio.com/role/DisclosureCompany 32 false false R33.htm 99940201 - Disclosure - Summary of significant accounting policies - Narrative (Details) Sheet http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails Summary of significant accounting policies - Narrative (Details) Details 33 false false R34.htm 99940202 - Disclosure - Summary of significant accounting policies - Reconciliation of cash (Details) Sheet http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails Summary of significant accounting policies - Reconciliation of cash (Details) Details 34 false false R35.htm 99940203 - Disclosure - Summary of significant accounting policies - Inventory (Details) Sheet http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails Summary of significant accounting policies - Inventory (Details) Details 35 false false R36.htm 99940204 - Disclosure - Summary of significant accounting policies - Collaboration and Royalty Revenue (Details) Sheet http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails Summary of significant accounting policies - Collaboration and Royalty Revenue (Details) Details 36 false false R37.htm 99940205 - Disclosure - Summary of significant accounting policies - Manufacturing Revenue (Details) Sheet http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesManufacturingRevenueDetails Summary of significant accounting policies - Manufacturing Revenue (Details) Details 37 false false R38.htm 99940206 - Disclosure - Summary of significant accounting policies - Liability for Sale of Future Royalties (Details) Sheet http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails Summary of significant accounting policies - Liability for Sale of Future Royalties (Details) Details 38 false false R39.htm 99940207 - Disclosure - Summary of significant accounting policies - Tangible Asset Impairment and Losses (Gains) on Transactions, Net (Details) Sheet http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTangibleAssetImpairmentAndLossesGainsOnTransactionsNetDetails Summary of significant accounting policies - Tangible Asset Impairment and Losses (Gains) on Transactions, Net (Details) Details 39 false false R40.htm 99940301 - Disclosure - Leases - Narrative (Details) Sheet http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails Leases - Narrative (Details) Details 40 false false R41.htm 99940302 - Disclosure - Leases - Lease costs (Details) Sheet http://www.ptcbio.com/role/DisclosureLeasesLeaseCostsDetails Leases - Lease costs (Details) Details 41 false false R42.htm 99940303 - Disclosure - Leases - Supplemental lease terms (Details) Sheet http://www.ptcbio.com/role/DisclosureLeasesSupplementalLeaseTermsDetails Leases - Supplemental lease terms (Details) Details 42 false false R43.htm 99940304 - Disclosure - Leases - Cash flow (Details) Sheet http://www.ptcbio.com/role/DisclosureLeasesCashFlowDetails Leases - Cash flow (Details) Details 43 false false R44.htm 99940305 - Disclosure - Leases - Lease payments (Details) Sheet http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails Leases - Lease payments (Details) Details 44 false false R45.htm 99940401 - Disclosure - Fair value of financial instruments and marketable securities - Marketable Securities (Details) Sheet http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails Fair value of financial instruments and marketable securities - Marketable Securities (Details) Details 45 false false R46.htm 99940402 - Disclosure - Fair value of financial instruments and marketable securities - Hierarchy (Details) Sheet http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails Fair value of financial instruments and marketable securities - Hierarchy (Details) Details http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecurities 46 false false R47.htm 99940403 - Disclosure - Fair value of financial instruments and marketable securities - Marketable Securities, Unrealized Gains (Losses) (Details) Sheet http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesUnrealizedGainsLossesDetails Fair value of financial instruments and marketable securities - Marketable Securities, Unrealized Gains (Losses) (Details) Details 47 false false R48.htm 99940404 - Disclosure - Fair value of financial instruments and marketable securities - Available-for-sale securities (Details) Sheet http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleSecuritiesDetails Fair value of financial instruments and marketable securities - Available-for-sale securities (Details) Details 48 false false R49.htm 99940405 - Disclosure - Fair value of financial instruments and marketable securities - Marketable Securities, Balance Sheet Disclosures (Details) Sheet http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesBalanceSheetDisclosuresDetails Fair value of financial instruments and marketable securities - Marketable Securities, Balance Sheet Disclosures (Details) Details 49 false false R50.htm 99940406 - Disclosure - Fair value of financial instruments and investments - Convertible senior notes (Details) Notes http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails Fair value of financial instruments and investments - Convertible senior notes (Details) Details 50 false false R51.htm 99940407 - Disclosure - Fair value of financial instruments and investments - Summary of changes in the fair value of the Company's Level 3 valuation (Details) Sheet http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanysLevel3ValuationDetails Fair value of financial instruments and investments - Summary of changes in the fair value of the Company's Level 3 valuation (Details) Details 51 false false R52.htm 99940408 - Disclosure - Fair value of financial instruments and investments - Fair Value Liabilities Measured (Details) Sheet http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails Fair value of financial instruments and investments - Fair Value Liabilities Measured (Details) Details 52 false false R53.htm 99940501 - Disclosure - Accounts payable and accrued expenses - Components (Details) Sheet http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails Accounts payable and accrued expenses - Components (Details) Details 53 false false R54.htm 99940502 - Disclosure - Accounts payable and accrued expenses - Restructuring (Details) Sheet http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesRestructuringDetails Accounts payable and accrued expenses - Restructuring (Details) Details 54 false false R55.htm 99940601 - Disclosure - Capitalization - Narrative (Details) Sheet http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails Capitalization - Narrative (Details) Details 55 false false R56.htm 99940701 - Disclosure - Net loss per share - Numerator and Denominator (Details) Sheet http://www.ptcbio.com/role/DisclosureNetLossPerShareNumeratorAndDenominatorDetails Net loss per share - Numerator and Denominator (Details) Details 56 false false R57.htm 99940702 - Disclosure - Net loss per share - Antidilutive (Details) Sheet http://www.ptcbio.com/role/DisclosureNetLossPerShareAntidilutiveDetails Net loss per share - Antidilutive (Details) Details 57 false false R58.htm 99940801 - Disclosure - Stock award plan - Narrative (Details) Sheet http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails Stock award plan - Narrative (Details) Details 58 false false R59.htm 99940802 - Disclosure - Stock award plan - Stock Option Activity (Details) Sheet http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails Stock award plan - Stock Option Activity (Details) Details 59 false false R60.htm 99940803 - Disclosure - Stock award plan - Assumptions Used (Details) Sheet http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails Stock award plan - Assumptions Used (Details) Details 60 false false R61.htm 99940804 - Disclosure - Stock award plan - Restricted Stock (Details) Sheet http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails Stock award plan - Restricted Stock (Details) Details 61 false false R62.htm 99940805 - Disclosure - Stock award plan - Share-based compensation expense (Details) - USD ($) $ in Thousands Sheet http://www.ptcbio.com/role/DisclosureStockAwardPlanShareBasedCompensationExpenseDetailsUSD Stock award plan - Share-based compensation expense (Details) - USD ($) $ in Thousands Details 62 false false R63.htm 99940901 - Disclosure - Debt - Liability for Sale of Future Royalties (Details) Sheet http://www.ptcbio.com/role/DisclosureDebtLiabilityForSaleOfFutureRoyaltiesDetails Debt - Liability for Sale of Future Royalties (Details) Details 63 false false R64.htm 99940902 - Disclosure - Debt - Senior Secured Term Loan (Details) Sheet http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails Debt - Senior Secured Term Loan (Details) Details 64 false false R65.htm 99940903 - Disclosure - Debt - 2026 Convertible Notes Narrative (Details) Notes http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails Debt - 2026 Convertible Notes Narrative (Details) Details 65 false false R66.htm 99940904 - Disclosure - Debt - Convertible Notes (Details) Notes http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails Debt - Convertible Notes (Details) Details 66 false false R67.htm 99940905 - Disclosure - Debt - Convertible Notes Interest Expense (Details) Notes http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails Debt - Convertible Notes Interest Expense (Details) Details 67 false false R68.htm 99941001 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 68 false false R69.htm 99941101 - Disclosure - Revenue recognition - Net Product Sales (Details) Sheet http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails Revenue recognition - Net Product Sales (Details) Details 69 false false R70.htm 99941102 - Disclosure - Revenue recognition - Collaboration and Royalty Revenue (Details) Sheet http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails Revenue recognition - Collaboration and Royalty Revenue (Details) Details 70 false false R71.htm 99941103 - Disclosure - Revenue recognition - Manufacturing Revenue (Details) Sheet http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails Revenue recognition - Manufacturing Revenue (Details) Details 71 false false R72.htm 99941104 - Disclosure - Revenue recognition - Performance Obligations (Details) Sheet http://www.ptcbio.com/role/DisclosureRevenueRecognitionPerformanceObligationsDetails Revenue recognition - Performance Obligations (Details) Details 72 false false R73.htm 99941201 - Disclosure - Intangible assets and goodwill - Definite-lived Intangibles (Details) Sheet http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangibles Intangible assets and goodwill - Definite-lived Intangibles (Details) Details 73 false false R74.htm 99941202 - Disclosure - Intangible assets and goodwill - Future Amortization (Details) Sheet http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillFutureAmortization Intangible assets and goodwill - Future Amortization (Details) Details 74 false false R75.htm 99941203 - Disclosure - Intangible assets and goodwill - Indefinite-lived Intangibles (Details) Sheet http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangibles Intangible assets and goodwill - Indefinite-lived Intangibles (Details) Details 75 false false R76.htm 99941204 - Disclosure - Intangible assets and goodwill - Goodwill (Details) Sheet http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillGoodwillDetails Intangible assets and goodwill - Goodwill (Details) Details 76 false false All Reports Book All Reports tmb-20240930.xsd tmb-20240930_cal.xml tmb-20240930_def.xml tmb-20240930_lab.xml tmb-20240930_pre.xml tmb-20240930x10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 95 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tmb-20240930x10q.htm": { "nsprefix": "ptct", "nsuri": "http://www.ptcbio.com/20240930", "dts": { "schema": { "local": ["tmb-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://sbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://sbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://sbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://sbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://sbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://sbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://sbrl.sec.gov/country/2024/country-2024.xsd", "https://sbrl.sec.gov/dei/2024/dei-2024.xsd", "https://sbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://sbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://sbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["tmb-20240930_cal.xml"] }, "definitionLink": { "local": ["tmb-20240930_def.xml"] }, "labelLink": { "local": ["tmb-20240930_lab.xml"] }, "presentationLink": { "local": ["tmb-20240930_pre.xml"] }, "inline": { "local": ["tmb-20240930x10q.htm"] } }, "keyStandard": 347, "keyCustom": 121, "axisStandard": 37, "axisCustom": 1, "memberStandard": 49, "memberCustom": 51, "hidden": { "total": 10, "http://fasb.org/us-gaap/2024": 3, "http://xbrl.sec.gov/dei/2024": 6 }, "contextCount": 105, "segmentCount": 33, "unitCount": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 105, "http://xbrl.sec.gov/dei/2024": 16 }, "report": { "R1": { "role": "http://www.ptcbio.com/role/DocumentCover", "shortName": "Cover", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "dei:DocumentType", "unitRef": null, "ssiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "dei:DocumentType", "unitRef": null, "ssiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets", "longName": "995200100 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_9_30_2024_BYYyFi8Yp0yxs8v9c5Ax1A", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_Ki5-vXyEWkOCOJXLAd54-w", "ssiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_BYYyFi8Yp0yxs8v9c5Ax1A", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "Unit_Standard_USD_Ki5-vXyEWkOCOJXLAd54-w", "ssiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "unique": true } }, "R3": { "role": "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheetsParenthetical", "longName": "995200105 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_9_30_2024_BYYyFi8Yp0yxs8v9c5Ax1A", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_5mYIwG4hn0KHWEJWB45KiQ", "ssiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_BYYyFi8Yp0yxs8v9c5Ax1A", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_5mYIwG4hn0KHWEJWB45KiQ", "ssiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations", "longName": "995200200 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Fe_IpluQUkObOSTEGj897A", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_Ki5-vXyEWkOCOJXLAd54-w", "ssiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Fe_IpluQUkObOSTEGj897A", "name": "ptct:CostOfGoodsandServiceExcludingAmortizationOfIntangibleAssets", "unitRef": "Unit_Standard_USD_Ki5-vXyEWkOCOJXLAd54-w", "ssiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "unique": true } }, "R5": { "role": "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfComprehensiveLoss", "longName": "995200300 - Statement - Consolidated Statements of Comprehensive Loss", "shortName": "Consolidated Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Fe_IpluQUkObOSTEGj897A", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_Ki5-vXyEWkOCOJXLAd54-w", "ssiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Fe_IpluQUkObOSTEGj897A", "name": "us-gaap:OtherComprehensiveForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "Unit_Standard_USD_Ki5-vXyEWkOCOJXLAd54-w", "ssiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "unique": true } }, "R6": { "role": "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficit", "longName": "995200400 - Statement - Consolidated Statements of Stockholders' Deficit", "shortName": "Consolidated Statements of Stockholders' Deficit", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lJVXiBsRKECCYWXtkSmLsQ", "name": "us-gaap:SharesIssued", "unitRef": "Unit_Standard_shares_eN1Yu4c4h0aacWsgKgj2nA", "ssiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lJVXiBsRKECCYWXtkSmLsQ", "name": "us-gaap:SharesIssued", "unitRef": "Unit_Standard_shares_eN1Yu4c4h0aacWsgKgj2nA", "ssiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "

gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpenses", "longName": "995210501 - Disclosure - Accounts payable and accrued expenses", "shortName": "Accounts payable and accrued expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.ptcbio.com/role/DisclosureCapitalization", "longName": "995210601 - Disclosure - Capitalization", "shortName": "Capitalization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.ptcbio.com/role/DisclosureNetLossPerShare", "longName": "995210701 - Disclosure - Net loss per share", "shortName": "Net loss per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.ptcbio.com/role/DisclosureStockAwardPlan", "longName": "995210801 - Disclosure - Stock award plan", "shortName": "Stock award plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.ptcbio.com/role/DisclosureDebt", "longName": "995210901 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingencies", "longName": "995211001 - Disclosure - Commitments and contingencies", "shortName": "Commitments and contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.ptcbio.com/role/DisclosureRevenueRecognition", "longName": "995211101 - Disclosure - Revenue recognition", "shortName": "Revenue recognition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwill", "longName": "995211201 - Disclosure - Intangible assets and goodwill", "shortName": "Intangible assets and goodwill", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.ptcbio.com/role/DisclosureSubsequentEvents", "longName": "995211301 - Disclosure - Subsequent events", "shortName": "Subsequent events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://sbrl.sec.gov/ecd/role/PppDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Fe_IpluQUkObOSTEGj897A", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R22": { "role": "http://sbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Fe_IpluQUkObOSTEGj897A", "name": "ecd:MtrTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Fe_IpluQUkObOSTEGj897A", "name": "ecd:MtrTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920203 - Disclosure - Summary of significant accounting policies (Policies)", "shortName": "Summary of significant accounting policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "99930203 - Disclosure - Summary of significant accounting policies (Tables)", "shortName": "Summary of significant accounting policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.ptcbio.com/role/DisclosureLeases", "longName": "99930303 - Disclosure - Leases - (Tables)", "shortName": "Leases - (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesTables", "longName": "99930403 - Disclosure - Fair value of financial instruments and marketable securities - (Tables)", "shortName": "Fair value of financial instruments and marketable securities - (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables", "longName": "99930503 - Disclosure - Accounts payable and accrued expenses - (Tables)", "shortName": "Accounts payable and accrued expenses - (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.ptcbio.com/role/DisclosureNetLossPerShareTables", "longName": "99930703 - Disclosure - Net loss per share - (Tables)", "shortName": "Net loss per share - (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.ptcbio.com/role/DisclosureStockAwardPlanTables", "longName": "99930803 - Disclosure - Stock award plan - (Tables)", "shortName": "Stock award plan - (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.ptcbio.com/role/DisclosureDebtTables", "longName": "99930903 - Disclosure - Debt - (Tables)", "shortName": "Debt - (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "ptct:LiabilityForSaleOfFutureRoyaltiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LongTermDebtTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillTables", "longName": "99931203 - Disclosure - Intangible assets and goodwill - (Tables)", "shortName": "Intangible assets and goodwill - (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.ptcbio.com/role/DisclosureCompanyDetails", "longName": "99940101 - Disclosure - The Company (Details)", "shortName": "The Company (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "ptct:NumberOfProducts", "unitRef": "Unit_Standard_product_nIf_IvoR1kKYwlactAzFPw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:NatureOfOperations", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R33": { "role": "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "longName": "99940201 - Disclosure - Summary of significant accounting policies - Narrative (Details)", "shortName": "Summary of significant accounting policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "As_Of_9_30_2024_BYYvFi8Yp0yxs8v9c5Ax1A", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "p", "us-gaap:MarketableSecuritiesPolicy", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_ggyagD3l0Gqou8sosM1g", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CreditLossFinancialInstrumentPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "unique": true } }, "R34": { "role": "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails", "longName": "99940202 - Disclosure - Summary of significant accounting policies - Reconciliation of cash (Details)", "shortName": "Summary of significant accounting policies - Reconciliation of cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "As_Of_9_30_2024_BYYvFi8Yp0yxs8v9c5Ax1A", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_BYYvFi8Yp0yxs8v9c5Ax1A", "name": "us-gaap:RestrictedCash", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "unique": true } }, "R35": { "role": "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails", "longName": "99940203 - Disclosure - Summary of significant accounting policies - Inventory (Details)", "shortName": "Summary of significant accounting policies - Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_9_30_2024_BYYvFi8Yp0yxs8v9c5Ax1A", "name": "us-gaap:InventoryRawMaterials", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ptct:InventoriesAndCostOfProductSalesPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_BYYvFi8Yp0yxs8v9c5Ax1A", "name": "us-gaap:InventoryRawMaterials", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ptct:InventoriesAndCostOfProductSalesPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails", "longName": "99940204 - Disclosure - Summary of significant accounting policies - Collaboration and Royalty Revenue (Details)", "shortName": "Summary of significant accounting policies - Collaboration and Royalty Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Fe_IpluQUkObOSTEGj897A", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_sxt_ProductOrServiceAxis_ptct_ManufacturingMember_K5JlY14aw0KNiYqdN8FoIQ", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "unique": true } }, "R37": { "role": "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesManufacturingRevenueDetails", "longName": "99940205 - Disclosure - Summary of significant accounting policies - Manufacturing Revenue (Details)", "shortName": "Summary of significant accounting policies - Manufacturing Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Fe_IpluQUkObOSTEGj897A", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_srt_ProductOrServiceAxis_ptct_ManufacturingMember_K5JlY14aw0KNiYqdN8FoIQ", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "unique": true } }, "R38": { "role": "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails", "longName": "99940206 - Disclosure - Summary of significant accounting policies - Liability for Sale of Future Royalties (Details)", "shortName": "Summary of significant accounting policies - Liability for Sale of Future Royalties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "ptct:ProceedsFromSaleOfFutureRoyalties", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_1_2024_To_6_30_2024_us-gaap_DebtInstrumentAxis_ptct_AndRRoyaltyPurchaseAgreementMember_3qDuYehYMUSH5I97le9cEg", "name": "ptct:ProceedsFromSaleOfFutureRoyalties", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "unique": true } }, "R39": { "role": "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTangibleAssetImpairmentAndLossesGainsOnTransactionsNetDetails", "longName": "99940207 - Disclosure - Summary of significant accounting policies - Tangible Asset Impairment and Losses (Gains) on Transactions, Net (Details)", "shortName": "Summary of significant accounting policies - Tangible Asset Impairment and Losses (Gains) on Transactions, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Mi7Hp57CPUO_plDSvCqlgw", "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ptct_SouthPlainfieldNewJerseyOfficeMember_UHBWQfMswEG4

*"false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As Of 6 30 2024 YXPOpWbeIkSY93x2ntITrA", "name": "ptct:EquityInvestmentsAndConvertibleDebtSecurities", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us gaap:MarketableSecuritiesTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "unique": true } }, "R46": { "role": "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails", "longName": "99940402 Disclosure Fair value of financial instruments and marketable securities Hierarchy (Details)", "shortName": "Fair value of financial instruments and marketable securities Hierarchy (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As Of 9 30 2024 BYYyFi8Yp0yxs8v9c5Ax1A", "name": "us gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As Of 9 30 2024 BYYyFi8Yp0yxs8v9c5Ax1A", "name": "ptct:FairValueAssetsTransfersBetweenLevel1Level2AndLevel3Amount", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "unique": true } }, "R47": { "role": "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesUnrealizedGainsLossesDetails", "longName": "99940403 Disclosure Fair value of financial instruments and marketable securities Marketable Securities, Unrealized Gains (Losses) (Details)", "shortName": "Fair value of financial instruments and marketable securities Marketable Securities, Unrealized Gains (Losses) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As Of 9 30 2024 BYYyFi8Yp0yxs8v9c5Ax1A", "name": "us gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As Of 12 31 2023 qgyagD3l0Gqou8sosM1g", "name": "us gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleSecuritiesDetails", "longName": "99940404 Disclosure Fair value of financial instruments and marketable securities Available for sale securities (Details)", "shortName": "Fair value of financial instruments and marketable securities Available for sale securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "As Of 9 30 2024 BYYyFi8Yp0yxs8v9c5Ax1A", "name": "us gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As Of 9 30 2024 BYYyFi8Yp0yxs8v9c5Ax1A", "name": "us gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesBalanceSheetDisclosuresDetails", "longName": "99940405 Disclosure Fair value of financial instruments and marketable securities Marketable Securities, Balance Sheet Disclosures (Details)", "shortName": "Fair value of financial instruments and marketable securities Marketable Securities, Balance Sheet Disclosures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "As Of 9 30 2024 BYYyFi8Yp0yxs8v9c5Ax1A", "name": "us gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As Of 9 30 2024 BYYyFi8Yp0yxs8v9c5Ax1A", "name": "us gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails", "longName": "99940406 Disclosure Fair value of financial instruments and investments Convertible senior notes (Details)", "shortName": "Fair value of financial instruments and investments Convertible senior notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "As Of 9 30 2024 us gaap DebtInstrumentAxis ptct ConvertibleSeniorNotes1.5DueSeptember152026Member QBup VvGXUmKiX m36esxw", "name": "us gaap:DebtInstrumentFaceAmount", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As Of 9 30 2024 us gaap DebtInstrumentAxis ptct ConvertibleSeniorNotes1.5DueSeptember152026Member us gaap FairValueByFairValueHierarchyLevelAxis us gaap FairValueInputsLevel2Member us gaap LongtermDebtTypeAxis us gaap ConvertibleDebtMember ndIXWF7Iq0aD7I7MRGOGLA", "name": "us gaap:DebtInstrumentFairValue", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "unique": true } }, "R51": { "role": "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanysLevel3ValuationDetails", "longName": "99940407 Disclosure Fair value of financial instruments and investments Summary of the fair value of the Company's Level 3 valuation (Details)", "shortName": "Fair value of financial instruments and investments Summary of changes in the fair value of the Company's Level 3 valuation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "As Of 9 30 2024 us gaap BusinessAcquisitionAxis ptct AgilisMember us gaap FairValueByFairValueHierarchyLevelAxis us gaap FairValueInputsLevel3Member us gaap IndefiniteLivedIntangibleAssetsByMajorClassAxis ptct UpstaxaMember 4shFXlpMQ0 XYdwKiWPnLQ", "name": "us gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiability Value", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 To 9 30 2024 us gaap BusinessAcquisitionAxis ptct AgilisMember us gaap ContingentConsiderationByTypeAxis ptct LiabilityDevelopmentandRegulatoryMilestoneMember us gaap FairValueByFairValueHierarchyLevelAxis us gaap FairValueInputsLevel3Member us gaap FairValueByLiabilityClassAxis us gaap CommitmentsMember dKM0V9e9GEuIlP0mF1iv8w", "name": "us gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "td", "tr", "table", "us gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "unique": true } }, "R52": { "role": "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "longName": "99940408 Disclosure Fair value of financial instruments and investments Fair Value Liabilities Measured (Details)", "shortName": "Fair value of financial instruments and investments Fair Value Liabilities Measured (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "Duration 1 1 2022 To 12 31 2022 us gaap BusinessAcquisitionAxis ptct AgilisMember z2Vh0WZoVE6qGozsQ 1q6G", "name": "ptct:PaymentOfMilestoneObligation", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As Of 12 31 2023 srt RangeAxis srt MinimumMember us gaap BusinessAcquisitionAxis ptct AgilisMember us gaap ContingentConsiderationByTypeAxis ptct LiabilityDevelopmentandRegulatoryMilestoneMember us gaap FairValueByLiabilityClassAxis us gaap CommitmentsMember us gaap MeasurementInputTypeAxis ptct DevelopmentandRegulatoryMilestoneMember us gaap ValuationTechniqueAxis us gaap ValuationTechniqueDiscountedCashFlowMember YTpTXBKcyUKoIeWKwwc6kw", "name": "ptct:RightsExchangeSettlementPotentialMilestonesValue", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "6", "ancestors": ["p", "td", "tr", "table", "us gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "unique": true } }, "R53": { "role": "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails", "longName": "99940501 Disclosure Accounts payable and accrued expenses Components (Details)", "shortName": "Accounts payable and accrued expenses Components (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "As Of 9 30 2024 BYYyFi8Yp0yxs8v9c5Ax1A", "name": "us gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "td", "tr", "table", "us gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As Of 9 30 2024 BYYyFi8Yp0yxs8v9c5Ax1A", "name": "us gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "td", "tr", "table", "us gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesRestructuringDetails", "longName": "99940502 Disclosure Accounts payable and accrued expenses Restructuring (Details)", "shortName": "Accounts payable and accrued expenses Restructuring (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "As Of 9 30 2024 BYYyFi8Yp0yxs8v9c5Ax1A", "name": "ptct:AccruedRestructuringCosts", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails", "longName": "99940601 Disclosure Capitalization Narrative (Details)", "shortName": "Capitalization Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "As Of 9 30 2024 BYYyFi8Yp0yxs8v9c5Ax1A", "name": "us gaap:CommonStockSharesAuthorized", "unitRef": "Unit Standard shares eN1Yu4c4h0azcWsgKqj2nA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 us gaap TypeOfArrangementAxis ptct AtMarketOfferingSalesAgreementMember l8B3Bur3ck6WvoDdW ckqA", "name": "us gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "Unit Standard shares eN1Yu4c4h0azcWsgKqj2nA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "us gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "p", "us gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "unique": true } }, "R56": { "role": "http://www.ptcbio.com/role/DisclosureNetLossPerShareNumeratorAndDenominatorDetails", "longName": "99940701 Disclosure Net loss per share Numerator and Denominator (Details)", "shortName": "Net loss per share Numerator and Denominator (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 Fe IpluQUkObOSTEGj897A", "name": "us gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "td", "tr", "table", "us gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 Fe IpluQUkObOSTEGj897A", "name": "us gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "td", "tr", "table", "us gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.ptcbio.com/role/DisclosureNetLossPerShareAntidilutiveDetails", "longName": "99940702 Disclosure Net loss per share Antidilutive (Details)", "shortName": "Net loss per share Antidilutive (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 9 30 2024 Mi7Hp57CPUO plDSvCqlgw", "name": "us gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit Standard shares eN1Yu4c4h0azcWsgKqj2nA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 To 9 30 2024 Mi7Hp57CPUO plDSvCqlgw", "name": "us gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit Standard shares eN1Yu4c4h0azcWsgKqj2nA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "longName": "99940801 Disclosure Stock award plan Narrative (Details)", "shortName": "Stock award plan Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 Fe IpluQUkObOSTEGj897A", "name": "us gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 To 9 30 2024 us gaap AwardTypeAxis us gaap StockOptionMember K12 HUCAUyOX266MSaOEQ", "name": "us gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 Fe IpluQUkObOSTEGj897A", "name": "us gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails", "longName": "99940802 Disclosure Stock award plan Stock Option Activity (Details)", "shortName": "Stock award plan Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "As Of 12 31 2023 us gaap AwardTypeAxis us gaap StockOptionMember DUfTowd9uUqnQRBQL0tyWg", "name": "us gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit Standard shares eN1Yu4c4h0azcWsgKqj2nA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As Of 12 31 2023 us gaap AwardTypeAxis us gaap StockOptionMember DUfTowd9uUqnQRBQL0tyWg", "name": "us gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit Standard shares eN1Yu4c4h0azcWsgKqj2nA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails", "longName": "99940803 Disclosure Stock award plan Assumptions Used (Details)", "shortName": "Stock award plan Assumptions Used (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 9 30 2024 us gaap AwardTypeAxis us gaap StockOptionMember K12 HUCAUyOX266MSaOEQ", "name": "us gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en US", "decimals": null, "ancestors": ["p", "td", "tr", "table", "us gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails", "longName": "99940804 Disclosure Stock award plan Restricted Stock (Details)", "shortName": "Stock award plan Restricted Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 Fe IpluQUkObOSTEGj897A", "name": "us gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 To 9 30 2024 us gaap AwardTypeAxis ptct RestrictedStockAndRestrictedStockUnitsMember xux5xz79UumFRtt93ER2A", "name": "us gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Unit Standard shares eN1Yu4c4h0azcWsgKqj2nA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "unique": true } }, "R62": { "role": "http://www.ptcbio.com/role/DisclosureStockAwardPlanShareBasedCompensationExpenseDetails", "longName": "99940805 Disclosure Stock award plan Share based compensation expense (Details)", "shortName": "Stock award plan Share based compensation expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 Fe IpluQUkObOSTEGj897A", "name": "us gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 To 9 30 2024 us gaap AwardTypeAxis us gaap StockOptionMember nFTjTwcbC0IWulr8gJdIUA", "name": "us gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "unique": true } }, "R63": { "role": "http://www.ptcbio.com/role/DisclosureDebtLiabilityForSaleOfFutureRoyaltiesDetails", "longName": "99940901 Disclosure Debt Liability for Sale of Future Royalties (Details)", "shortName": "Debt Liability for Sale of Future Royalties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "As Of 12 31 2023 qgyagD3l0Gqou8sosM1g", "name": "ptct:LiabilitySaleOfFutureRoyalties", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ptct:LiabilityForSaleOfFutureRoyaltiesTableTextBlock", "us gaap:LongTermDebtTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "As Of 12 31 2023 qgyagD3l0Gqou8sosM1g", "name": "ptct:LiabilitySaleOfFutureRoyalties", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ptct:LiabilityForSaleOfFutureRoyaltiesTableTextBlock", "us gaap:LongTermDebtTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails", "longName": "99940902 Disclosure Debt Senior Secured Term Loan (Details)", "shortName": "Debt Senior Secured Term Loan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 9 30 2024 Mi7Hp57CPUO plDSvCqlgw", "name": "us gaap:AmortizationOfFinancingCosts", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As Of 10 27 2022 us gaap CreditFacilityAxis us gaap LineOfCreditMember xMhzKho jE6iJQ KUgd5 A", "name": "us gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us gaap:LongTermDebtTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "unique": true } }, "R65": { "role": "http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails", "longName": "99940903 Disclosure Debt 2026 Convertible Notes Narrative (Details)", "shortName": "Debt 2026 Convertible Notes Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "As Of 9 30 2024 BYYyFi8Yp0yxs8v9c5Ax1A", "name": "us gaap:LongTermDebtNoncurrent", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration 9 1 2019 To 9 30 2019 us gaap DebtInstrumentAxis ptct ConvertibleSeniorNotes1.5DueSeptember152026Member us gaap LongtermDebtTypeAxis us gaap ConvertibleDebtMember j2Uv1XTv2km2Y0JHGmOvTQ", "name": "ptct:DebtInstrumentAdditionalAmountAvailableForRepurchase", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "unique": true } }, "R66": { "role": "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "longName": "99940904 Disclosure Debt Convertible Notes (Details)", "shortName": "Debt Convertible Notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "As Of 9 30 2024 us gaap DebtInstrumentAxis ptct ConvertibleSeniorNotes1.5DueSeptember152026Member QBup VvGXUmKiX m36esxw", "name": "us gaap:DebtInstrumentFaceAmount", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tmb 20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As Of 9 30 2024 us gaap DebtInstrumentAxis ptct ConvertibleSeniorNotes1.5DueSeptember152026Member QBup VvGXUmKiX m36esxw", "name": "us gaap:UnamortizedDebtIssuanceExpense", "unitRef": "Unit Standard USD Kj5 vXyEWkOCOJXLAd54 w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body

*"http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails", "longName": "99941103 - Disclosure - Revenue recognition - Manufacturing Revenue (Details)", "shortName": "Revenue recognition - Manufacturing Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "FirstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_Fe_IpluQuKObOSTEGj807A", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p", "td", "tr", "table", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_ptct_ManufacturingMember_4pfkejibLEmbjYqtn18NIA", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": { "p", "ix:continuation", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "unique": true } }, "R72": { "role": "http://www.ptcbio.com/role/DisclosureRevenueRecognitionPerformanceObligationsDetails", "longName": "99941104 - Disclosure - Revenue recognition - Performance Obligations (Details)", "shortName": "Revenue recognition - Performance Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "FirstAnchor": { "contextRef": "As_Of_9_30_2024_BYYvFi8Yp0yxs8v9c5Ax1A", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "p", "ix:continuation", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R73": { "role": "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails", "longName": "99941201 - Disclosure - Intangible assets and goodwill - Definite-lived Intangibles (Details)", "shortName": "Intangible assets and goodwill - Definite-lived Intangibles (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "FirstAnchor": { "contextRef": "As_Of_9_30_2024_BYYvFi8Yp0yxs8v9c5Ax1A", "name": "ptct:MilestonePayable", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p", "td", "tr", "table", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_srt_CounterpartyNameAxis_ptct_AlceaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ptct_WavHvraMember_0xRlw387MkSLX7EFdroxA", "name": "ptct:PaymentOfRoyaltyObligation", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": { "p", "ix:continuation", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "unique": true } }, "R74": { "role": "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillFutureAmortizationDetails", "longName": "99941202 - Disclosure - Intangible assets and goodwill - Future Amortization (Details)", "shortName": "Intangible assets and goodwill - Future Amortization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "FirstAnchor": { "contextRef": "As_Of_9_30_2024_BYYvFi8Yp0yxs8v9c5Ax1A", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_BYYvFi8Yp0yxs8v9c5Ax1A", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails", "longName": "99941203 - Disclosure - Intangible assets and goodwill - Indefinite-lived Intangibles (Details)", "shortName": "Intangible assets and goodwill - Indefinite-lived Intangibles (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "FirstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_5sZIoWMz0EyTDW9qlEOfYw", "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefiniteLivedExcludingGoodwill", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p", "td", "tr", "table", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_BYYvFi8Yp0yxs8v9c5Ax1A", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p", "td", "tr", "table", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "unique": true } }, "R76": { "role": "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillGoodwillDetails", "longName": "99941204 - Disclosure - Intangible assets and goodwill - Goodwill (Details)", "shortName": "Intangible assets and goodwill - Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "FirstAnchor": { "contextRef": "As_Of_9_30_2024_BYYvFi8Yp0yxs8v9c5Ax1A", "name": "us-gaap:Goodwill", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p", "td", "tr", "table", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_8_23_2018_To_9_30_2024_Rs8OGHupTUut4UoputWrgA", "name": "us-gaap:GoodwillPeriodIncreaseDecrease", "unitRef": "Unit_Standard_USD_Kj5-vXyEWkOCOJXLAd54-w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": { "p", "ix:continuation", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "tmb-20240930x10q.htm", "unique": true } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpenses"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accounts payable and accrued expenses", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": ["r490"] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails", "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued expenses", "totalLabel": "Accounts payable and accrued expenses", "documentation": "Sum of the carrying amounts as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r62", "r63"] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesMember", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities [Member]", "terseLabel": "Accounts payable and accrued expenses", "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r60", "r927"] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Amortization of discounts on investments, net", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r97"] }, "ptct_AccruedConsultingAndContractedResearchCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "AccruedConsultingAndContractedResearchCurrent", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting and contracted research.", "label": "Accrued Consulting and Contracted Research Current", "terseLabel": "Consulting and contracted research" } } }, "auth_ref": [] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails"], "lang": { "en-us": { "role": { "label": "Accrued Income Taxes, Current", "terseLabel": "Income tax payable", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": ["r63", "r131"] }, "ptct_AccruedRestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "AccruedRestructuringCosts", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesRestructuringDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for restructuring costs.", "label": "Accrued Restructuring Costs", "terseLabel": "Accrued restructuring costs" } } }, "auth_ref": [] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails", "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Royalties, Current", "terseLabel": "Royalties", "verboseLabel": "Accrued royalties", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r63", "r877"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transactions and other events and circumstances from nonowner sources." } } }, "auth_ref": ["r701", "r1071", "r1074", "r1075", "r1077", "r744", "r748"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive (loss) income", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r2", "r9", "r19", "r541", "r544", "r626", "r739", "r740", "r1062", "r1063", "r1064", "r1073", "r1074", "r1075", "r1077"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r993"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r76", "r927", "r1231"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r759", "r1073", "r1074", "r1075", "r1077", "r1163", "r1233"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r1006"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation" } } }, "auth_ref": ["r1006"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r1006"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r1006"] }, "ptct_AdjustedPercentageOfRetainedRoyaltyRightsAfterAssignedRoyaltyCapMet": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "AdjustedPercentageOfRetainedRoyaltyRightsAfterAssignedRoyaltyCapMet", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "documentation": "Adjusted percentage of retained royalty rights after the 2020 Assigned Royalty Cap is met.", "label": "Adjusted Percentage of Retained Royalty Rights After Assigned Royalty Cap Met", "terseLabel": "Adjusted percentage of retained royalty rights after the 2020 Assigned Royalty Cap is met." } } }, "auth_ref": [] }, "ptct_AdjustedPercentageOfRetainedRoyaltyRightsSoldAfterAssignedRoyaltyCapMet": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "AdjustedPercentageOfRetainedRoyaltyRightsSoldAfterAssignedRoyaltyCapMet", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "documentation": "Adjusted percentage of retained royalty rights sold after the 2020 Assigned Royalty Cap is met.", "label": "Adjusted Percentage of Retained Royalty Rights Sold After Assigned Royalty Cap Met", "terseLabel": "Adjusted percentage of retained royalty rights sold after the 2020 Assigned Royalty Cap is met" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r46", "r47", "r454"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ptct_AggregateCashProceedsFromSaleOfFutureRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "AggregateCashProceedsFromSaleOfFutureRoyalties", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "documentation": "Aggregate amount of upfront cash consideration received from the sale of future royalties.", "label": "Aggregate Cash Proceeds from Sale of Future Royalties", "terseLabel": "Aggregate upfront cash consideration received for sale of future royalties" } } }, "auth_ref": [] }, "ptct_AggregateRoyaltyPurchaseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "AggregateRoyaltyPurchaseAgreementsMember", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the aggregate of Royalty Purchase Agreements which sold a percentage of future royalty payments in exchange for cash consideration.", "label": "Aggregate Royalty Purchase Agreements [Member]", "terseLabel": "Aggregate Royalty Purchase Agreements" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r1039"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r965", "r975", "r985", "r1017"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r968", "r978", "r988", "r1020"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r1040"] }, "ptct_AgilisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "AgilisMember", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanysLevel3ValuationDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillGoodwillDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Agilis [Member]", "label": "Agilis", "terseLabel": "Agilis" } } }, "auth_ref": [] }, "ptct_AlceaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "AlceaMember", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "documentation": "Alcea [Member]", "label": "Alcea", "terseLabel": "Alcea" } } }, "auth_ref": [] }, "ecd_AllAdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r1006"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r1013"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r969", "r970", "r989", "r1013", "r1021", "r1025", "r1033"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r1031"] }, "ptct_AllanJacobsonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "AllanJacobsonMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Allan Jacobson.", "label": "Allan Jacobson [Member]", "terseLabel": "Allan Jacobson" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanShareBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Share-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r483", "r488"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Allowance for doubtful accounts receivable", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r171", "r253", "r300", "r304", "r306", "r1196"] }, "ptct_AmendedAndRestated2013LongTermIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "AmendedAndRestated2013LongTermIncentivePlanMember", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the Amended and Restated 2013 Long Term Incentive Plan.", "label": "Amended and Restated 2013 Long Term Incentive Plan [Member]", "terseLabel": "Amended 2013 LTIP" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": ["r90", "r397", "r1067", "r1177"] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "negatedLabel": "Amortization", "terseLabel": "Amortization of acquired intangible assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r77", "r347", "r351", "r890"] }, "ptct_AndRRoyaltyPurchaseAgreementAmendmentTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "AndRRoyaltyPurchaseAgreementAmendmentTrancheOneMember", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabil

*"auth_ref": ["r31"] }, "us-gaap_AreaOfRealEstateProperty": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfRealEstateProperty", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Area of Real Estate Property", "terseLabel": "Area of real estate property", "documentation": "Area of a real estate property." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails", "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r531"] }, "ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "AssetAcquisitionDevelopmentAndRegulatoryMilestones", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Development And Regulatory Milestones", "label": "Asset Acquisition, Development And Regulatory Milestones", "terseLabel": "Asset acquisition, development and regulatory milestones" } } }, "auth_ref": [] }, "ptct_AssetAcquisitionMilestoneAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "AssetAcquisitionMilestoneAmount", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Milestone, Amount", "label": "Asset Acquisition, Milestone, Amount", "terseLabel": "Asset acquisition, milestone, amount" } } }, "auth_ref": [] }, "ptct_AssetAcquisitionNetSalesMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "AssetAcquisitionNetSalesMilestone", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Net Sales Milestone", "label": "Asset Acquisition, Net Sales Milestone", "terseLabel": "Asset acquisition, net sales milestone" } } }, "auth_ref": [] }, "us-gaap_AssetImpairmentChargesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentChargesAbstract", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTangibleAssetImpairmentAndLossesGainsOnTransactionsNetDetails"], "lang": { "en-us": { "role": { "label": "Asset Impairment Charges [Abstract]", "terseLabel": "Asset impairment and losses (gains) on transactions" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r119", "r134", "r164", "r196", "r234", "r238", "r244", "r245", "r286", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r532", "r534", "r587", "r710", "r800", "r885", "r886", "r927", "r956", "r1130", "r1131", "r1183"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r159", "r173", "r196", "r286", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r532", "r534", "r587", "r927", "r1130", "r1131", "r1183"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "auth_ref": [] }, "ptct_AssignedRoyaltyPaymentRetainedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "AssignedRoyaltyPaymentRetainedPercentage", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "documentation": "Assigned Royalty Payment, Retained Percentage", "label": "Assigned Royalty Payment, Retained Percentage", "terseLabel": "Assigned royalty payment, retained percentage" } } }, "auth_ref": [] }, "ptct_AtMarketOfferingSalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "AtMarketOfferingSalesAgreementMember", "presentation": ["http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the At the Market Offering Sales Agreement.", "label": "At the Market Offering Sales Agreement [Member]", "terseLabel": "Sales Agreement" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesUnrealizedGainsLossesDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized, Gain", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r259"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesUnrealizedGainsLossesDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized, Loss", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r260"] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesUnrealizedGainsLossesDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r256", "r310", "r709"] }, "ptct_AvailableForSaleDebtSecuritiesConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "AvailableForSaleDebtSecuritiesConversionPrice", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the available-for-sale convertible debt securities.", "label": "Available-for-sale Debt Securities, Conversion Price", "terseLabel": "Conversion price - convertible note" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesAbstract", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Abstract]", "terseLabel": "ClearPoint Convertible note" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesBalanceSheetDisclosuresDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Marketable securities, Less Than 12 Months", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r263", "r706"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesUnrealizedGainsLossesDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale", "terseLabel": "Marketable securities - available for sale", "verboseLabel": "Fair Value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r257", "r318", "r561", "r702", "r914", "r918", "r1086", "r1167", "r1168", "r1169"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r1028"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r1029"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r1024"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r1024"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r1024"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r1024"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r1024"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r1024"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r1027"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close to Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r1026"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r1025"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r1025"] }, "country_BR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "BR", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "BRAZIL", "terseLabel": "Brazil" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r363", "r1198", "r1199"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r53", "r54", "r363", "r1198", "r1199"] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BaseRateMember", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Base Rate [Member]", "terseLabel": "Base Rate", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of significant accounting policies", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r98"] }, "ptct_BioElectronMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "BioElectronMember", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "BioElectron [Member]", "label": "BioElectron", "terseLabel": "BioElectron" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompany5Level3ValuationDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillGoodwillDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": ["r348", "r349", "r350", "r351", "r352", "r521", "r907", "r908"] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompany5Level3ValuationDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillGoodwillDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": ["r50", "r51", "r348", "r349", "r350", "r351", "r352", "r521", "r907", "r908"] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset", "negatedTerseLabel": "Change in the fair value of contingent consideration", "documentation": "Amount of increase (decrease) in the value of right to a contingent consideration asset." } } }, "auth_ref": ["r525", "r1066"] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in valuation of contingent consideration", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": ["r525", "r1066"] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails", "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent consideration payable", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r52", "r119"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails", "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r24", "r161", "r874"] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": ["r25", "r118"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, and restricted cash end of period", "periodStartLabel": "Cash and cash equivalents, and restricted cash beginning of period", "terseLabel": "Total Cash, cash equivalents and restricted cash per statement of cash flows", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r24", "r95", "r194"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1", "r95"] }, "ptct_CensaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "CensaMember", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Censa", "label": "Censa [Member]", "terseLabel": "Censa" } } }, "auth_ref": [] }, "ptct_ChangeInTaxableIncomeChangeInTaxCodeQualifyingResearchAndDevelopmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "ChangeInTaxableIncomeChangeInTaxCodeQualifyingResearchAndDevelopmentCosts", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Change in taxable income resulting from effects of a change in tax code regarding deduction of qualifying research and development costs under Section 174.", "label": "Change in Taxable Income, Change in Tax Code, Qualifying Research and Development Costs", "verboseLabel": "Increase in current taxable income resulting from the elimination of current deduction of qualifying R&D costs under Section 174." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r1004"] }, "ecd_ChngInFrVlAsOfVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrVlAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r1001"] }, "ecd_ChngInFrVlAsOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrVlAsOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r999"] }, "ptct_ChristineUtterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "Ch

```
"ClearpointEquityInvestmentsFvNi", "crd": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails",
"http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security of ClearPoint Neuro, Inc. measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "ClearPoint Equity Investments, FV-NI", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "ClearPoint Equity Investments" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r1005" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r1005" ] }, "ptct_CollaborationRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "CollaborationRevenueMember", "presentation": [
"http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails",
"http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Revenue generated under a collaboration agreement.", "label": "Collaboration Revenue [Member]", "terseLabel": "Collaboration revenue" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementMember", "presentation": [
"http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails",
"http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement [Member]", "terseLabel": "SMA license Agreement",
"documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity." } } }, "auth_ref": [ "r531" ] }, "us-gaap_CollaborativeArrangementAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
"http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
"verboseLabel": "Collaboration and royalty revenue", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r531" ] }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleSecuritiesDetails",
"http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesBalanceSheetDisclosuresDetails",
"http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesUnrealizedGainsLossesDetails" ], "lang": { "en-us": { "role": { "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "terseLabel": "Commercial paper", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents." } } }, "auth_ref": [ "r1135" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label":
"Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]",
"terseLabel": "Commitments and contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r104", "r366", "r857", "r1118", "r1123" ] }, "us-gaap_CommitmentsMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails",
"http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompany5Level3ValuationDetails" ], "lang": { "en-us": { "role": { "label": "Commitments [Member]", "terseLabel": "Commitments",
"documentation": "This element represents significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements." } } }, "auth_ref": [ "r70", "r125" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r944", "r945", "r946", "r948", "r949", "r950", "r951", "r1073", "r1074", "r1077", "r1163", "r1230", "r1233" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.ptcbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "documentation":
"Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r75" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized",
"presentation": [ "http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized",
"netLabel": "Common stock, authorized shares (in shares)", "terseLabel": "Common stock, authorized shares (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } },
"auth_ref": [ "r75", "r709" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [
"http://www.ptcbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued shares (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r75" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, outstanding shares (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r10", "r75", "r788", "r806", "r1233", "r1234" ] }, "ptct_CommonStockTradingArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "CommonStockTradingArrangementMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to company common stock.", "label": "Common Stock Trading Arrangement [Member]", "terseLabel":
"Common Stock Trading Arrangement" } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": [
"http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 76,952,124 shares at September 30, 2024. Authorized 250,000,000 shares; issued and outstanding 75,708,889 shares at December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r75", "r712", "r927" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r1010" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r1009" ] },
"ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r1011" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation
Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r1008" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive
Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r20", "r176", "r178", "r183", "r703", "r721", "r722" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [
"http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r32", "r34", "r55", "r56", "r249", "r856" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails",
"http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } },
"auth_ref": [ "r32", "r34", "r55", "r56", "r249", "r750", "r856" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [
"http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r32", "r34", "r55", "r56", "r249", "r856", "r1047" ] },
"us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [
"http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r32", "r34", "r55", "r56", "r249", "r856" ] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationByTypeAxis",
"presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails",
"http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompany5Level3ValuationDetails",
"http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationTypeDomain", "presentation": [
"http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails",
"http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompany5Level3ValuationDetails",
"http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "ptct_ContingentLiabilityCancellationAndForfeiture": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "ContingentLiabilityCancellationAndForfeiture", "crdr": "debit",
"presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Contingent Liability, Cancellation and Forfeiture", "label": "Contingent Liability, Cancellation and Forfeiture", "terseLabel": "Contingent liability, cancellation and forfeiture" } } }, "auth_ref": [] }, "ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.ptcbio.com/20240930", "localname": "ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount", "crdr": "debit", "presentation": [
"http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Contingent Liability cancellation and forfeiture, Milestone, Potential Achievements, Priority Review Voucher Amount", "terseLabel": "Contingent liability cancellation and forfeiture of potential milestone payments" } } }, "auth_ref": [] },
"ptct_ContingentLiabilityMilestonePotentialAchievementsDevelopmentalAndRegulatoryMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname":
"ContingentLiabilityMilestonePotentialAchievementsDevelopmentalAndRegulatoryMilestones", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of potential payments which may be due for developmental and regulatory milestones if achieved.", "label": "Contingent Liability, Milestone, Potential Achievements, Developmental and Regulatory Milestones", "terseLabel": "Potential developmental and regulatory milestones" } } }, "auth_ref": [] }, "ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname":
"ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation":
"Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone And Regulatory Approval", "label": "Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone", "terseLabel": "Potential sales milestones" } } }, "auth_ref": [] }, "ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname":
"ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount", "label": "Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount", "terseLabel": "Priority review voucher amount" } } }, "auth_ref": [] }, "ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetOfCancellationandForfeiture": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname":
"ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetOfCancellationandForfeiture", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture", "label": "Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture", "terseLabel": "Contingent liability, milestone, potential achievements, priority review voucher amount, net of cancellation and forfeiture" } } }, "auth_ref": [] },
"ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage",
"presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage", "label":
"Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage", "terseLabel": "Product sales (as a percent)" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails",
"http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesManufacturingRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "terseLabel": "Contract with customer, asset", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } },
"auth_ref": [ "r419", "r421", "r440" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [
"http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability",
"terseLabel": "Contract with customer, liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r419", "r420", "r440" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "presentation": [
"http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r419", "r420", "r440" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Contract liability revenues recognized in period", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r441" ] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ConvertibleDebtMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails",
"http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "terseLabel": "Convertible debt", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r106", "r382", "r383", "r388", "r389", "r390", "r393", "r394", "r395", "r396", "r397", "r891", "r892", "r893", "r894", "r895" ] }, "us-gaap_ConvertibleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtSecuritiesMember", "presentation": [
"http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Securities [Member]", "terseLabel": "ClearPoint convertible debt",
"documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder." } } }, "auth_ref": [ "r1135" ] }, "ptct_ConvertibleDebtSecurity": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.ptcbio.com/20240930", "localname": "ConvertibleDebtSecurity", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails",
"http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of investment in convertible debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtTableTextBlock", "presentation": [
"http://www.ptcbio.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Table Text Block]", "terseLabel": "Summary of convertible notes", "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount." } } }, "auth_ref": [] }, "ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault": { "xbrltype": "percentItemType", "nsuri":
"http://www.ptcbio.com/20240930", "localname": "ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the debt instrument principal and unpaid interest payable upon events of default.", "label": "Convertible Instruments Principal And Unpaid Interest Payable Upon Events Of Default", "terseLabel": "Convertible instruments principal and unpaid interest payable upon events of default" } } }, "auth_ref": [] }, "ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname":
"ConvertibleSeniorNotes1.5DueSeptember152026Member", "presentation": [ "http://www.ptcbio.com/role/DisclosureCompanyDebt2026ConvertibleNotesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails",
"http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails", "http://www.ptcbio.com/role/DisclosureDebtTables",
"http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails" ], "lang": { "en-us": { "role": { "documentation": "Convertible Senior Notes, 1.5%, Due September 15, 2026 [Member]", "label": "1.50% Convertible senior notes due 2026", "terseLabel": "1.50% Convertible senior notes due 2026" } } }, "auth_ref": [] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CorporateDebtSecuritiesMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleSecuritiesDetails",
"http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesBalanceSheetDisclosuresDetails",
"http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesUnrealizedGainsLossesDetails" ], "lang": { "en-us": { "role": { "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r904", "r906", "r914", "r928", "r942", "r1227" ] },
"ptct_CostOfGoodsandServiceExcludingAmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "CostOfGoodsandServiceExcludingAmortizationOfIntangibleAssets", "crdr": "debit",
"presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Cost of Goods and Service, Excluding Amortization Of Intangible Assets", "label": "Cost of Goods and Service, Excluding Amortization Of Intangible Assets", "terseLabel": "Cost of product sales, excluding amortization of acquired intangible assets" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "CounterpartyNameAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangibleAssetsDetails",
"http://www.ptcbio.com/role/DisclosureLeaseNarrativeDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r198", "r199", "r385", "r405", "r627", "r646", "r708", "r878", "r880" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label":
"Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [
"http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails", "http://www.ptcbio.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r372", "r1128" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CreditFacilityDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails", "http://www.ptcbio.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation":
"Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r372", "r1128", "r1129" ] }, "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditLossFinancialInstrumentPolicyTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Credit Loss, Financial Instrument [Policy Text Block]", "terseLabel": "Allowance for doubtful accounts", "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status." } } }, "auth_ref": [ "r297", "r298", "r299", "r301",
```

*"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureCompanyDetails", "http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails", "http://www.ptcbio.com/role/DisclosureDebtTables", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r16", "r62", "r63", "r120", "r124", "r200", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r891", "r892", "r893", "r894", "r895", "r925", "r1070", "r1119", "r1120", "r1121", "r1176", "r1178"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt instrument, basis spread on variable rate", "verboseLabel": "Basis spread on variable rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "ptct_DebtInstrumentConversionPeriodOnOrAfterSeptember202023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "DebtInstrumentConversionPeriodOnOrAfterSeptember202023Member", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the debt instrument redemption period on or after September 20, 2023." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Conversion price per share (in dollars per share)", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": ["r107", "r384"] }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionRatio1", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Conversion ratio", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount." } } }, "auth_ref": ["r42", "r66", "r110", "r111", "r384"] }, "ptct_DebtInstrumentConvertibleThresholdBusinessDays": { "xbrltype": "durationItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "DebtInstrumentConvertibleThresholdBusinessDays", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified business days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature.", "label": "Debt Instrument Convertible Threshold Business Days", "terseLabel": "Business days, period" } } }, "auth_ref": [] }, "ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature.", "label": "Debt Instrument Convertible Threshold Consecutive Trading Day Period", "terseLabel": "Consecutive trading day period" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Consecutive trading days, period", "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Stock price trigger", "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion." } } }, "auth_ref": [] }, "ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day.", "label": "Debt Instrument Convertible Threshold Sale Price Of Common Stock Conversion Rate Product Percentage Maximum", "terseLabel": "Maximum product of the closing sale price of shares of the Company's common stock and the applicable conversion rate for such trading day" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleThresholdTradingDays", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Threshold Trading Days", "terseLabel": "Trading days, number", "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCumulativeSinkingFundPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCumulativeSinkingFundPayments", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Cumulative Sinking Fund Payments", "terseLabel": "Sinking fund", "documentation": "Cumulative amount paid into a fund, which is used to retire the debt instrument." } } }, "auth_ref": ["r422"] }, "ptct_DebtInstrumentDurationDelayedDrawTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "DebtInstrumentDurationDelayedDrawTerm", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "documentation": "Period of time after closing of the credit agreement during which funds can be drawn subject to specified conditions.", "label": "Debt Instrument, Delayed Draw Term", "verboseLabel": "Fund draw term" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Principal", "verboseLabel": "Debt principal amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r382", "r594", "r595", "r892", "r893", "r925"] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Fair value of convertible notes", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": ["r390", "r586", "r892", "r893", "r1166", "r1167", "r1168", "r1169", "r1170"] }, "ptct_DebtInstrumentFloorInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "DebtInstrumentFloorInterestRate", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Floor Interest Rate", "label": "Debt Instrument, Floor Interest Rate", "terseLabel": "Debt instrument, floor interest rate", "verboseLabel": "Floor interest rate" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails", "http://www.ptcbio.com/role/DisclosureDebtLiabilityForSaleOfFutureRoyaltiesDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate of the liability component", "verboseLabel": "Effective interest rate", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": ["r65", "r400", "r594", "r595", "r925"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.ptcbio.com/role/DisclosureCompanyDetails", "http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate (as a percent)", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r65", "r383"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.ptcbio.com/role/DisclosureCompanyDetails", "http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "Long-term debt", "verboseLabel": "Assigned royalty payments", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r200", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r891", "r892", "r893", "r894", "r895", "r925", "r1070", "r1119", "r1120", "r1121", "r1176", "r1178"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.ptcbio.com/role/DisclosureCompanyDetails", "http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails", "http://www.ptcbio.com/role/DisclosureDebtTables", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r16", "r200", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r891", "r892", "r893", "r894", "r895", "r925", "r1070", "r1119", "r1120", "r1121", "r1176", "r1178"] }, "us-gaap_DebtInstrumentRedemptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionLineItems", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtTables"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption [Line Items]", "terseLabel": "Debt Instrument, Redemption [Line Items]", "documentation": "Line Items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period [Axis]", "documentation": "Information by period of debt redemption feature under terms of debt agreement." } } }, "auth_ref": ["r130"] }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodDomain", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period [Domain]", "documentation": "Period as defined under terms of the debt agreement for debt redemption features." } } }, "auth_ref": ["r130"] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Redemption price as percent of principal amount", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": ["r130"] }, "us-gaap_DebtInstrumentRedemptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionTable", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtTables"], "lang": { "en-us": { "role": { "label": "Debt Instrument Redemption [Table]", "terseLabel": "Debt Instrument Redemption [Table]", "documentation": "Disclosure of information about debt instruments or arrangements with redemption features. Includes, but is not limited to, description of debt redemption features, percentage price at which debt can be redeemed by the issuer, and period start and end for debt maturity or redemption." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://www.ptcbio.com/role/DisclosureCompanyDetails", "http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Long-term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r16", "r42", "r43", "r58", "r109", "r111", "r200", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r891", "r892", "r893", "r894", "r895", "r925", "r1070", "r1176", "r1178"] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Term", "terseLabel": "Term of the convertible notes", "verboseLabel": "Loan term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r107", "r384"] }, "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Debt Related Commitment Fees and Debt Issuance Costs", "terseLabel": "Debt issuance costs", "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses." } } }, "auth_ref": ["r90"] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "terseLabel": "Allowance for credit loss", "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r258", "r318", "r328", "r330"] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesUnrealizedGainsLossesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Period Increase (Decrease)", "terseLabel": "Increase in allowance for credit losses", "documentation": "Amount of increase (decrease) in allowance for credit loss of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r1107"] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesUnrealizedGainsLossesDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Writeoff", "terseLabel": "Write downs of available for sale debt securities", "documentation": "Amount of writeoff of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r329"] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "terseLabel": "Securities in an unrealized loss position greater than 12 months - Fair Value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r138", "r325", "r888"] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "negatedTerseLabel": "Securities in an unrealized loss position greater than 12 months - Unrealized losses", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r138", "r325"] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "terseLabel": "Securities in an unrealized loss position less than 12 months - Fair Value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r138", "r325", "r888"] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "negatedTerseLabel": "Securities in an unrealized loss position less than 12 months - Unrealized losses", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r138", "r325"] }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)", "negatedLabel": "Realized loss on ClearPoint convertible debt security", "terseLabel": "Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r1100"] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleSecuritiesDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesBalanceSheetDisclosuresDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesUnrealizedGainsLossesDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266"] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesTables"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Schedule of available-for-sale debt securities", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100"] }, "us-gaap_DebtSecuritiesAvailableForSaleTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTerm", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Term", "terseLabel": "Term of convertible note", "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in PnYnMnDTnHnMnS format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1167", "r1168", "r1169"] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)", "negatedLabel": "Unrealized loss on ClearPoint convertible debt security", "verboseLabel": "Unrealized Gain/(Loss)", "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r1092", "r1093"] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Total - Fair Value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss." } } }, "auth_ref": ["r136", "r323", "r888"] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss", "negatedTotalLabel": "Total - Unrealized losses", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r137", "r324"] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesTables"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]", "terseLabel": "Summary of unrealized losses and fair values of available-for-sale debt securities in a continuous unrealized loss position", "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r135", "r888", "r1106"] }, "us-gaap_DebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesMember", "presentation": ["http://www.

*"http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit)", "negatedLabel": "Deferred tax benefit", "terseLabel": "Deferred income taxes", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": { "r7", "r146", "r1072"] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliticesNarrative Details"], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Gross", "verboseLabel": "Deferred tax liability" "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": { "r71", "r72", "r122", "r500"] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": { "r494", "r495", "r711"] }, "ptct_DeferredRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "DeferredRevenueMember", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing deferred revenues.", "label": "Deferred Revenue [Member]", "terseLabel": "Deferred revenue" } } }, "auth_ref": [] }, "ptct_DepositsAndOtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "DepositsAndOtherAssetsNoncurrent", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Represents the carrying value of amounts transferred to third parties for security purposes and other noncurrent assets that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits and Other Assets Noncurrent", "terseLabel": "Deposits and other assets" } } }, "auth_ref": [] }, "ptct_DepositsAndOtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "DepositsAndOtherNoncurrentAssetsMember", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing deposits and other noncurrent assets.", "label": "Deposits and Other Noncurrent Assets [Member]", "terseLabel": "Deposits and other assets" } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": { "r7", "r234", "r241", "r245", "r885", "r886"] }, "ptct_DevelopmentMilestoneObligationPaymentsMade": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "DevelopmentMilestoneObligationPaymentsMade", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails", "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of development milestone obligation payments made during the period.", "label": "Development Milestone Obligation Payments Made", "terseLabel": "Development milestone obligation payments made" } } }, "auth_ref": [] }, "ptct_DevelopmentMilestoneObligationPaymentsMadeCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "DevelopmentMilestoneObligationPaymentsMadeCash", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails", "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of development milestone obligation cash payments made during the period.", "label": "Development Milestone Obligation, Payments Made, Cash", "terseLabel": "Development milestone obligation cash payments made" } } }, "auth_ref": [] }, "ptct_DevelopmentMilestonePaymentObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "DevelopmentMilestonePaymentObligations", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements.", "label": "Development Milestone Payment Obligation", "terseLabel": "Development milestone payment obligations" } } }, "auth_ref": [] }, "ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "DevelopmentMilestonePaymentObligationsCancellationAndForfeiture", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Development Milestone Payment Obligations, Cancellation and Forfeiture", "label": "Development Milestone Payment Obligations, Cancellation and Forfeiture", "terseLabel": "Development milestone payment obligations, cancellation and forfeiture" } } }, "auth_ref": [] }, "ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements.", "label": "Development Milestone Payment Obligations, Due on Second Anniversary Year of Merger Closing", "terseLabel": "Development milestone payments which the entity is obligated to pay" } } }, "auth_ref": [] }, "ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Development Milestone Payment Obligations, net of cancellation and forfeiture", "label": "Development Milestone Payment Obligations, Net of Cancellation and Forfeiture", "terseLabel": "Development milestone payment obligations, net of cancellation and forfeiture" } } }, "auth_ref": [] }, "ptct_DevelopmentandRegulatoryMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "DevelopmentandRegulatoryMilestoneMember", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails"], "lang": { "en-us": { "role": { "documentation": "Development and Regulatory Milestone [Member]", "label": "Development and Regulatory Milestone", "terseLabel": "Development and Regulatory Milestone" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesManufacturingRevenueDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Revenue recognition", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r439", "r897", "r898", "r899", "r900", "r901", "r902", "r903"] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesManufacturingRevenueDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r439", "r897", "r898", "r899", "r900", "r901", "r902", "r903"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlan"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock award plan", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r452", "r456", "r484", "r485", "r487", "r910"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3, 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K, the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as a quarterly report." } } }, "auth_ref": ["r960"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r992"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "eecd_DeddsOrOthrgsPdOnEqtyAwrdsNtOthrwsRfltdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "DeddsOrOthrgsPdOnEqtyAwrdsNtOthrwsRfltdInTtlCompForCvrdYrMember", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Deductions or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r1003"] }, "ptct_EarlyStageGeneTherapyProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "EarlyStageGeneTherapyProgramMember", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTangibleAssetImpairmentAndLossesGainsOnTransactionsNetDetails"], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in early-stage gene therapy programs.", "label": "Early-stage Gene Therapy Program [Member]", "terseLabel": "Early-stage gene therapy program assets" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net loss per share-basic and diluted (in dollars per share)" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.ptcbio.com/role/DisclosureNetLossPerShareNumeratorAndDenominatorDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Basic", "verboseLabel": "Net loss per share - Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r184", "r209", "r210", "r211", "r212", "r213", "r214", "r220", "r223", "r227", "r228", "r229", "r233", "r519", "r530", "r558", "r559", "r704", "r723", "r882"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.ptcbio.com/role/DisclosureNetLossPerShareNumeratorAndDenominatorDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted", "verboseLabel": "Net loss per share - Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r184", "r209", "r210", "r211", "r212", "r213", "r214", "r223", "r227", "r228", "r229", "r233", "r519", "r530", "r558", "r559", "r704", "r723", "r882"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureNetLossPerShare"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net loss per share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r209", "r230", "r231", "r232"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "terseLabel": "Effect of exchange rate changes on cash", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1175"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "verboseLabel": "Federal income tax statutory rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": ["r107", "r497", "r510", "r913"] }, "ptct_EmflazaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "EmflazaMember", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNarrativeDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the product Emflaza.", "label": "Emflaza", "terseLabel": "Emflaza" } } }, "auth_ref": [] }, "ptct_EmployeeDirectorAndConsultantStockOptionPlan1998EquityAndLongTermIncentivePlan2009AndStockIncentivePlan2013Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "EmployeeDirectorAndConsultantStockOptionPlan1998EquityAndLongTermIncentivePlan2009AndStockIncentivePlan2013Member", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Pertains to information pertaining to the 1998 Employee, Director and Consultant Stock Option Plan, 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan.", "label": "1998 Employee, Director, and Consultant Stock Option Plan, 2009 Equity and Long-term Incentive Plan, and 2013 Stock Incentive Plan", "verboseLabel": "1998 Employee, Director, and Consultant Stock Option Plan, 2009 Equity and Long-term Incentive Plan, and 2013 Stock Incentive Plan" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails"], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Employee compensation, benefits, and related accruals", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r63"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanShareBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r486"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanShareBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average remaining service period for recognition of unrecognized compensation cost", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDThHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r486"] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Employee Stock [Member]", "terseLabel": "Employee Stock Purchase Plan", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.ptcbio.com/role/DisclosureNetLossPerShareAntidilutiveDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Employee Stock Ownership Plan (ESOP), Plan Name [Axis]", "documentation": "Information by name of employee stock ownership plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOwnershipPlanESOPPlanDomain", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Employee Stock Ownership Plan (ESOP), Plan [Domain]", "documentation": "Entities identify multiple employee stock ownership plans by unique name." } } }, "auth_ref": ["r491"] }, "ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "EmployeeStockPurchasePlanVotingPercentageLimitPercent", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Employee Stock Purchase Plan, Voting Percentage Limit, Percent", "label": "Employee Stock Purchase Plan, Voting Percentage Limit, Percent", "terseLabel": "Employee stock purchase plan, voting percentage limit" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r958"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r958"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r958"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r1042"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r958"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r958"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r958"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype":

*balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." }], "auth_ref": ["r10", "r154", "r180", "r181", "r182", "r201", "r202", "r203", "r206", "r213", "r215", "r217", "r235", "r290", "r296", "r361", "r418", "r505", "r506", "r515", "r516", "r517", "r520", "r529", "r530", "r539", "r541", "r542", "r543", "r544", "r546", "r557", "r588", "r589", "r590", "r591", "r592", "r593", "r597", "r599", "r626", "r719", "r739", "r740", "r741", "r759", "r828"] }, "ptct_EquityInvestmentsAndConvertibleDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "EquityInvestmentsAndConvertibleDebtSecurities", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails",], "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable equity investments and convertible debt securities measured at fair value.", "label": "Equity Investments and Convertible Debt Securities", "periodEndLabel": "Ending Balance - Total", "periodStartLabel": "Beginning Balance - Total" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI, Current", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Marketable securities - equity investments", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": ["r165", "r585", "r876"] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "negatedLabel": "Unrealized gain on marketable securities - equity investments", "terseLabel": "Unrealized Gain/(Loss)", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r724", "r1104"] }, "us-gaap_EquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesMember", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Equity Securities [Member]", "terseLabel": "Marketable securities - equity investments", "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants." } } }, "auth_ref": ["r38", "r928", "r952", "r953", "r954", "r1236"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://sbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://sbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r1007"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://sbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://sbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r965", "r975", "r985", "r1017"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://sbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://sbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r962", "r972", "r982", "r1014"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://sbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://sbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r1013"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Financial assets and liabilities measured at fair value on recurring basis", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r561", "r562", "r575", "r914"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r561", "r562", "r575", "r914"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Valuation Inputs", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r563", "r564", "r565", "r918"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of assets and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": ["r563", "r564", "r565", "r918"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesTables"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Fair value measurement inputs and valuation techniques", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": ["r563", "r564", "r918"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": ["r566", "r567", "r568", "r569", "r570", "r571", "r576", "r916"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Changes in fair value", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ptct_FairValueAssetsTransfersBetweenLevel1Level2AndLevel3Amount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "FairValueAssetsTransfersBetweenLevel1Level2AndLevel3Amount", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis between Level 1, Level 2, and Level 3 of the fair value hierarchy.", "label": "Fair Value, Assets, Transfers Between Level 1, Level 2 and Level 3, Amount", "terseLabel": "Transfers of assets measured between Level 1, Level 2, and Level 3" } } }, "auth_ref": [] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": ["r566", "r567", "r568", "r569", "r570", "r571", "r576", "r916"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanyS3Level3ValuationDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r390", "r444", "r445", "r446", "r447", "r448", "r449", "r560", "r562", "r563", "r564", "r565", "r574", "r575", "r577", "r633", "r634", "r635", "r892", "r893", "r904", "r905", "r906", "r914", "r918"] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanyS3Level3ValuationDetails"], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": ["r566", "r567", "r568", "r569", "r570", "r571", "r576"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r561", "r562", "r563", "r565", "r914", "r1168", "r1171"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecurities"], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair value of financial instruments and marketable securities", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r570", "r572", "r573", "r574", "r577", "r578", "r579", "r580", "r581", "r700", "r914", "r919"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted prices in active markets for identical assets (Level 1)", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r390", "r444", "r449", "r562", "r575", "r633", "r904", "r905", "r906", "r914"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant other observable inputs (Level 2)", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r390", "r444", "r449", "r562", "r563", "r575", "r634", "r892", "r893", "r904", "r905", "r906", "r914"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanyS3Level3ValuationDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant unobservable inputs (Level 3)", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r390", "r444", "r445", "r446", "r447", "r448", "r449", "r562", "r563", "r564", "r565", "r575", "r633", "r892", "r893", "r904", "r905", "r906", "r914", "r918"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanyS3Level3ValuationDetails"], "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": ["r566", "r567", "r568", "r569", "r570", "r571", "r576"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanyS3Level3ValuationDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Changes in the fair value of warrant liability and SARs liability", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanyS3Level3ValuationDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "verboseLabel": "Fair Value", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r566", "r567", "r568", "r569", "r570", "r571"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanyS3Level3ValuationDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input." } } }, "auth_ref": ["r566", "r567", "r568", "r569", "r570", "r571", "r576"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesTables"], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of changes in the fair value of the Company's Level 3 valuation for contingent consideration payable", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": ["r566", "r571", "r576"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r561", "r562", "r563", "r565", "r914", "r1168", "r1171"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanyS3Level3ValuationDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3", "negatedLabel": "Reclassification to accounts payable and accrued expenses", "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy." } } }, "auth_ref": ["r570", "r576"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanyS3Level3ValuationDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": ["r567", "r576"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanyS3Level3ValuationDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "terseLabel": "Additions", "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r569", "r576"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanyS3Level3ValuationDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedLabel": "Rights Exchange settlement", "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r569", "r576"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanyS3Level3ValuationDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "verboseLabel": "Fair value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r566", "r576"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanyS3Level3ValuationDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r390", "r444", "r445", "r446", "r447", "r448", "r449", "r560", "r562", "r563", "r564", "r565", "r574", "r575", "r577", "r633", "r634", "r635", "r892", "r893", "r904", "r905", "r906", "r914", "r918"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring basis", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r914", "r1165", "r1166", "r1167", "r1168", "r1169", "r1171"] }, "ptct_FifthAnniversaryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "FifthAnniversaryMember", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Fifth Anniversary [Member]", "label": "Fifth Anniversary", "terseLabel": "Fifth Anniversary" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Interest Expense", "terseLabel": "Finance lease cost", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": ["r603", "r610", "r926"] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesCashFlowDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Operating cash flows from finance leases", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": ["r605", "r614"] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]", "terseLabel": "Finance leases" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability", "terseLabel": "Total", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": ["r602", "r618"] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Current", "terseLabel": "Finance lease liabilities- current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": ["r602"] }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":

*"http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid", "totalLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": ["r618"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r618"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r618"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r618"] }, "ptct_FinanceLeaseLiabilityToBePaidYearFourAndAfter": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "FinanceLeaseLiabilityToBePaidYearFourAndAfter", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year and after following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four and After", "terseLabel": "2028 and thereafter" } } }, "auth_ref": [ ] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: Imputed Interest expense", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": ["r618"] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesCashFlowDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Principal Payments", "terseLabel": "Financing cash flows from finance lease", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": ["r604", "r614"] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesSupplementalLeaseTermsDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate - finance lease", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": ["r617", "r926"] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesSupplementalLeaseTermsDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease terms - finance lease (years)", "documentation": "Weighted average remaining lease term for finance lease, in PnYnMnDTnHnMnS format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r616", "r926"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleSecuritiesDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesBalanceSheetDisclosuresDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesUnrealizedGainsLossesDetails"], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r302", "r303", "r307", "r308", "r313", "r322", "r326", "r327", "r398", "r415", "r547", "r582", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r720", "r888", "r914", "r916", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r928", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1100", "r1101", "r1102", "r1103", "r1164", "r1167", "r1168", "r1169", "r1170", "r1171"] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedPeriodEndLabel": "Ending balance - Accumulated amortization", "negatedPeriodStartLabel": "Beginning balance - Accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r163", "r332", "r353", "r890"] }, "ptct_FiniteLivedIntangibleAssetsAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "FiniteLivedIntangibleAssetsAdditions", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life.", "label": "Finite-Lived Intangible Assets, Additions", "terseLabel": "Additions" } } }, "auth_ref": [ ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillFutureAmortizationDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r355", "r870", "r890"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillFutureAmortizationDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "2024", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": ["r1248"] }, "ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndThereafter", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillFutureAmortizationDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year and years thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four and Thereafter", "terseLabel": "2028 and thereafter" } } }, "auth_ref": [ ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillFutureAmortizationDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r355", "r870", "r890"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillFutureAmortizationDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r355", "r870", "r890"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r346", "r348", "r349", "r350", "r352", "r353", "r357", "r358", "r665", "r669", "r870"] }, "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign Currency Translation", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Gross", "periodEndLabel": "Ending balance - Definite-lived assets, Gross", "periodStartLabel": "Beginning balance - Definite-lived assets, Gross", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a finite life." } } }, "auth_ref": ["r332", "r353", "r669", "r890"] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "verboseLabel": "Definite-lived intangible assets", "documentation": "Line Items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r346", "r353", "r357", "r358", "r359", "r665", "r870", "r890"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r346", "r348", "r349", "r350", "r352", "r353", "r357", "r358", "r870"] }, "us-gaap_FiniteLivedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMember", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Member]", "terseLabel": "Definite-lived intangible assets", "documentation": "Assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth_ref": [ ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r665", "r1114"] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Remaining amortization period", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r665"] }, "us-gaap_FiniteLivedIntangibleAssetsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsRollForward", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Roll Forward]", "terseLabel": "Definite-lived intangibles", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [ ] }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossUnrealized", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax", "negatedLabel": "Unrealized foreign currency transaction losses, net", "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r907", "r908", "r955", "r1173", "r1174", "r1232"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r969", "r979", "r989", "r1021"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r969", "r979", "r989", "r1021"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r969", "r979", "r989", "r1021"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r969", "r979", "r989", "r1021"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r969", "r979", "r989", "r1021"] }, "ptct_FormerCensaSecurityholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "FormerCensaSecurityholdersMember", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to former Censa securityholders.", "label": "Former Censa Securityholders [Member]", "terseLabel": "Former Censa Securityholders" } } }, "auth_ref": [ ] }, "ecd_FvVaIAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FvVaIAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r1002"] }, "ptct_GainLossOnDispositionAndImpairmentOfTangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "GainLossOnDispositionAndImpairmentOfTangibleAssets", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "documentation": "Amount of net gain (loss) on disposition and impairment of tangible assets.", "label": "Gain (Loss) On Disposition and Impairment Of Tangible Assets", "negatedLabel": "Tangible asset impairment and losses (gains) on transactions, net" } } }, "auth_ref": [ ] }, "us-gaap_GainLossOnSaleOfOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfOtherAssets", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Other Assets", "negatedLabel": "Disposal of asset", "documentation": "Amount of gain (loss) on sale or disposal of other assets." } } }, "auth_ref": ["r1067"] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTangibleAssetImpairmentAndLossesGainsOnTransactionsNetDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on sale of fixed assets", "terseLabel": "Gain (loss) on sale of fixed assets", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": ["r7"] }, "us-gaap_GainLossOnTerminationOfLease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnTerminationOfLease", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTangibleAssetImpairmentAndLossesGainsOnTransactionsNetDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Termination of Lease", "negatedLabel": "Gain on lease terminations", "terseLabel": "Gain on lease terminations", "verboseLabel": "Gain on termination of lease components", "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term." } } }, "auth_ref": ["r600"] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on extinguishment of debt", "terseLabel": "Loss on extinguishment of debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": ["r1100", "r1112"] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeographicConcentrationRiskMember", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic concentration risk", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": ["r33", "r856"] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillGoodwillDetails", "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Goodwill", "terseLabel": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r162", "r334", "r701", "r886", "r889", "r915", "r927", "r1110", "r1111"] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [ ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwill"], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible assets and goodwill", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": ["r1108", "r1112"] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": ["r333", "r345", "r889"] }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]", "terseLabel": "Indefinite-lived intangible assets", "documentation": "Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets." } } }, "auth_ref": ["r1112"] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillGoodwillDetails"], "lang": { "en-us": { "role": { "label": "Goodwill [Line Items]", "terseLabel": "Goodwill", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r889"] }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillPeriodIncreaseDecrease", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillGoodwillDetails"], "lang": { "en-us": { "role": { "label": "Goodwill, Period Increase (Decrease)", "terseLabel": "Changes in goodwill", "documentation": "Amount of increase (decrease) of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r1109"] }, "us-gaap_GuarantyLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GuarantyLiabilities", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Guaranty Liabilities", "terseLabel": "Bank guarantee denominated in foreign currency", "documentation": "The item represents a non-contingent liability for the fair value of an obligation to stand ready to perform over the term of a guaranty issued in the event that specified triggering events or conditions occur." } } }, "auth_ref": ["r133", "r116"] }, "ptct_HopewellCampusMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "HopewellCampusMember", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Hopewell Campus", "label": "Hopewell Campus", "terseLabel": "Hopewell Campus" } } }, "auth_ref": [ ] }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "negatedLabel": "Impairment", "verboseLabel": "Intangible asset impairment", "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value." } } }, "auth_ref": ["r347", "r1067", "r1116", "r1117"] }, "us

"http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax (expense) benefit", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r139", "r147", "r216", "r217", "r234", "r242", "r245", "r496", "r497", "r511", "r725", "r913"] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": ["r179", "r492", "r493", "r498", "r499", "r501", "r504", "r753"] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income taxes", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r26", "r193", "r502", "r503"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": [
"http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r6"] }, "ptct_IncreaseDecreaseInContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "IncreaseDecreaseInContingentConsideration", "crdr": "debit", "presentation": [
"http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation liability recognized arising from contingent consideration in a business combination.", "label": "Increase (Decrease) in Contingent Consideration", "terseLabel": "Payments on contingent consideration" } } }, "auth_ref": [ ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r663", "r1066"] }, "us-gaap_IncreaseDecreaseInDepositOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDepositOtherAssets", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Deposit Assets", "negatedLabel": "Deposits and other assets", "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": [
"http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventory, net", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities" } } }, "auth_ref": [ ] }, "us-gaap_IncreaseDecreaseInOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLiabilities", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesCashFlowDetails"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Liabilities", "negatedLabel": "Net decrease in operating lease liabilities due to lease modification and termination", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities that result from activities that generate operating income." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInReceivables", "crdr": "credit", "presentation": [
"http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Receivables", "negatedLabel": "Trade and royalty receivables, net", "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [
"http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [ ] }, "ptct_IncrementalBorrowingRateRemeasurementOfRemainingLeaseComponent": { "xbrltype": "perUnitItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "IncrementalBorrowingRateRemeasurementOfRemainingLeaseComponent", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Incremental borrowing rate of interest used to remeasure the remaining components of operating lease.", "label": "Incremental Borrowing Rate, Remeasurement of Remaining Lease Component", "terseLabel": "Incremental borrowing rate of interest used to remeasure the remaining components of operating lease" } } }, "auth_ref": [ ] }, "ptct_IndefiniteLivedIntangibleAssetsAccumulatedDepreciationForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "IndefiniteLivedIntangibleAssetsAccumulatedDepreciationForeignCurrencyTranslationGainLoss", "crdr": "debit", "presentation": [
"http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) accumulated amortization of an asset, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Indefinite-Lived Intangible Assets, Accumulated Depreciation, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign Currency Translation - Accumulated amortization" } } }, "auth_ref": [ ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails",
"http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanysLevel3ValuationDetails",
"http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r346", "r351", "r356", "r890"] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r346", "r356", "r359", "r890"] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r332", "r356", "r890"] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails",
"http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanysLevel3ValuationDetails",
"http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": ["r346", "r351", "r356", "r890"] }, "us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets, Period Increase (Decrease)", "terseLabel": "Change in indefinite-lived intangibles", "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r1116"] }, "us-gaap_IndefiniteLivedIntangibleAssetsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsRollForward", "presentation": [
"http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Roll Forward]", "terseLabel": "Indefinite-lived intangibles", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [ ] }, "us-gaap_IndefiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsNet", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Member]", "terseLabel": "Indefinite-lived intangible assets", "documentation": "Assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit." } } }, "auth_ref": [ ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://sbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://sbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://sbrl.sec.gov/ecd/role/ErrCompDisclosure",
"http://sbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://sbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r969", "r979", "r989", "r1013", "r1021", "r1025", "r1033"] }, "ptct_InducementStockIncentivePlan2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "InducementStockIncentivePlan2020Member", "presentation": [
"http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the 2020 Inducement Stock Incentive Plan.", "label": "2020 Inducement Stock Incentive Plan", "terseLabel": "2020 Inducement Stock Incentive Plan" } } }, "auth_ref": [ ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://sbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r1031"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://sbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r961", "r1037"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://sbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://sbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r961", "r1037"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://sbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://sbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r961", "r1037"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails",
"http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r346", "r1114", "r1116"] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails",
"http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "totalLabel": "Total", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": ["r90", "r395", "r401", "r894", "r895"] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Contractual interest expense", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": ["r90", "r396", "r894", "r895"] }, "us-gaap_InterestExpenseLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseLongTermDebt", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Interest Expense, Long-Term Debt", "terseLabel": "Payment of accrued interest", "documentation": "Aggregate amount of interest paid or due on all long-term debt." } } }, "auth_ref": ["r129", "r150", "r151"] }, "us-gaap_InterestExpenseNonoperatingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperatingAbstract", "presentation": ["http://www.ptcbio.com/role/DisclosureNonoperatingIncomeExpenseDetails"], "lang": { "en-us": { "role": { "label": "Interest Expense, Nonoperating [Abstract]", "terseLabel": "Interest expense" } } }, "auth_ref": [ ] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Interest Income (Expense), Nonoperating", "terseLabel": "Interest expense, net", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": ["r885", "r1065", "r1082"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r189", "r191", "r192"] }, "ptct_InventoriesAndCostOfProductSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "InventoriesAndCostOfProductSalesPolicyTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for inventories and cost of revenue.", "label": "Inventories And Cost Of Product Sales [Policy Text Block]", "terseLabel": "Inventory and cost of product sales" } } }, "auth_ref": [ ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "presentation": [
"http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": ["r1058"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails", "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventory, net", "totalLabel": "Total inventory", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r172", "r875", "r927"] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "presentation": [
"http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r1060"] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in progress", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": ["r1059"] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "presentation": [
"http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails"], "lang": { "en-us": { "role": { "label": "Inventory write-down", "terseLabel": "Inventory write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": ["r331"] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": ["r771", "r773", "r774", "r776", "r778", "r833", "r835", "r837", "r840", "r841", "r842", "r844", "r845", "r846", "r847", "r848", "r946"] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeCategorizationMember", "presentation": [
"http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": ["r771", "r776", "r778", "r833", "r835", "r837", "r840", "r841", "r842", "r844", "r845", "r846", "r847", "r848", "r946"] }, "ptct_IssuanceOfStockForMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "IssuanceOfStockForMilestonePayment", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Fair value of stock issued as payment of milestone.", "label": "Issuance of Stock for Milestone Payment", "terseLabel": "Non-cash stock consideration, milestone payment" } } }, "auth_ref": [ ] },
"ptct_LeaseCostExcludingFinanceLeaseCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "LeaseCostExcludingFinanceLeaseCosts", "crdr": "debit", "presentation": [
"http://www.ptcbio.com/role/DisclosureLeasesLeaseCostsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contracts, excluding finance lease costs.", "label": "Lease Cost, Excluding Finance Lease Costs", "totalLabel": "Total operating lease cost" } } }, "auth_ref": [ ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [
"http://www.ptcbio.com/role/DisclosureLeasesTables"], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of lease costs", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r1181"] }, "ptct_LeaseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "LeaseDisclosureTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureLeases"], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of information about leases.", "label": "Lease Disclosure [Text Block]", "terseLabel": "Leases" } } }, "auth_ref": [ ] }, "ptct_LeaseSupplementalCashFlowDisclosureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "LeaseSupplementalCashFlowDisclosureTableTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information related to leases.", "label": "Lease Supplemental Cash Flow Disclosure [Table Text Block]", "terseLabel": "Schedule of supplemental cash flow information related to leases" } } }, "auth_ref": [ ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases" } } }, "auth_ref": [ ] }, "us-gaap_LegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalFees", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Legal Fees", "terseLabel": "Legal fees", "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } }, "auth_ref": ["r1048"] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Leases", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r608", "r620"] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": ["r608", "r620"] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [
"http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": ["r607"] }, "ptct_LesseeOperatingLeaseBaseRentAbatement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "LesseeOperatingLeaseBaseRentAbatement", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of base rent abatement available if lessee is not subject to an event of default as defined in the lease agreement.", "label": "Lessee, Operating Lease, Base Rent Abatement", "terseLabel": "Base rent abatement" } } }, "auth_ref": [ ] }, "ptct_LesseeOperatingLeaseBaseRentAbatementPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "LesseeOperatingLeaseBaseRentAbatementPeriod", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Period of lessee's base rent abatement entitlement per terms of lease agreement.", "label": "Lessee, Operating Lease, Base Rent Abatement Period", "terseLabel": "Base rent abatement period" } } }, "auth_ref": [ ] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": [
"http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": ["r609"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesTables"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of future lease payments - Operating leases", "documentation": "Tabular disclosure of undiscounted cash flows of lessee

*"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease net of eligible base rent abatement.", "label": "Lessee, Operating Lease, Liability to be Paid, Net of Base Rent Abatement", "totalLabel": "Aggregate rent net of base rate abatement, initial term" } }, "auth_ref": [] }, "ptct_LesseeOperatingLeaseLiabilityToBePaidYearFourAndAfter": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "LesseeOperatingLeaseLiabilityToBePaidYearFourAndAfter", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due fourth fiscal year and after following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four and After", "terseLabel": "2028 and thereafter" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: Imputed interest expense", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r618"] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Renewal term", "documentation": "Term of lessee's operating lease renewal, in PnYnMnDTnHnMnS format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1180"] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Operating lease, term of contract", "documentation": "Term of lessee's operating lease, in PnYnMnDTnHnMnS format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1180"] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of credit", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r16", "r62", "r63", "r64", "r68", "r69", "r70", "r73", "r196", "r286", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r533", "r534", "r535", "r587", "r787", "r883", "r956", "r1130", "r1183", "r1184"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' deficit", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r80", "r126", "r715", "r927", "r1071", "r1105", "r1172"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "Liabilities and stockholders' deficit" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r64", "r160", "r196", "r286", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r533", "r534", "r535", "r587", "r927", "r1130", "r1183", "r1184"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "ptct_LiabilityDevelopmentMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "LiabilityDevelopmentMilestoneMember", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Liability, Development Milestone.", "label": "Development Milestones", "terseLabel": "Development Milestones" } } }, "auth_ref": [] }, "ptct_LiabilityDevelopmentandRegulatoryMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "LiabilityDevelopmentandRegulatoryMilestoneMember", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanysLevel3ValuationDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails"], "lang": { "en-us": { "role": { "documentation": "Liability, Development and Regulatory Milestone [Member]", "label": "Development and Regulatory Milestones", "terseLabel": "Development and Regulatory Milestones" } } }, "auth_ref": [] }, "ptct_LiabilityForSaleOfFutureRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "LiabilityForSaleOfFutureRoyalties", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized for sale of future royalties sold.", "label": "Liability for Sale of Future Royalties", "terseLabel": "Liability recognized for sale of future royalties." } } }, "auth_ref": [] }, "ptct_LiabilityForSaleOfFutureRoyaltiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "LiabilityForSaleOfFutureRoyaltiesPolicyTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for liability resulting from the sale of future royalties.", "label": "Liability for Sale of Future Royalties [Policy Text Block]", "terseLabel": "Liability for sale of future royalties" } } }, "auth_ref": [] }, "ptct_LiabilityForSaleOfFutureRoyaltiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "LiabilityForSaleOfFutureRoyaltiesTableTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity related to the liability resulting from the sale of future royalties.", "label": "Liability for Sale of Future Royalties [Table Text Block]", "terseLabel": "Summary of liability for sale of future royalties" } } }, "auth_ref": [] }, "ptct_LiabilityNetSalesMilestonesandRoyaltiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "LiabilityNetSalesMilestonesandRoyaltiesMember", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanysLevel3ValuationDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails"], "lang": { "en-us": { "role": { "documentation": "Liability, Net Sales Milestones and Royalties [Member]", "label": "Liability, Net Sales Milestones and Royalties [Member]", "terseLabel": "Net Sales Milestones and Royalties" } } }, "auth_ref": [] }, "ptct_LiabilityRegulatoryMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "LiabilityRegulatoryMilestoneMember", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails"], "lang": { "en-us": { "role": { "documentation": "Liability, Regulatory Milestone", "label": "Regulatory Milestones", "terseLabel": "Regulatory Milestones" } } }, "auth_ref": [] }, "ptct_LiabilitySaleOfFutureRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "LiabilitySaleOfFutureRoyalties", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtLiabilityForSaleOfFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of liabilities related to the sale of future royalties due within one year or the normal operating cycle, if longer.", "label": "Liability, Sale of Future Royalties, Current", "terseLabel": "Liability for sale of future royalties - current" } } }, "auth_ref": [] }, "ptct_LiabilitySaleOfFutureRoyaltiesContractSalePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "LiabilitySaleOfFutureRoyaltiesContractSalePrice", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of contract price for sale of specified percentage of future royalties per terms of agreement.", "label": "Liability, Sale of Future Royalties, Contract Sale Price", "terseLabel": "Contract price for sale of specified percentage of future royalties" } } }, "auth_ref": [] }, "ptct_LiabilitySaleOfFutureRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "LiabilitySaleOfFutureRoyaltiesCurrent", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Amount of liabilities related to the sale of future royalties due within one year or the normal operating cycle, if longer.", "label": "Liability, Sale of Future Royalties, Current", "terseLabel": "Liability for sale of future royalties - current" } } }, "auth_ref": [] }, "ptct_LiabilitySaleOfFutureRoyaltiesInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "LiabilitySaleOfFutureRoyaltiesInterestExpense", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtLiabilityForSaleOfFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of interest expense recognized related to the liability for the sale of future royalties per terms of the agreement.", "label": "Liability, Sale of Future Royalties, Interest Expense", "terseLabel": "Plus: non-cash interest expense recognized" } } }, "auth_ref": [] }, "ptct_LiabilitySaleOfFutureRoyaltiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "LiabilitySaleOfFutureRoyaltiesNoncurrent", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Amount of liabilities related to the sale of future royalties due after one year or the normal operating cycle, if longer.", "label": "Liability, Sale of Future Royalties, Noncurrent", "terseLabel": "Liability for sale of future royalties- noncurrent" } } }, "auth_ref": [] }, "ptct_LiabilitySaleOfFutureRoyaltiesRoyaltyRevenuePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "LiabilitySaleOfFutureRoyaltiesRoyaltyRevenuePayable", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtLiabilityForSaleOfFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of royalty revenue recognized during the period relating to the sale of future royalties payable under terms of the agreement.", "label": "Liability, Sale of Future Royalties, Royalty Revenue Payable", "negatedLabel": "Less: Non-cash royalty revenue payable to Royalty Pharma" } } }, "auth_ref": [] }, "ptct_LineOfCreditCommittedDelayedDrawTermLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "LineOfCreditCommittedDelayedDrawTermLoanFacilityMember", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit, Committed Delayed Draw Term Loan Facility [Member]", "terseLabel": "Committed Delayed Draw Term Loan Facility" } } }, "auth_ref": [] }, "ptct_LineOfCreditCommittedLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "LineOfCreditCommittedLoanFacilityMember", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time and the lender is committed to providing the funds.", "label": "Line of Credit, Committed Loan Facility [Member]", "terseLabel": "Committed Loan Facility" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAbstract", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Abstract]", "terseLabel": "Debt Facility" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLineItems", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r372", "r1070", "r1128"] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r61", "r67"] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityTable", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Table]", "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement." } } }, "auth_ref": ["r61", "r67", "r372", "r1070", "r1128"] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails", "http://www.ptcbio.com/role/DisclosureDebtTables"], "lang": { "en-us": { "role": { "label": "Line of Credit [Member]", "terseLabel": "Blackstone Credit Agreement", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "ptct_LineOfCreditUncommittedLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "LineOfCreditUncommittedLoanFacilityMember", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time and the lender is not obligated to loan funds.", "label": "Line of Credit, Uncommitted Loan Facility [Member]", "terseLabel": "Uncommitted Incremental Facility" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt", "terseLabel": "Net carrying amount", "totalLabel": "Net carrying amount", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r16", "r124", "r389", "r399", "r892", "r893", "r925", "r1194"] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Excluding Current Maturities", "verboseLabel": "Long-term debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r166"] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt"], "lang": { "en-us": { "role": { "label": "Long-Term Debt [Text Block]", "terseLabel": "Debt", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": ["r105"] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r16", "r1119", "r1120", "r1121"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": ["http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial papers, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r16", "r39", "r1119", "r1120", "r1121"] }, "ptct_ManufacturingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "ManufacturingMember", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesManufacturingRevenueDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "documentation": "Manufacturing product for third parties.", "label": "Manufacturing [Member]", "terseLabel": "Manufacturing revenue" } } }, "auth_ref": [] }, "ptct_MarketableEquityInvestmentsAndConvertibleDebtSecuritiesPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "MarketableEquityInvestmentsAndConvertibleDebtSecuritiesPurchases", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable equity investments and convertible debt securities.", "label": "Marketable Equity Investments and Convertible Debt Securities, Purchases", "terseLabel": "Investments Purchased - Total" } } }, "auth_ref": [] }, "ptct_MarketableEquityInvestmentsAndConvertibleDebtSecuritiesRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "MarketableEquityInvestmentsAndConvertibleDebtSecuritiesRealizedGainLoss", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) from marketable equity investments and convertible debt securities measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Marketable Equity Investments and Convertible Debt Securities, Realized Gain (Loss)", "terseLabel": "Realized Gain/(Loss) - Total" } } }, "auth_ref": [] }, "ptct_MarketableEquityInvestmentsAndConvertibleDebtSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "MarketableEquityInvestmentsAndConvertibleDebtSecuritiesUnrealizedGainLoss", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on marketable equity investments and convertible debt securities measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Marketable Equity Investments and Convertible Debt Securities, Unrealized Gain (Loss)", "terseLabel": "Unrealized Gain/(Loss) - Total" } } }, "auth_ref": [] }, "ptct_MarketableEquityInvestmentsAndConvertibleDebtSecuritiesUnrealizedGainLossForeignCurrencyTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "MarketableEquityInvestmentsAndConvertibleDebtSecuritiesUnrealizedGainLossForeignCurrencyTransaction", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) from foreign currency transaction on marketable equity investments and convertible debt securities.", "label": "Marketable Equity Investments and Convertible Debt Securities, Unrealized Gain (Loss), Foreign Currency Transaction", "terseLabel": "Foreign Currency Unrealized Gain/(Loss) - Total" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Marketable Securities", "terseLabel": "Marketable securities", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": ["r1057"] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesPolicy", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable securities", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": ["r57"] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesTables"], "lang": { "en-us": { "role": { "label": "Marketable Securities [Table Text Block]", "terseLabel": "Schedule of marketable securities", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "ptct_MarketableSecuritiesUnrealizedGainLossForeignCurrencyTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "MarketableSecuritiesUnrealizedGainLossForeignCurrencyTransaction", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) from foreign currency transaction on marketable securities.", "label": "Marketable Securities, Unrealized Gain (Loss), Foreign Currency Transaction", "terseLabel": "Foreign Currency Unrealized Gain/(Loss)" } } }, "auth_ref": [] }, "ptct_MassBioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "MassBioMember", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "MassBio", "label": "MassBio", "terseLabel": "MassBio" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails", "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": ["r368", "r369", "r370", "r371", "r450", "r489", "r565", "r662", "r733", "r735", "r749", "r779", "r780", "r834", "r836", "r838", "r839", "r843", "r868", "r869", "r887", "r896", "r909", "r918", "r919", "r923", "r924", "r930", "r1132", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r1005"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r1005"] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputDiscountRateMember", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails"], "lang": { "en-us": { "role": { "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Discount Rate", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": ["r1167", "r1168", "r1169"] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r363", "r364", "r365", "r918"] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r363", "r364", "r365", "r918"] }, "ptct_MilestoneAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "MilestoneAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Information by categories of milestones achieved.", "label": "Milestone [Axis]" } } }, "auth_ref": [] }, "ptct_MilestoneDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "MilestoneDomain", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Different categories of milestones defined by agreements.", "label": "Milestone [Domain]" } } }, "auth_ref": [] }, "ptct_MilestonePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "MilestonePayable", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpenses

*Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } }, "auth_ref": ["r1032"] }, "us-gaap_MutualFundMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MutualFundMember", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Mutual Fund [Member]", "terseLabel": "Mutual Funds", "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective." } } }, "auth_ref": ["r1135"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://sbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://sbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r1006"] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": ["http://www.ptcbio.com/role/DisclosureCompany"], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "terseLabel": "The Company", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": ["r140", "r148"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r190"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r190"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r95", "r96", "r97"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfComprehensiveLoss", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficit", "http://sbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to common stockholders", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r86", "r97", "r128", "r158", "r174", "r177", "r182", "r196", "r205", "r209", "r210", "r211", "r212", "r213", "r216", "r217", "r225", "r286", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r519", "r530", "r559", "r587", "r718", "r800", "r826", "r827", "r955", "r1130"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureNetLossPerShareNumeratorAndDenominatorDetails"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss - Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) available to common shareholders." } } }, "auth_ref": ["r186", "r209", "r210", "r211", "r212", "r220", "r221", "r226", "r229", "r530"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": ["http://www.ptcbio.com/role/DisclosureNetLossPerShareNumeratorAndDenominatorDetails"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose separately information pertaining to accounting pronouns to the table." } } }, "auth_ref": ["r152", "r153", "r154", "r155", "r156", "r157", "r204", "r205", "r206", "r207", "r208", "r211", "r218", "r233", "r250", "r251", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r360", "r361", "r364", "r505", "r506", "r507", "r508", "r509", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r522", "r523", "r524", "r526", "r527", "r528", "r529", "r530", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r583", "r584", "r596", "r597", "r598", "r621", "r622", "r623", "r624", "r625", "r626", "r666", "r667", "r668", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r751"] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle." } } }, "auth_ref": ["r30", "r152", "r153", "r154", "r155", "r156", "r157", "r204", "r205", "r206", "r207", "r208", "r211", "r218", "r233", "r250", "r251", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r360", "r361", "r364", "r505", "r506", "r507", "r508", "r509", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r522", "r523", "r524", "r526", "r527", "r528", "r529", "r530", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r583", "r584", "r596", "r597", "r598", "r621", "r622", "r623", "r624", "r625", "r626", "r666", "r667", "r668", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r751"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently issued accounting standards", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://sbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://sbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r1005"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://sbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://sbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r969", "r979", "r989", "r1013", "r1021"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://sbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://sbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r996"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://sbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://sbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r995"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://sbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://sbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r1013"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://sbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://sbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r1032"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://sbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://sbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r1032"] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonUsMember", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails"], "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Non-US [Member]", "terseLabel": "Non-US", "documentation": "Country of domicile other than United States of America." } } }, "auth_ref": ["r1230"] }, "ptct_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of interest expense included in net income relating to the liability for sale of future royalties that results in no cash flow.", "label": "Noncash Interest Expense, Liability Related to Sale of Future Royalties", "terseLabel": "Non-cash interest expense on liability related to sale of future royalties" } } }, "auth_ref": [] }, "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired", "terseLabel": "Acquisition of product rights and licenses", "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r27", "r28", "r29"] }, "ptct_NoncashOrPartNoncashFixedAssetsTenantImprovementAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "NoncashOrPartNoncashFixedAssetsTenantImprovementAllowance", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The amount of fixed assets added through tenant improvement allowances that an Entity acquires in a noncash (or part noncash) acquisition.", "label": "Noncash Or Part Noncash, Fixed Assets, Tenant Improvement Allowance", "terseLabel": "Fixed asset additions through tenant improvement allowance" } } }, "auth_ref": [] }, "ptct_NoncashRoyaltyRevenueSaleOfFutureRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "NoncashRoyaltyRevenueSaleOfFutureRoyalties", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of royalty revenue included in net income relating to sale of future royalties that results in no cash inflow (outflow).", "label": "Noncash Royalty Revenue, Sale of Future Royalties", "negatedLabel": "Non-cash royalty revenue related to sale of future royalties" } } }, "auth_ref": [] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanTables"], "lang": { "en-us": { "role": { "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Summary of information on the Company's restricted stock", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": ["r15"] }, "ptct_NumberOfBuildingsLeased": { "xbrltype": "integerItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "NumberOfBuildingsLeased", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Number of buildings leased during the period.", "label": "Number Of Buildings Leased", "terseLabel": "Number of buildings leased" } } }, "auth_ref": [] }, "ptct_NumberOfCountriesExceedingTenPercentNetSalesThreshold": { "xbrltype": "integerItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "NumberOfCountriesExceedingTenPercentNetSalesThreshold", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Number of countries exceeding the ten percent net product sales threshold.", "label": "Number of Countries Exceeding Ten Percent Net Sales Threshold", "terseLabel": "Number of countries exceeding 10% of net product sales" } } }, "auth_ref": [] }, "ptct_NumberOfLeaseComponents": { "xbrltype": "integerItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "NumberOfLeaseComponents", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Number of separate lease components in lease agreement.", "label": "Number Of Lease Components", "terseLabel": "Number of separate lease components" } } }, "auth_ref": [] }, "ptct_NumberOfLeaseComponentsTerminated": { "xbrltype": "integerItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "NumberOfLeaseComponentsTerminated", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Number of separate lease components terminated.", "label": "Number Of Lease Components Terminated", "terseLabel": "Number of separate lease components terminated" } } }, "auth_ref": [] }, "ptct_NumberOfMutualFundsInvestedInDenominatedInForeignCurrency": { "xbrltype": "integerItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "NumberOfMutualFundsInvestedInDenominatedInForeignCurrency", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "documentation": "The number of mutual funds invested in that are denominated in a foreign currency.", "label": "Number of Mutual Funds Invested In, Denominated in Foreign Currency", "terseLabel": "Number of mutual funds denominated in a foreign currency" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails"], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": ["r886", "r1081"] }, "ptct_NumberOfProducts": { "xbrltype": "integerItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "NumberOfProducts", "presentation": ["http://www.ptcbio.com/role/DisclosureCompanyDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "The number of products of the company.", "label": "Number of Products", "terseLabel": "Number of products", "verboseLabel": "Number of approved products" } } }, "auth_ref": [] }, "ptct_NumberOfTranchesToSellRetainedRoyalty": { "xbrltype": "integerItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "NumberOfTranchesToSellRetainedRoyalty", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "documentation": "Number of tranches in which the retained royalty portions may be sold under terms of amended agreement.", "label": "Number of Tranches To Sell Retained Royalty", "terseLabel": "Number of tranches to sell retained royalty" } } }, "auth_ref": [] }, "ptct_Numberofdistributors": { "xbrltype": "integerItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "Numberofdistributors", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails"], "lang": { "en-us": { "role": { "documentation": "Number of Distributors", "label": "Number of distributors", "terseLabel": "Number of distributors" } } }, "auth_ref": [] }, "ptct_Numberofterms": { "xbrltype": "integerItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "Numberofterms", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Number of renewable terms.", "label": "Number of terms", "terseLabel": "Number of renewable terms" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r133", "r884", "r1080", "r1082", "r1083", "r1084", "r1085"] }, "ptct_OperatingLeaseAllowanceForLeaseImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "OperatingLeaseAllowanceForLeaseImprovements", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of allowance for lease improvements provided by lessor under the terms of the lease agreement.", "label": "Operating Lease, Allowance for Lease Improvements", "terseLabel": "Allowance for lease improvements" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesLeaseCostDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Fixed lease cost", "documentation": "Amount of single lease cost calculated by allocating total lease cost, including variable lease cost, but is not limited to, single lease cost after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r611", "r926"] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Expense", "terseLabel": "Operating lease, expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r1170"] }, "ptct_OperatingLeaseLessorPaymentDueAtIssuanceOfTemporaryCertificateOfOccupancy": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "OperatingLeaseLessorPaymentDueAtIssuanceOfTemporaryCertificateOfOccupancy", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of payment due from lessor at issuance of temporary certificate of occupancy that lessee has committed to fund into the construction account for lease improvements provided under the terms of the lease agreement.", "label": "Operating Lease, Lessor Payment Due At Issuance of Temporary Certificate of Occupancy", "terseLabel": "Payment due from lessor at issuance of temporary certificate of occupancy" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityPaymentsDueAbstract", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]", "terseLabel": "Operating leases" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails", "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "verboseLabel": "Total", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r602"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities-current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r602"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities- noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r602"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesCashFlowDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r606", "r614"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease ROU assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r601"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "terseLabel": "Non-cash operating lease expense", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r1067"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesSupplementalLeaseTermsDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate - operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r612", "r926"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesSupplementalLeaseTermsDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease terms - operating leases (years)", "documentation": "Weighted average remaining lease term for operating lease, in `PnYnMnDTnHnMnS` format, for example, `P1Y5M13D` represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r616", "r926"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails"], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r63"] }, "us-gaap_OtherCommitmentsAbstract

"presentation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" }, "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "verboseLabel": "Other comprehensive (loss) income:" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r69" } }, "us-gaap_OtherMachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherMachineryAndEquipmentMember", "presentation": { "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTangibleAssetImpairmentAndLossesGainsOnTransactionsNetDetails" }, "lang": { "en-us": { "role": { "label": "Other Machinery and Equipment [Member]", "terseLabel": "Other fixed assets", "documentation": "Other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" }, "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "verboseLabel": "Other expense, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": { "r91" } }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": { "r1005" } }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": { "r967", "r977", "r980", "r1019" } }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": { "r970", "r980", "r990", "r1022" } }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": { "r970", "r980", "r990", "r1022" } }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": { "r994" } }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "ptct_PaymentOfFinanceLeasePrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "PaymentOfFinanceLeasePrincipal", "crdr": "credit", "presentation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "documentation": "Payment of Finance Lease Principal", "label": "Payment of Finance Lease Principal", "negatedTerseLabel": "Payment of finance lease principal" } } }, "auth_ref": [] }, "ptct_PaymentOfMilestoneObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "PaymentOfMilestoneObligation", "crdr": "credit", "presentation": { "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails" }, "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for milestone obligations paid.", "label": "Payment of Milestone Obligation", "terseLabel": "Milestone obligation payments made" } } }, "auth_ref": [] }, "ptct_PaymentOfRoyaltyObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "PaymentOfRoyaltyObligation", "crdr": "credit", "presentation": { "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" }, "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for royalty obligations paid.", "label": "Payment of Royalty Obligation", "terseLabel": "Royalty payments" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtExtinguishmentCosts", "crdr": "credit", "presentation": { "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "negatedTerseLabel": "Debt extinguishment costs related to senior secured term loan", "terseLabel": "Prepayment premiums, expenses and other exit fees", "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest." } } }, "auth_ref": { "r4" } }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "presentation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Payments of Debt Issuance Costs", "negatedLabel": "Debt issuance costs related to secured term loan", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": { "r23" } }, "ptct_PaymentsOnDeferredConsiderationObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "PaymentsOnDeferredConsiderationObligation", "crdr": "credit", "presentation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "documentation": "Payments on deferred and contingent consideration obligation.", "label": "Payments On Deferred Consideration Obligation", "negatedTerseLabel": "Payments on contingent consideration" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "presentation": { "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Payments to Acquire Debt Securities, Available-for-Sale", "negatedLabel": "Purchases of marketable securities - available for sale", "terseLabel": "Purchase of convertible note", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r22", "r187", "r254" } }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "presentation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Acquisition of product rights and licenses", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": { "r93" } }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "presentation": { "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities - equity investments", "terseLabel": "Investments Purchased", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": { "r1087" } }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of fixed assets", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": { "r93" } }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": { "r1004" } }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": { "r1004" } }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": { "r996" } }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": { "r1013" } }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": { "r1006" } }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": { "r995" } }, "ptct_PercentageOfMaximumRoyaltyPayableThereafterAssignedRoyaltyRights": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "PercentageOfMaximumRoyaltyPayableThereafterAssignedRoyaltyRights", "presentation": { "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyalitiesDetails" }, "lang": { "en-us": { "role": { "documentation": "Percentage of maximum royalty payable thereafter assigned royalty rights.", "label": "Percentage of Maximum Royalty Payable Thereafter Assigned Royalty Rights", "terseLabel": "Percentage of maximum royalty payable thereafter assigned royalty rights" } } }, "auth_ref": [] }, "ptct_PercentageOfTotalRoyaltyAssigned": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "PercentageOfTotalRoyaltyAssigned", "presentation": { "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyalitiesDetails" }, "lang": { "en-us": { "role": { "documentation": "Total percentage of royalty rights assigned.", "label": "Percentage of Total Royalty Assigned", "terseLabel": "Aggregate percentage of royalty rights sold" } } }, "auth_ref": [] }, "ptct_Percentageofnetproductsales": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "Percentageofnetproductsales", "presentation": { "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" }, "lang": { "en-us": { "role": { "documentation": "Percentage of net product sales", "label": "Percentage of net product sales", "terseLabel": "Percentage of net product sales threshold" } } }, "auth_ref": [] }, "ptct_PeriodAfterWhichLetterOfCreditMayBeReducedIfLeaseNotInDefault": { "xbrltype": "durationItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "PeriodAfterWhichLetterOfCreditMayBeReducedIfLeaseNotInDefault", "presentation": { "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" }, "lang": { "en-us": { "role": { "documentation": "Period after which Letter of Credit may be reduced if lease is not in default.", "label": "Period After Which Letter of Credit May be Reduced If Lease Not In Default", "terseLabel": "Period after which letter of credit may be reduced if lease is not in default" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": { "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" }, "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": { "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161" } }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": { "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" }, "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": { "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161" } }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": { "r997" } }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": { "r1041" } }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": { "r996" } }, "ptct_PotentialRoyalitiesDueNetProductSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "PotentialRoyalitiesDueNetProductSales", "crdr": "credit", "presentation": { "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" }, "lang": { "en-us": { "role": { "documentation": "The amount of potential royalties due on worldwide net product sales per terms of the collaboration agreement.", "label": "Potential Royalties Due, Net Product Sales", "terseLabel": "Potential royalty payments due on net product sales" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r1061" } }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": { "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails" }, "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaids and other current assets", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "ptct_ProbabilityofSuccessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "ProbabilityofSuccessMember", "presentation": { "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails" }, "lang": { "en-us": { "role": { "documentation": "Probability of Success [Member]", "label": "Probability of Success [Member]", "terseLabel": "Probability of Success" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDebtNetOfIssuanceCosts", "crdr": "debit", "presentation": { "http://www.ptcbio.com/role/DisclosureDebt2026ConvertibleNotesNarrativeDetails" }, "lang": { "en-us": { "role": { "label": "Proceeds from Debt, Net of Issuance Costs", "terseLabel": "Net proceeds from issuance of convertible notes", "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination." } } }, "auth_ref": { "r188" } }, "ptct_ProceedsFromPrincipalPaymentOfClearpointConvertibleDebtSecurity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "ProceedsFromPrincipalPaymentOfClearpointConvertibleDebtSecurity", "crdr": "debit", "presentation": { "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "documentation": "Cash inflow from the principal payment of Clearpoint convertible debt security during the period.", "label": "Proceeds from Principal Payment of Clearpoint Convertible Debt Security", "negatedLabel": "Redemptions/Sale", "terseLabel": "Proceeds from principal payment of Clearpoint convertible debt security" } } }, "auth_ref": [] }, "ptct_ProceedsFromSaleAndMaturityOfClearpointEquityInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "ProceedsFromSaleAndMaturityOfClearpointEquityInvestment", "crdr": "debit", "presentation": { "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of Clearpoint Equity Investment during the period.", "label": "Proceeds From Sale And Maturity Of Clearpoint Equity Investment", "negatedLabel": "Redemptions/Sale", "terseLabel": "Sale and redemption of ClearPoint Equity Investments" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "presentation": { "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Proceeds from Sale and Maturity of Marketable Securities", "negatedLabel": "Redemptions/Sale", "terseLabel": "Sale and redemption of marketable securities - equity investments", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "ptct_ProceedsFromSaleAndRedemptionOfMarketableEquityInvestmentsAndConvertibleDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "ProceedsFromSaleAndRedemptionOfMarketableEquityInvestmentsAndConvertibleDebtSecurities", "crdr": "debit", "presentation": { "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails" }, "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or redemption of marketable equity investments and convertible debt securities during the period.", "label": "Proceeds From Sale and Redemption of Marketable Equity Investments and Convertible Debt Securities", "negatedLabel": "Redemptions/Sale - Total" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "presentation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "terseLabel": "Sale and redemption of marketable securities - available for sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r21", "r187", "r254", "r285" } }, "ptct_ProceedsFromSaleOfFutureRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "ProceedsFromSaleOfFutureRoyalties", "crdr": "debit", "presentation": { "http://www.ptcbio.com/role/DisclosureDebtLiabilityForSaleOfFutureRoyaltiesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyalitiesDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "documentation": "Cash received for sale of future royalties during the current period.", "label": "Proceeds From Sale of Future Royalties", "terseLabel": "Cash received from Royalty Pharma", "verboseLabel": "Proceeds from sales of future royalties" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "presentation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of fixed assets", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": { "r92" } }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": { "r3", "r13" } }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockPlans", "crdr": "debit", "presentation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from employee stock purchase plan", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": { "r3" } }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": { "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" }, "lang": { "en-us": { "role": { "label": "Product [Member]", "terseLabel": "Net product revenue", "verboseLabel": "Product", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": { "r897" } }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": { "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" }, "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": { "r246", "r664", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r872", "r897", "r937", "r938", "r939", "r941", "r943", "r1124", "r1125", "r1133", "r1197", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1223", "r1223", "r1224", "r1225", "r1226", "r1228", "r1229" } }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": { "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" }, "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": { "r246", "r664", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r872", "r897", "r937", "r938", "r939", "r941", "r943", "r1124", "r1125", "r1133", "r1197", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1223", "r1223", "r1224", "r1225", "r1226", "r1228", "r1229" } }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": { "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTangibleAssetImpairmentAndLossesGainsOnTransactionsNetDetails" }, "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": { "r8", "r619" } }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": { "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTangibleAssetImpairmentAndLossesGainsOnTransactionsNetDetails" }, "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r619" } }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Fixed assets, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "r8", "r619", "r707", "r716", "r927" } }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": { "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTangibleAssetImpairmentAndLossesGainsOnTransactionsNetDetails" }, "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": { "r101", "r619" } }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": { "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" }, "lang": { "en-us": { "role": { "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Bad debt expense", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "au

*"r481", "r489", "r565", "r636", "r645", "r663", "r733", "r735", "r749", "r770", "r780", "r834", "r836", "r838", "r839", "r843", "r868", "r869", "r887", "r896", "r909", "r918", "r919", "r923", "r924", "r938", "r946", "r1122", "r1132", "r1168", "r1186", "r1187", "r1188", "r1189", "r1190" } }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "presentation": { "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTangibleAssetImpairmentAndLossesGainsOnTransactionsNetDetails" }, "lang": { "en-us": { "role": { "label": "Name of Property [Axis]" } } }, "auth_ref": ["r858", "r862", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247"] }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTangibleAssetImpairmentAndLossesGainsOnTransactionsNetDetails"], "lang": { "en-us": { "role": { "label": "Name of Property [Domain]" } } }, "auth_ref": ["r858", "r862", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247"] }, "us-gaap_ReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesNetCurrent", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Receivables, Net, Current", "terseLabel": "Trade and royalty receivables, net", "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value." } } }, "auth_ref": ["r927"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r962", "r972", "r982", "r1014"] }, "ptct_ReductionInLetterOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "ReductionInLetterOfCredit", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of reduction of letter of credit requirements pertaining to amendments to operating lease agreement.", "label": "Reduction In Letter of Credit", "terseLabel": "Return of letter of credit pertaining to amendments to operating lease agreement" } } }, "auth_ref": [ ] }, "us-gaap_RepaymentsOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfSecuredDebt", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Repayments of Secured Debt", "negatedTerseLabel": "Repayment of senior secured term loan", "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt." } } }, "auth_ref": ["r04"] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": ["r198", "r199", "r385", "r405", "r627", "r646", "r708", "r879", "r880"] }, "ptct_ResearchAndDevelopmentAndSalesMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "ResearchAndDevelopmentAndSalesMilestonesMember", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to certain research and development events and certain sales events on the basis of which certain milestones are achieved.", "label": "Research and Development and Sales Milestones [Member]", "terseLabel": "Research and Development and Sales Milestones" } } }, "auth_ref": [ ] }, "ptct_ResearchAndDevelopmentEventMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "ResearchAndDevelopmentEventMilestonesMember", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to certain research and development events on the basis of which certain milestones are achieved.", "label": "Research And Development Event Milestones", "terseLabel": "Research And Development Event Milestones" } } }, "auth_ref": [ ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r491", "r870", "r885", "r1191"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanShareBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [ ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r963", "r973", "r983", "r1015"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r964", "r974", "r984", "r1016"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r971", "r981", "r991", "r1023"] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails"], "lang": { "en-us": { "role": { "label": "Restricted Cash", "terseLabel": "Restricted cash included in deposits and other assets", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r1056", "r1068", "r1192", "r1195"] }, "ptct_RestrictedStockAndRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "RestrictedStockAndRestrictedStockUnitsMember", "presentation": ["http://www.ptcbio.com/role/DisclosureNetLossPerShareAntidilutiveDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Restricted Stock and Restricted Stock Units (RSUs)." "label": "Restricted Stock and Restricted Stock Units [Member]", "terseLabel": "Unvested restricted stock units" } } }, "auth_ref": [ ] }, "ptct_RestrictedStockUnitsPerformanceBasedPsusMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "RestrictedStockUnitsPerformanceBasedPsusMember", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails"], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, if specified performance targets are met within the specified performance period.", "label": "Restricted Stock Units, Performance-based (PSUs) [Member]", "terseLabel": "Performance-based restricted stock units (PSUs)" } } }, "auth_ref": [ ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [ ] }, "us-gaap_RestructuringChargesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringChargesAbstract", "presentation": ["http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesRestructuringDetails"], "lang": { "en-us": { "role": { "label": "Restructuring Charges [Abstract]", "terseLabel": "Restructuring costs" } } }, "auth_ref": [ ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureCompanyDetails", "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r77", "r112", "r714", "r743", "r748", "r750", "r789", "r927"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r154", "r201", "r203", "r203", "r206", "r213", "r215", "r217", "r290", "r296", "r361", "r505", "r506", "r515", "r516", "r517", "r520", "r529", "r530", "r539", "r542", "r543", "r546", "r557", "r597", "r599", "r739", "r741", "r759", "r1233"] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [ ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": ["r131", "r132", "r234", "r239", "r240", "r243", "r245", "r246", "r247", "r249", "r438", "r439", "r664"] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerMember", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Net product revenue", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": ["r249", "r1046"] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliticsPolicies"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": ["r149", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r871"] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognition"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue recognition", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r149", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r442"] }, "ptct_RevenueRecognitionMilestonePotentialAchievements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "RevenueRecognitionMilestonePotentialAchievements", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "documentation": "Remaining potential milestones that can be achieved.", "label": "Revenue Recognition, Milestone, Potential Achievements", "terseLabel": "Remaining potential milestones that can be achieved" } } }, "auth_ref": [ ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionPerformanceObligationsDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesManufacturingRevenueDetails"], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Remaining performance obligations", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": ["r145"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "auth_ref": [ ] }, "ptct_RightOfUseAssetDecreaseDueToLeaseModificationsAndTerminationsObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "RightOfUseAssetDecreaseDueToLeaseModificationsAndTerminationsObtainedInExchangeForFinanceLeaseLiability", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesCashFlowDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in operating lease right-of-use assets related to lease modifications and terminations.", "label": "Right-of Use Asset, Decrease Due to Lease Modifications and Terminations Obtained in Exchange for Finance Lease Liability", "terseLabel": "Net decrease in right-of-use assets due to lease modification and termination" } } }, "auth_ref": [ ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesCashFlowDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Right-of Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Amount of operating lease right-of-use assets obtained in exchange for operating lease liability." } } }, "auth_ref": ["r615", "r926"] }, "ptct_RightsExchangeAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "RightsExchangeAgreementMember", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Rights Exchange Agreement [Member]", "label": "Rights Exchange Agreement [Member]", "terseLabel": "Rights Exchange Agreement" } } }, "auth_ref": [ ] }, "ptct_RightsExchangeSettlementMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "RightsExchangeSettlementMeasurementInput", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails"], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure Rights Exchange Settlement.", "label": "Rights Exchange Settlement, Measurement Input", "terseLabel": "Rights Exchange Settlement measurement" } } }, "auth_ref": [ ] }, "ptct_RightsExchangeSettlementPotentialMilestonesValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "RightsExchangeSettlementPotentialMilestonesValue", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails"], "lang": { "en-us": { "role": { "documentation": "The potential milestone payments due under the Rights Exchange Settlement.", "label": "Rights Exchange Settlement, Potential Milestones, Value", "terseLabel": "Potential milestones" } } }, "auth_ref": [ ] }, "us-gaap_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyExpense", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Royalty Expense", "terseLabel": "Royalty expense since inception", "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property." } } }, "auth_ref": ["r87"] }, "us-gaap_RoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyMember", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails" "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Royalty [Member]", "terseLabel": "Royalty revenue", "documentation": "Money for usage-based right to asset." } } }, "auth_ref": ["r1134"] }, "ptct_RoyaltyPharmaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "RoyaltyPharmaMember", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Royalty Pharma.", "label": "Royalty Pharma [Member]", "terseLabel": "Royalty Pharma" } } }, "auth_ref": [ ] }, "ptct_RoyaltyPurchaseAgreementPaymentMaximum": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "RoyaltyPurchaseAgreementPaymentMaximum", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "documentation": "The aggregate amount of royalties to be received after which the percentage is adjusted under terms of the Amended and Restated Royalty Purchase Agreement ("Assigned Royalty Cap")", "label": "Royalty Purchase Agreement, Payment Maximum", "terseLabel": "Assigned Royalty Cap per terms of the royalty purchase agreement" } } }, "auth_ref": [ ] }, "ptct_RoyaltyPurchaseAgreementTerminationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "RoyaltyPurchaseAgreementTerminationPeriod", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "documentation": "Royalty purchase agreement termination period once there are no further royalty payment obligations.", "label": "Royalty Purchase Agreement, Termination Period", "terseLabel": "Royalty purchase agreement termination period once there are no further royalty payment obligations" } } }, "auth_ref": [ ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted Flag", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r1032"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated Flag", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r1032"] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": ["http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [ ] }, "ptct_SaleOfStockRemainingSharesAvailableForSaleAggregateOfferingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "SaleOfStockRemainingSharesAvailableForSaleAggregateOfferingValue", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "The aggregate value of remaining shares to be issued and sold under a sales agreement.", "label": "Sale of Stock, Remaining Shares Available for Sale, Aggregate Offering Value", "verboseLabel": "Aggregate value of remaining shares to be issued and sold" } } }, "auth_ref": [ ] }, "ptct_SaleOfStockSharesAvailableToBeIssuedAndSoldValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "SaleOfStockSharesAvailableToBeIssuedAndSoldValue", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Value of shares available to be issued and sold in stock transaction.", "label": "Sale of Stock, Shares Available to be Issued and Sold, Value", "terseLabel": "Value of shares available to be issued and sold in transaction" } } }, "auth_ref": [ ] }, "ptct_SalesAllowanceAndOtherRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "SalesAllowanceAndOtherRelatedCosts", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails"], "lang": { "en-us": { "role": { "documentation": "Sales Allowance And Other Related Costs", "label": "Sales Allowance And Other Related Costs", "terseLabel": "Sales allowance" } } }, "auth_ref": [ ] }, "ptct_SalesMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "SalesMilestonesMember", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to certain sales events on the basis of which certain milestones are achieved.", "label": "Sales Milestones", "terseLabel": "Sales Milestones" } } }, "auth_ref": [ ] }, "ptct_SalesRebatesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "SalesRebatesCurrent", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales rebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Sales Rebates, Current", "terseLabel": "Sales rebates" } } }, "auth_ref": [ ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "auth_ref": ["r451", "r1076"] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": ["r218", "r451", "r1044", "r1076"] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of components of accounts payable and accrued expenses", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [ ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.ptcbio.com/role/DisclosureNetLossPerShareAntidilutiveDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r31"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureNetLossPerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of historical dilutive common share equivalents outstanding", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r31"] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleSecuritiesDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesBalanceSheetDisclosuresDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesUnrealizedGainsLossesDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "verboseLabel": "Debt Securities, Available-for-sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266"] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "terseLabel": "Summary of market

*Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of computation of basic and diluted net loss available to common stockholders", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } }, "auth_ref": { "r1079" } }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of share-based compensation expense recorded in the statement of operations", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": { "r45" } }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnNonrecurringBasisTableTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of financial assets and liabilities that are required to be measured at fair value on a recurring basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": { "r165", "r166", "r167" } }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Intangible Asset, Finite-Lived [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": { "r346", "r353", "r357", "r358", "r359", "r665", "r870", "r890" } }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillTables"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of definite lived intangible assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": { "r890", "r1113" } }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillGoodwillDetails"], "lang": { "en-us": { "role": { "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": { "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r889" } }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Intangible Asset, Indefinite-Lived [Table]", "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset." } } }, "auth_ref": { "r346", "r356", "r359", "r890" } }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillTables"], "lang": { "en-us": { "role": { "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment." } } }, "auth_ref": { "r890", "r1116" } }, "ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest expense recognized related to convertible debt.", "label": "Schedule Of Interest Expense Recognized Related To Convertible Debt [Table Text Block]", "terseLabel": "Summary of interest expense recognized related to the Convertible Notes" } } }, "auth_ref": {} }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": { "r17", "r81", "r82", "r83" } }, "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtTables"], "lang": { "en-us": { "role": { "label": "Schedule of Line of Credit Facilities [Table Text Block]", "terseLabel": "Schedule of credit agreement", "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": { "r61", "r67" } }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTangibleAssetImpairmentAndLossesGainsOnTransactionsNetDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": { "r8", "r19" } }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Reconciliation of cash", "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": { "r14", "r118", "r1195" } }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanShareBasedCompensationExpenseDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": { "r453", "r455", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482" } }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of stock option activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant-date fair value." } } }, "auth_ref": { "r11", "r12", "r113" } }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of assumptions used to estimate fair values of grants made on the date of grant", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": { "r115" } }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillTables"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of estimated future amortization of intangible assets", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": { "r890", "r1115" } }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebtMember", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Secured Debt [Member]", "terseLabel": "Senior Secured Term Loan", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": {} }, "us-gaap_SecuredOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrMember", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Secured Overnight Financing Rate (SOFR) [Member]", "terseLabel": "Adjusted Term SOFR", "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral." } } }, "auth_ref": { "r1162" } }, "del-Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://sbrl.sec.gov/del/2024", "localname": "Security12bTitle", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": { "r957" } }, "del-SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://sbrl.sec.gov/del/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": { "r959" } }, "us-gaap_GeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "GeographicalDomain", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": { "r247", "r248", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r772", "r775", "r777", "r835", "r837", "r841", "r844", "r855", "r858", "r859", "r860", "r861", "r863", "r864", "r865", "r866", "r867", "r873", "r898", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r940", "r946", "r1133", "r1197", "r1201", "r1202", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1228", "r1229" } }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": { "r88" } }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanShareBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": {} }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": { "r6" } }, "ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails"], "lang": { "en-us": { "role": { "documentation": "Estimated period over which specified performance goals are to be met in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Performance Period", "terseLabel": "Performance period" } } }, "auth_ref": {} }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "terseLabel": "Award requisite service period", "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r910" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service, performance, or combination of both. 'PnYnMnDTnHnMnS' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": { "r910" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)", "verboseLabel": "Units forfeited (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": { "r473" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": { "r473" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": { "r471" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": { "r471" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Balance at the end of the period (in shares)", "periodStartLabel": "Balance at the beginning of the period (in shares)", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": { "r168", "r169" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of the period." } } }, "auth_ref": {} }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Balance at the end of the period (in dollars per share)", "periodStartLabel": "Balance at the beginning of the period (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": { "r468", "r469" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "auth_ref": {} }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": { "r472" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": { "r472" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Valuation assumptions" } } }, "auth_ref": {} }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield (as a percent)", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": { "r480" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility (as a percent)", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": { "r479" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate (as a percent)", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": { "r481" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanShareBasedCompensationExpenseDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Stock option plan", "verboseLabel": "Restricted Stock Awards and Units", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r453", "r455", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Number of additional shares authorized (in shares)", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": {} }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": { "r912" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPa

*and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r44"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted- average remaining contractual term" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at the end of the period (in shares)", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r462"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at the end of the period (in dollars per share)", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r462"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited/Cancelled (in shares)", "terseLabel": "Options forfeited (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r466"] }, "ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedExercisePriceAsPercentageOfFairMarketValueOfCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedExercisePriceAsPercentageOfFairMarketValueOfCommonStock", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the exercise price expressed as a percentage of the fair-market value of the common stock as of the date of grant, at which grantees can acquire the shares reserved for issuance of stock options awarded.", "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Granted Exercise Price as Percentage of Fair Market Value of Common Stock", "terseLabel": "Stock options granted, exercise price as percentage of the fair-market value of common stock at grant date" } } }, "auth_ref": [] }, "ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedToStockholdersWithSpecifiedOwnershipPercentageExercisePriceAsPercentageOfFairMarketValueOfCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedToStockholdersWithSpecifiedOwnershipPercentageExercisePriceAsPercentageOfFairMarketValueOfCommonStock", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the exercise price expressed as a percentage of the fair market value of the common stock as of the date of grant, at which grantees with specified common stock ownership percentage can acquire the shares reserved for issuance of stock options awarded.", "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Granted to Stockholders with Specified Ownership Percentage Exercise Price as Percentage of Fair Market Value of Common Stock", "terseLabel": "Stock options granted to stockholder with specified ownership percentage, exercise price as percentage of the fair market value of common stock at grant date" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r464"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value (in dollars per share)", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r474"] }, "ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions": { "xbrltype": "sharesItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the inducement grants for non-statutory stock options.", "label": "Inducement Grants For Non-Statutory Stock Options", "terseLabel": "Inducement grants for non-statutory stock options (in shares)" } } }, "auth_ref": [] }, "ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "documentation": "", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award Options Intrinsic Value [Roll Forward]", "terseLabel": "Aggregate intrinsic value (in thousands)" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "verboseLabel": "Outstanding at the end of the period (in dollars)", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r44"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at the end of the period (in shares)", "periodStartLabel": "Outstanding at the beginning of the period (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r460", "r461"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of options", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at the end of the period (in dollars per share)", "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r460", "r461"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted- average exercise price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Vested or Expected to vest at the end of the period (in dollars)", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r477"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Vested or Expected to vest at the end of the period (in shares)", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r477"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Vested or Expected to vest at the end of the period (in dollars per share)", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r477"] }, "ptct_StockholdersSpecifiedOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "StockholdersSpecifiedOwnershipPercentage", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the stockholder's specified ownership percentage of the entity's common stock used in determination of the exercise price of stock options granted.", "label": "Share Based Compensation Arrangement by Share Based Payment Award Stockholders Specified Ownership Percentage", "terseLabel": "Stockholder's specified ownership percentage" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r465"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited/Cancelled (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r466"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r464"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Expiration period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r911"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r478"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable at the end of the period (in dollars)", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r44"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable at the end of the period", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r44"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding at the end of the period", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r114"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Vested or Expected to vest at the end of the period", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r477"] }, "ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Purchase price of common stock, percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Shares, Issued", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": ["r10"] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesLeaseCostsDetails"], "lang": { "en-us": { "role": { "label": "Short-Term Lease Cost", "terseLabel": "Short-term lease cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": ["r612", "r926"] }, "ptct_SmaFoundationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "SmaFoundationMember", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the SMA Foundation.", "label": "SMA Foundation [Member]", "terseLabel": "SMA Foundation" } } }, "auth_ref": [] }, "ptct_SouthPlainfieldNewJerseyOfficeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "SouthPlainfieldNewJerseyOfficeMember", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTangibleAssetImpairmentAndLossesGainsOnTransactionsNetDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the Company's South Plainfield office in New Jersey.", "label": "South Plainfield, New Jersey Office [Member]", "terseLabel": "South Plainfield, New Jersey office" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r150", "r167", "r168", "r169", "r196", "r223", "r224", "r227", "r229", "r236", "r237", "r286", "r373", "r375", "r376", "r377", "r380", "r381", "r403", "r404", "r407", "r410", "r417", "r587", "r754", "r755", "r756", "r757", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r788", "r810", "r828", "r849", "r850", "r851", "r852", "r853", "r1043", "r1069", "r1078"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r10", "r75", "r78", "r79", "r154", "r180", "r181", "r182", "r201", "r202", "r203", "r206", "r213", "r215", "r217", "r235", "r290", "r296", "r361", "r418", "r505", "r506", "r515", "r516", "r517", "r520", "r529", "r530", "r539", "r541", "r542", "r543", "r544", "r546", "r557", "r588", "r589", "r590", "r591", "r592", "r593", "r597", "r599", "r626", "r719", "r739", "r740", "r741", "r759", "r828"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": ["r347", "r348", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r772", "r773", "r777", "r835", "r837", "r841", "r844", "r855", "r858", "r859", "r860", "r861", "r863", "r864", "r865", "r866", "r867", "r872", "r898", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r940", "r946", "r1133", "r1197", "r1201", "r1202", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1228", "r1229"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r201", "r202", "r203", "r235", "r599", "r664", "r752", "r770", "r781", "r782", "r783", "r784", "r785", "r786", "r788", "r701", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r801", "r802", "r803", "r804", "r805", "r807", "r811", "r812", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r828", "r947"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": ["r218", "r451", "r1044", "r1045", "r1076"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r201", "r202", "r203", "r235", "r252", "r599", "r664", "r752", "r770", "r781", "r782", "r783", "r784", "r785", "r786", "r788", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r801", "r802", "r803", "r804", "r805", "r807", "r811", "r812", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r828", "r947"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r966", "r976", "r986", "r1018"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-

*"http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails", "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of a milestone payable.", "label": "Stock Issued During Period, Shares, Milestone Payable", "terseLabel": "Issuance of common stock in connection with a milestone payable (in shares)", "verboseLabel": "Shares issued for milestone payment" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "verboseLabel": "Restricted stock vesting and issuance (in shares)", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": ["r10", "r74", "r75", "r112"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Exercise of options (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r10", "r74", "r75", "r112", "r465"] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock in connection with an employee stock purchase plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": ["r10", "r74", "r75", "r112"] }, "ptct_StockIssuedDuringPeriodValueMilestonePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "StockIssuedDuringPeriodValueMilestonePayable", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of milestone payable.", "label": "Stock Issued During Period, Value, Milestone Payable", "terseLabel": "Issuance of common stock in connection with a milestone payable" } } }, "auth_ref": [ ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "verboseLabel": "Restricted stock vesting and issuance, net", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": ["r10", "r112"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r10", "r75", "r78", "r79", "r112"] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": ["http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Equity Option [Member]", "terseLabel": "Stock option", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": ["r946"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance at the end of the period", "periodStartLabel": "Balance at the beginning of the period", "totalLabel": "Total stockholders' deficit", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r75", "r78", "r79", "r100", "r790", "r806", "r820", "r830", "r927", "r956", "r1071", "r1105", "r1172", "r1233"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "verboseLabel": "Stockholders' deficit:" } } }, "auth_ref": [ ] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [ ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureCapitalization"], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Capital structure", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r108", "r195", "r402", "r404", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r416", "r418", "r548", "r831", "r832", "r854"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [ ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureSubsequentEvents"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r628", "r629"] }, "ptct_SummaryOfInterestExpenseRecognizedRelatedToDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "SummaryOfInterestExpenseRecognizedRelatedToDebtTableTextBlock", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtTables"], "lang": { "en-us": { "role": { "documentation": "Table to disclose amount of interest expense recognized related to debt.", "label": "Summary of Interest Expense Recognized Related to Debt [Table Text Block]", "terseLabel": "Summary of interest expense recognized related to debt" } } }, "auth_ref": [ ] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowElementsAbstract", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activity" } } }, "auth_ref": [ ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash information" } } }, "auth_ref": [ ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r1012"] }, "us-gaap_TangibleAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TangibleAssetImpairmentCharges", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTangibleAssetImpairmentAndLossesGainsOnTransactionsNetDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Tangible Asset Impairment Charges", "verboseLabel": "Tangible asset impairment", "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value." } } }, "auth_ref": ["r59", "r102"] }, "ptct_TegsediMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "TegsediMember", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the drug Tegsedi.", "label": "Tegsedi [Member]", "terseLabel": "Tegsedi" } } }, "auth_ref": [ ] }, "ptct_Termforletterofcredit": { "xbrltype": "durationItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "Termforletterofcredit", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Term for letter of credit", "label": "Term for letter of credit", "terseLabel": "Term for letter of credit (in years)" } } }, "auth_ref": [ ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r1004"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r1011"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement" } } }, "auth_ref": ["r1031"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r1033"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.ptcbio.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [ ] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleSecuritiesDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesBalanceSheetDisclosuresDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesUnrealizedGainsLossesDetails"], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r398", "r415", "r547", "r582", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r720", "r914", "r916", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r928", "r1040", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1100", "r1101", "r1102", "r1103", "r1164", "r1167", "r1168", "r1169", "r1170", "r1171"] }, "ptct_TranslarnaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "TranslarnaMember", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the product Translarna.", "label": "Translarna", "terseLabel": "Translarna" } } }, "auth_ref": [ ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r1034"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r1035"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r1035"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r1033"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r1033"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r1036"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r1034"] }, "us-gaap_TreasuryStockSharesRetired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesRetired", "presentation": ["http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Shares, Retired", "negatedLabel": "Retired shares (in shares)", "documentation": "Number of shares of common and preferred stock retired from treasury during the period." } } }, "auth_ref": ["r10", "r75", "r112"] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails", "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r531"] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": ["http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "auth_ref": [ ] }, "us-gaap_GovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GovernmentAgenciesDebtSecuritiesMember", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesBalanceSheetDisclosuresDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesUnrealizedGainsLossesDetails"], "lang": { "en-us": { "role": { "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "Government obligations", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": ["r881", "r904", "r1193"] }, "us-gaap_UnamortizedDebtIssuanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnamortizedDebtIssuanceExpense", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Unamortized Debt Issuance Expense", "negatedLabel": "Less: Debt issuance costs", "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset." } } }, "auth_ref": [ ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r1030"] }, "ptct_UpstazaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "UpstazaMember", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanyLevel3ValuationDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Upstaza, gene therapy for treatment of AADC deficiency.", "label": "Upstaza [Member]", "terseLabel": "Upstaza" } } }, "auth_ref": [ ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r35", "r36", "r37", "r141", "r142", "r143", "r144"] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails"], "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": ["r563", "r564", "r918", "r1169"] }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueDiscountedCashFlowMember", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails"], "lang": { "en-us": { "role": { "label": "Valuation Technique, Discounted Cash Flow [Member]", "terseLabel": "Valuation Technique, Discounted Cash Flow", "documentation": "Valuation technique calculating present value of future cash flows." } } }, "auth_ref": ["r918", "r1167", "r1168", "r1169"] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueDomain", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails"], "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": ["r563", "r564", "r918", "r1169"] }, "us-gaap_ValuationTechniqueOptionPricingModelMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueOptionPricingModelMember", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails"], "lang": { "en-us": { "role": { "label": "Valuation Technique, Option Pricing Model [Member]", "terseLabel": "Valuation technique, option pricing model", "documentation": "Valuation technique using option pricing." } } }, "auth_ref": ["r918", "r1167", "r1168", "r1169"] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesLeaseCostsDetails"], "lang": { "en-us": { "role": { "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": ["r613", "r926"] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [ ] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": ["http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [ ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r1000"] }, "ptct_WarrenPremisesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "WarrenPremisesMember", "presentation": ["http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the leased premises in Warren, New Jersey.", "label": "Warren Premises [Member]", "terseLabel": "Warren Premises" } } }, "auth_ref": [ ] }, "ptct_WaylivraMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "WaylivraMember", "presentation": ["http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the drug Waylivra.", "label": "Waylivra [Member]", "terseLabel": "Waylivra" } } }, "auth_ref": [ ] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "WeightedAverageMember", "presentation": ["http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails"], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted Average" } } }, "auth_ref": ["r565", "r645", "r860", "r869", "r918", "r1185", "r1187", "r1190"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.ptcbio.com/role/DisclosureNetLossPerShareNumeratorAndDenominatorDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r222", "r229"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": ["http://www.ptcbio.com/role/DisclosureNetLossPerShareNumeratorAndDenominatorDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted-average shares outstanding:", "verboseLabel": "Denominator" } } }, "auth_ref": [ ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.ptcbio.com/role/DisclosureNetLossPerShareNumeratorAndDenominatorDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r220", "r229"] }, "ptct_WellcomeTrustLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20240930", "localname": "WellcomeTrustLimitedMember", "presentation": ["http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to The Wellcome Trust Limited.", "label": "Wellcome trust", "terseLabel": "Wellcome Trust" } } }, "auth_ref": [ ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r998"] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://f

Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r18": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r19":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-
14A" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "
(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45",
"Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230",
"SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r27": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r28": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r29": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" },
"r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-
50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10",
"Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275",
"SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section":
"50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50",
"Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic":
"50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505",
"SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r47": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r48": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "40", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1" }, "r49": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "40", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480489/718-40-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50",
"Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815",
"SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r57": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5" }, "r58": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r59":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "
(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-
10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "
(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-
10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "
(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-
10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "
(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-
10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "
(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r88": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "
(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" },
"r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards
Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic":
"360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r102": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" },
"r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" },
"r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r106": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10" }, "r107": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" },
"r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-
50-6" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10",
"Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r116": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r121": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r125": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r129": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph":
"(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r134": { "role":
"http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r138": { "role": "http://fasb.org/us-
gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7" }, "r139": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic":
"275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph":
"(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r145": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic":
"740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards
Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB",
"URI": "https://asc.fasb.org/606/tableOfContent" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r151": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r153": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "
(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r158": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" },

"r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-
10-45-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph":
"(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r164": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r168": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r171": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r175": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r180": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" },
"r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-
10-50-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph":
"(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r186": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r192": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" },
"r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-
10-50-2A" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph":
"(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r198": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r202": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" },
"r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r208": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph":
"(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r215": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting
Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r226": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r231": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" },
"r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-
10-50-3" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph":
"(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r240": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r245": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r251": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r259": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "
(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r265": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "
(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r271": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "
(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r276": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph":
"(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r282": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r287": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r292": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "
(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r297": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-4A" },
"r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479391/326-
20-30-5A" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "8A", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479366/326-20-35-8A" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-5" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic":
"20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r306": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-17" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-21" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3C" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3D" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic":
"20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.M.2.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483530/326-20-S99-1" }, "r315": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479175/326-30-30-1B" },
"r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "13A", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479148/326-30-35-13A" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "7A", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-7A" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3A" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "3C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3C" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3D" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r324": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r331": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" },
"r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-
10-S45-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r334": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" },
"r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-
20-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r341": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "
(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r347": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" },
"r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "
(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r353": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "
(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r358": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "
(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r363": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "
(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r368": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r372": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r375": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r378": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r381": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r386": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r391": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r396": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic":
"20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r400": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r406": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r411": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r416": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r424": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r429": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" },
"r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-
10-50-17" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic":

"10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r436": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r442": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" },
"r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "
(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r447": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "
(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r452": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r454": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" },
"r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-
10-35-3" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "
(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r461": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "
(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r465": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "
(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r469": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "
(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r473": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "
(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r478": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "
(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r483": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "
(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r488": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r498": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r506": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "
(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r511": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic":
"323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r515": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic":
"323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r519": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r524": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "
(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805",
"SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r529": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "
(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r534": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "
(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r539": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "
(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r544": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "
(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r549": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "
(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r554": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "
(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r559": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r565": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "
(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r570": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "

(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r576": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph":
"(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r581": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r586": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" },
"r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r593": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" },
"r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-
30-45-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "
(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r600": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479092/842-20-40-1" },
"r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r606": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r612": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "
(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r617": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r623": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "
(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r627": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" },
"r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r629": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "
(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r634": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "
(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r639": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "
(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r645": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic":
"50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r650": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "
(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860",
"SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r655": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "
(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860",
"SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r660": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "
(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r665": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" },
"r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic":
"235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r672": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r677": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic":
"235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r681": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic":
"235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r685": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic":
"235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r689": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic":
"235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r693": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" },
"r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-
235-50-7" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic":
"280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932",
"SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r701": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r705": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r709": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r712": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r715": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r719": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r723": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" },
"r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r730": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r735": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph":
"(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r740": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "
(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r745": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "
(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section":
"65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r750": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" },
"r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-
10-50-3" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r756": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r761": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" },
"r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic":
"205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r766": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic":
"205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r770": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" },
"r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic":
"210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r775": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" },
"r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic":
"210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r780": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r783": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r786": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r790": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r794":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r798": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r802":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r806": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic":
"220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r812": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r815": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r818": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r821": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r824": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r828":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r832": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r835": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r838": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r841": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D",
"Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r844": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7",
"Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r847": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7",
"Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic":
"505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r851": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic":
"505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948",
"SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" },
"r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-
310-50-2" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r860": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r863": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r866": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978",
"SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r870": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" },
"r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic":
"944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H",
"Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r876": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "
(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification",
"Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r881": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r882": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" },
"r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r884": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r887": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r891": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic":
"20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r892": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" },
"r893": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-
20-55-69C" }, "r894": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r895": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r900": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r901": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph":
"(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r902": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r903": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r904": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r905": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r906": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r907": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r908": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r909": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r910": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r911": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r912": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r913": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r914": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r915": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r916": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r917": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r918": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r919": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r920": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r921": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r922": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r923": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r924": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r925": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r926": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" },
"r927": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-
10-55-10" }, "r928": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r929": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r930": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r931": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r932": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r933": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r934": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r935": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r936": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic":
"235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r937": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r938": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r939": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r940": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph":
"(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r941": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r942": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification",
"Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r943": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r944": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r945": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r946": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" },
"r947": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r948": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph":
"(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r949": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r950": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r951": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r952": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r953": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r954": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7",
"Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r955": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r956": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r959":
{ "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r962": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F",
"Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i",
"Sentence": "A" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r966": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section":
"6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1",
"Subparagraph": "ii" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r971": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F",
"Section": "19", "Paragraph": "a" }, "r973": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r974": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r975": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r976": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph":
"1", "Sentence": "iii" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r978": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r979": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r980": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r981": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r982": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section":
"18", "Paragraph": "a" }, "r983": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r984": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r985": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r986": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",

"Subparagraph": "1", "Sentence": "iii" }, "r987": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r988": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r989": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r990": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" },
"r991": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r992": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K,
10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r993": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r994": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r995": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r996": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r997": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v",
"Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r998": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection":
"v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r999": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r1000": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section":
"402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r1001": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r1002": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number":
"229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r1003": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r1004": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-
K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1005": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1006": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" },
"r1007": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1008": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1009": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1010": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1011": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5",
"Subparagraph": "iv" }, "r1012": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1013": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1014": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1015": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1016": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number":
"229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1017": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1018": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w",
"Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1019": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1",
"Subparagraph": "i", "Sentence": "D" }, "r1020": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i",
"Sentence": "E" }, "r1021": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1022": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1023": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1024": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1025": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section":
"402", "Subsection": "x", "Paragraph": "2" }, "r1026": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii",
"Sentence": "A" }, "r1027": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1028": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1029": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1030": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1031": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1032": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1033": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection":
"a", "Paragraph": "2", "Subparagraph": "A" }, "r1034": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" },
"r1035": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1036": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1037": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1038": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1039": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1040": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1041": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section":
"402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1042": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T",
"Number": "232", "Section": "405" }, "r1043": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1044": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r1045": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1049": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation
S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402",
"Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)",
"Publisher": "SEC" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r1054": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r1055": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r1056": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1059": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1062": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" },
"r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1067": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1071": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1074": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
}, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1080": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1085": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-14" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1090": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1094": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1099": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1103": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1111": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/350-30/tableOfContent" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "
(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1116": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1122": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/450/tableOfContent" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482050/460-10-25-4" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r1128": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1131": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1136": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1140": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1144": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1148": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1152": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1156": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1160": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1164": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-
54B" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1166": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1169": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r1174": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" },
"r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r1180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1181": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" },
"r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1186": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1190": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section":
"S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic":
"320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1194": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1197": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",
"SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1201": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1205": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
}, "r1206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1210": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1214": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1218": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1222": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1226": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r1228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1229": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",
"SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1230": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1232": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1233": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1234": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1235": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1236": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1237": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph":
"2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1238": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic":
"320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1239": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic":
"360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1242": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1245": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1248": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } }
} ZIP 96 0001070081-24-000023-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001070081-24-000023-xbrl.zip M4$L#!!0 (':$9UG<+"#F(!X I9 0 0 =&UB+3(P,C0P.3,P+GAS M9.T]:W/C-I+?2M^K^ \]?-ENU\G-F,IY*LB7;XXGW[)'/']FSV[LL61$(2-A2A M@*1MY==?
–_@0'R !BO(,G&-5:F(1Z 8:W6@T&HW&#W][7OK.(Q4AX\&/>T?[MAWL.#5SNL6#^XUX79W[7C=,,&].'>?H/ MLH+S%!T//CA'1P??'QP?'K]QOO]P#/^=.+#@Z>GI_U5Y$X9WW?Y4F(Y/#T!\DD4"3:-(WK) MQ?*"SDCL1S 4P6\Q\673,$(^Q3$H52@4PY &X0?H0ZFQIY-
]+N;0T.'1P3]O MKN]E][+*'ET)ZN((E&">I\+/H$X/!/?IP:9F!AN'(RP)<\@9":<2*BN1U&75 MW5@(8/$ZKRX;":F[/^>/!UEI"43066.WWAU :4XS%'A1&7-:[^U!4IA7]1M1 MGAS\|YH%OQ;HB]:K!OID2:FSH8B:QB,O*@'$D6@9="@M=&1.R$K9#RPH8?6!
M@A8*L7@*DR'O-7/5#(&"&GD-PY$7E0&BE6A #26EJC2(E\!Y%H$JRDL-1>0".=N$.5S1QA:M104$9+F!N] MJ\JB4N7G&J/2B7IT>GIZ($OS#D2B,O2E3D/Q 18C^N/1X7BHQ2<\IB$3*^Z1BP((Q*XM#CY68O(5^N#]HWTZC@? M^I;!\S9S5"H9IM1 [Q(-
Q"K3>42GS5,:"\M3Q/4:6.)ZU8JC,)XV5L;"!.'G M/SF.7+%($/!(3BO\E'U_&?G>X M3;<:P=*/&3=VS:/\8SB935:9QFUA5@. EFO'[5S;H'7XS-D@'OAGSK]SOH01 M6. 2^DBO>6C*QC]!0M=GX>QH/?QC*[9_, S"&7!-'8E18I['-O85!=1L.KX!$& M@XOU!8T(\U.>]L;2RNG3-
Z!\3X"YFV:0ZTE+R-EPTY9#\L:<5=H:5,X;=+Y+ MF_S+(0*(;BFL-T*/Q.!]D =6$ 7::CZ]B40E/CL M=^I](K"11T.1-G'^*[6]DZ(W)845>^8\8M=P;9UEG7/8IG<."3QGF??%"?/. M /RFC\ZFDW]U-MUT9#^=[Y*>_F40SQ<0S_$CC"A^NN3BGA1+=BJ/^F;T OAF
MUP*8=VHTXV(4DG+Y(&UMTI;:ZB&L1CB"P";X(F+J?7Q>P?Z7AK@7YD'+DK8% M!IV,O*T;CEDKN,A)"4"!($E##DU;DOO!K+&!\:V,OZ#3Z)X&#.8QSA7]/5"Q MO.8D:&"SMKZ.J:=U4Q-QXLY.HG52O XB=A#SP$$M!||Y;'1%A"=0GWG4J.S; MJNKY5E/8*=\|*&!V)>F.]?
QA&JTB6'X?Q= M$M3 R:UP:%A\=%R?FIMV"'(;D@IWGC:%B[9LS2DV-[!_&W?I?<3=7Q?<JZB M.3EC+HL,':2O:QWCNR> ML^F?7/N2'CK?R3[^!2\I[%+OY5P.R>R>#AHW+&\YI4SWP$NE90@'F\7,U78!IA%CI?8&"6@_M:24K%F%0K^RQ[AQ/4UO'TW=U[T 9XW
F9\RXSS1"#]PM%?<+ I,PB)C' +B% M>080.@9^7Y^4Z.:#'S I]7!"1(PSM8![X&.[;QH#,-2U,X/3MKTU'!SN13TH*3 M-3&PM@-KQV$8+^7XA5_"1B/:"$;/TOHUV3I+"\@=Q#YPLP,WI7G(7!EZ"=^- MN-D H^=F/>*DSLT-\K1TX&8'M8LFA\RWANX%V)(.M*MAYD"-
L&@YW0]4$2A MBK&IT51FAW,+C66[EX'SVI#<;>,^.L'JN'U:MZ/2L-XA7F-'?#X^/'Y7O>"B MLXZ-X?3\;0K;1O2*S*#R;S]#:>K(*) ?M2NLSM ZKE;T]6-]Y^R)IR/@X8V M"]Q?LBAS&L-P8DP1#4QBQ+N :CA\=*AP-&W02[J]AJ8%ATVO,X32&]8ZZ?)XT M_YE&MX)
[L1OAT_AK#Z7BKN,Z1Q=6*#?+4,Y4V(!?B8=7MRMFM(OJW1:/G M>\W9H>;[$*: :SGH$)+?#5C/\YH=IN;Y$&>_"S[?4@&[EB7&)4VF/ILG^2^- M.=T.KN=US5>BYG6A&:?0SL#M;:^]7R0]HM=@_7B;>DV,[X%))P.*"WW::^M9 MFR,?
&RW4'R1B:XFX"KR=R80>EUX]:JN 5BHVK0YRL3NYV,SSKE)0A=3SO+8: M:'F>M3'P5\7?]$63< Y(1B<-3S#.1 4E#&^"&(>Z0@?Z6""A> MT(@!0:;IZ,M 6C8=2>^686YZY[L2]F"'M&2C:$A#H>/(D28!Q3#D6]_8W.[2
MI9YAO?)*#/QLS*>KSIVKYT=CVNEAK'=VB6LW5[+TO-SU#=%!!+:)Z^XS27G@\& M0= #%QIB-U11&?H1;PB7&D:Y6P1%AX@)+4],0B3<(L:!649':/I3,CUKS"(< M!H9T\UUW<%;K6=3YH&K@EM++,PWI;S&0^A$?]U+X([S/5[3>:)R[[+VAF\V7V2X:DR7W>";>?
R2<\7 8?\V5IW MJY]'I3(=CT[J/,]?*!LXL',GK)ICO7#I/P"SX<-@M"-:N6 5,P';O?UMEM MFE9C8*NYLU#-1'4E'+0?H9]FV"1%S 6GE! [Z$71W\,DL5I@'6 ML=/HX!L_9LW(E;?0T\75N_F!SDCLZ<9_DE@CH_[H5L"1I]+_VV$'3VXUZT MG(Y@!7MS"#;HOX#2_>>EG]5
["4Q>9X*?Y^+^<'QX>%)(BG5P4G;S5 0X=:P M/)U($? U -9"Y#P%=Z7I^%!UO<]YV!'1 $7NA)589Q]-(&$=*6I+%3VD>23 M:5>2 (3Z+TK-UKM$T#RP; Z]#V2U8L&,XZ?T0Q#PI/?R&WX" MT>0B<@*RI.&*N*G@A,#F@M =GQ35PNAH_VC/"=T%79)K[LIO&["*O-
9!]Z'9 M5-A:>I!U(*3N_IP_'E#70VQOFAM65L<_Y#S;KE6/LBZM9M7QCVZMUFHKQ MEHFZ:24(_AIE<"\-#HZ'IV8CW@)I1>)]1?2-'Q""'=F')= 2E_A]V8D-+U M5O[R(N.!R !P!-YNS8'31+$%=(YW?LP:]X4H06$/3I$'1^^,^S$CX50BB\,1 MX@I-!+ (-"=DEA6#F2O
MP<1,%ZN=, MCO;?7L3P817)GA^]Q>QG-0]W@+5S!))@QTV6P!L&]B?B ;T%@]"4^&-WP>AC M\IKZ+6 73*:Q8?3I'SP&X1+C)8HL[&[Y[!P7,C\Q'<"+(2U]'N(6D MSX@?[DC4^Q,?"2"#4F"N#$NZX[P/Y6+[3 6YLHS2<6&O^317'K>#3=.[RV7WL MNC0,:S]RK9*%RC!-
F'4;"W EVK-T"?B9K^@3T'I.EJNX/G?4Q1;.&GD8/79_MBUF8)3B4>0=SCA6(,JC[DMQR!?6VG!M-4QW/X]!=SV0B,,!GH!X4,$6]LR'_MMLME]L.RX+OD3 OF6>"R59;%(U'RFHI?5?DUODLH]N=Z5OX_4YRMIE>0K:3IQ-|D$3<2]-R9+9| N-Z4O MM->UQ9#9_'K@-F2
MY4EK@%S0%?181OU-(A0)&:T'VV\W%IC+]C1&NJIVR)'>Z&+S111^?$[>6,WM MIY]MK*EGH=&,#XL&$4QTFEQB#L%^*]8%EY%^ZP?Z')WYW/VU0&MGR"KU45;T M;1=6-()G7/@TBJC@LVQFY'0VE-MG(9AI)&/GZ&[06;K(YA3AN7Z!Z,KW+7Q=
M7O3!8]!2F,K#RTS;]]7[CL[QT]R+]7@%)N!C:9O4'?0;[X1KD\5L[S#V/+FU M!_]DT3)^)$SV!,3SC]]2O7#CEL$4W(X5S,"G6'Y"#=|!*'_Y$L!*75_1.H%9 MN,"E][1PMQ?[: &GN3]P'8K$@"WF+LYKMDM'N-=BO=V0,#QCO,;GRG<+&:EX
MVJ!5DY6$N"NHIJB#>3&^G%9Y>RDE[7>43!_#1QYXP>>!FDW>GE'9<3O$ M::F%5U;LES[G(B/U#NA]7 (4-?NZ4+:@3RL4L*MB\X!F[[JD-MH=AFS#UXU' MJ.S^-@2QD>!,^MMDG5?V,VIJV+JWHLQC[M/G]"5)G'*EWYT+M1BE\QJ&PIG9WJP&W'J+M
JEHLY_$+\$**\S-!)4UQ\6?$@2?LUF:47'M1!A[V1?@,30S]JN3S7)#8D MV1-Z3&%E=(2S4EZ@NS.\T(\)O]?BD;GTX[/KQWA&"EHM^[F@F@)"%] MT%CJ-BP8CLC-W%>6,[DF#\80%DK"YQB[QF<>0X_%$,KBQQ6%QG,AEQGH+];(W#2HY6]S(%93Y6*O.P92-D FSI
MGB'U#X43O%-+A4CE@4C6KP5DUL##_P,-#'S,"+Y MDL>886R,=FWI6+$3G*4Z_)K"=HQ.5G+[$QMC^#M#VC'M"YR[H^C6!I&ML# E:#R? M"YD7$LM32]:R*!<((GR2_R"28".D@RO,SRDQI% M?GI#GF#R;?
SS*EC%1;:;@Q1EP:,N6Q+_:SI8FS]:'[1N#]&KVJL[]*5R7U6V M*,";-Q$+ HQ'$L4CSVYP"G>Z5/;?.NZB6ZC%:XBN*#B\.L23O*X($FD>;UX M4!I8C57LL*1D_XHO*>5O_FSZW&@|=H>U@^A+?-^ 7H-MX]6>I"O$EZ?>C,+A
MS,""DKJYUS]L7T3(U)_Z;L0=%%QBM6++%U9\]4PW]-"CZ,:IN MJPLH"XN^8(*ZR<-/:2("DIKU25P VO1'IZ?O/_X6@]9%KP8/YIBPIF+U'Y[B M!EBQ'3BJVYS?H&T+UX3*3??4%EFKKT"5:]BI \Y]T%@KSH(H81BF;PHC>:9Q M^?B9%0G3U7QM!%X^!NQ+

*#K;0V0>"T\4U;I0,U5'#,?`%X^:V##|QP\"M27>M3T10WRR|R,`+]],+H:K3Q"#=W;20I0R<)3U;S:^,453I.9V^0FK>7|C.M9X^B+|/5 @3NXI5#G(5!>GUIE|0;VO%D_UQ.I;*M.2%|U3^8FOBC9?RC#E8*

M%M(ZCI*XT\5[G]12,RH.5;=0C[32T)Y2L5Z .%B45' 67%I=@Q_>.+8#.]M8:03VNM*[_.LNZP/G7A>(]KW7\.XN9CT>IH723> HVUFKTX68'QZ1Q7L1? M'"]&6Tk7+%08(.IB"UFBBL$|DT`8>@M[#82%E)8C3K/X+V)F %)O7?I7UO`M@L)\]G2 TC5;TG8N@[*.19,0^.56XNJDQ>$D5O6G0}`MZ5QKI1$0:W.H44N!%Y94D"B<1"Q(`=Q7*L,V)9N15[<@Z"F10>U4P.RF<>`M707U?s#]=BGE.Z7Y)+|@2:AZO>.5.4VKI8HU]B3D47 ZYXUYP$E1.=@K7`MC_<,2RG]D0=@=19T VA0>78D0OJD5?U;+6Y0BN\,<D5L^^2I.<4PT]`N\NQ M 0(+F0R|^2&/HGR_ZM@=<^6_E&^C%'!F#//"%U4+|[LM5>"#1^$:D MPQP A8_GW%`.1,?5=9 HKC6HVFW2%,%919SAJ68'HH#@^]'RW<"TG=2G MF?R\5#6K;@W7.,) %7AtUD{1P}(+6-Y7NZ K05TFFP4,G}]YD(12NNOTE52 M4S\B>[DF7LL@^Z>< D],8KD,)#>]HF$#* M\'~<>R'|MRL<<$KO6#|+:><25[}+.,|T40FM2VD4O%.MGP&UG.LI+]L ,V'3^G!&z}:7>CE=`2\l8@$4\5N0DEN&`7TDR^4J-#66HC%84|D`QC!9MWV}/U@59F(

M+KD&6SXZ[HF3|RXQ5:G2-#@C)+2NN,AH814%>UDD+5(f% R@R,-M13 M22,.,.^-ZL%M%# ^13V526GZHD5+?\M!90MIS+|\(,"?.A-5I192D;<'>* MZKDOAQ +Z<5OZC>RVA5Q?C7F@A#5LGZ\7 %%1)+51RYVCM'U(8ND)I2,Y

M00UZF^K4#K"7HPCZH[+9A9M0)6K7(),KL8kG<4LBQWA;%;80&)9WIJ_U-M N8,=Xd=]2AY>2.^XP_M^L+2^>)6 NACGQE,,Q4<-]!7,VH=#],=>AD M1E3 3>V6(]NPMI)_'L,Y.AS) [^ #B!^09N,]^BVT<<\# 81G&?4S@=E]) M,^ %/0W6Q(_4,^^?

5^464C'^4(P;#,#.7 "FOMT,IBRVD XCA_]YQ?#PI@^M*-WYQTJ]##\4.C?>_1>.& Q;R=P@)!5 ; E!^.OS1YU<46TM'F0),WD?$/ MM+#)XZ9RL;FCQ'AG&*I5CGF,M%<G[>KGZ2,1.OH>^?I$ WBX259KV)-!5G6;6&#&A;R&)D)R,0DN6'C3T"??

M//"NEO"0<04RN-IQPQH?<3#W0!P UX&.,.51R54Q)20\FTZEW"#BL MU&+R-KX\K'E= 5+6Z'&,M,5XVG2^XQDJF7,+$TV?78BV@`>,FG6`XEZ1OP M-B F^DTE6G).ILEZ=15D6=LON5 ^E5F.\ XU6K2&=8],S6EPP=`3WV`@@#M=

(VT-LOHZVWNK&E>-,GRF,LKJK.S:.F,0^.RJF!?0&L6?N>=3E2S6(A;(]+T MQR5[IEZ9A6%ZJP5DNJD"?GJ<U-Ne>.:U#%.IX("U<*%YEG2>.0'03P<O7MP.MTVL9LGF>1XM;.?@c%?>?R?`DY%2-> 3&2PH=0>`674+)M@\523X.W3^.%0D-MWU&6?ELPCA

(D)D&9,DI .]+44I#!0 (>S9UE%8<)+Q# E-A M =&=-3(P;O0.3,P7-CA;9&7%6MSVR5&MG<"):#2<]N.=JLN<6XB.TEW M6MVS

*1@(#45(E!3{!)^P\7;!;$'0D;M@>U#+!V\I(A?B*8#`M$ZZ18M"9I]^N!+M5TR_C +0.*P^>5D(0?TK\ZK_%7VI$<Z0GIG<L.0Q(#<(`M|*A`!FE<6]^18NGI%V9@K(=5(@,VLH>`MD.@0KU"2I6N<_^#@6ICF!+;VH&K4S?5?L&U5/W&X#@66'8@)D>KEYN#1,.I2T MLF<%ZK@H^/.6G087/G3\U#@8-B>M)N9M,@HS=,;37^^), ^6^S"7F1YX&/C)+GT M%P/)+2,V'E%.+3TGO$#*T[QD]DS_34[?KG%>,.&]F`>FGVV]|%16-<4#TCO*BY$@ M>Z, ZYV2>]MV8+]24(\B8+:0;5CMPE>?P@V,]@F`7SWBHLSW8;FO MJG" (ZRIC#!#,.9]86K*9M+4$'6U8XV&6LW\VAHPU5AME,"IC=^Q-W'26KPN[<^P7N[U;/]V3]V&CLZSPG&Y(S=\'0\$=:OL,%)5@ MVW12[U4\FG]LW,,]Y7WIV0-,'X1O'T>]V<FZN[%$T,: ; sCXK=_)% MO=O58X5A^JV52+SR;CI.8%_;O)D] M?]+M9,]V,5ED,3_8KWRXY]]^EZWU"1SK"9)E.POG]2,5@-,@@R1WGUG76Q MV07B,6M X7-9?@KR/W]OUIAZD\,.HZQ]5MZ'DEV+U8/=V9,W8(A5)>G<# M^1P35'OO<(I>.IXQ^9D-K@>]%/4'5$:U\%IKP^0_113DQV\%CF&]H'IEY5(=-0^']+0IV5>LY#[B"N&314E@N_ AX~$!A1'S 3 M9]5H+LB0:& BET.9,9C@++D>(4?=#D_)Q)@ K0+9M4S=]Z\RAE"6AZ=0+W@VCGHRF9!A%(O86,]Z"OV3Z(A>B(1ROV?!X\==L^ M144[RPCE0P\|!<;+=5ZB+=)$> (@)LIJ66:S(=?>,ERKV]8?W'L6 M8GU*4UNDS'BV]0(!]]3*,?(?N7@`!'E;@cE]5FW M(#T?A;YG2^>I F=D!4;S548^<2]!49[..D0O?],]9K]3OBAIGE\(06(1++7MZ^5++IXA]:+C3;/(^*\&Q(0RBF^Xe@9KP^BLU%$%4M7 14BF@#L'2M?C%,V3'& M ENRU^\>J86K*9H<[ E5066B4B%W3)N-BVV>$]CD^2#NLD)<;=;3RQ, MWV+8ER!+7W8))XZ$)<[+&DX0U#J3N RDV!?=+2%R#E+!=!<%GGiWQ`1`J_07=&L M]D]%*`008=?2$>[^%.%>[*(%1P^<7PR/N^,,,7M V3#]$H?>]

*M1EL^>+9,R5B*DWT9Q^G^]P^?A M/N`3C.[#\;/7I&:3GQVV 7;FT8K9-W8W8FK0.RA !UMG=%]5ED= M=ZKY2(FG+B^]4UO-Y HT5OSUQ%*@=/]5[?HNU5'K(&-"<i^5P%5B;I2D M<5D,7[%61]E\5W0(OE&D50X,6 IXI^2P)V614\AW1=[eIH,%<9]%,:78]I,R29X7V-81121?*M/HcB^28<7R+T2QC]D MV4$BI\A.OH5&AOvG*B2@]HU"""],,U,3U)ZQ%THA5Bi\)EX5C6!9K,6@ MUADZ[X0S/2UB5=.@GZX[=!"CCX,'Q&&]I-ME%,6T2I#86KT=E?CAI#N-ME;> M'19WP=0K830(IFWUO)0%7X(MI_%+6RZ5Y[;P=K"79Q]/$;SL.XP]Y'.(E M555*, #%;WR_N=GB_%.0 X'+7X-D3WXA/.5WI*U@c. 23I6@!F`7 %`6 WIX& M_H2&5!?T&C>NU% [(e?YD?Z5C@ !H2AZ(,Q2BI(6+J,BNJ$M4PZJ4NWJX3)\ MO5%^.C8HZEI'9IP"F&Y$,!U#?N;#**#E2OWM26(&8* ?H/GBY# MS4'<'(VKMWYW-.1MVQ([&XG3CKPY+BV1D M4$AJC,GOX%@<UBZA[EAJQ3^S0&U1#*(-@0%9*CDQR<[1#E^W,,,U$\%,%TUP M7O0ULAMO^&^]E=@)QRV0%P?]RF-$Y1,/61DDJ3EPW(S0%,;5DM=I7%KC^IP.M5=6C^:\V166>$,?9.8CBPZ5M4QUS66GX\DAN5^:S\JF5GC8B^ _2^5FD+(-Q I M-U"'-@Z3\YXQ0(V2%0^QIPZ>OGZ)E.0#,(X('Z(@OJB52H5BC5@2! ERY`MJK&.BI FKCYI\.X1_PZ7)GU,5.VI4M+%f>=K0]DVMT,>RTDA/[K\#Y^MP3]_M[]9[3T:3H=<KW0S%=TEVP@#6%(ZOH*%>>DKND%LI7+^QO:\/MGC^(E+K+TO4SSK<W'+.F+)/HEV=?Z>?YFF]H$_\:^/HLDH+)6^@=M4OTFSSO-6<-6 ^>2I.5R4*8(O*+$ION:9?ZF<]#9?$<BC2YX$0@<`V74<I@=@>5R&25;0 MF5$Y[*-#0IYR2>=<, +HGX3CX%?BY+.'YG-@3N;C5%@]T^GTUB _L=PV'Q^%Q M88B9D3P E9fZ]>C\C\F368WVG56OF,[*RI[O.%?3#SCAB09]V1#$%H,.05'PL@<6 =]2 MYWBC3[O+'88,8 1A=#IC0^:+"ABY`UAAH|+' 0[,2/9R+2=72,3=\(4U@ M0!AMWM24 XN)CR>QR;'O(\-R50%MB?)P6<,A],FU<&<$PBMX-Q(ZJB,4G M7UXT;[>],UMJ?Q$N#$PLDAR 4,\ 5(\ ]-$1,25=9C\'COERO<[Q.B@QBAO, M?AEF=(N\W63[@P90<^.U07OT(.9F#8+RU\U WE.ND*.$K=A8"` LP%R M1,$F.)?$V<? 0M?Q4FH&,FZ2\>.7FIKQA\#*V,/I?-X&= *,OW(P.4N=P1 MX'O((!P0%IL0,5QJ82 !)T^@<3 C<9,2A; M*TO=3(V<GO +>MH, ^ELA=7BQPIK9D0$/*IMI6Z^*"OBPH%$3VJO:'Q8||Q7^#T M@U;6|US|&|= W,28CGJ82-KRDRUU0P(MzLI*8TA9^2XNXQ #UC,*.9;%]8G!0'G9+,V0Z9B XZ;F\>]W2,DS;$5Z -6 M7'.N/G^2*+P/*8BGLHL . +&I?% \Y76,ZEV4+V0Y4/LBT^XYZU@M19@TMP9 M:#0'N>=5!WS6K(&8\%O@DIRO1*75=0%$Q09,/O.^IC.GF3)FA@FI#]* a M%,$ J_+B^#B?;D_]B'Q0S&G6:%A4]B, $[YAXSZI$Y5\O1.8EB5RN"TF M^3> 4QYN&Y%/M%P> @39^`F;(Z@Z&+ -(D.F=E#VG4KY^QK/ G,H;9P>3W'T'V-I*#,&%#@3<3'+?] K)`.YNF .^R4L,5\7]9) Pe"# .G>.OQ>,K7^= = M#I"!H^C9P(+1OA>/EKL&M^Q)XO[8?5\(.6G ^MW?ZQ SA/Q;W48[^\=D;1 MKNRW.(@.(.[#*TN[5I\E&GE + ,53Y*R6I>,]E#-7Z\'ZSPZUYP^A V?L*5? M2)6&1,"D6Y-

XGI DIK]DJGLHO5WDOK!+BOOA,N'#S*V(%*@0)2,4H\V3W%@%=6553+ ^,P I/1)Z35<.7 E B/M?I_04Q N6#U\;=@NZ/?D_IR_ OW3ES!2 P7F>$= -'&.@VE5\.]MKWUC D@=0 #CHF MOCR5R?H,@:?MPLCEX69,49M)WE#$O%)!T>4U8!#GW &)?;*:6,,=@N'BY6%^<= MH'>]G$'=!Q3|>9:P5GF2]Y39B*B1X1&R7R`.]W4SMSAR?>$#?]@=2$!C)(;$#U) 55BW:9AML5/ M)3&4 G1A5!LO]?%,<8KPc,VR6L%0EW!#A<%!116IF;ZE/I08C+<#1 M%M&EEW6C}YQD.ZHN3;64%K@WD=&\FK!

L^05KQ:XN40UNCY`C-]DY`,.M4V M8/N1$B*=?:,@\U;'5<*I.M.AA&6F?@@3'KVI\=(ZFV\'(S0=I.K@9.5YIA;7\O:KP%K@MTDIHKOI?= MI`Q.^D&D5593^B>Y6-) 8EH6F3%A:\EFW@IEA)KQ%-^BHJ+!0G.ZT<4.M=CID;.W^)>0&:.HP]D-S,*.?

3E;/.R-]Q>`218KK'#\&!QIVV.ZA9K5E M2%<v)[FIMVOV?5<0\= M1K@H_B>)&?">>)B@^Z8YU1R(<&=p)81/DV\.36=UO2;E(5O.I:#"2A<+9)?*P4@=?:^%).C%.QUZ0L$\4I>BW>.dLDFH_.MCX-=4IZ2\>.;M',,D?[F8OWR+DX)%@&i*VVIN-8Y M6/C\N>N,TRNING3)?TVCM>3,TM>96MAP'#H+;<%MMXI+%3%ZUQ.?:C.MPNRPO+08+]#%$ZJ[^.%%%